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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease targeting 
preferentially motor neurons. Cyclophilin A (CypA) was identified as a hallmark of disease in 
mutant SOD1 (mSODl) animal models o f familial ALS (fALS) at a presymptomatic stage, and in 
sporadic (sALS) patients (Massignan 2007; Nardo 2011). Moreover, CypA was enriched in the 
spinal cord aggregates of mSODl mice and sALS patients (Basso 2009). CypA is an ubiquitous 
protein with multiple functions relevant to the CNS, where it is abundantly expressed.
Insights into CypA function in ALS were provided via a proteomic analysis of its interacting 
proteins, that functionally associated CypA with different proteins networks. In particular, it 
extensively binds proteins regulating RNA metabolism, including several hnRNPs and TDP-43, a 
major disease protein in ALS. TDP-43 and CypA interact in the nucleus, in an RNA-dependent way. 
CypA has a key role in the stabilization of TDP-43/hnRNP A2/B1 interaction, and TDP-43-mediated 
HDAC6 expression regulation, properties impaired in TDP-43 ALS-mutants, possibly because of a 
loss-of-interaction with CypA. CypA interacts also with mSODl, suggesting a gain-of-interaction 
specifically linked to fALS. Mice expressing mSODl and lacking CypA show increased levels of 
insoluble mSODl and hyperphosphorylated TDP-43 in the spinal cord at the onset.
This thesis work shows that CypA has a protective role in ALS: as a chaperone (for mSODl) and in 
maintenance of multi-protein (TDP-43/hnRNPs) complex stability. Regardless the cause of the 
disease, mSODl or alterations in TDP-43, the interaction with CypA is impaired and it is co­
sequestered in proteinaceous aggregates, altering its protective activities. The net effect is the 
formation of pathological inclusions that may lead to a compromised RNA metabolism. CypA 
being a key interacting partner of both mSODl and TDP-43 can represent the "missing link" of 
these two patho-mechanisms in ALS and an interesting target for therapeutic interventions.
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TDP-43 TAR DNA binding protein-43
TIF Triton X-100 insoluble fraction
Trp (W) tryptophane
Tyr(Y) tyrosine
UBIs ubiquitinated inclusions
UBQLN2 ubiquilin 2
UMN upper motor neuron
UPR unfolded protein response
VAPB VAMP/synaptobrevin-associated membrane protein B
VCP valosin-containing protein/p97
WB Western blotting
WT wild-type
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I. INTRODUCTION
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Many neurogenetic disorders are caused by the mutation of ubiquitously expressed genes. 
Amyotrophic lateral sclerosis is one such disorder.
1. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is an adult-onset fatal neurodegenerative disorder 
characterised by progressive muscular paralysis reflecting degeneration of motor neurons (MNs) 
in the primary motor cortex (upper motor neurons, UMN), motor nuclei in the brainstem and 
anterior horn cells of the spinal cord (lower motor neurons, LMN). In particular, ALS refers to one 
specific form of MN disease, in which there are both UMN and LMN signs. "Amyotrophy" refers to 
the atrophy of muscle fibres, which are denervated as their corresponding anterior horn cells 
degenerate, leading to weakness of affected muscles and visible fasciculations. "Lateral Sclerosis" 
refers to hardening of the anterior and lateral corticospinal tracts as MNs in these areas 
degenerate and are replaced by gliosis (Rowland 2001).
Clinical, pathological and genetic advances indicate heterogeneity in phenotype, pathological 
substrate and genetic predisposition, suggesting that ALS should be considered a syndrome rather 
than a single disease entity (Deng 2010; Beleza-Meireles 2009; Beghi 2011). Although the clinical 
presentation and progression of ALS vary considerably, the course is inexorably progressive, and 
patients die within three to five years after presentation, usually from respiratory failure, due to 
denervation of the diaphragm and respiratory muscles.
Although ALS is the most common disorder of MNs, it is considered a rare disease. The majority of
ALS cases are sporadic (sporadic ALS or sALS), although 5-10% of cases show a Mendelian pattern
of inheritance (familial ALS or fALS) (Byrne 2011). Sporadic and familial forms share similar
pathological hallmarks. SALS is a complex disease, in which genetic and environmental factors
combine to increase the risk of developing the condition (Deng 2010). Despite extensive efforts to
understand the molecular mechanisms causing this disease, nowadays ALS still lacks an effective
therapy, and the single drug approved for use in patients, riluzole, only slightly prolongs survival.
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1.1 Clinical presentation
The features o f ALS were first clearly described as a clinicopathological entity by the French 
neurobiologist and physician Jean Martin Charcot (Charcot 1869; Charcot 1874). However, before 
that Bell, Aran, Duchenne, and Cruveilher made important observations that contributed to the 
understanding of the clinical and pathological syndrome (Tyler 1991; Aran 1850; Duchenne de 
Boulogne 1851; Cruveilhier 1853; Goetz 2000; Rowland 2001).
1.1.1 Main clinical features 
Disease phenotype is often classified by the site o f onset. Approximately two thirds (65%) of 
patients with typical ALS have a spinal form of the disease (classical 'Charcot ALS1). They present 
with symptoms related to focal muscle weakness where the symptoms may start either distally or 
proximally in the upper limbs and lower limbs. Rarely, patients may notice focal muscle wasting 
before onset o f weakness, and some patients may present with a spastic paraparesis. Patients 
may have noticed fasciculations (as involuntary muscle twitching) or cramps preceding the onset 
of weakness or wasting for some months (or years), but rarely are these the presenting 
symptoms. Although it is usually asymmetrical at onset, the other limbs develop weakness and 
wasting sooner or later, and most patients go on to develop bulbar symptoms and eventually 
respiratory symptoms (although not necessarily in that sequence). Gradually, spasticity may 
develop in the weakened atrophic limbs, affecting manual dexterity and gait. During late stages of 
the disease patients may develop 'flexor spasms', which are involuntary spasms occurring due to 
excess activation of the flexor arc in a spastic limb. Occasionally encountered symptoms include 
bladder dysfunction, sensory symptoms, cognitive symptoms and multi-system involvement (e.g. 
dementia, parkinsonism).
30% of patients present with bulbar onset ALS, usually in the form of dysarthria o f speech and 
dysphagia. Limb symptoms can develop almost simultaneously with bulbar symptoms or within 1 - 
2 years. Almost all patients with bulbar symptoms develop sialorrhoea (excessive drooling) due to
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difficulty swallowing saliva and mild UMN type bilateral facial weakness which affects the lower 
part of the face. 'Pseudobulbar' symptoms such as emotional lability and excessive yawning are 
seen in a significant number of cases.
About 5% of cases with ALS present with respiratory weakness without significant limb or bulbar 
symptoms (De Carvalho 1996; Chen 1996). These patients present with symptoms of type 2 
respiratory failure or nocturnal hypoventilation such as dyspnoea, orthopnoea, disturbed sleep, 
morning headaches, excessive day time somnolence, anorexia, decreased concentration and 
irritability or mood changes (Polkey 1999).
Examination early in the course of limb onset disease usually reveals focal muscle atrophy 
especially involving the muscles of the hands, forearms or shoulders in the upper limbs, and 
proximal thigh or distal foot muscle in the lower limbs. Fasciculations are usually visible in more 
than one muscle group. Spasticity is evident in the upper limbs by increased tone and a supinator 
'catch', and in the lower limbs with a patellar 'catch' and clonus together with hypertonia. Tendon 
reflexes are pathologically brisk in a symmetrical manner, including finger jerks in the upper limbs 
and positive crossed adductor reflex in the lower limbs. Abnormal spread of tendon reflexes 
beyond the stimulated muscle group may be evident. In patients with bulbar dysfunction, 
dysarthria may arise from either LMN pathology or pseudobulbar palsy from UMN disorder, 
leading to slow slurred speech or a nasal quality. On examining the cranial nerves, the jaw jerk 
may be brisk, especially in bulbar-onset disease. An UMN type facial weakness affects the lower 
half o f the face causing difficulty with lip seal and blowing cheeks, but often varying degrees of 
UMN and LMN facial weakness coexist. The gag reflex is preserved and is often brisk while the 
soft palate may be weak. Patients develop fasciculations and wasting of the tongue, and tongue 
movements are slowed due to spasticity. The rest of the cranial nerves remain intact, although in 
late stages of the disease patients may very rarely develop a supranuclear gaze palsy (Okuda 
1992; Kobayashi 1999).
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As disease progresses, patients develop the characteristic picture o f the combination of UMN and 
LMN signs coexisting within the same central nervous system (CNS) region, affecting the bulbar, 
cervical, thoracic and lumbar territories. Patients who are kept alive by tracheostomy assisted 
ventilation are found to eventually develop a profound state of motor paralysis termed the 
'totally locked-in state' (TLS), where there is paralysis o f all voluntary muscles and varying degrees 
of oculomotor impairment (Hayashi 1989; Sasaki 1992).
ALS probably begins a long time before its clinical manifestation, since a large number o f MNs are 
lost before any clinical signs develop (Cote 1993; Kennel 1996). Unfortunately, at the moment no 
neuropathological, neurophysiological nor biochemical markers are yet available to identify a 
patient as potentially susceptible for ALS prior to symptom onset (Swash 2000).
11.2 Cognitive and behavioural impairment
Recent findings revealed that the selectivity of ALS for the motor system is not absolute. In fact, 
patients with ALS may exhibit a range of cognitive abnormalities ranging from impaired frontal 
executive dysfunction in 20-40% of patients, to overt frontotemporal lobar degeneration (FTLD) in 
up to 15% of cases (Leigh 2003; Phukan 2007 and 2012; Strong 2008 and 2009; Raaphorst 2010; 
Elamin 2011). FTLD is characterised by personality change, irritability, poor insight and pervasive 
deficits on frontal executive tests (Phukan 2007; Strong 2009), while executive dysfunction is 
associated with impaired judgement and impulsivity, and is a strong negative prognostic indicator 
(Elamin 2011; Phukan 2011). Behavioural impairment in the absence of cognitive abnormalities 
can also occur (Strong 2009; Raaphorst 2010), and both cognitive and behavioural dysfunction 
may precede or follow the onset of motor symptoms. However in the majority o f cases, the rate 
of cognitive decline is very slow as compared to the devastating motor deterioration. 
Neuropathological and neuroimaging studies have indicated that this subset o f patients with ALS- 
dementia may represent part of a spectrum between patients with pure FTLD and ALS (Ince 1998; 
Phukan 2007).
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1.2 Histopathological features 
In order to acquire a better understanding of the aetiology and the pathogenesis o f ALS MN 
death, the pathologists are usually dependent on autopsy samples from ALS patients at a terminal 
phase of the disease, thus they can supply only little information about previous clinical stages. 
The pathological hallmarks of ALS are the degeneration and loss of MNs with astrocytic gliosis and 
the presence of intraneuronal inclusions in degenerating neurons and glia. UMN pathology in ALS 
is indicated by depopulation o f the Betz cells in the motor cortex (Brodmann area 4), variable 
astrocytic gliosis affecting both the grey matter and underlying subcortical white matter o f the 
motor cortex, and axonal loss within the descending pyramidal motor pathway associated with 
myelin pallor and gliosis of the corticospinal tracts (Wharton 2003; Ince 2007). LMN pathology 
primarily affects the ventral horn MNs of the spinal cord (SpC) and brainstem. There is relative 
sparing of the motor nucleus of Onufrowicz in the S2 spinal segment and the cranial nerve 
oculomotor nuclei (Kato 2003; Iwata 1978). The number of LMNs can be reduced by up to 50% at 
autopsy (Ince 2000) but there is considerable variation both between cases and between different 
spinal levels within cases (Ince 2007). The remaining neurones are atrophic and contain 
intraneuronal inclusions such as:
-»  Ubiquitinated inclusions (UBIs) or ubiquitin-immunoreactive (Ub-IR)
According to their morphology, UBIs can be divided into more compact spherical bodies, also 
defined as Lewy body-like inclusions, or skein-like inclusions which have a filamentous profile. 
The former are found also in other disorders, like Parkinson's disease (PD) (Jellinger 2008), 
whereas the latter can be considered a specific hallmark of ALS. In patients, UBIs are 
frequently found in the LMN of the SpC and brainstem and are localized both in normal 
appearing MNs and in some shrunken cells. They are almost universal in ALS and its variants 
(95% of cases) (Leigh 1991 and 1988; Lowe 1988; Ince 2003). Protein constituents o f these 
inclusions have been partially characterised. Recently, the TAR DNA binding protein 43 (TDP- 
43) has been identified as the major component of these UBIs (Neumann 2006; Tan 2007; Arai
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2006) and, as in the case of TDP-43, several of the proteins encoded by genes mutated in a 
small subset of ALS, such as superoxide dismutase 1 (SOD1), fused in sarcoma (FUS), optineurin 
(OPTN), ubiquilin 2 (UBQ.LN2), neurofilament heavy polipeptide (NEFH), valosin-containing 
protein (VCP), C9orf72 and p62 are prominent components of such inclusions (Deng 2010; 
Mackenzie 2007; Shibata 1996; Keller 2012).
—> Bunina bodies
Bunina bodies are small, eosinophilic, intracytoplasmatic inclusions localized in the soma or 
dendrites o f MNs but not in their axoplasm. Although not all ALS patients necessarily have 
Bunina bodies, they are currently considered a specific histopathological hallmark o f ALS 
(Bunina 1962; Piao 2003), since they are rarely described in other conditions. At the 
ultrastructural analysis, they appear like electrondense, amorphous material containing 
tubular and vesicular structures; they can also contain filaments and other cellular micro­
organelles (Kato 2003). They stain positive for cystatin C, a protein inhibitor o f lysosomal 
cysteine proteases, but they are usually negative for ubiquitin, and do not contain TDP-43 
(Okamoto 2008).
Hyaline conglomerate inclusions (HCIs)
HCIs are argyrophilic inclusions seen in SpC MNs that stain for phosphorylated and non 
phosphorylated neurofilaments that can be in association with other cytoplasmic proteins and 
organelles (Schochet 1969; Leigh 1989; Sasaki 1991). They are associated mainly w ith fALS and 
rarely seen in sALS cases. However these inclusions do not seem very specific for ALS 
pathology, in fact they have also been described in other neurodegenerative diseases and are 
found in normal individuals too (Leigh 1989).
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Moreover, both UMNs and LMNs of ALS patients might show signs of fragmentation of the Golgi 
apparatus (Mourelatos 1994; Fujita 2005) and morphological alterations of mitochondria (Hirano 
1984; Swerdlow 1998).
Contrary to early belief that ALS was a disease exclusive to the motor system, there is now 
significant evidence to suggest that ALS is in fact a multisystem disorder. Extra motor pathology is 
found in regions such as the frontotemporal cortex, hippocampus, thalamus (Brownell 1970), 
substantia nigra (Al-Sarraj 2002), spinocerebellar pathways (Swash 1986), dorsal columns (Lawyer 
1953) and peripheral sensory nerves (Dyck 1975; Bradley 1983).
1.3 Epidemiology and aetiology
ALS is one of the most common neuromuscular diseases worldwide, and people o f all races and 
ethnic backgrounds are affected. ALS affects worldwide 1.5-2.7 (average incidence 1.89) per 
100.000 individual/year and has a prevalence which ranges from 2.7 to 7.4 (average prevalence 
5.2) per 100.000 (Worms 2001; Silani 2011). The frequency of ALS is reduced in populations of 
non-European or mixed ethnicity and genetic admixture might be protective (Cronin 2007; 
Zaldivar 2009). The incidence of ALS in Europe is 2-3 people per 100.000 of the general 
population, and the overall lifetime risk o f developing the condition is 1:400 (Johnston 2006; 
Alonso 2009; Cronin 2007). In populations o f European extraction, ALS is more common in men 
than in women by a ratio o f 1.2-1.5:1.7. This disparity is largely attributable to the increased 
frequency of spinal-onset ALS in men (Kuzuhara 2011). Explanations for this male excess have 
been also attributed to possible protective hormonal factors in women, increased likelihood of 
males being exposed to putative risk factors and under ascertainment of elderly women in some 
population registers (Armon 2003; Nelson 2000).
In contrast to other neurodegenerative diseases, such as PD and Alzheimer's disease (AD), the risk 
o f developing ALS peaks between the ages of 50 and 75 years, and declines thereafter (Logroscino
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2010; Chid 2009; O'Toole 2008). This feature suggests that ALS is not a disease of aging, but rather 
a disease for which age is one of numerous risk factors.
A particularly high frequency of ALS cases that often present with parkinsonism and dementia was 
first described in 1945 in the Chamorro tribe who live on the Pacific island of Guam (Steele 2005). 
A similarly high frequency of ALS has been reported in two separate areas in the Kii peninsula of 
Honshu island, Japan (Kuzuhara 2005). The frequency of ALS in Guam has declined rapidly over 
the past five decades, although elevated rates of PD and dementia persist (Steele 2005), as do 
increased rates o f ALS in parts of Japan (Kuzuhara 2011). A high content o f cyanotoxins has been 
reported in the diet of the indigenous population in Guam. However, detailed epidemiological and 
toxicological studies do not support the hypothesis that these forms of ALS result from cyanotoxic 
effects, and no environmental toxin has been conclusively identified (Steele 2008). The 
pathobiology underlying these disease clusters remains unclear.
Sporadic forms of ALS likely result from complex interplay between genetic predisposition and 
environmental exposures. In fact, although a number o f genes have been identified as causative 
of fALS, genetic studies have also been performed in sALS, finding candidate genes which confer 
susceptibility to sALS (see ALS genetics section). Environmental factors that confer an increased 
risk o f developing ALS outside of Guam and the Kii peninsula have also been difficult to identify 
(Sutedja 2009) and currently no robust evidence or conclusive proof exists for any environmental 
factor as a causative or risk factor for sALS. Clustering of ALS has been identified in certain 
occupations, possibly including individuals deployed in military service (Kasarskis 2009; Horner 
2008) and professional soccer activity, although not in other athletes (Chio 2005 and 2009). In 
particular, given the high excess of deaths for ALS among soccer players during the last decade, 
several hypothesis have been formulated including also chronic misuse of drugs (most often anti­
inflammatory) and doping, dietary supplement, pesticides used on the playgrounds, head and SpC 
trauma or microtrauma history (Al-Chalabi 2005). Other environmental factors that have been 
associated with ALS include smoking (Armon, 2009; Alonso 2010) and exposure to pesticides,
lead, organic toxins, and electromagnetic radiation (Sutedja 2009).
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In the last years also persistent viral Infection has been considered a possible cause of sALS 
(Rowland 2001). Selective vulnerability o f MNs to certain viruses, such as Polio virus, some 
entero- and retroviruses, has been described; in particular, retroviral infections may cause MN 
damage and ALS-like syndromes in both laboratory animals and humans. Epidemiological and 
experimental data suggest a pathogenetic link between HIV infection and ALS. Patients w ith HIV- 
associated ALS syndrome displayed significant reversal of neurological symptoms after 
antiretroviral therapy. However, although evidence exists that correlate viral infections to some 
forms of ALS, as of yet no causal relationship has been proved.
The theory of an autoimmune cause of ALS is controversial. Activated microglia and T-cells have 
been found in the SpC of patients with ALS who have IgG antibodies against both MNs and 
voltage-gated calcium channels (Appel 1999; Pullen 2000). However, immunotherapy has not 
been effective in patients with ALS: corticosteroids, plasmapheresis, intravenous immune 
globulin, cyclophosphamide, and whole-body radiation have all failed.
1.4 ALS genetics
The genetic landscape in ALS is changing rapidly. The principle that ALS is rarely familial (Charcot 
1881) has persisted until 1990s, when several genes have been found associated with both fALS 
and sALS. In a similar way, for several years, only one gene was known to have a role in ALS 
pathogenesis, SOD1. However, in the very last few years there has been considerable success in 
finding ALS genes, together with rapid advances in the relationship of the genetic subtypes with 
pathological subtypes and clinical phenotype.
Similarly to other neurodegenerative diseases, like AD, PD or prion disease, ALS occurs 
predominantly in a sporadic manner (sALS), although several fALS mutations have been identified 
as causative in rare sporadic cases of disease. Recently, considerable evidence of a further genetic 
contribution to all ALS types has been generated, pointing out the lack of clear distinction 
between hereditable and apparently sporadic ALS (Al-Chalabi 2012). Indeed, many cases
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designated as sALS actually represent fALS with reduced disease penetrance. In addition, the fALS 
label does not exclude the possibility that environmental, endogenous or epigenetic factors 
contribute to the disease. Thus, large effect of Mendelian genes can account for 75% of inherited 
forms and about 14% of those with no obvious familial history, even if the underlying causes 
remain largely unknown (Andersen 2011). Moreover, it is increasingly clarified that ALS is not only 
a monogenic, but often a digenic or polygenic disease with variable penetrance. In addition, 
mutations in the genes unequivocally linked to an ALS phenotype predominantly cause disease 
with high penetrance and a lower mean age of onset than sALS (and will be easily recognized as 
fALS), but may, in some rare individuals, give rise to other neurodegenerative syndromes, 
sometimes in combination with ALS, thus underlying their pleiotropic character (Al-Chalabi 2012).
1.4.1 Genetic causes
ALS is a genetically heterogeneous disorder, with several causative genes and mapped loci (Table 
1). To date, seventeen loci with established ALS causation have been reported (OMIM®, Online 
Mendelian Inheritance in Man® at NCBI) and at least nine other loci have been mapped and pend 
confirmation. Most o f these are identified via genetic linkage analysis in affected families and 
display an autosomal dominant inheritance pattern with some autosomal recessive pedigrees 
reported. The genes associated with ALS show no common biological denominator, but can be 
divided into six main categories: oxidative stress (SOD1), mRNA processing (FUS, TARDBP, ANG, 
SETX, TAF15, ELP3, ATXN2 and C90RF72), endosomal vesicle trafficking (ALS2, VAPB, FIG4 and 
OPTN), ubiquitination and protein degradation (VCP, UBQLN2, SQSTM1 and UNC13A), axonal 
transport (DCTN1, CHMP2B, SPG11, PFN1 and NEFH), and other functions (SIGMAR1).
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ALSl SODl Cu/Zn superoxide dismutase 21q22! Adult
AD/AR,
denovo Rosen etal., 1993
ALS2 ALS2 Alsin 2q33.2 Juvenile AR Hadano etal., 2001
ALS3 unknown unknown 18q21 Adult AD Hand et al., 2002
ALS4 SETX Senataxin 9q34 Juvenile AD Chen etal., 2004
ALS5 SPG 11 Spatacsin 15q21! Juvenile AR Orlacchio et al., 2010
ALS6 FUS Fused in sarcoma 16pll.2 Adult AD, AR, detiovo
Vance etal., 2009 
KwiatkoWski et al., 2009
ALS7 unknown unknown 20pl3 Adult AD Sapp et al., 2003
ALS8 VAPB VAMP-associated protein B 20ql3.3 Adult AD Nishimura et al., 2004
ALS9 ANG Angiogenin 1 4 q ll2 Adult AD Chen etal., 2010
ALS10 TARDBP TAR-DNA binding protein (TDP-43) lp36.2 Adult ADandAR
Gitcho etal., 2008 
Sreedharan et al., 2008 
Kabashi etal., 2008
ALSU FIG4 Polyphosphoinositidephosphatase 6q21 Adult AD Chow et al., 2009
ALS12 OPTN Optineurin 10pl3 Adult AD and AR Van Es etal., 2009
ALS13 ATXN2 Ataxin 2 12q24! Adult AD Elden et al., 2010
ALS14 VCP valosin-containing protein 9pl3 Adult AD Johnson etal., 2010
ALS15 UBQLN2 Ubiquilin 2 Xpll.21 Adult X-linked Deng et al., 2011
ALS16 SIGMAR1 Sigma non-opioid receptor! 9pl3.3 Juvenile AD Al-Saif etal., 2011
ALS17 CHMP2B
Charged Multivesicular 
Body Protein 2B 3 p l2 ! Adult AD Parkinson etal., 2006
ALS-FTD C90RF72 Chromosome 9 open reading frame 72 9p21.2 Adult AD
DeJesus-Hernandez et al., 2011 
Renton et al., 2011
ND TAF15 TATA box binding protein •associated factor
1 7 q ll.l-
q ll.2 Adult ADandAR Ticozzi et al., 2003
ND DCTN1 Dynactin 2pl3 Adult - Munch et al., 2004
ND DAO D-aminoacid oxidase 12q24 Adult AD Mitchell et al., 2010
ND NEFH Neurofilament heavy polypeptide
22ql2.1-
ql3.1 Adult AD
Figlewics etal., 1994 
Vecchio etal., 1996 
Rookeet al., 1996 
Tomkins et al., 1998 
Al-Chalabi etal., 1999
ND PRPH Peripherin 12ql2 - -
Gro-Louiset al., 2004 
Leung et al., 2004
ND PFN1 Profilin 1 1 7 p l3 ! Adult AD Wu etal., 2012
ND SQSTM1 Sequestosome l /p 6 2 5q35 Adult -, denovo Fecto et al., 2011 Rubino etal., 2012
ALS-FTD-P MAPT Microtubule-associated 
protein tau 17q21 Adult AD
Siddiqueand Hentati, 1995 
Hosier et al., 2000 
Wilhelmsen et al., 2004
Table 1 Established and selected ALS-associated genes as of September 2012.
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; FTD, frontotemporal dementia; ND, 
not determined; P, parkinsonism.
-»  ALS1 -  Cu/Zn superoxide dismutase (SOD1)
In 1993, the first ALS gene was identified as SOD1, coding for the copper/zinc superoxide
dismutase (Rosen 1993). It scavanges the superoxide ion, a free radical that is formed during
mitochondrial respiration, by catalyzing the reaction: 402' + 2H+ -»  H20 2 + 0 2 (McCord 1969).
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S0D1 is a ubiquitously expressed homodimeric protein and it is found mainly in the cytoplasm, 
where it represents ~1% of all cytoplasmic proteins, but it has also been detected in the 
intermembrane space in mitochondria, and in the nucleus. SOD1 has been the most heavily 
researched protein in ALS following linkage of the SOD1 gene to ALS. In different populations, 12- 
23% of patients diagnosed with fALS and 2-7% of sALS patients carry a SOD1 mutation. There are 
now 166 recorded mutations in its 153 evolutionarily conserved amino acids (Figure 1). Most ALS- 
causing SOD1 mutations are missense, with nonsense and deletion mutations being much rarer. 
Eight silent and nine intronic mutations have also been reported, presumed to be non-pathogenic 
(Andersen 2011). All mutations are associated with autosomal dominant fALS, except for D90A 
and D96N, which can cause both dominant and recessive ALS (Andersen 1995; Robberecht 1996; 
Orrell 2000). The most frequent SOD1 mutation is A4V. Penetrance, clinical manifestations, age of 
onset, disease progression and survival vary greatly among specific mutations. Although FTD can 
occur in individuals with SOD1 mutation, this is not a common finding (Wicks 2009). 
Neuropathologically, ALS patients with SOD1 mutation show loss of anterior horn neurons in the 
cord but, while there is immunopositivity for ubiquitin and p62 in the form o f skeins or rounded 
inclusions, there is usually negativity for TDP-43 (Mackenzie 2007; Tan 2007).
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Figure 1 Mutations identified in SOD1 in sporadic and familial ALS cases.
Schematic diagram (modified from Turner 2008) of human SOD1 primary sequence with exons, 
introns, metal binding domains (Cu, Zn), intramolecular disulfide bond (SH). Mutation legend: grey, 
missense; purple, insertion; red, deletion; blue/green, silent; A, inframe deletion; X, truncation. 
SOD1 mutations are updated at the http://alsod.iop.kcl.ac.uk/als website.
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How it is that almost any mutation in the protein sequence can apparently result in subsequent 
MN death through what seems to be a common mechanism is unclear. Initially it was 
hypothesised that mutations would impair the enzymatic activity of the protein, thus resulting in 
increased cellular levels of reactive oxygen species, oxidative stress, and neuronal death (Deng 
1993). However, subsequent studies revealed that some mutants retain full catalytic activity. 
Additional evidence against a loss-of-function hypothesis came from animal models: knock out of 
endogenous SOD1 in mice does not lead to spontaneous MN disease (Reaume 1996), while 
transgenic mice (Gurney 1994) and rats (Nagai 2001) overexpressing human SOD1 carrying the 
mutations found in human ALS patients do. Also, the expression of mutant SOD1 alleles in cell 
culture models induces neuron death (Pasinelli 1998). Both in vivo and in vitro studies strongly 
suggest that reduced catalytic SOD1 activity does not account for the observed pathology. 
Currently, it is believed that mutated SOD1 either loses some protective property, such as the 
ability to reach the nucleus to scavenge DNA-damaging free radicals (Sau 2007) or, more likely, it 
acquires a general toxic gain-of-function, such as propensity to aggregate. Indeed, several studies 
showed that mutant SOD1 is prone to misfolding and forms cytoplasmic aggregates. In turn, 
aggregates may lead to cell death by sequestering other cytoplasmic proteins essential for 
neuronal survival, by clogging the ubiquitin/proteasome system, by depleting chaperones, or by 
disrupting mitochondria, the cytoskeleton and/or axonal transport (reviewed in Pasinelli 2006; 
Boillee 2006). To date, there is no conclusive explanation of how mutations in the SOD1 gene 
cause ALS.
->  ALS2 -  Alsin (ALS2)
Autosomal recessive mutations in the ALS2 gene have been linked to young or infantile onset MN
degeneration with slow progression (Hadano 2001; Yang 2001), resembling ALS or primary lateral
sclerosis or juvenile-onset ascending hereditary spastic paraparesis (Devon 2003; Eymard-Pierre
2002; Lesca 2003). To date, at least 19 different mutations in the 34 exons of the ALS2 gene have
been described. Except for two recently identified missense mutations, all other mutations in the
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ALS2 gene lead to a premature stop codon and likely result in protein instability and loss-of- 
function of the encoded protein alsin (Yamanaka 2003). However, mice lacking alsin surprisingly 
did not recapitulate the symptoms o f MN disease, but showed only subtle deficits in motor 
performance, probably because of potential compensatory mechanisms within the mouse 
genome (Cai 2005; Hadano 2006; Yamanaka 2006).
Alsin is ubiquitously expressed and is abundant in neurons, where it is localized to the cytosolic 
portion of the endosomal membrane. Alsin acts as a guanine nucleotide exchange factor for the 
small GTPase Rab5 in vitro (Otomo 2003; Topp 2004), suggesting a possible involvement in 
vescicular trafficking, cytoskeletal organization and endosomal dynamics. In addition, alsin can 
interact with the small Rho GTPase Racl (Otomo 2003; Topp 2004; Tudor 2005), mediating actin 
dynamics related to neuritic outgrowth. However, the physiological function of alsin is still 
unclear.
->  ALS3
In a large European family in which at least 20 members had autosomal dominant, adult-onset 
ALS, a genome-wide search established linkage to chromosome 18q21 (Hand 2002). This locus 
was associated to ALS3 and it was the first adult-onset reported since ALS1.
-»  ALS4-Senataxin (SETX)
Nine missense mutations have been described in the senataxin gene (SETX) in unrelated families 
with a rare, childhood- or adolescent-onset, slowly progressive form of ALS (Chen 2004). 
Homozygous or compound heterozygous SETX mutations, mostly leading to a premature 
termination o f the protein product, have been also identified in patients with ataxia-ocular 
apraxia-2 (Moreira 2004).
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Senataxin is a ubiquitously expressed DNA/RNA helicase, possibly involved in repairing DNA 
double-strand breaks following oxidative stress (Suraweera 2007). Moreover, it binds RNA 
polymerase II and other proteins involved in mRNA transcription and processing, suggesting that 
it is involved in transcriptional regulation (Suraweera 2009). These observations suggest that 
mutations in SETX may cause neuronal degeneration through dysfunction of the helicase activity 
or other steps in RNA processing.
- >  ALS5 -  Spataxin (SPG11)
Twelve homozygous or compound heterozygous mutations have been identified in the SPG11 
gene in 10 unrelated pedigrees (Orlacchio 2010). ALS5 is an autosomal-recessive, juvenile-onset 
MN disease characterised by distal muscle atrophy and weakness associated with pyramidal signs 
and involvement o f bulbar muscles. The majority of the identified variants are frameshift 
mutations or nonsense substitutions. Homozygous mutations in the same gene have been 
previously been described in patients with autosomal recessive hereditary spastic paraplegia with 
thin corpus callosum (ARHSP-TCC) (Stevanin 2007) and have been recently identified in early- 
onset L-dopa-responsive parkinsonism with pyramidal signs (Paisan-Ruiz 2010). However, none of 
the ALS5 patients displayed features suggestive o f a concomitant ARHSP-TCC.
SPG11 is composed of 40 exons and encodes for the 2443-residue long protein spatacsin. The
protein contains four putative transmembrane domains, suggesting that it may be a receptor or a 
transporter, a leucine zipper and a coiled-coil domain. The physiological role of spatacsin is still 
unknown, although it is reputed to be involved in axonal transport (Salinas 2008) and it is
important for proper development o f the axons of spinal MNs (Martin 2012).
-»  ALS6 -  Fused in sarcoma/Translocated in liposarcoma (FUS/TLS)
Mutations in the FUS/TLS gene have been recently identified as the primary cause of fALS linked
to chromosome 16 (Kwiatkowski 2009; Vance 2009). Mutations in FUS/TLS occur in 4-5% of fALS
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cases (approximately 0,4% of all ALS). The clinical picture in patients with FUS/TLS mutations is 
LMN dominant and, often, upper limb onset, but otherwise they are indistinguishable from sALS. 
Although ALS is the commonest phenotype observed, ALS-FTD or FTD alone also occurs. 
Originally, FUS was found to have a role as a sarcoma gene, with translocation or fusion gene 
rearrangement involved in myxoid liposarcoma and low-grade fibromyxoid sarcoma pathogenesis. 
The FUS/TLS gene encodes a 526 amino acids (aa) protein that belongs to the family of 
multifunctional DNA/RNA binding proteins. It contains an N-terminal Gln-Gly-Ser-Tyr rich domain 
(QGSY region) followed by a glycine-rich domain, an RNA recognition m otif (RRM), an Arg-Gly-Gly 
(RGG) repeat-rich domain, zinc finger domains and highly conserved extreme C-terminus that 
encodes for a non-classical nuclear localisation signal (NLS) that is recognized by transportin-1 
(Figure 2B).
FUS is almost ubiquitously expressed, it shows nuclear and cytoplasmic localisation (Andersson 
2008) and continuously shuttles between the two compartments (Zinszner 1997). It is implicated 
in numerous cellular processes including: cell proliferation, DNA repair, transcription regulation, 
and RNA and microRNA (miRNA) processing, although its precise function is poorly characterised. 
FUS can also be involved in neuronal plasticity and in maintenance of dendritic activity by 
transporting messenger RNA (mRNA) to dendritic spines for local translation (Fujii 2005a and 
2005b).
The majority of ALS linked missense mutations are clustered in the extreme C-terminal portion of 
the protein, with several o f them leading to disruption o f NLS, which impairs trasportin-1- 
mediated nuclear import (Dormann 2010), and disrupt the interaction with other FET proteins 
(EWS and TAF15). Disruption of nuclear import by ALS-causing mutations may explain why FUS is 
redistributed to the cytoplasm and incorporated into stress granules. Indeed, FUS seems to 
behave similarly to TDP-43 in that it is nuclear in the normal state but found to be cytosolic in ALS 
cases, although FUS pathology is rarer than TDP-43 pathology in post-mortem examination 
(Kwiatkowski 2009; Lagier-Tourenne 2009; Neumann 2009; Vance 2009).
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Figure 2 Mutations identified in TDP-43 and FUS/TLS in ALS cases and in rare FTLD patients.
(A) Forty-four mutations have been identified in TDP-43 in sALS and fALS patients and in rare FTLD 
patients, with most lying in the C-terminal glycine-rich region. The putative prion domain comprises 
amino acids from 277 to 414. (B) Forty-six mutations have been identified in FUS/TLS in sALS and 
fALS cases and in rare FTLD patients. Most mutations are clustered in the last 17 aa and in the 
glycine-rich region and the putative prion domain comprises aa 1-239. * TDP-43 variant (A90V) 
reported in a FTLD/ALS patient. Adapted from Da Cruz 2011.
FUS immunohistochemistry shows normal staining of FUS in the nuclei o f many neurons and glial 
cells, but aggregates o f FUS in the cytoplasm of LMNs, as well as in dystrophic neurites 
(Kwiatkowski 2009; Vance 2009). However, some of the nuclear staining is preserved in neurons 
w ith FUS inclusions, indicating tha t the protein is not fully sequestered in pathological conditions
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(Rademakers 2010; Aizawa 2000). FUS positive cytoplasmic and nuclear inclusions have also been 
identified in several subtypes of FTLD cases, neuronal intermediate filament inclusion disease, 
basophilic inclusion body disease and atypical FTLD (Neumann 2009), and are collectively named 
FTLD-FUS, althought, in contrast to ALS-FUS, they are not associated with FUS gene mutations 
(Mackenzie 2010). Ubiquitin and p62 positive cytoplasmic inclusions in the anterior horn of the 
SpC are rare (Mackenzie 2010), contrary to FTLD-FUS inclusions (Lee 2006), and TDP-43 positive 
inclusions are notably absent (Kwiatkowski 2009; Vance 2009). Interestingly, EWS, TAF15 and 
transportin-1 have been reported to co-localise with FUS within cytoplasmic inclusions in FUS- 
FTLD but not in ALS-FUS, thus distinguishing the two pathologies and implicating different disease 
mechanisms (Neumann 2011; Brelstaff 2011; Davidson 2012; Troakes 2012).
ALS7
In the same genetic analysis where ALS6 locus was identified, a novel ALS locus was discovered in 
another family on chromosome 20pl3 and termed ALS7 (Sapp 2003).
-»  ALS8-VAMP-associated protein B (VAPB)
Mutations in the VAMP/synaptobrevin-associated membrane protein B (VAPB) gene was 
correlated with late-onset, autosomal dominant, slowly progressive MN degeneration with ALS 
and ALS-FTD. Missense mutations were observed in several large Brasilian (Nishimura 2004 and 
2005; Landers 2008) and German pedigrees (Funke 2010), also in association with C9orf72 
mutations (van Blitterswijk 2012).
The VAPB gene encodes a ubiquitously expressed homodimer, which belongs to a family of 
intracellular vesicle-associated/membrane-bound proteins. It associates with microtubules and is 
presumed to regulate vesicle trafficking (Nishimura 2004; Kanekura 2006). In particular, VAPB has 
been shown to act during transport through the endoplasmic reticulum (ER), Golgi apparatus and 
secretion. The ALS-mutant P56S-VAPB dramatically disrupts the sub-cellular distribution of VAPB
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and induces the formation of intracellular protein aggregates (Nishimura 2004). In addition, P56S- 
VAPB contributes to nuclear envelope defects (Tran 2012) and perturbs anterograde 
mitochondrial axonal transport by disrupting calcium homeostasis and affecting the 
M irol/kinesin-1 interaction with tubulin (Morotz 2012). Moreover, VAPB is physiologically 
involved in the unfolded protein response (UPR), suggesting that ALS mutations may contribute to 
the MN degeneration also by impairment of the proteasome activity (Moumen 2011).
ALS9 - Angiogenin (ANG)
Although heterozygous missense mutations in the coding region of ANG have been reported in 
both fALS and sALS patients, in association with functional loss of protein function, later studies 
also demonstrated ANG mutations in control subjects (Greenway 2004 and 2006; van Es 2009 and 
2011; Fernandez-Santiago 2009; Gellera 2008; Conforti 2008). Furthermore, ANG variants were 
detected in ALS families with incomplete penetrance or in association with mutations in TARDBP 
or FUS (van Blitterswijk 2012). Patients showed typical ALS, and one presented ALS-parkinsonism 
and later developed FTD (van Es 2009). In addition, a large international collaborative study 
showed that ANG mutations are a risk factor for ALS, as well as for PD (van Es 2011). These 
features indicate an oligogenic disease model of ALS and suggest that multiple genetic factors 
influence phenotypic characteristics (van Blitterswijk 2012)
Angiogenin is a 14 kDa ribonuclease and its angiogenic activity is related to its ability in regulating 
tRNA transcription, ribosome biogenesis, protein translation and cell proliferation (Moroianu 
1994; Smith 2006). The majority o f the mutations described are predicted to disrupt angiogenin 
secretion, ribonucleolytic activity and/or nuclear translocation, ultimately resulting in 
angiogenesis impairment (Wu 2007; Sebastia 2009). Thus, a deficiency in angiogenin function may 
result in insufficient transcription in MNs which require robust ribosome biogenesis due to the 
demand o f long-distance axonal transport. ANG mutations have also been shown to affect neurite 
extension/pathfinding and survival of MNs (Subramanian 2007 and 2008).
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ALS10- TDP-43 (TARDBP)
The discovery that neuronal cytoplasmic UBIs in patients with ALS or FTD contain TDP-43 
(Neumann 2006), prompted the analysis o f TARDBP, the gene that encodes this protein, in ALS 
families. Since 2008 (Gitcho 2008; Sreedharan 2008; Kabashi 2008), 44 heterozygous mutations 
have been described in individuals with sALS and fALS, nearly all affecting the C-terminus (Figure 
2A), and all but one are missense (Chio 2011), the exception being Tyr374X (Daoud 2009). 
TARDBP mutations account for 4-6% of fALS cases, and 0.5-2% cases of diagnosed sALS (Andersen 
2011). Although ALS is the commonest phenotype, FTD, either in other individuals o f the same 
family or in those with ALS, has also been reported, usually manifesting as behavioral changes, 
but also with semantic dementia. Although disease progression is more rapid than usual, the 
phenotype is indistinguishable from sALS. Also neuropathological features are similar to those of 
sALS, with neuronal loss, gliosis and Bunina bodies in the anterior horn o f the SpC, and pallor of 
the corticospinal tracts. In unaffected neurons TDP-43 localises in the cell nucleus, while it is 
absent from the nuclei o f neurons with UBIs, suggesting a nucleo-cytoplasmic redistribution of the 
protein. Immunohistochemically, there are TDP-43 positive cytoplasmic inclusions in UMNs and 
LMNs, but also in other regions of the CNS including frontal and temporal cortex (Van Deerlin 
2008; Yokoseki 2008). These observations lead to intense speculations on the pathogenic role of 
TDP-43 in ALS: toxicity might be caused by aggregating TDP-43 being sequestered away from its 
normal function or, conversely, TDP-43 aggregates might have a toxic gain-of-function 
independent of the protein's physiological cellular activities (Lagier-Tourenne 2010; Strong 2010; 
Ticozzi 2010; van Blitterswijk 2010).
TDP-43 is a 414 aa multifunctional DNA/RNA binding protein belonging to the heterogeneous 
nuclear ribonucleoprotein (hnRNP) family. The function of TDP-43 in the nervous system is 
uncertain. TDP-43 was originally identified as having roles in human immmunodeficiency virus 
(HIV) infection and cystic fibrosis (Ou 1995; Buratti 2001). TDP-43 and FUS have striking structural 
and functional similarities, implicating alterations in RNA processing as central in ALS (see 
Pathogenic hypothesis section).
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->  ALS11 -  Polyphosphoinositide phosphatase (FIG4)
Mutations in FIG4 have been recently identified in both sALS and fALS patients, suggesting that 
this gene is another cause of this disease (Chow 2009). Mutations in FIG4 are also responsible for 
a variant of Charcot Marie Tooth disease, a peripheral-nerve disorder (Chow 2007). FIG4 is a 
phosphoinositide 5-phosphatase that regulates the cellular levels of phosphatidylinositol 3,5- 
bisphosphate, a lipid involved in signalling processes and retrograde trafficking o f endosomal 
vescicles to the trans-Golgi network (Rutherford 2006).
->  ALS12 -  Optineurin (OPTN)
Recently, mutations in OPTN, a gene already known to be mutated in primary open angle 
glaucoma and ataxia (POAG), were found to cause ALS (Maruyama 2010). Most of the individuals 
with OPTN mutations showed a relatively slow progression and long disease duration, although 
the clinical phenotypes were not homogeneous. The mechanisms through which dominant and 
recessive mutations cause ALS are likely to differ, as are the mechanisms through which different 
mutations result in ALS or POAG phenotypes. OPTN mutations abolished the inhibition of 
activation of nuclear factor kappa B (Maruyama 2010). Effects on localisation of the optineurin 
protein and nuclear factor kB signaling probably account for differences in phenotypic expression. 
Intracytoplasmic neuronal inclusions, positive for optineurin were observed in SpC tissue of 
patients with OPTN mutation, as were skein-like inclusions (Maruyama 2010). TDP-43 or SOD1- 
positive inclusions of sALS or SODl-fALS patients were also noticeably immunolabeled by anti- 
optineurin antibodies. However, further studies have produced differing results regarding the 
presence of optineurin-positive inclusions in ALS and other neurodegenerative conditions 
(Hortobagyi 2011; Osawa 2011).
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->  ALS13 -  Ataxin 2 (ATXN2)
CAG-trinucleotide repeat expansion in the ATXN2 gene to 34 or more repeats is associated to 
spinocerebellar ataxia type 2 (SCA2). Very recently, an intermediate length expansion (27-33 
repeats) on one allele in ATXN2 gene has been linked to sALS and fALS cases, with fewer than 27 
repeats having no clinical phenotype (Elden 2010; Lee 2011; Daoud 2011; Van Damme 2011; Ross 
2011; Gispert 2012; Chen 2011; Van Langenhove 2011). The frequency of this genetic alteration is 
about 4.7% in familial cases. ALS13 shows an earlier onset and mislocalisation of TDP-43 from 
nucleus to cytoplasm (Elden 2010). This association raises the possibility that ALS and ataxia may 
also form a spectrum of disease in the same way as ALS and FTD (Al-Chalabi 2012), and this is 
further supported by the finding of ataxia in some patients with SOD1 or SETX mutations 
(Andersen 1996; Hirano 2011; Yasser 2010).
-»  ALS14-Valosin-containing protein (VCP)
Mutations in the VCP gene, already linked to the genetic disease inclusion body myopathy 
associated with Paget's disease of bone and FTD (IBMPFD) (Watts 2004), were found also to be 
associated with features of ALS in some patients (Kimonis 2008). Furthermore, VCP mutations 
have been linked to 1-2% of isolated familial cases, which are associated with ubiquitin-positive 
TDP-43 deposition (Johnson 2010). Affected individuals presented with ALS disease in adulthood 
with a classic ALS phenotype, and none had evidence of Paget disease. In another family, two 
patients had ALS-FTD, and a third had Paget disease followed by ALS, suggesting an overlap with 
IBMPFD. Very recently, mutations in VCP have been found also in isolated sALS patients (Dejesus- 
Hernandez 2011; Abramzon 2012) and in individuals diagnosed with PD (Chan 2012; Spina 2012) 
or AD (Kaleem 2007; Mehta 2012). The findings indicate an expanded and variable phenotypic 
spectrum for VCP mutations.
VCP is an ubiquitous and highly abundant protein that accounts for more than 1% of protein in 
the cell cytosol and is known to have various chaperone-like activities. It is essential in cells where
it is involved in a wide variety of functions: nuclear envelope reconstruction, post-mitotic Golgi 
reassembly, ER-associated degradation (ERAD) pathway during the "quality control process" and 
apoptosis (Halawani 2006). It is an ATPase characterised by the presence of the N-terminal 
domain involved in ubiquitin binding (Ogura 2001; Dai 2001). Indeed, VCP is essential for the 
turnover o f aggregation-prone proteins associated with neurodegenerative diseases, in a fine- 
tuned balance with HDAC6. In particular, while VCP promotes proteasomal degradation of 
aggregating proteins and ubiquitin turnover, HDAC6 favours the accumulation of ubiquitinated 
protein aggregates and inclusion body formation (Boyault 2006). Interestingly, histopathological 
studies revealed positive staining for VCP in neuronal nuclear inclusions in Huntington's disease 
(HD), and in intraneuronal UBIs in ALS with dementia, ballooned neurons in Creutzfeldt-Jakob 
disease, dystrophic neuritis of senile plaques in AD, and Lewy bodies in PD (Hirabayashi 2001; 
Mizuno 2003). In addition VCP was found aggregated and nitrated in the SpC of symptomatic 
G93A-SOD1 mice (Basso 2009). Furthermore, VCP physically interacts with the E3-ubiquitin ligase 
Dorfin, functionally regulating recognition and ubiquitylation of ALS-mutant SOD1 to enhance its 
degradation (Niwa 2002), and the two proteins are colocalised in the ubiquitylated inclusions in 
the affected neurons of ALS and PD (Ishigaki 2004). Thus, mutations in VCP together with its 
localisation in UBIs in various neurodegenerative disordes, provide evidence directly implicating 
defects in the ubiquitination/protein degradation pathway in MN degeneration.
->  ALS15 -  Ubiquilin 2 (UBQLN2)
A five-generation family showing X-linked dominant transmission of ALS has shown linkage and 
cosegregation o f a mutation in the UBQLN2 gene (Deng 2011). In the same study, five different 
proline substitutions in the PXX repeat domain of UBQLN2 were identified as causative of ALS in 
five unrelated families. The age of onset ranged from 16 to 71 years, with males having a 
significantly younger age of onset than female, presumably because they are hemizygous for the 
mutation, while females are heterozygous. Some patients manifested both ALS and FTD. 
Pathologic analysis o f SpC autopsy samples revealed axonal loss in the corticospinal tract, loss of
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anterior horn cells, and astrocytosis. Ubiquilin-2-positive skein-like inclusions from ALS15 patients 
were immunoreactive also for ubiquitin, p62, TDP-43, FUS, and optineurin, but not SOD1. The 
brain o f patients with UBQLN2 mutations with ALS-FTD, showed ubiquilin-2 inclusions in the 
hippocampus, small inclusions in the neuropil, and large inclusion in some pyramidal neurons. 
This type of hippocampal pathology had not previously been observed in any other 
neurodegenerative disorder, indicating that ubiquilin-2 is widely involved in ALS-related 
dementia. Prominent ubiquilin-2 pathology was observed also in ALS-FTD, sALS and fALS cases 
w ithout UBQLN2, suggesting a common final pathway for all ALS (Andersen 2011).
Ubiquilin-2 is one of the four members o f the ubiquitin-like protein family. Ubiquilins are 
characterised by the presence of an N-terminal ubiquitin-like domain, that binds to subunits in the 
proteasome, and a C-terminal ubiquitin-associated domain, that binds to the polyubiquitin chains 
that are typically conjugated onto proteins marked for degradation by the proteasome. Ubiquilin- 
2 has a unique repeat region containing 12 PXX tandem repeats. Mutations in ubiquilin-2 may 
change the ubiquitin modification on substrates, influence recognition by p62 and reduce the 
clearance of ubiquitinated misfolded proteins (Chen 2012), suggesting that defects in the protein 
degradation pathway are a shared pathogenic mechanism in ALS.
-»  ALS16 -  Sigma non-opioid receptor 1 (SIGMAR1)
The homozygous E102Q substitution in a highly conserved residue of the SIGMAR1 gene was 
identified in affected members of a consanguineous Saudi Arabian family with juvenile ALS (Al-Saif
2011). Patients had a very early age of onset (1-2 years) of lower limb spasticity and weakness, 
with slow progression, w ithout bulbar or respiratory or cognition involvement.
In addition, a heterozygous transversion (672*51G-T) in the 3-prime untranslated region (3'-UTR) 
of the SIGMAR1 gene was identified in affected members of an Australian family with FTD and/or 
MND (Luty 2010). This mutation alters SIGMAR1 transcript stability and increases protein 
expression, resulting in pathogenic alterations o f TDP-43 and FUS.
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SIGMAR1 encodes a ER chaperone that binds a wide variety of ligands, including neurosteroids, 
psychostimulants, and dextrobenzomorphans. It is ubiquitously expressed and enriched in MNs. 
In vitro, the mutant protein forms detergent-resistant complexes and decreases the viability of 
MNs.
-»  ALS17 -  Charged Multivescicular Body protein 2B (CHMP2B)
Heterozygous mutations in the CHMP2B gene were identified in 1% of patients with ALS 
(Parkinson 2006; Cox 2010). A different heterozygous mutation was identified in an unrelated 
man with FTD-ALS. All had symptoms of predominant LMN degeneration w ithout UMN 
involvement. Neuropathologic examination showed no evidence of corticospinal involvement on 
conventional stains, consistent with the lack of UMN clinical signs. Severe loss of MNs at all levels 
o f the SpC, and surviving neurons had UB-/p62-/TDP-43-positive inclusion bodies. Skein-like 
inclusion bodies and Bunina bodies were notably absent in these patients. Previously, CHMPB2 
gene association (Brown 1995; Gydesen 2002) and heterozygous mutations were reported in 
unrelated patients with FTD (Skibinski 2005; Momeni 2006; Van der Zee 2008).
CHMP2B is a member o f ESCRT-III (endosomal sorting complex required for transport III), which is 
required for formation of the multivesicular body, a late endosomal structure involved in 
lysosome-mediated degradation of endocitosed proteins and in autophagy. It is widely expressed 
in all neuronal populations, especially in the hippocampus, frontal and temporal lobes, and 
cerebellum and not in astrocytes or oligodendrocytes (Skibinski 2005). Mutations o f CHMP2B may 
contribute to MN injury through dysfunction o f the autophagic clearance of cellular proteins, and 
the formation of UBIs (Cox 2010).
ALS-FTD - C90RF72
The existence of a common genetic aetiology between ALS and FTD was proposed with the finding 
of ALS and FTD in multiple generations in a large Swedish family (Gunnarson 1991). Every affected
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patient had a parent with either ALS or FTD, and no individual had both conditions, suggesting 
that a common genetic factor could cause either conditions. Linkage analysis in this and in similar 
pedigrees, pointed to a major locus on 9p21.2 for fALS, fALS-FTD, fALS with parkinsonism, and 
also sALS in some populations (Morita 2006; Vance 2006; Pearson 2011; Laaksovirta 2010; Boxer 
2011; Rollinson 2011), suggesting a possible single founder for this form of disease (Mok 2011). 
Recently, the causative gene defect has been reported as a massive hexanucleotide-repeat 
expansion, (GGGGCC)n, in the intron between noncoding exons la  and lb  of the uncharacterised 
gene chromosome 9 open reading frame 72 (C90RF72) (Dejesus-Hernandez 2011; Renton 2011; 
Gijselinck 2012). Normal individuals have, at most, 23 repeats, whereas individuals with ALS or 
FTD can have up to 1600 repeats. This repeat expansion was present in up to 62% of the cases 
with both fALS and FTD, 46% of the cases with fALS, and 21% of the cases with sALS. Therefore, it 
is currently the most important genetic risk factor for ALS, and it is not a common cause of AD or 
PD (Zhengrui 2012). Patients with the mutation presented with typical motor features of ALS, 
although subjects with the C90RF72 mutation had more frequent bulbar onset (Stewart 2012). 
Dementia was significantly more common in ALS patients and families w ith the C90RF72 mutation 
and was usually early-onset FTD. There was striking clinical heterogeneity among the members of 
individual families with the mutation. The associated neuropathology was a combination of ALS 
with TDP-43-positive inclusions and FTLD-TDP. In addition, a consistent and specific feature of 
cases with the C90RF72 mutation was the presence of UB-/p62-positive, TDP-43-negative 
inclusions in a variety of neuroanatomical regions, such as the cerebellar cortex. Speculatively, the 
dynamics o f such a hexanucleotide-repeat expansion may explain the variability in phenotypes 
and disease penetrance in these families, and the association to the 9p21 locus o f many cases 
with apparently sporadic disease.
In addition, C90RF72 repeat expansions were found in combination with TARDBP, or SOD1, or 
FUS mutations in affected individuals within fALS families (van Blitterswijk 2012). The presence of 
a second mutation supports the hypothesis of an oligogenic aetiology o f ALS, implying that 
additional genetic factors contribute to ALS pathogenesis in some C90RF72 families. Moreover,
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this also suggests that genetic modifiers exist that determine why some individuals with C90RF72 
repeat expansion develop ALS, whereas others develop FTD or a combination of ALS and FTD. 
Furthermore, C90RF72 large repeat expansions were present in <1% of families apparently 
affected with AD (Majounie 2012).
In normal individuals, at least three alternatively spliced C90RF72 transcripts (variants 1-3) are 
expressed in most tissues, including brain, with predominantly a cytoplasmic and synaptic 
localisation (Dejesus-Hernandez 2011). The mutation results in the loss of one alternatively 
spliced C90RF72 transcript, leading to a significant overall reduction in C90RF72 transcripts 
encoding C90RF72 isoform a, thus suggesting a possible loss-of-function mechanism. In addition, 
the formation of toxic nuclear RNA foci in post-mortem cerebral cortex and SpC tissue of C90RF72 
expanded repeat carriers, suggested also a possible gain-of-function mechanism. Indeed, RNA 
foci, a common feature o f non-coding repeat expansion disorders, are composed of the repeated 
nucleotides that sequester RNA-binding proteins, leading to dysregulation of alternative mRNA 
splicing (Todd 2010; Miller 2000; Sofola 2007; Timchenko 1996; White 2010). Thus, these 
observations add evidence to RNA misprocessing as a potential pathogenic mechanism in both 
ALS and FTD.
->  Other ALS-associated genes
Susceptibility to ALS has been associated with mutations in other genes, including:
- TAF15 and EWSR1
The TATA-binding protein-associated factor 15 (TAF15) is a member of the FET protein family, that
includes also FUS and EWSR1. In 2011, six changes in TAF15 gene were identified in a cohort of
263 familial cases (Ticozzi 2011). Immunohistochemical analysis of FET proteins, showed
differentiation in FUS-pathology between ALS and FTD. In particular, while ALS-FUS showed only
accumulation o f FUS, inclusions in FTLD-FUS revealed co-accumulation of all members of the FET
protein family, suggesting a more complex disturbance of transportin-mediated nuclear import of
48
proteins in FTLD-FUS compared to ALS-FUS (Neumann 2011). Recently, two studies (Couthouis 
2011 and 2012) have confirmed additional TAF15 missense polymorphisms in sALS patients and 
found three in the Ewing sarcoma breakpoint region 1 (EWSR1) gene, suggesting that all three 
genes of the FET family are involved in fALS, sALS or FTD, and promote discrete proteinopathies 
and phenotypes.
Dynactin (DCTN1)
The DCTN1 gene encodes for the p l50 subunit of the dynein/dynactin transport complex. A 
dominantly transmitted missense mutation (G59S) was identified (Puls 2003) that caused an adult 
onset, slowly progressive atypical MN disorder with vocal cord paresis, and weakness of facial and 
hand muscles. Subsequently, three additional heterozygous missense mutations have been found 
in sporadic and familial patients with classic ALS (Munch 2004). Interestingly, heterozygous 
mutations in DCTN1 have also been identified in Perry syndrome, a rapidly progressive, autosomal 
dominant atypical parkinsonism characterised by weight loss, depression, nocturnal 
hypoventilation, and the presence in the extrapyramidal system of TDP-43 immunoreactive 
inclusions indistinguishable from those found in ALS (Farrer 2009).
Dynactin is a component of the dynein complex, the molecular motor that plays critical role in 
intracellular and axonal transport. This complex is required for fast retrograde transport of 
vesicles, organelles, RNAs and proteins along microtubules. The G59S mutation appears to affect 
the binding o f the dynactin-dynein motor complex to microtubules (Puls 2003). Impaired 
dynein/dynactin function can explain several pathological features observed in ALS patients and is 
shown to induce MN disease in mice overexpressing dynamitin, characterised by defects in 
vesicular transport in cell bodies o f MNs, axonal swelling and axo-terminal degeneration and 
autophagic cell death (LaMonte 2002).
49
D-amino acid oxidase (DAO)
A unique mutation (R199W) in the D-amino acid oxidase (DAO) gene was associated with classical 
adult onset fALS in a three generational kindred (Mitchell 2010). DAO is an enzyme controlling the 
levels of D-serine, a coagonist at the glycine site of the NMDA glutamate receptor. Increased 
levels o f D-serine and its producing enzyme, serine racemase, have been found in the SpC of ALS 
patients and G93A-SOD1 mice (Sasabe 2007). It has been proposed that DAO mutations, in ALS 
patients, participate to the buildup of D-serine in the CNS, thus contributing to excitotoxicity.
Neurofilament heavy polypeptide (NEFH)
Six deletions within the C-terminal lysine-serine-proline (KSP) phosphorylation domain of the 
NEFH gene, encoding for the neurofilament heavy subunit, have been found in several sALS 
patients and in a pedigree with autosomal dominant fALS (Figlewicz 1994; Tomkins 1998; Al- 
Chalabi 1999). However, another study on 117 unrelated fALS cases did not identify any mutation 
in the KSP region of NEFH (Rooke 1996). The possible explanations are that such genetic variation 
only causes low penetrance disease, so fALS would rarely result, or that associations in apparently 
sALS are false positives. Nevertheless, neurofilaments are interesting potential candidate genes in 
ALS pathogenesis, not only because of their restriction to neurons, but also because 
neurofilamentous inclusions are found in degenerating LMNs in ALS.
Peripherin (PRPH)
A homozygous missense mutation and a heterozygous frameshift deletion in the PRPH gene, 
encoding for peripherin, have been identified in sALS patients (Gros-Louis 2004; Leung 2004). 
Immunohistochemical analysis o f their SpC showed the presence of aggregates containing 
peripherin within surviving MNs.
Peripherin is a neuronal intermediate filament protein primarily expressed in autonomic nerves 
and in peripheral sensory neurons. It is involved in axonal outgrowth, and commonly detected
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within UBIs in MNs of ALS patients (He 2004). Mice overexpressing wild-type peripherin develop 
over time a selective degeneration of spinal ventral roots and motor axons, as well as 
intermediate filament inclusions within MNs (Beaulieu 1999).
Profilin 1 (PFN1)
Different mutations within the PFN1 gene have been recently reported to cause ALS in two large 
families (Wu 2012). Further analysis identified that mutations in the PFN1 gene can account for 1 - 
2% of fALS. Cells expressing PFN1 mutants contain UBIs that in many cases contain TDP-43.
PFN1 is crucial for the conversion of monomeric (G)-actin to filamentous (F)-actin. PFN1 mutants 
display decreased bound actin levels and can inhibit axon outgrowth. Furthermore, primary MNs 
expressing mutant PFN1 display smaller growth cones with a reduced F/G-actin ratio. These 
observations further document that cytoskeletal defects have a major role in MN diseases and 
disruption of cytoskeletal pathway contribute importantly to ALS pathogenesis.
p62/sequestosome 1 (SQSTM1)
Several mutations in the SQSTM1 gene, which encodes the p62 protein, were described in 
independent cohorts o f patients with either FTLD, fALS or sALS, with an overall frequency around 
3% (Fecto 2011; Rubino 2012). Previous histopathologic studies have shown that p62 is present in 
protein aggregates in neurodegenerative disorders such as AD, PD, HD and Pick disease, 
multisystem atrophy and ALS (Nakaso 2004; Babu 2005; Kuusisto 2001; Zatloukal 2002). In 
particular, p62 colocalises with UBIs in ALS patients with CHMP2B or C9orf72 mutations or other 
forms o f ALS, and in the G93A-SOD1 mouse model of fALS, suggesting a common pathogenic 
mechanism (Nakano 2004; Parkinson 2006; Mizuno 2006; Gal 2007; Al-Sarraj 2011). Furthermore, 
p62 colocalizes with TDP-43-/UBQLN2-positive cytoplasmic UBIs in patients with FTLD-MND (Hiji 
2008), and with FUS-/TDP-43-positive UBIs in patients with sALS, non-SODl fALS, and ALS with 
dementia (Deng 2010).
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p62 is a multifunctional protein with an important dual role in protein degradation via the 
proteasome (Seibenhener 2004), and as a link between protein aggregation and autophagy 
(Bj0rk0y 2006) via its interaction with LC3/Atg8 (Pankiv 2007). SQSTM1 mutations may confer a 
toxic gain-of-function through novel protein interactions and deregulation of cell signaling 
pathways or may also lead to protein misfolding and aggregation. Indeed autophagy is a critical 
pathway for degrading misfolded and/or damaged proteins, including mutant SOD1, that can be 
recognized by p62 in a ubiquitin-independent fashion and targeted for autophagy (Gal 2009), as 
well as TDP-43. Indeed, overexpression of p62 reduces TDP-43 aggregation in an autophagy- and 
proteasome-dependent manner (Brady 2011). Furthermore, substrate recognition by p62 is not 
limited to misfolded protein aggregates, but also includes organelles, such as mitochondria (Kim 
2008). These observations provide evidence of autophagy dysregulation as a possible pathogenic 
process in ALS.
Microtubule-associated protein tau (MAPT)
Tau is a member of the microtubule-associated protein family, which binds to tubulin and has the 
principal function o f stabilizing microtubules and promoting their assembly. In addition, tau is 
likely to regulate motor protein-mediated transport of vesicles and organelles along the 
microtubules by modulating their stability (Sato-Harada 1996; Ebneth 1998). In FTD with 
parkinsonism, mutation of the tau gene affects the alternative splicing of exon 10, resulting in an 
excess o f four repeat tau isoforms; this may cause a reduced binding of tau to microtubules in 
axons. No case of pure ALS has been associated with tau mutations (Siddique 1995; Hosier 2000; 
Wilhelmsen 2004; Ogaki 2012).
Reports on novel ALS related mutations constantly extend the list of genes that might be 
implicated in the disease although most o f them are still awaiting for the conclusive studies that 
prove the associations emerged from genetic screenings. Testing for mutations in the established 
monogenic ALS genes has now become part of the clinical investigation of ALS, although only a
small group of patients carry such a mutation. The revised diagnostic ALS criteria now couple the 
finding o f progressive LMN lesions with a pathogenic mutation as sufficient grounds to establish a 
diagnosis o f ALS, thus expediting the diagnostic process. As a general rule, only patients with a 
diagnosis o f fALS are tested, but as more is learnt about the genetics o f sALS this may change. At 
present, DNA testing is recommended only for mutations in SOD1, TARDBP and FUS.
1.4.2 Genetic susceptibility 
In addition to the genes now claimed as being causative in ALS, several candidate genes have 
been proposed to increase the risk of ALS based on hypotheses of ALS causation, genome-wide 
association (GWA) or exome capture sequencing studies (Table 2). Mutations in these genes may 
occasionally give rise to an ALS phenotype or a mixed phenotype. Although the results are still 
controversial and preliminary, studying these genes may give further insight into the possible 
pathogenetic mechanisms involved in ALS.
ELP3 Elongation Protein 3 Microsatellite Simpson 2009
UNC13A Muncl3-1 SNP Van Es 2009 Shatunov 2010
DPP6 Dipeptidyl-peptidase 6 SNP Van Es 2008 Cronin 2008
VEGF Vascular endothelial growth factor SNP, haplotype Lambrechts 2003
SMN Survival motor neuron Copy number variation Corcia 2002 Veldink2005
PON1 Paraoxonase SNP Slowik 2006
HFE Hemochromatosis SNP Wang 2004 Yen 2004
KIFAP3 Kinesin-Associated Protein 3 SNP Landers 2009
APOE Apolipoprotein E Haplotype Li 2004 Zetterberg 2008
APEX1 Apurinic endonuclease SNP Hayward 1999
Table 2 Selected genes putatively associated with ALS as of September 2012.
Abbreviations: SNP, single-nucleotide polymorphism.
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Elongation Protein 3 (ELP3) codes for an RNA processing protein. GWAS associated ELP3 
gene with ALS in populations from the UK, Belgium and the USA (Simpson 2009). Mutations 
of the same gene were identified as the cause of neurodegeneration in a fly model.
UNC13A is a diacylglycerol and phorbol ester receptor that regulates the release of 
neurotransmitters such as glutamate at neuromuscular synapses. Rodent UNC13A is a 
presynaptic protein with an essential role in synaptic vesicle priming (Rossner 2004). A GWAS 
revealed significant association for the SNP rsl2608932 located at 19pl3.3 that maps to a 
haplotype block within the boundaries of UNC13A, with ALS (Van Es 2009). Meta-analysis of 
the GWAS data with existing studies on the ALSGene website confirms that this is an 
extremely strong association (Lill 2011). Furthermore, in cohorts of sALS patients with Italian, 
Dutch, Belgian, or Swedish descent, UNC13A was confirmed as a modifier of prognosis, thus 
providing a new potential therapeutic target aimed at slowing disease progression (Chio 
2012; Diekstra 2012).
Dipeptidyl-peptidase 6 (DPP6), a component of type A neuronal transmembrane potassium 
channels, was found associated with ALS in two GWAS of sALS datasets from Ireland, the US 
and The Netherlands and different populations of European ancestry (van Es 2008; Cronin 
2006) but was not replicated in subsequent studies on Italian, Polish, French, Canadian, 
Chinese patients (Chio 2009; Fogh 2011; Daoud 2010; Li 2009).
Vascular endothelial growth factor (VEGF) has been identified as a candidate gene on the 
basis o f a transgenic mouse model that showed progressive MN degeneration as a 
consequence of deletion of the hypoxia response element in the promoter o f VEGF 
(Oosthuyse 2001). A number of studies initially associated specific haplotypes of the VEGF 
promoter with increased risk of developing ALS (Lambrechts 2003), however recent reports 
failed to confirm any association between polymorphisms in the VEGF promoter and sALS
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thus ruling out a causative role in the pathology (Lambrechts 2009; Gros-Louis 2003; Chen
2006).
Survival m otor neuron 1 and 2 (SMN1, SMN2) are neuron-specific proteins involved in RNA 
processing. Deletions or mutations of SMN1 cause child-onset spinal muscular atrophy, 
whereas variations in SMN2 copy number affect disease severity. A study conducted on 600 
sALS cases found that altered copy number o f SMN1 occurred more frequently in cases than 
in controls. It has been suggested that disruptions to the genomic organization of the SMN 
region may result in lower total SMN protein levels, thus increasing susceptibility of ALS 
(Corcia 2002 and 2006; Veldink 2001 and 2005).
Paraoxonase (PON) enzymes (PON1, PON2 and PON3) are a major detoxifying system for 
organophosphorous compounds and are also involved in protecting cells against oxidative 
damage. Several studies have suggested an association between common haplotypes in the 
PON cluster and sALS susceptibility (Saeed 2006; Slowik 2006; Cronin 2007; Morahan 2007; 
Landers 2008; Valdmanis 2008), although published GWAS and a metanalysis o f the literature 
failed to replicate these results (Wills 2009; Ricci 2011; Chen 2012; van Blitterswijk 2012). A 
recent study, identified eight mutations in the PON cluster in 12 patients, o f which nine were 
fALS and three sALS. All were heterozygous missense or splice site mutations, with the 
exception of a single homozygous mutation in PON2, identified in an autosomal recessive 
pedigree (Ticozzi 2010). Since, however, the segregation of the mutations with the disease 
could not be proven, nor functional data are available, further studies will be needed to 
validate the role o f PON mutations in ALS pathogenesis.
Hemochromatosis (HFE) is involved in iron metabolism and was selected as a candidate gene 
for sequencing because iron promotes oxidative stress, and abnormally high iron levels have 
been found in ALS SpC. There have been several independent replications of association in
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populations from the UK, Ireland, Italy, Netherlands, USA and China (Goodall 2005; Sutedja 
2007; Wang 2004; Yen 2004), but a recent study could not replicate these findings (Praline
2012).
Kinesin-Associated Protein 3 (KIFAP3) is an ubiquitously expressed protein that associates 
with kinesin to mediate anterograde transport of vesicles along microtubules. A GWAS 
conducted on sALS cases from the U.S. and Europe revealed a significant association between 
two variants that lead to reduced expression of KIFAP3 gene, and a 14 month survival 
advantage. This suggests that decreased expression of KIFAP3 is associated with an increase 
in survival in sALS (Landers 2009). However this association was not replicated in a 
subsequent study (Traynor 2010).
Apolipoprotein E (APOE) epsilon4 gene variant is a risk factor for AD. While no major 
influence of APOE on disease risk was detected in sALS and fALS patients, a gene dose- 
dependent effect has been associated with the age at which ALS manifests (Li 2004; 
Zetterberg 2008). Recently, a GWAS in the French population provided evidence for a 
contribution o f the e4 allele in the occurrence of bulbar-onset ALS amongst men, suggesting 
that men are normally protected by androgens against bulbar onset and that the e4 allele 
inhibits this protection, perhaps by interfering with the androgen pathway (Praline 2011).
Apurinic endonuclease gene (APEX1) was initially selected on the basis of its protective role 
against oxidative stress. A variant of this gene showed moderate association with ALS 
(Hayward 1999) although it was not confirmed in the Italian population (Coppede 2010).
Epha4 is a receptor in the ephrin axonal repellent system and has been recently identified as
a modifier of ALS in animal models and humans (Van Hoecke 2012). In particular, in sALS
patients, Epha4 expression inversely correlates with disease onset and survival, and loss-of-
function mutations are associated with long survival. In addition, genetic as well as
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pharmacological inhibition o f Epha4 signaling rescues mutant SOD1 phenotype and 
axonopathy induced by expression of TDP-43 or knockdown of SMN1 in zebrafish and 
increases survival in mouse and rat models of ALS.
Lack of overlap among these studies underlie the heterogeneous nature of this disease and 
highlights the necessity to analyse ALS associated SNPs in a very large population of patients and 
controls. Moreover genetic variants in sALS cases are not sure causes of disease whereas their 
meaning rely on susceptibility to a major risk of the disease which is generally linked and related 
to restricted and different population cohorts.
Nevertheless, the information provided by genetic studies toward the understanding of the 
pathogenesis o f both fALS and sALS has been invaluable. It has led over the years to the 
identification of novel cellular pathways involved in MN degeneration, has provided potential 
therapeutic targets, and made possible the engineering of animal models o f ALS. Undoubtedly, 
the discovery o f novel ALS associated genes, will dramatically further our knowledge of ALS 
pathogenesis.
1.5 Pathogenic hypotheses
The pathogenic mechanisms underlying neurodegeneration in ALS are multifactorial and operate 
through inter-related molecular and genetic pathways (Figure 3). Specifically, putative 
mechanisms of toxicity targeting MNs in ALS might result from a complex interplay between 
oxidative stress, excitotoxicity, mitochondrial dysfunction, combined with accumulation o f protein 
aggregates, and alterations of axonal transport and RNA processing. Convergence of multiple 
pathways is likely to mediate disease onset and progression, and this partially reflects the failure 
of most single therapeutic approaches in patients (Peviani 2010).
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Figure 3 Main pathogenic mechanisms in ALS.
They include glutamate-mediated excitotoxicity, protein misaggregation (SOD1, TDP-43 and FUS), 
oxidative stress, mitochondrial dysfunction, impaired axonal transport and impaired RNA processing. 
All these alterations can ultimately lead to neuronal death and to a loss of neuromuscular 
connectivity and muscle atrophy. Activation of microglia results in secretion of proinflammatory 
cytokines, resulting in further toxicity. Adapted from Kiernan 2012.
Most current knowledge on the mechanisms leading to the degeneration of MNs in ALS has come 
from the study of fALS cases, in which mutations in single genes have been identified. Indeed, 
since the clinical and pathological profiles of sALS and fALS are similar, it can be predicted that 
evidence emerging from studies on ALS-causing gene mutations may apply also to sALS. However, 
since the discovery of SOD1 mutations as causative genetic factor for fALS, several hypotheses 
have been formulated on the possible molecular players involved in the neurodegeneration, and 
the pathways leading to neuronal death appear to be complex even in this defined genetic 
subgroup. In addition, one biochemical difference appears to be the absence of pathologic TDP-43 
(a hallmark o f affected neurons in sALS and FTD) in fALS cases due to SOD1 mutation (Mackenzie
2007). Nevertheless this observation remains controversial since there are contrastating results
on human cases and mutant SOD1 mice (Robertson 2007; Turner 2008; Shan 2009).
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1.5.1 Oxidative stress 
Early evidence suggesting a role for oxidative damage in ALS came from the identification of 
markers of oxidative stress in the cortex and SpC of patients with sALS and fALS and in transgenic 
mouse models o f the disease (Bowling 199S; Beal 1997; Ferrante 1997; Andrus 1998). In 
cerebrospinal fluid (CSF) samples from ALS patients, increased levels o f oxidative stress markers 
have been reported too (Smith 1998; Simpson 2004; lhara 2005; Siciliano 2007). Oxidative stress 
and accumulation of reactive oxygen species (ROS) is known to cause cell death. The increase of 
oxidative damage with age fits with middle- or advanced-age onset of ALS, although the age 
related disease pattern suggests that ALS occurs within a succeptible group within the population 
rather than being a disease of aging (Logroscino 2010).
ROS and reactive nitrogen species (RNS) are molecular entities that can react with cellular 
components, causing detrimental effects on their function. Reactive species include both free 
radicals (species capable of independent existence containing one or more unpaired electrons) 
and other molecular species listed in Table 3. The majority o f ROS derive from the incomplete 
metabolic reduction of oxygen to water during the oxidative phosphorylation o f the mitochondrial 
respiratory chain, where superoxide radical anion (02#~) is formed. The mitochondrion is the 
major site of ROS production. All these species can cause oxidative damage to proteins, lipids, 
RNA and DNA, as documented in postmortem tissue from sALS and SODl-related fALS cases, as 
well as in mutant SOD1 (mSODl) murine and cellular models, already in the early presymptomatic 
disease stages (Shaw 1995; Shibata 2001; Fitzmaurice 1996; Chang 2008). Such damage can alter 
protein conformations and disrupt enzyme active sites, change the properties o f cellular 
membranes by oxidation of unsaturated fatty acids, and introduce mutations into DNA. 
Interestingly, the SOD1 protein itself seems to be particularly susceptible to oxidative post- 
translational modification (Andrus 1998). In addition, recently developed cellular models of ALS- 
mutant TDP-43 indicate that the presence of this mutant protein also induces oxidative stress in 
MN cell lines (Duan 2010).
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Reactive species
Free radicals Non radicals
Superoxide, 0 2* ' Hydrogen peroxide, H20 2
Hydroxyl, OH* Peroxynitrite, ONOO'
Carbonate, C 03*" Peroxynitrous acid, ONOOH
Peroxyl, R02* Nitrous Acid, H N 02
Table 3 Most common reactive species.
They include ROS and RNS, radicals and not radicals species. All of them are oxidizing agents.
As mutations in a major anti-oxidant enzyme, SOD1 gene, account for 20% of fALS cases, there is 
significant interest in this mechanism. Indeed, it has been hypothesised that mutated SOD1 
(mSODl) may acquire a toxic function and become a source of oxidative stress. Mutations in this 
anti-oxidant enzyme may alter its folding, impairing either the structural and the catalytic sites, 
thus leading SOD1 to catalyse aberrant oxidative reaction, altering subsequently the structure and 
the functionality of other essential proteins (Cleveland 2001). A number of chemical models have 
been proposed to explain mechanisms which can trigger oxidative stress in m50Dl:
- Peroxidase hypothesis (Figure 4B): the reduced form of mSODl (Cu1+-bound state) can accept 
hydrogen peroxide as a substrate thus producing the extraordinary reactive hydroxyl radical, OH*, 
leading to a cascade of peroxidation (Wiedau-Pazos 1996).
- Peroxynitrite hypothesis (Figure 4C): mSODl may accept abnormal substrates such as 
peroxynitrite (ONOO ) (formed by the spontaneous combination of superoxide and nitric oxide), 
thus causing aberrant nitration of tyrosine residues on different proteins (Beckman 1993).
- Backward catalysis (Figure 4D): mSODl protein fails to bind zinc properly, thus destabilizing the 
structure o f the enzyme, and allowing a rapid reduction of Cu2+. to Cu1+. In its reduced state 
mSODl catalyses the conversion of oxygen into superoxide (backward catalysis), rather than 
dismutation. The superoxide produced would then combine in the enzymatic active site with 
freely diffusing nitric oxide, thereby producing peroxynitrite (ONOO ), which can promote 
intracellular damage, including protein nitration (Estevez 1999).
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Figure 4 SOD1 chemistry.
W T-SODl enzyme uses superoxide ion as a substrate, producing H20 2 and molecular oxygen (0 2) as products 
(A). fALS linked SOD1 mutants may acquire aberrant chemical reactivity, leading to production of highly 
reactive hydroxyl radicals (B) or to abnormal nitration of other proteins (C-D). Adapted from Cleveland 2001.
However, the concept that mSODl provokes aberrant oxyradical reactions still remains quite 
controversial and recent evidence suggests that mSODl may cause oxidative stress by 
mechanisms beyond its catalytic activity. In particular, mSODl in microglia increases NADPH 
oxidase (NOX)-mediated superoxide production (Harraz 2008). Nevertheless, the manipulation of 
wild-type SOD1 levels in mSODl mice (Jaarsma 2000; Deng 2006), has provided some evidence 
that heightened oxygen-mediated toxicity is unlikely to be the main player in the degeneration of 
MNs. Thus, oxidative stress might link and potentially exacerbate other proposed pathogenic 
mechanisms such as excitotoxicity, mitochondrial impairment, protein aggregation, ER-stress, 
axonal transport defects and alterations in signaling from astrocytes and microglia (Rao 2004; 
Duffy 2011; Wood 2003; Kanekura 2009; Blackburn 2009; Sargsyan 2005). In addition, although
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antioxidant therapies were the most effective class of drug at improving survival in mSODl mice, 
they have not yet shown benefit in patients (Benatar 2007; Orrell 2007).
1.5.2 Mitochondrial dysfunction 
Mitochondria are cellular fueling pumps implicated in many neurodegenerative disorders (Boillee 
2006). Morphological and biochemical mitochondrial abnormalities, such as swelling and 
vacuolization, have been reported in both sALS and fALS patients, animal and cellular model of 
the disease. In particular, postmortem and biopsy samples from SpC, nerves and muscles show 
abnormalities in mitochondrial structure, number, localisation (Wiedemann 1998; Siklos 1996), 
electron transfer chain complexes and DNA (Vielhaber 2000). In addition, mitochondrial 
mutations have been described in ALS patients (Dhaliwal 2000; Ro 2003). Nonetheless in vitro and 
in vivo studies of ALS-mSODl models evidenced the presence of mitochondrial pathology in 
addition to a reduced chain activity and therefore a decrease in ATP synthesis and disruption of 
energy metabolism, impaired calcium buffering, mitochondria depolarization and worsening of 
these defects with disease progression (Kong 1998; Higgins 2003; Bendotti 2001; Sasaki 2004; 
Rizzardini 2006; Jung 2002; Damiano 2006; Menzies 2002).
Moreover, several studies have shown that mSODl can directly damage these organelles (Figure 
5). In fact, a fraction of both wild-type and mSODl is localized in the mitochondrial outer 
membrane, intermembrane space and matrix (Higgins 2002; Pasinelli 2004; Vijayvergiya 2005). 
SOD1 localisation to mitochondria occurs only in affected tissues, and preferentially for mSODl 
(Liu 2004). Furthermore, mSODl strongly triggers cell death when targeted to mitochondria and, 
when interacting with these organelles, it is able to form protein aggregates and to cause 
cytochrome c (CytC) release (Takeuchi 2002). The mislocalisation in mitochondria o f mutant forms 
of the protein may account for the toxic gain-of-function of the enzyme through a number of 
mechanisms, such as abnormal interaction with mitochondrial proteins, like Bcl-2 (Pasinelli 2004), 
rendering them unavailable for anti-apoptotic functions. Alternatively, SOD1 accumulating and
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aggregating in the outer mitochondrial membrane can clog the protein importation machinery, 
thus resulting in severe dysfunction (Liu 2004).
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Figure 5 The mitochondrion as a target of mSODl toxicity.
SODl is not just a cytoplasmic protein but it has recently been observed in mitochondrion in 
different sub-compartments. mSODl can form insoluble aggregates that could directly damage the 
mitochondrion, thus leading to the release of the CytC, and caspase activation. There is an inhibition 
of the translocator outer membrane (TOM) complex, preventing mitochondrial protein import and 
an aberrant interaction with Bcl-2, important in the apoptotic prevention. Adapted from Pasinelli 
2006.
These organelles are especially critical to MNs, as these cells must meet extraordinary energetic 
demands. However, mitochondrial dysfunction in ALS does not seem to be restricted only to MNs 
as it is also present in other tissue, particularly the skeletal muscle. Interestingly, the lifespan of 
transgenic mSODl mice is increased by a highly energetic diet compensating both the metabolic 
defect and the MN function. Nevertheless, it is still unknown whether mitochondria can 
contribute directly to pathogenesis or are only innocent bystanders, and whether mitochondrial 
abnormalities and dysfunction can both result from or cause oxidative toxicity.
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1.5.3 Excitotoxicity
Glutamate is the main excitatory neurotransmitter in the CNS and, in normal synaptic 
transmission it is released, after depolarization, in the synaptic space and there can bind to 
specific glutamate postsynaptic receptors. To prevent the aberrant activation of glutamate 
receptors, glial cells and neurons express glutamate transporters (EAATs) that facilitate the 
removal of glutamate from the synaptic cleft. Excitotoxicity refers to a neuronal injury caused by 
prolonged and excessive excitation, typically by glutamate-induced stimulation o f the 
postsynaptic glutamate receptors such as cell surface NMDA (N-methyl-D-aspartate) and AMPA 
(a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors. Glutamate's toxicity is 
thought to result in massive calcium influxes in the cytoplasm that are potentially detrimental 
through calcium-activated processes and molecules, leading to increased nitric oxide and free 
radicals formation, and triggering programmed cell death.
Glutamate-mediated neurotoxicity was first proposed as a mechanism when increased levels of 
glutamate were discovered in the CSF of a subset of ALS patients (Rothstein 1990). This elevation 
has been attributed to a significant reduction in the expression and activity of the astroglial 
glutamate clearing transporter EAAT2, observed in the cortex and SpC in most cases (~65%) of 
sALS and in transgenic ALS mice (Rothstein 1995; Trotti 1999; Howland 2002), thus evidencing 
that neuronal degeneration is not a cell-autonomous process. It is still not clear how EAAT2 
disruption occurs (given the absence of evidence for mutations, altered expression or splicing in 
ALS patients), and whether this is a cause or a consequence of neuronal loss (Foran 2009).
In addition, in vitro studies have demonstrated that MNs are particularly sensitive to glutamate 
excitotoxicity mediated through AMPA receptors (Carriedo 1996) (Figure 6). In particular, a defect 
in the RNA editing o f the AMPA GluR2 subunit, or a lack of this receptor subunit, have been 
shown to be involved in the selective vulnerability of MNs in ALS by conferring calcium 
permeability to AMPA-gated channels (Kawahara 2004). Indeed MNs display a diminished 
capacity in respect to other types of neurons, to buffer calcium (Alexianu 1994). These increased
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Ca2+ levels are evidenced also by the appearance of calcium-containing deposits in the LMNs of 
sALS patients and G93A-SOD1 mice (Siklos 1996 and 1998). Treatments with AMPA receptor 
antagonists slow disease progression and increase survival o f mSODl mice, suggesting that AMPA 
receptors may represent promising targets for therapies (Van Damme 2003; Tortarolo 2006).
In addition, a recently identified ALS-linked gene encodes D-amino acid oxidase (DAO), the 
enzyme responsible for the oxidative deamination of D-amino acids, one of which (D-serine) is an 
activator and co-agonist of NMDA receptors (Mitchell 2010). Thus, mutations in DAO could 
potentially contribute to MN excitotoxicity.
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Figure 6 Schematic overview of excitotoxic MN death.
Glutamate released from the presynaptic neuron stimulates AMPA receptors on the postsynaptic 
neuron. MNs express a large number of Ca2+permeable receptors lacking the GluR2 subunit. As a 
consequence, glutamatergic stimulation increases the intracellular Ca2+ concentration and because 
of the low Ca2+-buffering capacity of MNs part of this Ca2+ could be uptaken by the mitochondria. 
The presence of mSODl in neurons as well as in astrocytes interferes at different levels with this 
process. Consequently, the balance is shifted from normal glutamatergic communication to 
excitotoxic MN death. Adapted from Grosskreutz 2010.
Increased glutamate clearance has been considered a possible therapeutic approach. Indeed,
Riluzole which is the only drug currently approved for the treatment o f ALS patients, is believed to
antagonize glutamate-mediated excitotoxicity, although its precise mechanism o f action is rather
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controversial. Overall, abnormal glutamate metabolism and loss o f glutamate transporters in ALS 
patients, along with proved MN susceptibility to glutamate toxicity and clinical efficacy of anti­
glutamate agents support the role of glutamate excitotoxicity in ALS, although clear evidence that 
it is a primary disease mechanism is lacking.
1.5.4 Impaired axonal transport
MNs are highly polarized cells and have extensive dendritic arbors and axonal processes that may 
reach up to one metre in length in humans, and rely on active efficient intracellular transport 
systems to convey newly made materials to even the farthest reaching nerve endings (which 
includes synaptic structures at the neuromuscular junction) and needed nutrients back to the cell 
body. These systems consist of anterograde (slow and fast) and retrograde transport systems, and 
rely on "molecular motors": the kinesin and the dynein-dynactin complexes for anterograde and 
retrograde transport, respectively (Figure 7).
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Figure 7 Schematic overview of axonal transport.
The motors for anterograde and retrograde fast axonal transport are the kinesins and dynactin 
complex proteins, respectively; microtubules provide the tracks for these motors. Vesicles for 
transport are sorted and loaded onto transport motors both in the cell body and the distal nerve 
terminal. The former are transported not only into the axon but also into dendrites. Those in the 
distal nerve terminal permit uptake and axosomatic movement of substances such as trophic 
proteins. Adapted from Pasinelli 2006.
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The reduced activity o f axonal transport o f the cytoskeleton is one of the earliest pathological 
events seen both in patients (Sasaki 1996) and in mSODl mice (Zhang 1997; Williamson 1999). 
The SODl mouse model shows evidence of axonal degeneration and slowed anterograde and 
retrograde transport o f several cargoes (Borchelt 1998; Murakami 2001; De Vos 2008). Recently, a 
possible molecular mechanism for axonal transport impairment in ALS pathology was provided by 
mSODl proteins interaction with both the anterograde motor protein kinesin-2 complex via KAP3 
(kinesin-associated protein 3) and the retrograde motor protein complex dynein-dynactin (Zhang 
2007; Strom 2008). As previously reported, also organelles, such as mitochondria, are transported 
by the kinesin and dynein motor complexes. Recent in vitro studies have shown that mSODl can 
alter mitochondrial transport in both anterograde (De Vos 2007) and retrograde directions 
(Magrane 2009), thus resulting in inefficient delivery or removal o f distal mitochondria, with 
fewer mitochondria in axons and nerve terminals. This could in turn cause the defective transport 
of other cargoes, because of the energy requirement o f axonal transport.
Moreover, abnormal accumulation of neurofilaments in the cell body and proximal axons of MNs 
has been described in both sALS and fALS patients (Hirano 1984; Carpenter 1968). Neurofilaments 
are the most abundant cytoskeletal proteins in MNs and play a key role in defining and 
maintaining the structure of the axon; their disruption can induce these proteins to form 
inclusions that can damage MNs, producing symptoms bearing many similarities to ALS. 
Peripherin and a-internexin are two intermediate filament proteins that colocalize with 
neurofilaments and are found in axonal inclusions in ALS patients (Corbo 1992); their 
overexpression in transgenic mice causes MN degeneration (Robertson 2003). A further evidence 
that disruption of axonal transport could have a role in the pathogenesis o f ALS come from the 
genetic: variants or mutations in the genes encoding the MAPT, NEFH, PRPH, DCTN1 and PFN1 
have been recently described in ALS patients (see ALS genetics section). In addition, mutations in 
the kinesin genes are known to cause other neurodegenerative motor diseases such as hereditary 
spastic paraplegia and type 2A Charcot-Marie-Tooth disease (Reid 2002; Zhao 2001).
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1.5.5 Protein misfolding and aggregation 
Abnormal protein aggregates are a common feature of the vast majority of neurological diseases. 
These lesions, in the form of extra- and intra-cellular inclusions containing ubiquitin, are a 
hallmark o f both sALS and fALS (see Histopathological Features section), suggesting a shared 
pathogenic link. However, the role of protein aggregation in ALS pathogenesis is unclear: they 
might cause cellular toxicity, be only by-products of the neurodegeneration process or even a 
mean of cell protection by sequestering toxic proteins (Cleveland 1999; Tran 1999).
-»• SODl aggregates
The hypothesis o f toxicity from protein aggregation in ALS initially arose from the discovery of 
intracellular inclusions in MNs and astrocytes in mouse models and patients with mSODl 
(Watanabe 2001; Kato 1999). Insoluble SODl-containing aggregates appear before or coincident 
with onset of disease symptoms and increase in abundance with disease progression, suggesting 
that SODl aggregation may be an early event in disease pathogenesis (Johnston 2000; Wang
2002). Aggregates can be composed of different proteins such as SODl, ubiquitin, dorfin, 
neurofilaments, peripherin; additionally, chaperones and proteasome subunits may also be 
sequestered (Watanabe 2001; Strong 2005; Basso 2009).
The oligomerisation hypothesis has been proposed as an alternative mechanism to the oxidative 
damage hypothesis (see Oxidative stress section 1.5.1), to explain the toxicity acquired by mSODl 
in ALS. Mutant proteins are likely to cause disease through a toxic gain-of-function, possibly an 
increase in the propensity o f the protein to misfold and aggregate because of conformational 
instability. SODl conformational stability seems to be tightly linked to Cu2+ and Zn2+ ion 
coordination, which drives the formation of an intramolecular disulfide bond; metallation and 
disulfide bond promote the homodimerisation of SODl subunits (Arnesano 2004). Indeed, in vitro 
studies have shown that in contrast to stable, dimeric wild-type SODl, mutant proteins are more 
prone to oligomerize over time and to form SODl-rich fibrils (similar to some forms of p-amyloid 
protein) (Ray 2004; Matsumoto 2006), suggesting that the conversion of soluble SODl into
68
amyloid fibrils may play an important role in the aetiology of fALS. Generally, the mutations can 
determine both local perturbations of the secondary, tertiary or quaternary structure, diminishing 
the metal coordination or altering the net charge (Shaw 2007). In addition, SODl aggregation 
might also be promoted by ROS: the active site Cu2+ ion can react w ith hydrogen peroxide, leading 
to enzyme inactivation (Valentine 2002) and therefore promoting the population of metal free 
(thus destabilised) SODl states. The common result is a destabilization of the enzyme causing 
non-native interactions with itself or other proteins, thus altering their normal function and 
leading to high-molecular weight species that ultimately aggregate.
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Figure 8 Models for SODl-mediated toxicity.
SODl-mediated toxicity linked to altered conformation and aggregation of mSODl subunits. Adapted 
from Cleveland 2001.
Various hypotheses have been proposed regarding the cytotoxicity o f SODl aggregates (Figure 8), 
including the disruption of axonal transport (Stokin 2005), the aberrant binding o f apoptosis 
regulators (Pasinelli 2004; Tomik 2005) and chaperones proteins, such as heat shock proteins 
(HSPs), that are crucial for the correct folding of many other important cellular proteins (Shinder 
2001; Okado-Matsumoto 2001). Indeed, the overall chaperone activity is modestly diminished in 
SpC of G93A-SOD1 mice, suggesting that insufficient levels o f chaperones can be partially
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responsible for the accumulation of insoluble aggregates (Bruening 1999). In addition, treatments 
with arimoclomol, which increases HSPs expression, extend lifespan of ALS transgenic mice 
(Kieran 2004). Nevertheless, recent studies proposed that aggregation occurs despite HSPs 
expression (Krishnan 2008) which anyway contribute in protecting MNs (Patel 2005).
Aggregated SODl has also been linked to perturbations in mitochondrial function and calcium 
homeostasis (Hervias 2006; Sumi 2006), and progressive failure o f the proteasome system to 
eliminate ubiquitinated aggregates (Cleveland 2001; Cheroni 2005 and 2009; Kabashi 2008). 
Consistent with the latter hypotesis, aggregates in mSODl mice are intensely immunoreactive to 
antibodies for ubiquitin (Stieber 2000; Watanabe 2001), whose role is to label and target 
misfolded and inactive proteins to the proteasome machinery. Thus, proteasome activity could be 
inhibited by SODl and this pathologic starting event could trigger the accumulation of aberrantly 
folded forms of SODl and other proteins (Cleveland 2001). Finally, unfolded protein response, 
which follows a severe ER-stress, may contribute to protein misfolding and aggregation. Indeed, 
two ER chaperones recognized as markers of ER stress, GRP78 and protein disulfide isomerase 
(PDI), are up-regulated in G93A-SOD1 mice MNs, in sALS patients and in fALS cases linked to SODl 
and TDP-43 (Tobisawa 2003; Zetterstrom 2011; Atkin 2006 and 2008; Honjo 2011). Misfolded 
SODl can specifically aggregate in the ER-Golgi compartments, thus impairing also the Golgi 
apparatus that has been detected fragmented in MNs of sALS and fALS patients (Okamoto 2010).
-» TDP-43 inclusions
TDP-43 misaccumulation was observed in all variants of ALS, with rare reports in ALS-mSODl 
cases (Mackenzie 2007; Robertson 2007; Tan 2007; Okamoto 2011; Sumi 2009). Besides ALS and 
FTLD-U, TDP-43 cytoplasmic accumulation and loss of nuclear localisation in affected neurons are 
now reported in a number of neurodegenerative conditions, including a fraction of AD, PD and HD 
patients (reviewed in Lagier-Tourenne 2010). In most ALS cases, the cytoplasmic accumulation of 
TDP-43 was seen mainly in neurons and glia of the primary motor cortex, brainstem motor nuclei 
and SpC (Mackenzie 2007). ALS patients MNs, showing a normal TDP-43 staining, have a normal
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Golgi apparatus profile, whereas Golgi fragmentation is detectable in neurons with cytoplasmatic 
TDP-43 inclusions, thus suggesting that aggregation of TDP-43 in the cytoplasm can be linked to 
impairment in the secretory pathway mediated by the Golgi (Okamoto 2010).
The C-terminal domain of this protein is crucial for spontaneous aggregation and several 
mutations, within this domain, increase the number of TDP-43 aggregates, thus promoting 
toxicity (Johnson 2009). The observation that ALS-linked mutations increase the stability of TDP- 
43 protein (Guo 2011; Johnson 2009; Ling 2010) supports the view that protein aggregation may 
initiate the pathogenic cascade in ALS.
Moreover, pathological TDP-43 is hyperphosphorylated and cleaved to generate C-terminal 
fragments o f approximately 25kDa (Neumann 2006; Arai 2006) (Figure 9). The phosphorylation of 
full length TDP-43 results in a product of 45kDa that was observed in FTLD-U and ALS brains. 
Although the pathological significance of TDP-43 phosphorylation is not yet known, it has been 
proposed that this modification might promote TDP-43 aggregation. In vitro studies have 
demonstrated that phosphorylation of recombinant TDP-43 leads to an increase in the level of 
TDP-43 oligomers (Hasegawa 2008). Additionally, abundant filaments, immunopositive for 
S409/S410 phosphorylation-specific TDP-43 antibody, have been observed by electron 
microscopy (Hasegawa 2008). Although phosphorylation may enhance TDP-43 oligomerization, it 
may not actually be necessary for aggregation to occur: recent findings have suggested that 
phosphorylation occurs late in the conversion of soluble to insoluble TDP-43, thus indicating that 
it is not an essential prerequisite for TDP-43 aggregation (Dormann 2009) and that is not required 
for C-terminal cleavage (Zhang 2009).
TDP-43 truncation is supposed to be region specific; in fact an enrichment in C-terminal fragments 
was observed in TDP-43 inclusions in the hippocampus and cortex of FTLD-U and ALS cases, while 
lesions in MNs consist primarily of full-length TDP-43 (Igaz 2008). Several in vitro studies have 
shown that C-terminal fragments of TDP-43 are more likely than full-length TDP-43 to form 
insoluble cytoplasmic aggregates that become phosphorylated, ubiquitinated and toxic to cells 
(Igaz 2009; Nonaka 2009; Arai 2010). It has been also demonstrated that the expression of C-
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term inal TDP-43 fragments in cultured cells leads to an aberrant sequestration of the endogenous 
full-length protein, depleting it from the nucleus (Nonaka 2009), while another study showed 
retention o f normal nuclear expression, thus suggesting a pure toxic effect o f cleavage products 
(Zhang 2009). In addition, C-terminal fragments may also affect TDP-43 function aberrantly 
interacting w ith hnRNP A/B proteins, and thus perturbing the equilibrium o f available hnRNPs 
inside the cell. Indeed, TDP-43 is able to bind hnRNPs A/B through its C-terminal domain (Buratti 
2005) and, like TDP-43, hnRNPs are involved in RNA processing and, in physiological condition 
they are able to continuously shuttle between the cytoplasm and the nucleus. However hnRNPs 
have not been found in TDP-43 positive inclusions (Neumann 2007). Moreover, the cleavage of 
TDP-43 itself results in loss o f TDP-43 function, given that truncations products lack key functional 
domains (Buratti 2001).
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Figure 9 Physiological and pathological TDP-43.
(A) Under physiological conditions, TDP-43 primarily resides in the nucleus, although the protein has 
the capacity to shuttle between the nucleus and the cytoplasm. TDP-43 has roles in regulating 
transcription, splicing, and mRNA stabilization. (B) In pathological conditions, TDP-43 is cleared from 
the nuclear compartment and accumulates in the cytoplasm. Pathological TDP-43 has been 
demonstrated to be hyperphosphorylated and/or ubiquitinated and also C-terminal cleaved. TDP-43 
is also more prone to aggregation. Adapted from Chen-Plotkin 2010.
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The expression o f mutant TDP-43 in cultured cells results in increased formation of C-terminal 
fragments, with even more aggregation and toxic effects than the wild-type protein (Kabashi 
2010; Nonaka 2009; Arai 2010; Barmada 2010). In vivo studies [conducted in fru it fly (Drosophila 
melanogaster), mice and rats] have shown that overexpression of wild-type human TDP-43 can 
cause the abnormal formation of TDP-43 cytoplasmic inclusions, with the associated 
neurodegeneration and motor dysfunction (Li 2010; Wils 2010; Tatom 2009). Whereas results 
from transgenic animal models overexpressing mutant forms of human TDP-43 are rather 
inconsistent and difficult to interpret, indicating that the pathogenic mechanism in TDP-43 
proteinopathy is still unresolved.
- >  FUS/TLS inclusions
As for TDP-43 proteinopathies, also FUS cytoplasmic inclusions have been detected in a growing 
number o f neurodegenerative disorders (Doi 2010; Woulfe 2010). Analyses of the brains and SpCs 
of ALS patients with FUS mutations have revealed normal staining of FUS in the nuclei of many 
neurons and glial cells, while it is partially cleared from those nuclei in neurons that contain 
cytoplasmic aggregation (Neumann 2009; Tateishi 2009; Kwiatkowski 2009; Vance 2009). In vitro 
expression o f C-terminal FUS mutations has revealed variable increases in cytoplasmic 
concentrations of FUS that are compatible with the disruption o f its nuclear localisation signal and 
impaired transportin-mediated nuclear import (Dormann 2010), suggesting that an altered 
nuclear import o f FUS can represent a crucial event in disease pathogenesis.
In contrast with TDP-43 proteinopathies, FUS lacks most o f the post-translational modifications 
(such as hyperphosphorylation, ubiquitination and cleavage) that have been reported for TDP-43. 
Thus, if common mechanisms underlie toxicity mediated by TDP-43 and FUS, this divergence in 
the biochemical properties of the proteins may suggest that these alterations are not key 
contributors to pathogenesis (Da Cruz 2011).
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-> p62 inclusions
The presence of p62 in ubiquitin-positive inclusions in many different neurodegenerative 
diseases, including ALS-FTD, further provides evidence for a potential common mechanism in 
these disorders, namely, proteins misfolding and impaired proteasomal digestion and autophagy. 
In addition, mutations in VCP, ubiquilin 2, and p62 (see ALS genetics section), further contribute 
to alter or impair proteasomal digestion and different steps of the autophagic process, leading to 
accelerated neurotoxicity, as the catabolic mechanisms of proteasomal degradation and 
lysosomal-mediated autophagy are hoverwhelmed, and undigested misfolded proteins wreak 
havoc in the cell (Appel 2012).
Nevertheless, it is not yet clear which one among these events is the cause and which one is the 
consequence of ALS: it can be proposed that a vicious circle where aggregation and impairment of 
protein folding and degradation are both present and involved in the pathology.
1.5.6 Impaired RNA processing 
Reports from nearly 10 years ago first showed aberrant exon and intron splicing of astroglial 
glutamate transporter EAAT2 as the cause of abnormal RNA metabolism in sALS (Lin 1998). During 
the last decade, the discovery o f alterations in TDP-43, FUS and C9orf72 firm ly established ALS as 
a disease of impaired RNA processing. Nevertheless, the role of RNA metabolism in ALS is further 
underscored by disease-causing mutations in ANG, SETX, TAF15 and ELP3, encoding for proteins 
involved in RNA processing, as well as by the recognition of intermediate length polyglutamine 
expansions in ATXN2, a RNA binding protein, as a risk factor for ALS (see ALS genetics section). 
TDP-43 and FUS, are both abnormally aggregated and mislocalised in ALS and FTLD. They display 
structural similarities and participate in multiple levels of mRNA processing, such as transcription,
splicing, transport and translation (Buratti 2008; Janknecht 2005) (Figure 10). With the exception
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of a mutation located in a RRM, all TDP-43 mutations identified are located in the C-terminal 
domain o f the protein, which is important for interactions with members o f the hnRNP family of 
splicing regulators (Buratti 2005; D'Ambrogio 2009; Kabashi 2008; Lagier-Tourenne 2009). Recent 
technologies coupled with high-throughput sequencing have improved the ability in identifying 
RNA targets. Thus, over 6000 TDP-43 RNA targets have been identified, including transcripts of 
genes relevant to neurodegeneration, such as FUS, VCP, TARDBP, progranulin and choline 
acetyltransferase, transcripts encoding proteins involved in RNA metabolism, synaptic function 
and CNS development (Sephton 2011; Polymenidou 2011; Tollervey 2011), suggesting that 
disrupting the function of a single RNA-binding protein can affect at the same time many 
alternative spliced transcripts (Licatalosi 2008). Moreover, multiple RNA targets o f TDP-43 are 
deregulated in ALS, when TDP-43 is mutated or depleted, suggesting that a nuclear loss-of- 
function is likely to contribute to the pathophysiology of ALS (Xiao 2011).
TDP-43 was initially proposed to repress transcription by binding to the TAR DNA sequence of 
HIV-1 (Ou 1995) and to mouse SP-10 gene promoter (Abhyankar 2007). FUS can influence the 
general transcriptional machinery associating with RNA polymerase II and TFIID complex 
(Bertolotti 1996; Yang 2000). In response to DNA damage it can also be recruited by noncoding 
RNAs transcribed in the 5' regulatory region of the gene encoding cyclin D l, leading to the 
repression of cyclin D l transcription (Wang 2008).
Beyond transcription, these two proteins have also a role in splicing regulation. They associate 
with other splicing factors and their depletion or overexpression affects the splicing pattern of 
specific targets (Buratti 2005; Freibaum 2010). In particular, TDP-43 regulates tha alternative 
splicing o f the cystic fibrosis transmembrane regulator (CFTR) (Buratti 2001), and promotes the 
inclusion of SMN exon 7 (Bose 2008). Abnormal expression of peripherin splice variants (Xiao 
2008), mRNA-editing errors o f the GluR2 AMPA receptor subunit (Kawhara 2004) and other 
splicing alterations (Rabin 2010) have been reported in sALS patients.
Although TDP-43 and FUS are mainly nuclear proteins, they are also present in the cytosol, where 
their binding onto RNA 3'UTRs has been linked with other aspects of RNA metabolism, like
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stabilization, transport, translation or degradation. Indeed, TDP-43 binding sites were identified 
on the 3'UTR of several genes involved in ALS pathogenesis including FUS, the glutamate 
transporter EAAT2 and the light chain of neurofilament (NFL) (Polymenidou 2011). In particular, 
TDP-43 stabilises NFL mRNA, whose levels are decreased in degenerating spinal MNs in ALS 
(Strong 2007). Moreover, in neurons TDP-43 and FUS are found in RNA-transporting granules 
which translocate to dendritic spines following different neuronal stimuli (Fujii 2005; Wang 2008; 
Belly 2005; Elvira 2006). TDP-43 depletion reduces dendritic branching and synaptic formation in 
drosophila neurons (Lu 2009; Feiguin 2009); while cultured neurons from FUS-/- mice show 
abnormal spine morphology (Fujii 2005). Collectively, these works suggest that both proteins 
could play a role in the modulation of synaptic plasticity by influencing mRNA stabilization, 
transport and local translation in neuronal cells, and as a consequence of the mislocalisation and 
aggregation could thereby contribute to MN injury. In agreement with this hypothesis, other 
studies have shown that TDP-43 and FUS are components of cytoplasmic RNA stress granules, 
cytoplasmic foci containing mRNA and ribonucleoprotein (RNP) complexes in which the 
translation is stalled under stress conditions (Colombrita 2009; Moisse 2009; Nishimoto 2010). 
Hence it is plausible that the physiologic TDP-43- or FUS-containing stress granules may transform 
into pathogenic inclusions during neurodegeneration. Therefore, sequestration of specific cellular 
RNAs within cytoplasmic TDP-43 and FUS inclusions may deplete the cell of essential RNA 
components, contributing to pathogenesis, and possibly explaining the observation that TDP-43 
and FUS binding to RNA is linked to their cytotoxicity independently of their propensity to 
aggregate (Elden 2010; Sun 2011; Voigt 2010). Indeed, an interesting possibility is that 
aggregation might cause TDP-43 to bind RNA more avidly; alternatively, or in addition, RNA might 
stabilize or divert TDP-43 to adopt specific misfolded forms that are highly toxic (King 2012).
The high expression level of microRNAs (miRNAs) and the exclusive expression of certain miRNAs 
in the CNS highlights their biological importance at all stages of neural development as well as in 
differentiated neurons. In particular, miRNA activity is essential for long-term survival of 
postmitotic spinal MNs and for the bidirectional signaling between MNs and skeletal muscle fibers
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at neuromuscular synapses. Several miRNAs potentially implicated in skeletal muscle and 
neuromuscular junction regeneration were de-regulated in ALS brains and specific miRNAs 
disease-related changes were detected at an earlier stage of sALS (Williams 2009; Russell 2012; 
De Felice 2012). TDP-43 and FUS may also be involved in these pathways, since they participate in 
miRNA biogenesis through association with the Drosha complex (Buratti 2008). In addition, TDP- 
43 is also involved in the next steps of miRNA maturation, via interactions with argonaute 2 and 
DDX17 (Freibaum 2010). Indeed, TDP-43 binds miRNA let-7b and miR-663 and, following TDP-43 
knockdown, their levels were deregulated (Buratti 2010).
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Major steps in RNA processing and relative DNA/RNA targets. Modifed from Fiesel 2011.
Another mechanism of RNA toxicity in ALS and FTLD is caused by pathological (G4C2)3o-i6oo
hexanucleotide repeat expansions in nontranslated regions of the C90RF72 gene. As established
in other neurological diseases, especially myotonic dystrophy types 1 and 2 or Fragile X-associated
tremor ataxia syndrome (FXTAS), pathogenicity is initiated at the RNA level through two possible
pathways, (i) Consistent with a loss-of-function mechanism and supported by the 50% reduction
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in C9orf72 transcript levels in patients with expansions, repeats prevent the expression of the 
normal protein (haploinsufficiency of C90RF72). (ii) In addition, expanded RNA forms pathogenic 
nuclear RNA foci that trap specific RNA-binding proteins with affinity for the expanded RNA, 
resulting in their depletion and loss-of-function (protein sequestration mechanism) (DeJesus- 
Hernandez 2011). hnRNP A2/B1 is a potentially interesting RNA-binding protein in this context, 
since it interacts with the C/G-rich repeats that form RNA foci in another neurodegenerative 
condition (FXTAS) (Sofola 2007) and is also a direct interactor of TDP-43 (Buratti 2005). Thus, 
these observations could possibly explain the presence of TDP-43-based pathology in expanded 
repeats carriers and add evidence to RNA misprocessing as a common pathogenic mechanism in 
ALS and FTD.
The RNA-based mechanisms described are extensively coupled with protein misfolding and 
aggregation, suggesting that these defects are inevitably interconnected in neurodegenerative 
processes. Moreover, both contribute to neurogegeneration broadly, thus, regardless which one 
is the primary or secondary event, they represent key steps in the pathological cascade, further 
supporting the hypothesis (Dormann 2011) of a "multiple hit" pathogenesis of ALS.
1.5.7 Insufficientneurotrophic/growthfactors 
signaling
Neurons development and maintenance is dependent on crucial trophic factors supply. Decreased 
levels o f neutrophic factors (e.g. CTNF, BDNF, GDNF and IGF-1) have been observed in ALS 
patients post-mortem and in in vitro models (Anand 1995; Elliott 1996; Oppenheim 1996). A 
neuroprotective role for trophic factors is supported by studies in animal models of ALS 
demonstrating delayed disease onset and progression (Wang 2007; Storkebaum 2005; Azzouz 
2004; Kaspar 2003). Nevertheless, human trials have failed so far to follow up on that success 
(Borasio 1998; Lai 1997).
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In addition, mutations in VEGF have been reported as causative o f MND in mice and, in some 
populations, mutations in VEGF and angiogenin are indicated as risk factors in sALS (see ALS 
genetics section). These angiogenic factors are thought to influence MNs via direct neurotrophic 
effect and via their action to maintain blood flow to these highly metabolically active cells. The 
reduced vascular perfusion that occurs with age, the increased incidence of ALS in males who are 
more likely to develop vascular disease compared to premenopausal females, and smoking as risk 
factor for ALS, provide circumstantial evidence that supports this mechanism.
1.5.8 Contribution of non-neuronal cells and 
neuroinflammation
A growing body of evidence suggests a non-cell-autonomous mechanism in ALS pathogenesis as 
well as in MN protection. Indeed, the restricted expression of mSODl only in MNs or in other 
cellular populations led to the conclusion that in ALS multiple cell types are differentially 
implicated in the selective degeneration of MNs. Thus, defective non-neuronal cells in the local 
microenvironment are required to fully recapitulate disease symptomatology in murine models, 
whereas functional non-neuronal cells could play a protective role in halting disease propagation. 
Likewise, therapeutic manipulation within neurons alone only prevents degeneration while 
surrounding cells, notably astrocytes and microglia, appears capable of modifying disease 
progression.
Glial cells, that normally support the neuronal function, outnumber MNs in the brain by five to 
ten times. When the function of the brain is imbalanced, glial cells move from a resting state to an 
activated state, and can either preserve neurons from damage or contribute to their 
degeneration. In normal conditions astrocytes provide nutrients for neurons, and also ensure the 
efficient and correct cell-cell interactions. Microglial cells instead perform a pivotal role in the CNS 
as the chief mediator of immune function. The role of both cell types in ALS development is not 
yet very well understood. Overall, it is likely that glial cells do not trigger the neurodegeneration
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and have little effect on the early disease phase, but have a striking impact on later disease 
progression. Prevailing hypotheses for astrocyte contribution include direct or indirect 
contributions to glutamate-induced excitotoxicity, impaired metabolic support, alterations in 
gliotransmission, or direct release of diffusible neurotoxic factors, such as proinflammatory 
cytokines and chemokines.
Although ALS is not primarily a disorder of autoimmunity or immune dysregulation, there is 
considerable evidence that inflammatory processes and non-neuronal cells may play a part in ALS 
pathogenesis. Indeed, microglial and dendritic cell activation and infiltrating lymphocytes were 
observed in the SpC of ALS patients and mSODl mice (Troost 1989 and 1990; Kawamata 1992; 
Henkel 2004; Hall 1998; Appel 2010), suggesting the involvement of the innate and adaptive 
immune responses. These activated non-neuronal cells produce some key inflammation meditors 
such as interleukins, COX-2, TNFa and MCP-1, and evidence of upregulation is found in CSF or SpC 
specimens of ALS patients or in vitro models (Aimer 2001; Robertson 2001; Sekizawa 1998; Wilms
2003). Recently, denervation was demonstrated to occur prior to inflammation in mSODl mice, 
suggesting that peripheral nerve inflammation is probably not the cause of denervation, but 
rather a response to the neurodegenerative process (Kano 2012). Indeed, microglial activation 
occurs at presymptomatic stage in mSODl mouse model and is sustained throughout the course 
of the disease. Activated microglia release mediators that cause astrocytes to downregulate the 
production of neurotrophic factors and, in turn, secrete additional inflammatory moleculs that 
further activate microglia, closing thus a vicious circle. A similar inflammatory response is 
preceded by evidence of a "dying back phenomenon" which includes motor axon degeneration 
and alterations of the neuromuscular junction (Fischer 2004). These and other observations 
further suggest that neuroinflammation may indeed contribute to the pathoprogression of MN 
degeneration (Beers 2011). Immunomodulatory therapies have been envisaged for ALS; clinical 
trials o f neuroprotective agents, including stem cells and non-neuronal cells directed approaches 
are ongoing.
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1.6 Experimental models of ALS
Major breakthroughs in the field of ALS research derived from the identification of mutations in 
genes as a cause of ALS, that allowed the development o f experimental models o f the disease. In 
particular, the expression of mutant forms of the relative proteins in laboratory animals and cells 
is widely used to study the pathology and its progression, and to test potential therapeutic 
approaches. In vivo models are particularly useful to investigate complex cellular processes at 
different stages of the disease, whereas in vitro models are useful tools for the study of the 
molecular mechanisms underlying neurotoxicity. These models are clearly not precise replicas of 
the human condition, but the key issue in working with them is that cellular and biochemical 
pathways are largely conserved.
1.6.1 In vitro models
In vitro cell cultures are the most widely used system developed to study individual cell types 
under stress conditions. Several in vitro models have been developed to investigate the cellular 
processes involved in the pathogenesis of ALS. The main advantage offered by in vitro systems is 
the possibility to dissect specific molecular pathways in defined cell populations. In addition, 
although these experimental models have intrinsic drawbacks, thanks to their relative ease of 
manipulation they have often been regarded as the starting point for testing pharmacologic 
treatments, or for studying the toxic effects induced by expression o f mutant genes linked with 
ALS.
In vitro models currently used in ALS research comprise both transgenic and wild-type neuronal­
like, MN-enriched, astrocyte and microglial cultures, as well as ALS patients derived lymphocytes 
and fibroblasts. MN cultures, including either primary fetal neuronal or glial cell cultures (Spalloni 
2004; Tortarolo 2004; Gingras 2007) or co-cultures systems (Ferri 2004; Bilsland 2008) have been 
used to study non-cell autonomous mechanisms of ALS pathogenesis and identify neuroprotective
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pathways (Bendotti 2004). As an alternative approach organotypic cultures of SpC sections from 
postnatal rodents have been produced (Drachman 2000). Recently, neuronal cultures are 
obtained from both embryonic cells and induced pluripotent stem cells (iPS), with the advantage 
of creating patient specific lines that carry human ALS linked mutations (Marchetto 2010; Mitne- 
Neto 2011; Haidet-Phillips 2011). Usually, to study specific features of ALS, MN-like hybridoma cell 
line, such as NSC-34 or SH-SY5Y, or other immortalized cell lines are employed. In particular, 
immortalized cell lines transiently or stably expressing wild-type and mutant ALS-related genes 
have been created, as for SOD1 and TDP-43, or are in development (Gomes 2008; Ferri 2006, 
Colombrita 2009, Duan 2010; Babetto 2005; Raimondi 2006; Liu 2009).
1.6.2 In vivo models
Animal models are an invaluable experimental paradigm to examine the multiple aspects of the 
pathogenesis of a neurodegenerative disease, particularly when many cellular systems are 
involved, as in ALS. A great advantage of such models is the possibility to investigate the earliest 
cellular and molecular events that initiate the neuropathological process, and to monitor the 
mechanisms that influence disease progression at each clinical stage, from onset to death. 
Transgenic rodents have also provided the benchmark preclinical tool for evaluation of potential 
therapeutic pharmacological agents and diagnostic markers.
Murine models are the most widely used in vivo model for studies on ALS/MND (reviewed by 
Peviani 2010), and can be subdivided into:
spontaneous mutants, derived from natural mutations occurring in genes that lead to 
impairment o f the motor system, including PNM (Martin 2002), Wasted (Newbery 2005) 
and Wobbler (Schmitt-John 2005) mice;
N-ethyl-N-nitrosurea (ENU)-induced mutants, obtained by the induction of point 
mutations in the genome through exposure to the alkylating agent ENU (Hafezparast 
2003; Puls 2003);
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targeted mutants, transgenic animals expressing mutated genes linked to ALS or knock­
out mice.
In particular, identification of ALS-causative genes allowed genetic modeling of ALS in rodents as 
well as in easy-to-manipulate organisms including Drosophila, C. elegans and zebrafish. Indeed, 
fALS gene knock-in mice recapitulate most of clinical symptoms and histopathological marks 
encountered in patients (Turner 2008; Wergorzewska 2009). Nevertheless, it must be kept in 
mind that identical mutations result in surprisingly divergent phenotypes in different strains and 
no model perfectly mimics the human disease. Available genetic animal models comprise murine 
and rat strains bearing wild-type or mutated human gene, or gene knock-outs for SOD1, TDP-43, 
ALS2, ADAR2, Dynactin, FUS, VCP, while some other are being developed ahead with the 
discovery o f novel ALS genetic determinants. Transgenic animals show clinical signs associated 
with MN disease, or some features of MN impairments without reducing life span.
The most widely used animal model of ALS is represented by transgenic mice expressing the 
human SOD1 gene with mutations found in patients. Indeed, mSODl transgenic mice have 
become widely accepted and, over the last 15 years, an almost exclusive animal model o f ALS. At 
present, transgenic expression of 12 human SOD1 mutations driven by the endogenous promoter 
is disease-causative and uniformly lethal in mice and rats, despite consistent variation in 
transgene copy number, protein level, dismutase activity and neuropathology between different 
mutants (Turner 2008). In addition, the background effect of the gender or the mouse strain on 
the age of onset, disease duration and several pathological features, suggest the existence of 
strong modifying genetic factors (Alexander 2004; Heiman-Patterson 2005). Nevertheless, these 
animals develop a phenotype that closely resembles ALS, with an adult onset progressive motor 
paralysis, muscle wasting and reduced lifespan. Pathological changes mainly consist o f depletion 
of MNs in the SpC, gliosis, axonal swelling and presence of UBIs in surviving MNs, and muscular 
atrophy. In contrast, mice overexpressing or knock-out for wild-type SOD1 do not develop ALS-like 
phenotype.
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mSODl model proved to be useful to identify non-neuronal cell targets o f SOD1 toxicity, 
misregulated neurotrophic and cell death pathways, and to survey other genetic interactors that 
can modify the disease. Indeed, around 100 genetic cross-breeding experiments with transgenic 
mSODl mice have been performed to verify molecular mechanisms proposed to drive ALS 
pathogenesis in vivo (glutamate-induced excitotoxicity, axonal transport blockade, mitochondrial 
dysfunction, neuroinflammation, protein misfolding and apoptosis).
In particular, the mouse model most extensively used in ALS is a line expressing human SOD1 with 
the Gly93Ala substitution. Despite the relative rarity of this mutation, it has been studied 
intensely as it was the first mutation to be modeled in mice (Gurney 1994), and due to the ready 
availability of the G93A-SOD1 mouse. Established in 1994, the G93A-SOD1 mouse model is 
internationally accepted as a robust model for ALS research. Transgenic mice carrying 23 copies of 
the human gene are considered the standard model of ALS in therapeutic studies (Bendotti 2004). 
The model develops a motor system disease prevalently affecting LMNs. Clinical onset of 
symptoms is generally established when mice present tremors and impairment of motor tasks, 
concomitant with hindlimbs paresis. MNs loss is present already before symptoms onset and 
further increase with the progression of the disease. The earliest pathological sign in these mice is 
the vacuolization of large neurons in the anterior horns of the SpC (Bendotti 2001), as a 
consequence of rough-ER dilatation and degenerating mitochondria. Starting with symptoms 
onset, astrocytosis and microglial activation are detected. With disease progression, also 
forelimbs are affected, and an increase in SpC protein inclusions, ubiquitin-proteasome 
impairment, ER-stress, gliosis and degenerated MNs are detected. Mice die about one month 
after symptoms onset (Bendotti 2004; Turner 2008).
While several studies have reported promising results in SOD1 rodent models prolonging survival
o f the animals and preventing MNs loss, the therapeutic relevance of animal models remains
questionable, as most preclinical trials failed to translate into effective therapies for ALS patients.
Recently, it has been suggested that the results of most trials performed so far in mSODl mouse
are likely to reflect some variables intrinsic to the model, such as genetic background and vast
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phenotypic variability, as well as those associated with preclinical studies management, rather 
than actual drug effects. Thus, attempts to standardize preclinical testing in animal models have 
been made and findings from promising therapies in transgenic mSODl mice now await 
successful translation in patients.
1.7 Biomarkers of ALS
The National Institutes of Health has defined a biomarker as "an objective measurement that acts 
as an indicator of normal biological processes, pathogenic processes or pharmacological 
responses to therapeutic intervention" (Biomarkers Definitions Working Group 2001).
1.7.1 Significance of biomarkers in ALS 
Limited understanding of ALS pathogenesis along with a lack o f diagnostic and prognostic tools 
impair efficient detection and treatment of the disease. In fact, the mean diagnostic delay from 
the appearance of the first symptoms to a correct diagnosis o f ALS has been reported to be 
between 8 and 15 months. Advanced progression of the disease at the time of diagnosis is 
detrimental to the management of the disease, because it limits the possibilities for effective 
therapeutic intervention and clinical trials. For this reason, the establishment o f early diagnostic 
biomarkers might be clinically very useful to identify and screen individuals at risk o f developing 
ALS before symptoms onset. Biomarkers would also enable an earlier and correct diagnosis by 
distinguishing patients with ALS from those with other neurological diseases, as well as 
discriminate between ALS subtypes. In addition, biomarkers that correlate with disease 
progression could serve as surrogate end points markers to facilitate the screening for effective 
therapeutic strategies by mpnitoring drug efficacy and toxicity. Indeed, this would facilitate go-no- 
go decisions during clinical trials, increasing safety and efficacy, and overall speeding drug 
development. Current efforts are underway with both large consortia and individual groups being 
involved in biomarkers identification.
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A consensus has been found for the development of magnetic resonance imaging (MRI) markers, 
"dry markers" (Turner 2011); major candidates are decreased fractional anisotropy within the 
corticospinal tract and the posterior body of the corpus callosum (Unrath 2011). Furthermore, a 
number of biochemical markers, "wet biomarkers", not only for the diagnosis, but also for the 
longitudinal assessment of ALS have been suggested. However, they have not been validated 
between internationally active laboratories and probed in large cohorts of patients.
Most of the current research efforts are focused on the discovery of protein biomarkers in 
biofluids and tissue samples. Disease specific material (spinal cord, brain stem, motor cortex) is 
not available for diagnostics or monitoring in ALS. Thus, tissue-based biomarker analysis for ALS is 
limited to muscle biopsy in living patients and postmortem CNS and muscle tissue samples, that 
are representative of advanced and end stages of the disease. Major candidate samples for wet 
biomarker development include blood plasma (Mitchell 2010), peripheral blood mononuclear 
cells (PBMCs) (Nardo 2011), CSF (Ryberg 2010; Jesse 2011) and skin biopsies (Weis 2011). 
Advantages of the use of blood and CSF as surrogate tissues for biomarker discovery regard their 
availability for routine sampling during all stages of disease and well optimized standard operating 
procedures for sample acquisition, processing, and storage. CSF contains proteins released from 
different neuronal and non neuronal cell types while blood samples provide also information on 
systemic events. Moreover, an important benefit for current and future proteomic studies is the 
existence of consistent knowledge on their proteome. Urine and saliva represent alternative 
sources of protein, or more likely, peptide biomarkers, that are readily available through non- 
invasive collection.
1.7.2 Biologic markers of ALS 
Technologies that can quantify changes in protein levels or identify abnormal post-translational 
modifications (PTMs) of proteins have enabled detailed searches for protein-based biomarkers for 
ALS. Indeed, several recent studies have identified individual proteins and/or protein panels from
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blood samples and CSF that represent putative ALS biomarkers. At the same time, these protein 
biomarkers, demonstrating the presence of anomalies in various pathways implicated in ALS, can 
also provide new insights into the pathogenesis of the disease and can support the identification 
of new targets for drug treatment.
The first blood based study has lead to the discovery of aminoaciduria in some patients with 
disrupted calcium metabolism and neuromuscular symptoms (Patten 1978). More recent findings 
have revealed higher concentrations of tyrosine in the serum, and glutamate (excitotoxicity 
hypothesis) in the plasma, as well as decreased concentrations of large neutral amino acids (Camu 
1993; llzecka 2003). An increased concentration o f excitatory aa, notably glutamate and 
aspartate, has also been observed in the CSF o f patients with ALS (Rothstein 1990), as well as 
increased neurofilaments concentration (Rosengren 1996).
On the basis o f the presence of oxidative stress and inflammation as important pathogenic 
effectors in ALS, an increase in 4-hydroxy-2,3-nonenal and monocyte chemoattractant protein 1-a 
levels have been detected in serum of ALS patients (Simpson 2004; Baron 2005). Moreover, 
altered levels of multiple inflammatory cytokines (IL-2, IL-6, IL-10, IL-15 and GM-CSF) and 
individual chemokines (MCP-1 and IL-8) have been detected in the CSF and in blood (IL-8, CCL11, 
CCL24 and CCL26) of ALS patients (Mitchell 2009; Kuhle 2009).
Altered concentration of growth factors, such as plasma-transforming growth factor-beta 1 in 
plasma (llzecka 2002), VEGF, FGF2, HGF, GDNF and PEDF in CSF (Moreau 2006; Johansson 2003; 
Kern 2001; Grundstrom 2000; Kuncl 2002), IGF-1 in both fluids (Hosback 2007), angiogenin in 
serum (Cronin 2006) were also observed.
In the last few years, the use of mass-spectrometry-based proteomics has greatly increased the 
yield of candidate biomarkers for ALS. In particular, cystatin C and transthyretin have been 
identified as candidate biomarkers for ALS in different studies in CSF and blood samples, in 
association with the neuroendocrine protein 7B2, the neurosecretory protein VGF or fetuin-A in 
CSF (Ranganathan 2005; Pasinetti 2006; Ryberg 2010; Brettschneider 2010). In addition, a
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longitudinal study on CSF samples identified cystatin C as a prognostic indicator o f disease 
progression (Wilson 2010). Interestingly, one protein, galectin-3, emerged as a candidate 
biomarker for ALS, as it was highly enriched in G93A-SOD1 tissues, as well as in human ALS SpC 
and CSF (Zhou 2010).
Recently, two-dimensional differential in gel electrophoresis (2D-DIGE), a robust fluorescence- 
based quantitative system, with subsequent MALDI-TOF/TOF mass spectrometry, was used to 
identify protein alterations in PBMC from patients with ALS (Nardo 2011). A panel o f 14 protein 
biomarkers was validated and the following combinations of proteins may be useful in clinic:
CLIC1, actinNT and hnRNP A2/B1, to support diagnosis with 98% discriminatory power; 
ERP57, to discriminate between patients with high and low disease severity with 89% 
discriminatory power;
ERP57, TDP-43 and CypA, to determine disease progression (confirmed in an independent 
set of sporadic patients in a pilot longitudinal study);
CypA and IRAK4, to significantly distinguish ALS from other neurological disorders with 
91% discriminatory power;
CypA, GSTOl, FUBP1, CLIC1 and actinNT, to link pathogenic events between human and 
animal models. Indeed, these are translational biomarkers, since showed similar changes 
in PBMC of sALS patients and G93A-SOD1 rats, and were also altered in the SpC of G93A- 
SOD1 rodents before disease onset.
It is difficult to know whether the proteomic changes reported in ALS are a consequence or a 
cause of its complex pathology. Moreover, many of these proteins are not unique for the disease. 
Thus, further investigations are required to validate these initial findings and pursue the role of 
these proteins in a clinical context as diagnostic or surrogate markers of the disease.
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1.7.3 TDP-43 as a biomarker in ALS
TDP-43 can be considered a biochemical marker o f ALS and FTLD. Following its identification as 
the main component of UBIs (Neumann 2006; Arai 2006), several human tissues have been 
analysed for TDP-43 levels or the presence of aggregates, in order to evaluate the possibility of 
using TDP-43 as a biomarker to detect disease onset and progression. The presence of abnormal 
TDP-43 levels or modifications has been detected in CSF (Kasai 2009; Noto 2011; Steinacker 
2008), blood plasma (Foulds 2008; Kuiperij 2010), circulating lymphomonocytes (De Marco 2011; 
Nardo 2011), skin biopsies (Suzuki 2010) and skeletal muscle (Soraru 2010) from sALS patients. 
The most promising sources of TDP-43 material to be used for biomarker studies include PBMCs 
and CSF (Buratti 2012).
Interestingly, TDP-43 levels in the CSF are increased only in ALS patients and not in patients with 
other neurodegenerative or inflammatory diseases such as PD, multiple sclerosis, or Guillain-Barre 
syndrome, thus indicating a specificity for this pathology (Noto 2010). Moreover, lower CSF TDP- 
43 levels are associated with shorter survival time, thus suggesting that among ALS patients, 
lower levels of TDP-43 in the CSF may reflect its accumulation in cortical and spinal MNs and 
thereby are associated with a worst prognosis.
1.7.4 Cyclophilin A is a candidate biomarker for 
ALS
The protein cyclophilin A (CypA) recently emerged as a lead biomarker candidate for ALS from the 
proteomic analysis of PBMC of sALS patients conducted in our laboratory (Nardo 2011). In 
particular, increased levels of CypA were first identified in a small group of patients (n = ll)  
compared with healthy controls, and then verified on a relatively large cohort o f patients (n=60). 
Multivariate logistic regression analyses showed that CypA was able to differentiate two levels of 
disease severity and, more importantly, to distinguish ALS from other neurological disorders. In 
the same study, a well-characterised and relevant model o f ALS, the G93A-SOD1 rat, was analysed
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and CypA showed an interesting correlation with sALS patients. Indeed, CypA was up-regulated in 
the rat model PBMC, as observed for patients and, more interestingly, its up-regulation was 
detectable also in SpC ventral horns, where the population of MNs is enriched. In both cases CypA 
altered levels were detectable already at pre-symptomatic stages of the disease.
Moreover, CypA is a secreted protein that could potentially be measured in human biofluids. 
Indeed CypA was also analysed in CSF of sALS patients where it was increasingly concentrated in 
comparison with healthy controls and with multiple sclerosis patients (unpublished results from 
the lab).
In addition, alterations in CypA had been previously reported by our lab in two proteomic studies 
conducted in the G93A-SOD1 mouse model. In particular, extracts from the lumbar SpC of pre- 
symptomatic G93A-SOD1 mice were analysed to identify the cellular pathways specifically altered 
in the tissue mainly affected by the disease. Fifteen proteins differentially expressed were 
identified, including mitochondrial proteins, molecular chaperones, proteins involved in oxidative 
stress and in protein degradation pathways (Massignan 2007). Among them, a specific alteration 
of CypA isoform pattern was observed: an up-regulation of the phosphorylated-acidic isoform and 
a down-regulation of the N-terminal acetylated-basic isoform. Thus, CypA PTMs are altered in an 
animal model of ALS, as well as in PBMCs from sALS patients (unpublished results from the lab). 
Another proteomic study performed in our laboratory,, identified the proteins enriched in the 
triton-insoluble fraction, as a model of protein aggregates, in the SpC of WT-SOD1 and G93A- 
SOD1 mice at different stages of the disease (Basso 2009). In mSODl mice SpC, CypA was found 
aggregated already at early-symptomatic stage and was highly enriched in aggregates at end 
stages of the disease. Interestingly, CypA was present also in the insoluble fraction of the SpC of 
sALS patients.
CypA should be thus further investigated for its potential as a marker for differentiating ALS from 
disease mimics, for monitoring disease progression and response to therapies in patients and ALS 
animal models. Furthermore, since CypA alterations were found both in periphery and in affected
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tissue o f mouse and human ALS, it should be further studied also as a putative key modulator of 
the disease, in order to unravel its possible involvement in ALS pathogenesis and progression.
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2. Cyclophilin A
CypA is an ubiquitous and highly expressed protein that can be involved in several pathways. 
However, the specific roles it plays in the CNS and in neuronal cells, where it is abundantly 
expressed, have not been defined yet.
In 1984, Fischer and his coworkers isolated the first prolyl isomerase from porcine kidney, as an 
enzyme able to accelerate the proline-limited folding reactions of many proteins in vitro. A 
surprising result emerged when the porcine prolyl isomerase was sequenced. It was found to be 
identical to CypA, the cytosolic binding protein for the immunosuppressive drug CsA. In fact, this 
protein was discovered twice in 1984: by virtue of its tight binding with CsA, and by its catalytic 
activity as a PPIase. CypA is the most abundant among the cyclophilins and is widely distributed in 
almost all tissues in prokaryotes and eukaryotes.
2.1 The cyclophilins family
Cyclophilins (Cyps) form a large family of proteins with two main recognised features: the 
peptidyl-prolyl cis-trans isomerase (PPIase) (Fischer 1984) and the immunosuppressive activity 
(Handschumacher 1984). Cyps are highly conserved proteins since have been documented in 
every Domain of life including Archaea, Bacteria and Eukaryotes. In humans, Cyps are found in 
most tissues with remarkable heterogeneity in distribution, and are mainly expressed in brain and 
kidney (Koletsky 1986). Their presence has been documented in most cellular compartments, 
including the mitochondria, ER, Golgi, nucleus and cytoplasm (Galat 2003; Wang 2005), which 
implies their importance in cellular functions. Nine major Cyps have been identified: CypA, CypB, 
CypC, CypD, CypE, Cyp20, Cyp40, CypH and CypNK. All Cyps share a common domain of 
approximately 140-180 residues, the cyclophilin-like domain (CLD) (Figure 11), surrounded by a 
localisation domain, which is unique to each family member and determins the subcellular 
compartmentalization and the functional specialisation (Galat 2003; Marks 1996; Arevalo- 
Rodriguez 2004). Little is known on the genomic structure of cyclophilins genes, which are not 
linked each other in the genome.
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Figure 11 Representations of the molecular structure of cyclophilins.
The eight (3-strands which form the characteristic cyclophilin (3-barrel are shown in yellow; while the 
two a-helices flanking the barrel are shown in red.
—» CypA, the archetypal cyclophilin, is encoded by the PPIA gene on chromosome 7pl3, is 
composed of 165 residues encoding a 18kDa protein, which contains only the CLD. It is 
mainly located in the cytoplasm, although it is found also in the nucleus or it can be released 
by several cellular types. It is found in all tissue of mammals where it represents the 0.1-0.4% 
of the total proteins in the cell (Galat 2003).
-»  CypB is a ubiquitous protein composed of 208 aa encoded on the chromosome 15q21-q22 
(Galat 2003). The overall structure of CypB resembles that of CypA with two extensions at the 
N- and C-terminals (Mikol 1994). The N-terminal fragment contains an ER signal sequence, 
thus CypB main localisation is in this organelle and participates in protein secretory pathway 
(Galat 2003; Wang 2005).
-> CypC is a 212 aa protein encoded on chromosome 5, which gives rise to a 22kDa protein 
(Galat 2003). CypC has a structure similar to that of CypA, differing mainly in the 
conformation of three surface loop regions (Ke 1993), and like CypB is found in the ER.
—» CypD is encoded on chromosome 10q22-q23 and is a 40kDa protein encoded by 370 aa 
(Galat 2003). CypD has a signal sequence for mitochondria (Andreeva 1999; Galat 2003; 
Wang 2005).
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-»  CypE is encoded on chromosome lp32 and is a 33kDa protein made of 301 residues (Galat 
2003). CypE shows an N-terminal RNA-binding domain, which localises it in the nucleus (Mi 
1996).
->  Cyp40, is encoded in chromosome 4q31.3 and is a 40kDa protein made by 301 residues 
(Galat 2003). This protein is mainly cytosolic and consists of a CLD with a domain similar to 
tetraticopeptide (TPR) repeats which is implicated in protein-protein interaction (Ratajczak 
2003).
->  CypNK is the largest cyclophilin and was first identified from natural killer cells. It is 
composed of 1403 amino acids, encodes a 157kDa protein, and its gene is on chromosome 
3p23-p21 (Galat 2003). This cyclophilin contains a large, hydrophilic and positively-charged C- 
terminal and is localised in cytoplasm of natural killer cells.
2.1.1 Cyps peptiyl-prolyl cis-trans isomerase 
activity
Although protein folding is a spontaneous process, many proteins in vivo require assistance by 
two kinds of protein factors: foldase, such as PPIase, and protein disulfide isomerase (PDI), that 
catalyse the formation and exchange of disulfide bonds, as well as molecular chaperones.
The structural conservation throughout evolution as well as the PPIase activity o f all cyclophilins 
highlights the importance of this enzymatic reaction. Peptide bonds have a partial double bond 
character and can exist in two distinct isomeric forms: c/s and trans. Ribosomes synthesise 
peptide bonds with a trans isomeric form, corresponding to a lower energy-state, since side 
chains are 180° opposite each other and sterically favoured. For all aa residues the trans 
conformation is more energetically favourable than the c/s one. Unlike other peptide bonds, those 
preceding proline (Pro) (peptydil-prolyl bonds) often occur in the c/s conformation, and in 
oligopeptides, cis-trans isomerisations about these bonds are intrinsically slow processes with 
high activation energies (~90kJ mol'1). Prolyl isomerisations might retard in vitro folding and also 
de novo protein folding in the cell.
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Figure 12 Peptidyl-prolyl cis-trans isomerase activity of cyclophilins.
(A) Schematic illustration of the trans and the c/'s isomers of the petide bond between proline and 
another aa. The interconversion between the two forms is catalyzed by cyclophilins or other PPIases.
(B) Energy diagram for prolyl cis-trans isomerisation. Modified from Lu 2007.
Since the conversion of proteins from c/s to trans at Xaa-Pro bonds is often a rate-limiting step in 
protein folding and activity (Baneyx 2004), Cyps can accelerate protein folding in vitro (Schmid 
1995) catalysing this intrinsically slow conversion (Figure 12). Indeed, Cyps act stabilising the cis- 
trans transition state, thus accelerating isomerisation, a process important both in de novo 
protein folding and refolding processes, but also during the assembly of multidomain proteins 
(Gothel 1999). For example, blocking the cis-trans isomerase activity o f Cyps cause a delay in the 
maturation o f collagen (Steinmann 1991; Kruse 1995). Moreover, a number o f studies detected 
the presence of Cyps in the nucleus, including CypG, CypE, PPIL1, CypH, PPIL2 and PPIL3a/b, 
where they can interact directly with splicing factors (Horowitz 2002), be part o f the spliceosomal 
complexes (Jurica 2003; Cheri 2007), or bind the C-terminal domain of the RNA polymerase II 
(Bourquin 1997). The involvement of Cyps in these processes seems to be an ancient and 
universal tra it due to their presence in the splicing and transcriptional machinery in a multitude of 
taxa. Given the constitutive and ubiquitous nature o f RNA processing, the presence of Cyps in the
95
splicing machinery may be significant in modulating spliceosomal activity (Mesa 2008). Indeed 
Cyps have been demonstrated to catalyse a number of transport and foldase reactions that 
possibly assist in the assembly/disassembly dynamics of the spliceosome as well as in its coupling 
to the transcription machinery. In addition, it is possible that the capacity of Cyps to alter folding 
may provide accessibility and a mechanism for activating/inactivating spliceosomal proteins.
In addition to PPIase activity, Cyps exhibit also chaperone activity in vitro (Freskgard 1992). A 
chaperone binds to unfolded states and prevents the polypeptide chain from making illicit 
associations with other unfolded proteins or being trapped in misfolded conformations. While 
multidomain Cyps have been shown to conduct the chaperone activity in domains different from 
the catalytic one, small single-domain Cyps, such as CypA, present both isomerase and chaperone 
activities in the active site (Moparthi 2010). Nevertheless, Cyps role in vivo is not clear, and they 
can have two possible functions, which are not mutually exclusive. First, Cyps may participate in 
protein folding (Schiene 2000), with only an incremental effect, thus arguing against their 
essential role in protein maturation. Indeed, all deletions of cyclophilin genes in yeast produce 
strains that are viable, as is the mutant that lacks all the cyclophilins (Dolinski 1997). Secondly, 
PPIases can bind at hydrophobic patches on their target proteins without necessarily isomerising 
a peptidyl-prolyl bond, thereby preventing misfolding (Baker 1994; Ferreira 1996; Arie 2001) 
and/or modulating activity of the target protein (Braaten 1997; Streblow 1998; Shen 1998; 
Crenshaw 1998; Wu 2000). Moreover, PPIase enzymes could be also involved in repairing 
damaged proteins due to environmental stresses including thermal stress, UV irradiation, changes 
in the pH of the cell environment, and treatment with oxidants (Parsell 1993).
2.1.2 Cyps immunosuppressant activity 
Cyps show an immunosuppressant activity by binding to the potent immunosuppressant agent 
Cyclosporin A (CsA), and for this reason they are also called immunophilins. CsA is a hydrophobic 
cyclic undecapeptide produced by the fungus Tolypocladium inflatum  (Borel 1989). Beginning in 
the 1980s, CsA was used as an immunosuppressive drug and is now employed for prophylaxis and
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treatment of allograft rejection following organ or tissue transplants. Actually, CypA was firstly 
recognised as the main target of CsA (Handschumacher 1984). Subsequently further Cyps were 
characterised and several members of the cyclophilin family were shown to have varying degrees 
of affinity for the drug CsA. The inhibitor constant, Kj is the binding affinity o f an inhibitor to its 
enzyme and is an indication of how potent an inhibitor is, thus it represents the concentration 
required to produce half maximum inhibition: lower Kj means lower inhibitor concentration to use 
to obtain the result. Kj values of CsA inhibitory activity have been determined for CypA (2.9nM), 
CypD (6.7nM), CypC (7.7nM) and CypB (8.4nM) (Daum 2009). Therefore, CsA binds and inhibits 
with more efficiency CypA, with an IC50 (the concentration of CsA that induces 50% of inhibition) 
of 25nM, whereas CypB, the least efficient cyclophilin, shows and IC50 o f 84nM (Mikol 1994).
Figure 13 Cyclophilin A and cyclosporin A complex.
(A) Ribbon diagrams of CypA/CsA. The CypA residues directly involved in the binding with CsA are 
shown as blue sticks, while CsA is shown in red stick representation. (B) Predicted surface of CypA in 
complex with CsA.
The immunophilin super family is classified into three major subfamilies, including the CsA binding 
proteins (Cyps) (Pemberton 2006), FK506 binding proteins (FKBPs) (Ho 1996) and parvulins 
(Fujiyama 2002). The functional role o f CypA and of the other immunophilins in 
immunosuppression does not involve their PPIase activity or the catalysis o f a protein folding 
reaction. Rather, these proteins are recruited by CsA and FK506 for association in tight complexes. 
In mammals CsA-cyclophilin complex, but neither the drug itself nor the protein alone, is able to 
bind calcineurin and inhibit its phosphatase activity in vitro and in vivo (Fruman 1992). In fact,
A B
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calcineurin is a calcium-calmodulin-activated serine/threonine phosphatase, and its inhibition 
blocks the translocation of the nuclear factor of activated T cells (NF-AT) from the cytosol to the 
nucleus, thus stopping the transcription of genes encoding cytokines such as interleukin-2 (Liu 
1991; O'Keefe 1992). Ideed, under physiologic conditions NF-AT is transported to the nucleus 
upon dephosphorylation and there binds to the enhancer of the interleukin-2 gene promoting its 
expression. X-ray structure analyses of human cyclophilin-CsA complex have shown that the 
residues involved in the binding with CsA are approximately those composing the hydrophobic 
active site of the enzyme (Figure 13).
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Figure 14 Ribbon diagram of CypA/CsA/Cn ternary complex.
The crystal structure of this super complex has recently been determined to a resolution of 2,8A. CsA 
is shown in ball-and-stick representation. CnA is in yellow; CnB is in red; CypA is in green; Ca2+ ions 
are cyan balls. Modified from Jin 2002.
The CsA/CypA complex binds with a high affinity to the ternary complex formed with calcineurin A 
(CnA), calcineurin B (CnB) and calmodulin (Cdl) (Figure 14). The binding of CsA-CypA complex to 
calcineurin increases the complex stability; this is possible because upon CsA binding to CypA the 
charges and hydrophobic surfaces of the drug-protein become more congruent with the binding 
site on calcineurin (Hornbogen 1992).
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2.2 CypA structural features
X-ray and NMR studies have revealed that human CypA is characterised by the presence of eight 
anti-parallel (3-strands that together form a right-handed (3-barrel, with an a-helix at either ends 
(Richardson 1981; Sawyer 1987) and another short a-helix located between residues 119-122. 
These structured regions of the protein are connected by loops. One of these loops (Lysll8- 
Hisl26) and four (3-strands make up the binding site for CsA (Kallen 1991; Ke 1991) (Figure 15). 
The interior cavity of the barrel in CypA is highly hydrophobic, indeed the compact core of the 
protein is formed by seven aromatic and other hydrophobic residues.
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Figure 15 Aa sequence of human CypA with elements of secondary structure.
The crucial catalytic residues involved in the PPIase activity are shown in the boxes. The green 
triangles indicate the residues interacting with CsA. Low - - - - -  - - -H ig h  conservation (source: 
PDB; Protein Data Bank)
The active site of the human CypA is localized to the outer surface and is formed by the residues 
R55, F60, M61, Q63, A101, F113, W121, L122 and H126 (Ke 1994; Zhao 1997; Howard 2003) 
(Figure 16). Analyses of the aligned sequences of the human CLDs have revealed that aa crucial 
for PPIase activity and the aa composing the aromatic/hydrophobic network are the most well 
conserved in all 19 sequences of the human CLDs. In particular, the equivalent sequence positions 
occupied by Arg55 in CypA are highly conserved in the sequences of the human CLDs (Ke 2004). 
Indeed, Arg55 (in human CypA) is extremely conserved in all cyclophilins because it plays a crucial
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role in PPIase catalysis. The active site of the wild-type enzyme is structurally very stable and puts 
Arg55 in a favourable position to perform its catalytic role in the transition state. Arg55 
guanidinium group facilitates catalysis by anchoring the substrate proline oxygen and stabilizing 
sp3 hybridization of the proline nitrogen in the transition state (Howard 2003). The substitution of 
the Arg55 with an alanine residue causes a 1000-fold reduction in the catalytic efficiency 
(Zydowsky 1992). Moreover, also F60A and H126Q substitutions retain less than 1% of the wild- 
type catalytic efficiency, thus indicating a key role also for these residues in PPIase catalysis 
(Zydowsky 1992).
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Figure 16 Human CypA active site.
(A) Residues composing the active site of CypA. (B) Surface representation of CypA with residues 
involved in PPIase activity highlighted in blue.
2.3 CypA localisation
CypA is widely distributed in all tissues, but it is found with the highest concentration in the CNS 
where it is located primarily in neurons (Goldner 1996). Despite its abundance in the CNS, its 
primary functions in this compartment remain largely undefined. Nevertheless, CypA seems to be 
implicated in neuronal differentiation (Hovland 1999; Nahreini 2001; Chiu 2003; Song 2004; Urano
2006) and in adult cortical plasticity and reorganisation following retinal injury (Arckens 2003).
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In the cell, CypA is mainly localised in the cytoplasm, but it can be found also in the nucleus 
(Krummerei 1995), despite the absence of a classic nuclear localisation signal. Indeed, CypA 
contains a M9-like m otif which is necessary for transportin 1, an importin protein, recognition to 
mediate protein nuclear import (Pan 2008). In addition, CypA can also be secreted from a huge 
variety o f cell types, in response to different stimuli (Seko 2004; Sherry 1992, Suzuki 2006; Jin 
2000). CypA release is mediated by vescicle transport and plasma membrane binding, processes 
mediated by actin remodelling, RhoGTPase activity and phosphorylation of myosin II light chain 
(Suzuki 2006). Moreover, CypA has been found in human urine (Pisitkun 2004), plasma (Endrich
1998), synovial fluids of patients with rheumatoid arthritis (Billich 1997) and in rat cortical primary 
cultures exosomes (Faure 2006). CypA is believed to play several important roles both inside the 
cell and in the extracellular space. However none of these functions is essential for viability since 
transgenic mice lacking both copies of CypA gene (CypA-/-) suffer no obvious decrease in life span 
(Colgan 2004).
2.4 CypA intracellular functions
CypA has a dual folding role: it can act as an acceleration factor in protein folding thanks to its 
well characterised ability to catalyse the cis-trans isomerisation of peptidyl-prolyl bonds (Kern 
1995), and as a chaperone, increasing the yield of native protein during the folding reaction 
(Freskgard 1992).
2.4.1 CypA isomerase activity 
CypA-catalysed prolyl isomerisation can have a profound impact on many key proteins in diverse 
cellular processing, including cell growth, stress responses, cell signalling, immune response, viral 
infection, cytokinesis. Unlike covalent modification or global unfolding, proline isomerisation is an 
intrinsic conformational exchange process that has the potential to direct ligand recognition and 
to control protein activity within the confines of the native state (Andreotti 2003). Indeed, o f the
naturally occurring aa, proline is unique and appears to fulfil multiple roles in the context of
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native, folded proteins. In some proteins, proline isomerisation may confer conformer-specific 
properties to a native protein fold by modulating the features of a protein surface. Alternatively, a 
conformational heterogeneous proline residue may cause minimal structural perturbations, but 
could instead serve as a recognition site for PPIase. The c/s and trans isomers of many proteins 
have distinct functions, and their conversions by PPIases can function as a new general class of 
protein regulatory switches. Indeed, the cis and trans isomers provide stable local motifs that 
differ dramatically in structure, thereby providing a mechanism for selecting distinct pools of 
binding partners, even in the context of otherwise unstructured regions of proteins. Therefore, 
cis-trans isomerisation is a molecular switch that can be used in an enzyme-regulated manner to 
help control the timing of biological events such as isomer-specific protein-protein interactions, as 
well as the amplitude and duration of a cellular process (Lu 2007).
NMR and X-ray studies have shown CypA in complex with the HIV-1 capsid protein (Gamble 1996; 
Campos-Olivas 1999) and with the interleukin-2 tyrosine kinase (Itk) (Brazin 2002; Andreotti 
2003). In these cases a similar equilibrium of the cis-trans isomerisation state ratio of the 
substrates has been observed, that is altered when they are in complex with CypA, suggesting 
that an increase in the cis conformation of the bound substrate may be a general mechanism for 
CypA to mediate the control o f the protein function.
The HIV-1 capsid protein forms the conical core structure at the center of the mature virion and
can bind with high affinity human CypA, thereby packaging it into the virion. Through this
interaction CypA is able to promote both the formation and the infectivity o f human
immunodeficiency virus (Luban 1993; Bosco 2002; Braaten 1996 and 2001; Sokolskaja 2004). The
N-terminal portion of HIV-1 capsid protein binds efficiently human CypA's active site (Howard
2003; Gamble 1996; Campos-Olivas 1999) (Figure 17); in particular, CypA binds to an exposed
proline-rich loop in the HIV-1 capsid protein A (CA) domain of HIV-1 Gag envelope protein that has
been demonstrated to have 44,4% identity with the sequence of another CypA interactor, that is
CD147 (Yurchenko 2002). This indicates that microorganisms can also use prolyl cis-trans
isomerisation as a regulatory mechanism to gain entry into host cells. The binding site for CypA,
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Gly89-Pro90 in capsid, exists in the cis and trans forms and CypA can catalyse Gly89-Pro90 
isomerisation, thus suggesting a role in maturation or disassembly o f viruses. Indeed, conditions 
that disrupt CA-CypA interaction, such as mutational inactivation o f the CypA binding site or 
inhibition by CsA, inhibit replication of most HIV-1 strains, and HIV-1 replication is attenuated in a 
human T-cell line that lacks CypA (Braaten 1996). In this case, the Cyp-CA interaction seems to 
block the recognition o f the HIV-1 virion by the host cell restriction factor Refl, an intrinsic 
antiviral cellular protection mechanism (Howard 2003; Towers 2003). CypA was also shown to 
enahance HCV RNA replication stimulating the RNA binding ability o f the NS5A protein, 
modulating the conformation of the RNA binding m otif by cis-trans isomerisation (Foster 2011).
Figure 17 CypA/HIV-1 capsid complex.
X-ray structure of the N-terminal portion of the HIV-1 capsid (yellow) interacting with the PPIase 
cavity of CypA (green). The CypA residues involved in the catalytic actvity are shown in blue. A loop 
of the capsid protein (that contains 4 prolines) can undergo the cis-trans isomerisation and the 
following conformational switch (Howard 2003).
In addition, CypA may also have an important role in the immune response through the 
interaction with the tyrosine kinase Itk, a non-receptor protein that participates in the 
intracellular signaling events leading to Th2 cell activation. NMR structural studies combined with 
mutational analysis have shown that CypA can bind to the Itk SH2 domain which is generally in a 
cis conformation, and catalyse the cis-trans isomerisation of the Asn286/Pro-287 imide bond 
(Figure 18). The cis conformer of Itk is likely an inactive form of the enzyme and CypA acts as a
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repressor, thus maintaining its inactivated form. CypA PPIase activity, via interaction with Itk and 
proline-dependent conformational switch, can thus regulate substrate recognition and mediate 
regulatory interactions in CD4+T-cell activation (Brazin 2002; Colgan 2004; Andreotti 2003).
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Figure 18 Model of Itk regulation by CypA.
The imide bond preceding Pro287 in the Itk SH2 domain spontaneously interconverts between cis 
and trans conformers. The self-associated, dimeric form of Itk predominates for the cis imide bond 
containing conformer (left), while the trans imide bond within the SH2 domain (denoted SH2*) 
favours interactions with signaling partners, such as Slp-76 (right). Interconversion between the two 
conformations of Itk likely occurs via the monomeric form of the enzyme (center). Itk catalytic 
activity is inhibited by the PPIase activity of CypA. Adapted from Colgan 2004.
The importance of CypA PPIase activity in cell signalling has also been documented. Crk is a 
member of an adaptor protein family that has several SH2 and SH3 domains. NMR studies have 
revealed that cis-trans isomerisation of the prolyl bond at position Gly237-Pro238 (located 
between two of the SH3 domains) is very slow and that PPIase binding to the SH3 domain 
facilitates an opening of the "gate," where the isomerisation rate is increased and the adaptor 
forms an "open," less restricted active conformation, that is catalysed by CypA (Figure 19) (Sarkar
2007).
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Figure 19 Model of the equilibrium of conformational states of Crk.
The intramolecular inhibitory SH3N/SH3C interaction is stabilised by the c/s conformer of the Gly237- 
Pro238 prolyl bond, whereas the trans conformer favours an uninhibited state. Activation occurs by 
PPII ligand binding to a low population of uninhibited states wherein SH3N binding site is accessible, 
thereby shifting the equilibrium towards the SH3N-PPII ligand bound state. Pro238 acts as a 
molecular switch that has the intrinsic capacity to regulate the autoinhibition of Crk. Adapted from 
Sarkar 2007.
CypA constitutively associates with prolactin receptor (PRLr) and Janus kinase 2 (Jak2) (Syed 2003) 
(Figure 20), resulting in enhanced Jak2 and Stat5 activity. In particular, CypA directly acts on PRLr 
through Pro-334, mediating a conformational change within the PRLr/Jak2 complex. Thus, CypA is 
required for effective PRLr-induced signaling, a mechanism particularly relevant in the progression 
of human breast cancer (Zheng 2008).
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Figure 20 Regulation of the PRLr/Jak2 complex by CypA.
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(i) CypA is constitutively associated with PRLr and Jak2 during unstimulated conditions, (ii) Upon 
binding of PRL to PRLr, CypA positively regulates Jak2 activity by exerting its isomerase activity, (iii) 
presumably through its switching function of a cis-trans peptidyl prolyl isomerase. Ablation of CypA 
PPI activity by cyclosporine A (CsA) and other approaches inhibits PRL signaling and might be a novel 
therapeutic strategy in the treatment of human breast cancer. The red arrow in (ii) denotes cis-trans 
interconversion of proline 334 in the X-box motif of the PRLr; the red circle containing P indicates 
phosphorylation of JAK2 kinase, PRLr, and signal transducer and activator of transcription 5a 
(Stat5a). Adapted from Clevanger 2009.
These findings suggest that prolyl isomerisation is emerging as a complementary regulatory 
mechanism to control signalling networks.
2.4.2 CypA chaperone activity 
CypA posseses a chaperone function independent of its PPIase activity. CypA is indeed a natural 
"protein-philin" (Greek philin= friend) that interacts with proteins to guide their proper folding 
and assembly (Barik 2006). In particular, CypA transiently interacts with the early folding 
intermediates o f its protein substrates and can function as a hydrophobic collector basket for 
misfolding-prone regions and can, at later stages, protect the protein from misfolding, thereby 
preventing incorrect interactions leading to aggregation.
A list of protein containing a consensus peptide for CypA binding has been identified in 2005 
(Piotukh 2005), however until now very few substrates of its chaperone activity have been clearly 
identified. The effects shown by CypA on creatine kinase (Yang 1997; OU 2001), carbonic 
anhydrase II (Freskgard 1992), citrate synthase (Moparthi 2010), and stefin B (Smajlovic 2009) 
refolding indicate that CypA could act as a chaperone in vitro. CypA chaperone activity in living 
cells was firstly demonstrated on procollagen I triple-helix, whose correct folding was accelerated 
by CypA and delayed by CsA treatment (Steinmann 1991).
Interestingly, CypA chaperone activity has been directly associated with ALS. In particular, the
death-inducing effect o f mutant V148G-SOD1 overexpression in PC12 neuronal cells was
potentiated by CsA treatment, and overexpression of wild-type CypA, but not the PPIase-deficient
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mutant R55A, restored cell survival rate in mSODl neurons. This effect was correlated with an 
overall decreased cellular PPIase activity, indicating that mSODl-induced death was mediated by 
an increase in misfolded proteins and that CypA can have a protective intracellular activity (Lee 
1999). These data also suggest that the chaperone activity o f CypA can restore the balance inside 
the cell and a surplus o f CypA can be useful for the maintenance of protein homeostasis.
2.4.3 CypA and oxidative stress 
CypA is a protein generally up-regulated after oxidative stress. Since CypA behaves as a molecular 
chaperone for proteins, its higher expression is thought to contribute to the correct folding of 
misfolded proteins that can accumulate due to oxidative stress, thus displaying a strong 
cytoprotective effect (Lee 1999; Hu 2000; Matsumoto 2005).
CypA mRNA levels are elevated in cortical neuronal culture after exposure to ischemic insult
(Boulos 2007) and in rat brain microvessels after traumatic brain injury in vivo (Redell 2007). CypA
is up-regulated in cortical neurons pre-conditioned with cycloheximide, which targets protein
synthesis, heat stress or MK801, an NMDA membrane receptor blocker, and thus less sensitive to
further ischemic stress, suggesting that CypA can be involved in neuroprotective pathways against
ischemic injury (Meloni 2005). Moreover, cortical neuronal cultures pre-conditioned with
erythropoietin (EPO), a potent neuroprotective factor against hypoxia-induced oxidative stress
(Liu 2005), show increased levels of intracellular CypA, which is thus implicated in protective
effect induced by EPO (Meloni 2006). Furthermore, hypoxia has been demonstrated to stimulate
the production of CypA mRNA and protein also in cancer cells (Choi 2007). In addition, CypA
overexpression increases the growth rates o f human embryonic brain cells (Nahreini 2001),
protects neurons from oxidative stress (induced by cumene hydroperoxide) and in vitro ischemia
(induced by oxygen glucose deprivation) (Boulos 2007). Whereas the down-regulation o f CypA
levels decreases the viability of cardiomyocyte cultures treated with t-butylhydroperoxide (Doyle
1999). Moreover, CsA is neurotoxic for both cortical and hippocampal neurons (McDonald 1996;
Kaminska 2001), and is able to mediate the generation of ROS by inhibiting PPIase activity in
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cultured myoblasts (Hong 2002). According to these evidences, a neuroprotective role for CypA 
could be hypothesised.
Other studies have highlighted CypA capability to bind to peroxiredoxins (Prx) activating their 
peroxidase activity (Lee 2001). CypA supports antioxidant activity of Prxll and PrxVI, both against 
thiol and ascorbate. Specifically two cysteine of CypA, C ysll5  and Cysl61, are involved in the 
activation and in the reduction o f Prx. CypA is also able to bind the antioxidant enzyme 
gluthatione-S-transferase (Piotukh 2005). Furthermore, CypA was shown to be part of a cytosolic 
heat-shock protein-immunophilin chaperone complex (Uittenbogaard 1998), and to bind the heat 
shock protein Hsp90 (Nadeau 1993). Moreover, CypA is able to bind the antioxidant protein Aopl 
in T-cells and to increase its protection activity on glutamine synthetase from oxidative 
inactivation, in a CsA-independent way (Jaschke 1998). Also the expression of the yeast 
homologous of CypA, Cprl has been shown to be activated by stress conditions, indicating that 
Cprl may participate in protecting the cell against cellular stresses (Arevalo-Rodriguez 2004). The 
overexpression of Cprl also drastically increases cell viability in the presence of stress inducers, 
both in yeast and E.coli, illustrating the importance of Cprl as a molecular chaperone and as 
rescue protein, in the presence of adverse conditions (Kim 2010a, 2010b).
2.4.4 CypA and apoptosis 
As previously mentioned CypA can localise also in the nucleus. Apoptosis is generally related to 
DNA fragmentation and several works have demonstrated an active function of CypA in DNA 
degradation (Montague 1994). CypA displays sequence and structural similarities with NUC18, a 
18kDa nuclease isolated from apoptotic rat thymocytes (Gaido 1991). CypA is able to degrade 
single-stranded, double-stranded and supercoiled DNA in a Ca2+/M g2+ dependent way, and 
independently of CsA inactivation. Thus CypA also possesses a nuclease activity independently 
from its PPIAse function (Montague 1997), that is similar to the activity o f apoptotic 
endonucleases. Moreover, CypA was found in the nucleus of macrophages, where it exhibited a
zinc-dependent DNA binding activity and PPIase activity only in the absence of zinc ions.
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A pro-apoptotic activity of CypA is also supported by several reports demonstrating CypA 
interaction with the apoptosis inducing factor (AIF) (Cande 2004). AIF is a flavoprotein with NADH 
oxidase activity, normally contained in the mitochondrial intermembrane space (Susin 1999). 
Under pathological conditions, AIF translocates from the mitochondria to the cytosol and then to 
the nucleus (Daugas 2000), where it undergoes electrostatic interactions with the DNA and 
tethers CypA to chromatin (Ye 2002). The AIF/CypA complex then causes DNA degradation, and 
the two proteins together have a higher DNase activity than each protein alone (Cande 2004). In 
dying neurons, the lethal translocation of AIF to the nucleus requires the interaction with CypA, 
suggesting a model in which two proteins that normally reside in separate cytoplasmic 
compartments acquire novel properties when moving together to the nucleus (Zhu 2007). 
Interestingly, AIF is abundant in MNs and reactive astrocytes in the SpC of G93A-SOD1 transgenic 
mice, where its expression is increased with disease progression (Oh 2006). Moreover, in the 
symptomatic mSODl mice AIF translocates from mitochondria to the nucleus of degenerating 
MNs, thus suggesting that AIF may play a role in MN death in an ALS mouse model (Oh 2006). In 
addition, in sALS patients both MNs and astrocytes show co-localisation with AIF, and biochemical 
analyses indicate nuclear translocation of AIF in the degenerating MNs in the SpC of ALS patients 
compared to healthy controls (Shibata 2009). Interestingly, CypA was demonstrated to co-localise 
with AIF in MNs of lumbar SpC, both by biochemical and immohistochemical assays (Tanaka 
2010). Moreover, AIF and CypA cooperate in inducing apoptosis since (i) cells lacking CypA are 
relatively resistant to AIF-induced cell death, (ii) in WT-CypA cells AIF silencing reduces apoptosis 
events and (iii) transfection with mutant forms of AIF that are unable to bind CypA abolishes 
apoptosis (Cande 2004). In the same way, disruption of CypA yeast orthologue Cprl abrogates cell 
death induced by AIF overexpression (Wissing 2004). The pro-apoptotic activity o f CypA mediated 
by AIF has also been reported in vivo: after an hypoxia-ischemia insult, CypA knock-out mice 
showed a reduced brain infarct volume and neuronal loss (Zhu 2007). This protective effect is 
explained by a reduced nuclear translocation o f AIF in the neurons of CypA knock-out mice 
located in the damaged area. Interestingly, also CypA translocation to nuclei is reduced in AIF-
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deficient mice (Zhu 2007). Therefore, these data suggest that CypA and AIF translocation and 
activity need the presence of both factors and strengthen the hypothesis of the involvement of 
CypA in apoptosis and possibly in ALS.
CypA can also be involved in excitotoxicity-mediated apoptosis due to an increased calcium influx 
in the cell mediated by glutamate receptors (Capano 2002). Indeed, CsA can suppress glutamate 
toxicity in hippocampal neurons (Uchino 1995) and cortical neurons (Nieminen et al. 1996). Thus, 
although CypD can be involved in this protection mechanism, given that CypA is the main 
intracellular ligand for CsA, CypA has been proposed to play a role in the excitotoxin-induced 
apoptosis (Capano 2002). Silencing CypA in rat neuronal cells treated with glutamate and NO has 
the same reducing effect on caspase-8, -9, -6 and -3 activation as CsA, suggesting that CypA- 
caspase activation is mediated by CypA PPIase activity (Capano 2002). In this context, an 
involvement of CypA-calreticulin interaction has also been hypothesised (Reddy 1999), suggesting 
that it may inhibit calcium fluxes required for apoptosis, even if no demonstration is yet available. 
Notably, stable heterodimers composed of CypA and cytochrome c (CytC) were described in brain 
tissue and in the cytoplasm of apoptotic cells in vitro (Bonfils 2010). CypA was shown to inhibit 
CytC-dependent procaspase-3 activation in a cell-free system, suggesting that an anti-apoptotic 
effect o f CypA may be due to the ability o f CypA to bind free cytoplasmic CytC. The regulation of 
caspase-3 mediated by CypA is still unclear.
Concluding, it is still difficult to understand whether CypA is an anti- or pro-apoptotic factor, since 
the results obtained are still controversial.
2.4.5 CypA and the subcellular localisation of 
proteins
A role for CypA has also been hypothesised in promoting the functional expression o f membrane 
proteins. Indeed, CsA treatment, inhibiting both CypA PPIase and chaperone activities, resulted in 
impaired cell-surface externalisation of the homo-oligomeric acetylcholine receptor containing
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the a7 subunit (Helekar 1994), the homo-oligomeric 5-hydroxytryptamine type 3 receptor 
(Helekar 1997), the Kir2.1 potassium channel (Chen 1998), the insulin receptor (Shiraishi 2000) 
and the creatinine transporter (Tran 2000). In particular, the specific involvement o f CypA PPIase 
activity in the maturation of the homo-oligomeric receptors containing nicotinic acetylcholine 
subunit a7 has been demonstrated (Helekar 1994), since overexpression of WT-CypA, but not the 
PPIase-deficient mutant R55A, reversed the effect of CsA. Furthermore, the cell surface 
expression level of the creatine transporter was reduced by CsA treatment in muscle cells, 
w ithout significantly altering its total expression level, but with a concomitant decrease in 
creatine uptake (Tran 2000). Therefore, the resulting creatine-depletion in the muscle could 
adversely affect the energy metabolism, which in turn might lead to muscle myopathy, that is a 
clinically relevant muscle disorder developed on chronic CsA therapeutic treatment. In addition, 
CypA is also involved in the functional expression of the Na+-Ca2+ exchanger (NCX1), a major Ca2+ 
regulating protein (Elbaz 2010). Indeed, CypA knockdown reduced NCX1 surface expression, 
transport activity, and Na+-dependent Ca2+ fluxes, but did not change the total amount o f NCX1 
expression, thus suggesting a post-translational modulation effect o f CypA, not mediated by its 
PPIase activity. CypA is also a regulator of SERCA2b in human platelets (Rosado 2010), where it 
can act as Ca2+ modulator (Elvers 2012).
Furthermore, a role for CypA has been hypothesised in nuclear transport o f cellular factors. In 
fact, in addition to AIF, CypA cytoplasm-nuclear transport activity has been reported also for the 
zinc-finger-containing protein Zprlp (Ansari 2002) and the spliceosomal RNA-binding protein 
hnRNP A2/B1 (Pan 2008). In particular, in S. cerevisiae the nuclear export o f Zprlp  was defective 
in CypA-lacking cells, and rescue of this defect was correlated with PPIase activity (Ansari 2002). 
Moreover, CypA was observed in complex with CXCR4, the cognate receptor o f the stromal cell- 
derived factor 1 (SDF-1)/CXCL12, in endosomal compartments (Pan 2008), and CXCL12 stimulation 
o f CXCR4 induced phosphorylation and nuclear translocation of CypA in a transportin-1- 
dependent manner. Furthermore, in response to CXCR4 activation CypA formed a complex hnRNP 
A2, which underwent nuclear export, thus suggesting a regulatory role o f CypA in the trafficking of
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hnRNP A2. Interestingly, hnRNP A2 is one of the best characterised interactor of TDP-43, it is 
among the most abundant nuclear protein, and it shuttles rapidly between the nucleus and the 
cytoplasm playing important roles in all steps of mRNA metabolism. In addition, CypA played a 
role in CXCL12-induced activation and nuclear translocation of ERK1/2, and in chemotactic cell 
migration toward CXCL12 gradients, suggesting a possible involvement of CypA in chemotaxis. 
These findings highlight the importance of this poorly explored function of CypA, whose relevance 
could be linked to ALS patho-mechanisms involving TDP-43.
Possibly CypA can exert these effects through maintenance of a normal actin structure. The 
regulation of actin polymerisation requires de novo nucleation of actin filaments, which relies on 
the activation of the Arp2/3 complex by N-WASP (Suetsugu 2001). CypA can bind N-WASP, and its 
PPIase activity is required to protect degradation of N-WASP, thus stabilising its complex 
formation with Arp2/3, and in turn favouring the nucleation/initiation of F-actin polymerisation 
(Calhoun 2009). In addition, CypA knockdown or CsA treatment resulted in an altered actin 
cytoskeleton in U202 cells (a human osteosarcoma cell line) (Calhoun 2009), Jurkat cells (a T-cell 
line), peripheral blood lymphocytes (isolated from CsA-treated patients) (Haskova 1994), chick 
cardiomyocytes (Kotcz 1999). Moreover, like actin, CypA was found to be a prominent component 
o f slow axonal transport in chicken sciatic nerve, and to be localised in neuritis at points of 
branching, occasional swellings and growth cones (Yuan 1997). These findings raised the 
possibility that CypA could co-operate with Hsc70 in maintaining the native folding of actin and 
associated proteins during transit in axons, and assembly and disassembly in growth cones. Thus, 
CypA PPIase and chaperone activities may be further important in relation to neurons. 
Furthermore, CypA was shown to colocalise with microtubules and to exist in the form of a 
heterocomplex containing tubulin and dynein in vitro (Galignana 2004a). CypA associated to 
dynein indirectly, by binding to dynamitin in a PPIase-dependent manner (Galignana 2004b). 
These data suggest that CypA may perform a general function related to the binding, and possibly 
recognition, o f cargo for retrograde movement system as a CypA/dynamitin/dynein/microtubule 
complex (Figure 21).
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Figure 21 Model of CypA/dynamitin/dynein/microtubule heterocomplex.
Dynein is a large multi-subunit complex composed of two heavy chains (HC) that have the processive 
motor activity, three intermediate chains (1C), and some light chains (not shown). Cyclophilins (Cyp), 
such as CypA, link the client protein (cargo) bound to hsp90, to the dynamitin (Dyt) component of 
the dynein heterocomplex for retrograde movement along microtubules. Modified from Galigniana 
2004.
In addition, although CypA has been traditionally considered a cytoplasmic protein, CypA nuclear 
localisation has been reported in several studies, also associating it w ith possible nuclear 
functions. In yeast cells, CypA interacted with and modulated the activity o f two histone 
deacetylase (HDAC) complexes, Sin-Rpd3 and Set3C, which both control meiosis (Arevalo- 
Rodriguez 2000 and 2005), possibly suggesting that CypA can affect gene expression by 
interacting with HDAC. Moreover, an epigenetic function of CypA was demonstrated in p l9  cells, 
where CypA protected the paternal allele o f Peg3 from DNA methylation and inactive histone 
modification (Lu 2006). Furthermore, CypA and YY1, a zinc finger transcriptional factor, interacted 
to mediate transcriptional activation, and CsA disrupted this complex (Yang 1995). CsA also 
blocked the nuclear transport o f cytoplasmic transcription factors, primarily NFAT, thereby 
inhibiting the activation o f cytokine transcription (Flanagan 1991; Emmel 1989; Jain 1993; 
McCaffrey 1993). CsA also inhibited transcription mediated by AP-3, Oct-1 and NF-kB (Frantz 
1994), further suggesting a possible association with CypA. In a model o f neuronal differentiation, 
the nuclear translocation of CypA, the appearance of hypophosphorylated retinoblastoma (RB) 
and the enhancement of RB/CypA complex formation correlated with retinoic acid induced 
neuronal differentiation (Chiu 2003). The evidence of enriched CypA and colocalisation of RB with
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CypA in the nucleus of primary adult sensory neurons substantiated the important event of RB- 
mediated neuronal differentiation of p l9  EC cells.
In summary, the hydrophobic cavity of CypA and the surrounding residues could be associated to 
various exposed loops of different proteins or receptors, but which physiological effects all those 
interactions may have and how their possible disruption (for example by using CsA) could alter 
some cellular processes still remain unclear.
2.5 CypA extracellular functions
CypA is released under inflammatory stimuli by macrophages/monocytes (Sherry 1992; Kim 2005; 
Yuan 2010), leukocytes (Xu 1992), astrocytes (Lafon-Cazal 2003) and under oxidative stress by 
vasculature smooth muscle cells (Jin 2000; Suzuki 2006), mouse fibroblasts (Jin 2000), myocytes 
(Seko 2004), endothelial cells (Jin 2004; Kim 2004), platelets under coagulating conditions 
(Coppinger 2004), and neurons (Boulos 2007). Extracellular CypA shows a proinflammatory 
cytokine-like behaviour, a chemoattractant effect and has been implicated in oxidative-stress 
induced cellular death. The extracellular functions of CypA are mediated by the interaction with 
its ubiquitous Ig-like receptor, CD147 (EMMPRIN) (Yurchenko 2002). Secreted CypA binds and 
activates the cell surface of its receptor CD147, leading to the phosporylation of ERK1/2 and Akt 
(Boulos 2007; Yurchenko 2002). Evidence was provided for a protective effect of CypA on neurons 
from oxidative stress and in vitro ischemia through CD147 activation of the ERK1/2 pathways. In 
addition, CypA interaction with CD147 increases the expression of the anti-apoptotic protein Bcl-2 
(Seko 2004). Moreover, CypA/CD147 signaling stimulates the phosphorylation of c-jun NH2- 
terminal kinase (JNK), p38 kinase and Ikb (Jin 2004; Seko 2004; Yurchenko 2002). CypA can also 
promote the production and secretion of other pro-inflammatory cytokines, like TNFa, IL-8, 
MCP1, IL-ip  (Jin 2004; Kim 2004; Kim 2005). From a biological point of view the CypA/CD147 
mediated signaling seems to induce cell migration, proliferation and differentiation. Indeed, 
through the interaction with CD147, CypA can also trigger intracellular pathways involving
metalloproteinases (MMPs) activation (Seizer 2010; Yang 2008; Wang 2010; Yuan 2010).
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Interestingly, and suggesting a potential role o f CypA signalling in ALS pathogenesis, activation of 
MMP-2 and MMP-9 has been observed in ALS patients and animal models (Fang 2009 and 2010; 
Lim 1996; Niebroj-Dobosz 2010), and knocking-out MMP9 gene in G93A-SOD1 mice results in 
extending the life span of these animals (Kiaei 2007). Recently, elevated levels o f CD147 have 
been observed in ALS patient serum (Itzecka 2011) and increasing levels o f CD147 mRNA have 
been reported in G93A-SOD1 lumbar SpC (Yoshihara 2002). Regulating the interaction between 
CypA and its receptor, has been considered as an attractive pharmacological target in a variety of 
acute and chronic inflammatory disease models (Yurchenko 2010), and should be considered as a 
therapeutic option also in ALS.
In addition, the analyses of CypA knockout mice in other disease context suggest interesting 
functions of CypA in pathogenetic mechanisms possibly relevant for ALS. Indeed, CypA knockout 
mice displayed a reduced injury and marked attenuation of ROS production, MMPs activation and 
MCP-1 secretion following aortic aneurism (Satoh 2009), effects linked to a lack o f interaction 
with CD 147. Moreover, CypA was suggested as a key target for treating APOE-mediated 
neurovascular injury and the resulting neuronal dysfunction and degeneration, such as AD, since 
the APOE increased blood brain barrier susceptibility to injury was mediated by CypA activation of 
nuclear factor k B-MMP9 pathway in pericytes (Bell 2012). Furthermore, CypA was investigated as 
an inflammatory factor promoting atherosclerosis, and a reduction of extracellular CypA was 
demonstrated to promote eNOS down-regulation and a marked decrease of TNF-induced 
apoptosis (Nigro 2011).
Moreover, a catalytic role for CypA has also been hypothesised in CD147 mediated signalling.
Indeed, the PPIase-deficient mutant R55A-CypA shows only little activity compared to WT-CypA
(Yang 2007), suggesting that the interaction is mediated through CypA active site. NMR studies
demonstrated that CypA binds and catalyses the isomerisation of a single site within CD147:
Pro211, a residue predicted to lie just outside the extracellular membrane. CD147 Pro211 exists in
an inherent cis-trans equilibrium in the absence of CypA; when CypA is present, it can mediate the
catalysis of this site, leading to an higher rate o f prolyl-bond interconversion and to an higher cis
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content (Schlegel 2009) (Figure 22). CypA mediated CD147 isomerisation on the outside of the cell 
may result in a conformational rearrangement of the receptor inside the cell, that is responsible 
of the following signal transduction. These data demonstrate that CypA can regulate the cis-trans 
"conformational switch" of its protein substrates both inside and outside the cells.
i 1 Pro211 *~)
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Figure 22 CypA mediated isomerisation of CD147 receptor.
CypA can alter the inherent cis-trans equilibrium of CD147 Pro211 through its PPIase activity. 
Adapted from Schlegel 2009.
Although CD147 is the only known cellular protein receptor for extracellular CypA, possibly other 
cell surface receptors exist. Indeed, CypA was also found to associate with CD99, a surface 
glycoprotein with essential roles in inflammation and immune responses, mediating and affecting 
CD99 signaling pathways (Kim 2004). Therefore, CypA could exert possibly multiple functions 
binding different molecular targets, with a mechanism dependent on the cell type, as well as on 
the type and duration of the triggering event.
In addition, CypA has been suggested as a marker of cell death, since it is released from 
necroptotic cells as a result of early membrane permeabilisation (Christofferson 2010). 
Furthermore, the presence of increased levels of secreted CypA was described in human serum in 
the nanomolar range (Endrich 1998), in several inflammatory diseases, such as rheumatoid 
arthritis (Jin 2000 and 2004; Tegeder 1997), in HIV infection (Billich 1997; Endrich 1998) and by
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progressive solid tumors (Arora 2005; Huang 2006). Whether CypA is protective or detrimental 
when secreted is still debated.
2.6 CypA post-translational modifications
CypA displays multiple cellular localisations, inside and outside the cell, and has important roles in 
many key cellular processes, nevertheless the molecular mechanisms underlying its pleiotropic 
activities are still a matter of study. It is likely that the different functions played by CypA might be 
modulated by its high propensity to undergo co- and post-translational modifications (PTMs) 
(Table 4). Indeed, PTMs have been demonstrated to be crucial in regulating the functions of many 
eukaryotic proteins.
2.6.1 Phosphorylation
Phosphorylation is a reversible PTM occurring in cytoplasm to folded proteins well after their 
synthesis and it is mediated by protein kinases using ATP as the phosphoryl donor, whereas the 
phosphoryl group is removed by specific phosphatases. Protein phosphorylation is an important 
regulatory mechanism in both prokaryotic and eukaryotic organisms. It usually occurs at serine, 
threonine, and tyrosine residues in eukaryotic proteins and results in a conformational change in 
the structure o f many enzymes and receptors, causing their activation or inactivation. Indeed, the 
addition of a phosphate (P04*‘) to a polar R group of an amino acid can turn a hydrophobic 
portion of a protein into a polar and extremely hydrophilic region.
CypA has been demonstrated to be phosphorylated on Ser21 in mouse brain, and on Thrl57 in 
hepatocarcinoma cells (Gevaert 2005; Vosseller 2005). In particular, phSer21 has been found to 
influence neuronal protein maturation and folding. Moreover, one study indicates that the C- 
terminal domain o f CXCR4 receptor can mediate CypA phosphorylation and this modification may 
stimulate the nuclear translocation of CypA (Pan 2008). However, the precise effect of 
phosphorylation in the molecular dynamics o f CypA is not well understood; furthermore it is still
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unknown which are the kinase and phosphatase regulating CypA phosphorylation or which is the 
trigger for this PTM.
g jg g jg
i Met Partial N-terminal methionine removal Chevalier 2012
2 Val Partial N-terminal acetylation
Massignan 2007; 
Chevalier 2012
21 Ser Phosphorylation Vosseler 2005
9 Asp Methylation at acidic groups Chevalier 2012
13 Asp Methylation at acidic groups Chevalier 2012
15 Glu Methylation at acidic groups Chevalier 2012
21 Ser Phosphorylation Gavaert 2005
23 Glu Methylation at acidic groups Chevalier 2012
28 Lys Acetylation Choudhary 2009
28 Lys Ubiquitination Meierhofer 2008
31 Lys Acetylation Chevalier 2012
44 Lys Acetylation
Choudhary 2009; 
Chevalier 2012
48 Tyr Phosphorylation Gavaert 2005
49 Lys Acetylation Choudhary 2009
52 Cys Glutathionylation Ghezzi 2006
55 Arg ADP-ribosylation Dinovo 2006
62 Cys Glutathionylation Ghezzi 2006
62 Cys S-nitrosylation Wu 2011
69 Arg ADP-rybosylation DiNovo 2006
76 Lys Acetylation Choudhary 2009
77 Ser Phosphorylation Gavaert 2005
82 Lys Acetylation
Choudhary 2009; 
Chevalier 2012
84 Glu Methylation at acidic groups Chevalier 2012
85 Asp Methylation at acidic groups Chevalier 2012
86 Glu Methylation at acidic groups Chevalier 2012
93 Thr Phosphorylation Gavaert 2005
110 Ser Phosphorylation Gavaert 2005
115 Cys S-nitrosylation Camerini 2007
125 Lys Acetylation
Choudhary 2009; 
Kim 2006
131 Lys Acetylation Choudhary 2009
134 Glu Methylation at acidic groups Chevalier 2012
140 Glu Methylation at acidic groups Chevalier 2012
143 Glu Methylation at acidic groups Chevalier 2012
157 Thr Phosphorylation Gavaert 2005
161 Cys S-nitrosylation Wu 2011
Table 4 Human CypA co- and post-translational modifications.
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2.6.2 S-glutathionylation
S-glutathionylation is an important PTM occurring under normal conditions as well as during 
oxidative stress. This modification is selective, occurring only on cysteine residues positioned in 
specific context on the surface of target proteins. S-glutathionylation is the formation of a 
disulfide bond between Cys in a protein and Cys in the tripeptide glutathione (GSH). Glutathione is 
the most abundant non-protein thiol in cells and, as a major antioxidant, it is maintained in a 
reduced (GSH) state. In the presence of reactive oxygen and nitrogen species, GSH donates a 
reducing equivalent and becomes highly reactive. It can partner with another molecule o f reactive 
glutathione, forming glutathione disulfide (GSSG). Alternatively, it can react with the sulfhydryl 
group of cysteines on proteins. Glutathionylation of proteins is a reversible process since 
glutaredoxins can reduce proteins. This process in cells is useful to maintain the correct redox 
state (GSH/GSSG) and to regulate protein functions (Creighton 1996; Casagrande 2002).
CypA contains four Cys, and none of them is stably involved in disulfide bridges, thus are all 
potential sites o f glutathionylation. CypA glutathionylation has been observed in vivo (Fratelli 
2002 and 2003). In particular, Cys52 and Cys62 are targets o f glutathionylation in T-lymphocytes 
(Ghezzi 2006). The glutathionylation of these two Cys residues results in a decrease of the a-helix 
content o f the protein, increasing the portion o f the unstructured protein (Ghezzi 2006). 
Moreover, Cys52 is close to Arg55, the main aa involved in PPIase activity, whereas both Cys52 
and Cys62 are close to Phe60 and Arg55 that are part of the CsA-CypA binding domain. Therefore, 
this modification could alter CypA function by altering its structure. In particular, in vitro 
glutathionylated CypA showed a significantly lower CsA-dependent inhibitory effect on calcineurin 
phosphatase activity (unpublished data from the lab).
2.6.3 Acetylation
Acetylation describes a reaction that introduces an acetyl functional group, whereas deacetylation 
is the removal of the acetyl group. In living cells, acetylation occurs as a co-translational and post- 
translational modification of proteins.
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Acetylation of the e-amine of specific lysine residues in proteins is a dynamic modification that 
plays a key role in regulating transcription and other DNA dependent nuclear processes, but it is 
also involved in subcellular localisation and protein stability. This PTM was initially discovered on 
histones (Vidali 1968) as part of gene regulation. However, also non-histone proteins, such as p53, 
are lysine-acetylated (Gu 1997). Regulatory enzymes, such as acetyl-CoA-dependent histone 
acetyltransferases (HATs) and zinc-dependent histone deacetylase (HDACs), catalyze these 
reactions (Figure 23). Despite the fact that Lys acetylation can affect a wide range of proteins and 
can possibly contribute to the regulation of several nuclear and cytoplasmic functions (Lammers 
2010) the role o f this PTM in different cellular proteins remains to be established. Interestingly, 
lysine-acetylation and its regulatory enzymes are also intimately linked to aging and several major 
pathological states such as cancer, neurodegenerative disorders, and cardiovascular diseases 
(Blander 2004; Carrozza 2003; McKinsey 2004).
Figure 23 Lysine can be acetylated by HATs and de-acetylated by HDACs.
Several acetylated lysines have been identified using large proteomic approaches in vitro 
(Choudhary 2009). One recent study has highlighted the specific role of Lysl25 acetylation on 
CypA dynamics (Lammers 2010). Acetylation on this residue does not seem to substantially 
rearrange the active site, however it markedly affects its surface electrostatics: Lysl25 provides 
the strongest patch of positive charge in the active site (Figure 24) and its charge is largely 
neutralized by the acetyl group. This charge change mediated by the acetyl group reduces the 
affinity o f CypA for CsA 20-fold and decreases CypA-catalysed cis-trans isomerisation. Moreover, 
acetylated-Lysl25 CypA-CsA complex mediates a two-fold decrease in calcineurin inhibition 
(Lammers 2010).
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Figure 24 CypA Lysl25.
Lysl25 is shown in red whereas the residues of the active site are shown in blue. Lysl25 residue is 
located in a loop surrounding the active site and acetylation in this position alter the active site 
charge. (A) Ribbon representation of CypA. (B) Electrostatic surface potential of CypA.
Acetylation o f the N-terminal a-amine of proteins is a widespread co-translational modification in 
eukaryotes; 80-90% of human proteins are modified in this manner. This modification is 
performed by N-a-acetyltransferases enzymes. Despite being a conserved and widespread 
modification, little is known about the biological role of N-a-terminal acetylation. CypA is 
acetylated on the N-terminal a-amine of the Val2 residue (Massignan 2007), following methionine 
cleavage. The intriguing feature is that only a portion of CypA proteins are acetylated at their N- 
terminus, whereas the other remains unmodified, thus suggesting a possible functional role for N- 
terminal acetylation in this protein. In particular, CypA was found to be more N-terminally 
acetylated in T h l than in Th2 T-cells leading to the assumption that this modification can be 
involved in T-cell functions (Rautajoki 2004). In the context of ALS, CypA has been found partially 
N-terminal acetylated in the SpC of pre-symptomatic G93A-SOD1 mice (Massignan 2007). 
However, it has not been established yet whether it has a role in MN degeneration.
2.6.4 ADP-rybosylation 
ADP-rybosylation is mediated by ADP-rybosil transferases which cleave the cofactor NAD+ and 
transfer the ADP-rybosyl moiety to proteins. This modification is reversible since the poly(ADP-
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rybose) glycohydrolase can remove the ADP-rybosyl group. It occurs preferentially in the nucleus 
and can affect Arg, Asn, Lys, His and Glu (Creighton 1996).
Human CypA can be subjected to ADP-ribosylation on Arg55 and 69 by the opportunistic 
pathogen Pseudomonas aeruginosa, thus leading to moderate decrease in PPIase activity (=20%) 
and affecting the ability to bind calcineurin (DiNovo 2006).
2.6.5 S-nitrosylation
Nitrosylation is a reversible modification mediated by transnitrosylase enzyme. This modification 
occurs at Cys and a nitric oxide (NO) is attached to the sulfhydryl group in a covalent manner, 
providing a mechanism for redox-based physiological regulation. The NO can be also detached 
from proteins by specific denitrosylases enzymes. S-nitrosylation occurs physiologically in cell, 
determining protein function and structure (Derakhshan 2007), and it obviously increases in 
oxidative stress conditions where NO is highly abundant.
CypA has been found to be S-nitrosylated at Cys62, C ysll5  and Cysl61 (Wu 2011; Camerini 2007). 
Although the role of CypA S-nitrosylation is unknown, it is possible to hypothesise that CypA 
serves as a NO scavenger during nitrative stress.
2.6.6 Ubiquitination
Ubiquitination is a reversible modification which attaches an ubiquitin molecule to a Lys (Huang 
2010). This physiological modification is used by the cell to deliver proteins through the 
proteasome system in order to degrade them. CypA is ubiquitinated at Lys28 (Meierhofer 2008), 
which is a residue that can be acetylated too, suggesting that acetylation on this position could be 
important in regulating the successive ubiquitination. Indeed, it is possible that ubiquitination is 
blocked by the presence of the acetyl group on this residue, thereby preventing protein
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proteasomal degradation. This mechanism was first described for p53 (Ito 2002; Tang 2008) and 
later for others human proteins.
CypA has been described with a lot of potential PTMs. Nevertheless, still little is known about 
their biological significance. Thus, a deeper characterization is required to better understand CypA 
functionality. Moreover, CypA PTMs have been described to be especially important in ALS 
pathology, where a variation in CypA isoform pattern was found in lumbar SpC of G93A-SOD1 
mice at the pre-symptomatic stage (Massignan 2007). Therefore, studying CypA PTMs could give 
insights into ALS patho-mechanisms.
123
AIMS OF THE 
THESIS
HYPOTHESIS OF THE STUDY
ALS is a neurodegenerative disorder characterised by the accumulation of aggregated proteins. 
Either in sporadic patients and in mSODl animal models of ALS, CypA is up-regulated early in the 
pathology (Massignan 2007; Nardo 2011), and is enriched in SpC aggregates at symptomatic and 
end stages of the disease (Basso 2009). CypA is widely expressed in many tissues, but it is found in 
the highest concentration in the CNS and is located primarily in neurons and MNs (Goldner 1996). 
Nevertheless, the specific role that CypA plays in ALS and in neurons and MNs has not been 
defined yet. Indeed, although the primary intracellular function of CypA is the PPIase activity 
(Fischer 1989), as a chaperone protein CypA may be involved in the pathogenesis o f ALS, since 
protein misfolding and aggregation are hallmarks of human ALS and animal models o f the disease 
(Cheroni 2005; Basso 2009).
The hypothesis of this study is that progressive neurodegeneration in ALS, either caused by 
mutant SOD1 or alterations in TDP-43, could be mediated by impaired association with a common 
chaperone protein, CypA. Therefore, CypA can have a protective role in ALS through its 
intracellular activities in neurons and MNs, that are particularly vulnerable to the detrimental 
effects o f misfolded and/or aggregated proteins.
AIMS OF THE STUDY
-»  To provide insights into CypA intracellular functions that could be relevant in ALS.
->  To unravel if CypA is involved in ALS pathogenesis and whether it influences the 
neurodegenerative process.
The specific issues pursued during the study are:
->  Development o f a cellular model system of fALS to investigate how CypA could exert its 
functions and possible effects in the disease.
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-»  Identification of CypA cytosolic and nuclear interactors in vitro, validation of the most 
interesting binding partners in vivo, and functional analysis of these protein complexes for 
their relevance in the disease.
->• Functional characterization o f CypA PTM associated to its localisation and activity on specific 
substrates, in normal and pathological conditions.
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III. MATERIALS AND
METHODS
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1. CELLULAR CULTURES
Experiments performed in this work were done on HEK293 cells (ATCC CRL-1573). The 293 cell line 
was derived by transformation of primary cultures of human embryonic kidney cells with sheared 
adenovirus (Ad)5 DNA (Graham 1977). HEK293 cells were kindly provided by Dr. David Harris 
(Boston University, School of Medicine).
HEK293 cells were plated in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) containing 
10% fetal bovine serum (Invitrogen), 2mM L-glutamine (Invitrogen), 1% non-essential amino acids 
(VWR International PBI) and a 1:100 dilution penicillin/streptomycin (Invitrogen). Cells were 
maintained at 37°C in a humidified atmosphere at 95% air and 5% C02.
1.1 Stable clones generation
Wild-type human SOD1 (WT-SOD1) or human SOD1 carrying a single base mutation that produces 
a protein with alanine instead of glycine in position 93 (G93A-SOD1) were stably expressed in 
HEK293 cells. Plasmids encoding WT- or G93A-SOD1 were generated in the laboratory of Dr. 
Caterina Bendotti at the "Mario Negri" Institute for Pharmacological Research (Tortarolo 2004). 
HEK293 cells were transfected with pcDNA3.1(+)-Hygro or -G418 expression plasmids using 
Lipofectamine™ 2000 (Invitrogen), according to the manufacturer's instructions. One day after 
transfection cells were passaged at high dilution into fresh growth medium. HEK293 cells stably 
expressing the constructs were selected with 200|ig/ml Hygromycin (Sigma) or 1200pg/ml G418 
(Invitrogen) for 15-20 days, then individual clones were isolated and maintained using lOOpg/ml 
Hygromycin or 800|ig/ml G418. Isolated resistant clones were tested for human SOD1 expression 
by Western blotting (WB) using an anti-SODl antibody (Millipore).
1.2 Plasmid DNA transfection
The day before transfection, an appropriate number of HEK293 cells was plated into a 24-well 
plate in 500|il o f serum-containing growth medium without antibiotics, so that cells would have
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been 80-90% confluent at the time of transfection. Cells were incubated at 37°C in a 5% C02 
incubator overnight.
The following day, for each transfection sample, complexes were prepared as follow:
• 0.8pg plasmid DNA were diluted in 50pl Opti-MEM® I Reduced Serum Medium (Invitrogen);
• 1.8pl Lipofectamine™ 2000 (Invitrogen) were diluted in 50pl Opti-MEM®.
After 5min of incubation at room temperature (RT), the diluted DNA was combined with diluted 
Lipofectamine™ 2000 (total volume = lOOpI) and they were incubated at RT for 20min to allow 
DNA-lipid complexes to form. lOOpI of complexes were added directly to each well containing 
cells and medium. Cells were incubated at 37°C in a C02 incubator for 24-48 hours prior to testing 
for transgene expression. Medium was changed after 4-6 hours.
Alternatively, FuGENE® HD Transfection Reagent (Promega) was used, with a FuGENE®:DNA ratio 
of 2.5:1.0. The day of transfection, for each sample, a 0.020pg/pl plasmid solution was prepared 
as follow:
• 0.5pg plasmid DNA were diluted in 25pl Opti-MEM®;
• 1.4pl FuGENE® HD reagent was added and mixed carefully.
After 5-10min of incubation at RT, 25pl of complexes were added to each well, and mixed. Cells 
were incubated at 37°C in a C02 incubator for 24-48 hours prior to testing fo r transgene 
expression.
Transfection conditions, such as plasmid DNA concentration, cell confluency, the DNA:lipid ratio 
and the duration of the transfection were optimized in this cellular model. Transgene expression 
was detected monitoring the protein level by direct WB analysis.
1.3 Silencing
RNA interference (RNAi) is the sequence-specific gene silencing induced by small interfering RNAs 
(siRNAs), double-stranded RNA molecules, 21 nucleotides in length. RNAi was used as a tool to 
manipulate gene expression.
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In this cell line and for each siRNA molecule tested, optimum transfection and silencing 
efficiencies were achieved by adjusting: cell density at the time of transfection, amount and type 
of lipid reagent, siRNA concentration and length o f exposure o f cells to lipid-siRNA complexes. 
Calibration of knockdown efficiency was done with 5/10/20/30/50/80/100nM siRNA for 
24/48/72/96h using WB analysis. On the basis of calibration, lOnM siRNA for CypA and 5nM 
siRNA for TDP-43 were used. siRNA molecules used are listed in Table 5.
siRNA Company target seq target GENE
SI04145925 Qiagen AGCCAGGTACTTGGTGCTACA 3'-UTR PPIA
SI04193469 Qiagen A AG G G ATACCCTT CCC ACTAA 3'-UTR PPIA
SI04240824 Qiagen CACTAAGGACTTGGTTTCTCA 3'-UTR PPIA
SI04351718 Qiagen CTGGGTGATACCATTCAATGT 3'-UTR PPIA
D-004979-17-0005 Thermo Scientific UCCUAGAGGUGGCGGAUUU 3'-UTR PPIA
4616 Applied Biosystems 5'-AGGAUUUGGUUAUAAGGGUTT-3' EXON PPIA
s310 Ambion 5'-GGGUGAUACCAUUCAAUGUtt-3' 3'-UTR PPIA
s311 Ambion 5'-GCAG U U AG AUG UCAGGACAtt-3' 3'-UTR PPIA
s312 Ambion 5'-CCACCUUAACAGACCUCUAtt-3' 3'-UTR PPIA
S57823 Ambion 5'-AGCAGAAAAUUUUCGUGCUtt-3' EXON 2 PPIA
4616 Applied Biosystems 5'-ACCCUUAUAACCAAAUCCUTT-3' scramble none
12935-300 Invitrogen medium GC duplex content scramble none
SI00739501 Qiagen 5 '-CACACTACAATTG ATAT CAAA-31 3'-UTR TARDBP
Table 5 siRNA duplex molecules used in this study.
The day before transfection, 24-well plates were inoculated with an appropriate number o f cells 
in serum-containing medium (without antibiotics) such that they would be 50-70% confluent the 
following day. Cells were plated between 0.1 and 4.0 x 105 cells in 0.5ml of medium and incubated 
at 37° C in a 5% C02 incubator overnight.
Fifteen to sixty minutes prior to transfection, medium was aspirated from the wells and 250pl of
fresh growth medium (without antibiotics) were added to each well. For each well to be
transfected, 25pl o f serum-free medium containing 0.75pl of siLentFect Lipid Reagent (BioRad)
were prepared and 25pl o f OptiMEM medium were supplemented with CypA or TDP-43 siRNA. As
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a negative control for these experiments, a scrambled siRNA of approximately the same length 
and the same GC% content, and possessing a sequence not targeting any known vertebrate 
transcript, was used. The diluted siRNA was added to the diluted siLentFect and mixed. When 
RNAi molecules were co-transfected with plasmid DNA, 0.6pg of DNA were added to the lipid- 
siRNA complexes. This mixture was incubated at RT for 20min to allow lipid-siRNA complexes to 
form. After this incubation time complexes were added directly to cells in serum-containing 
medium. The plate was rocked back and forth to mix and incubated at 37°C in a C02 incubator. 
Twenty-four hours after transfection the media was substituted with fresh growth medium for an 
additional 24-48 hours. Gene silencing was monitored at the protein level 24-72hours after 
transfection.
1.4 Cell survival
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is a colourimetric assay 
system used to assess cell viability as a function of redox potential. MTT assay is based on the 
ability of a mitochondrial dehydrogenase enzyme from viable cells to convert the water-soluble 
tetrazolium rings o f the pale yellow MTT and form insoluble purple formazan crystals which are 
largely impermeable to cell membranes, thus resulting in their accumulation within healthy and 
metabolically active cells. The formazan is then solubilized by the addition o f DMSO (Dimethyl 
sulfoxide) and its concentration is determined by optical density.
Cells were seeded in 24- or 48-well plates one day before treatment. Depending on the 
experiment performed, 1 to 3 days after treatment culture medium was removed and cells were 
incubated with a solution: 0.32 mg/ml MTT resuspended in LOCKE's buffer (NaCI 154 mM, KCI 5.6 
mM, MgCI2 1 mM, CaCI2 2.3 mM, HEPES 8.6 mM, Glucose 5.6 mM). Cells were incubated at 37°C 
for at least 30min. The crystals were solubilized by the addiction of DMSO for 30min at RT. The 
concentration was quantified by spectrophotometric means (excitation OD-575nm was measured 
in Infinite® 200 multimode plate reader, Tecan). Data (n>6 replicates) were expressed as 
percentage of absorbance compared to non-treated control cells.
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2. ANIMAL MODELS
All animal tissues used in this study were collected by Dr. Silvia Pozzi and Laura Pasetto in our 
laboratory or by the laboratory of Dr. Caterina Bendotti (Molecular Neurobiology Lab., Mario 
Negri Institute, Milan). All animal models considered in the study were housed under standard 
conditions (temperature of 21 ± 1°C, relative humidity of 55 ± 10% and 12h light/dark schedule), 
3-4 per cage, food and water supplied ad libitum. Procedures involving animals and their care 
were conducted in conformity with Institutional guidelines that are in compliance with national 
(D.L. No. 116, Suppl. 40, Feb. 18, 1992 Circolare No. 8, G.U., 14 luglio 1994) and international laws 
and policies (EEC Council Directive 86/609. OJ L 358,1, Dec.12,1987; NIH Guide for Care and use 
of Laboratory Animals, U.S. National Research Council, 1996). Before every analysis, animals were 
deeply anesthetized with 20pl/g o f Equitensin (1% pentobarbital, 4% chloral hydrate, 2% 
MgS047H20, 40% propilenglicole, 10% ethanol) by intra-peritoneal injection and killed by 
decapitation.
2.1 G93A-SOD1 mouse model
G93A-SOD1 mice on a C57BL/6JOIaHsd (C57) or 129S2/SvHsd (129Sv) genetic background and 
corresponding non-transgenic littermates were used in this study. Both mouse lines derive from 
the originally obtained from Jackson Laboratories (B6SJL-TgNSOD-l-SODl-G93A-lGur) line, which 
expresses about 20 copies of mutant human SOD1 with a Gly93Ala substitution. Animals were 
maintained on a C57BL/60laHsd or 129S2/SvHsd background (more than 30 or 10 breeding, 
respectively) at Harlan Italy S.R.L. (Bresso, Milano, Italy). G93ASOD1G93a transgenic mice were 
identified with PCR on DNA tail biopsies. These two strains showed a different disease onset and 
progression and different survival length.
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2.1.1 S0D1G93A C57 mice
A hSODlG93A C57BL/6JOIaHsd mouse line was maintained heterozygote for the transgene by 
repeated backcrossing of heterozygote G93A-SOD1 male mice with non-transgenic females 
C57BL/6 JOIaHsd. Heterozygote mice G93A-SOD1 developed first signs o f neuromuscular junction 
loss and denervation at 8 weeks of age while symptoms are clearly visible at 16 weeks of age 
when 40% of MNs are lost. From 16 to 20 weeks of age mice progressively worsen presenting 
reduction in the extension reflex o f the hind limbs, when mice are raised by the tail, and muscular 
weakness, revealed by the increasing difficulty in staying on the rotating bar. Complete paralysis 
of hind limb appeared at 20 weeks of age when over the 60% of motor neurons were lost (Peviani 
2010).
2.1.2 G93A-SOD1129sv mice
The hSODlG93A 129S2/SvHsd mouse line was obtained in the laboratory o f Dr. Bendotti by 
repeated backcrossing of S0D1G93A C57BL/6JOIaHsd male mice with 129S2/SvHsd female mice, 
leading to heterozygote transgenic mice on the homogeneous 129Sv background. Mice showed a 
faster and more severe pathology compared to the G93A-SOD1 C57 transgenic line. They 
generally developed first signs of neuropathology at the MN level around 4 weeks o f age, while 
the first symptoms of muscular dysfunction appeared around 14 weeks of age, w ith progressive 
reduction in the extension reflex of the hind limbs. At about 15 weeks of age mice showed a 
progressive muscular weakness, revealed by the increasing difficulty in staying on the rotating 
bar. At 18 weeks of age animals presented hind limbs complete paralysis and could not recover if 
laid on one side (Pizzasegola 2009).
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2.2 CypA knockout mice
To study the function of CypA in vivo, CypA wild-type (CypA+/+), heterozygous (CypA+/-) or 
knockout (CypA-/-) mice were analysed and compared to non-transgenic littermates. CypA 
knockout mice were identified with PCR on DNA tail biopsies.
CypA knockout mice 129S6/SvEvTac PpiatmlLubn/PpiatmlLbn mice (Ppia is the gene for CypA) were 
obtained from Charles River Laboratories (France) and maintained on 129S6/SvEvTac background. 
CypA knockout mice were generated (Colgan 2000) in the laboratory of Dr J. Luban (Department 
of Microbiology and Department of Medicine, Columbia University College of Physicians and 
Surgeons, New York City, USA) and further characterised in the same laboratory (Colgan 2004 and 
2005). Homologous recombination between a targeting vector containing the neomycin 
resistance (neor) gene controlled by the mPpia promoter and the endogenous allele results in the 
replacement of all but the last 60bp of CypA-coding sequences with a neomycin-resistance gene 
cassette (Colgan 2000). Genotype distribution from CypA+/- x CypA+/- backcrosses did not follow 
Mendel laws. Jackson Laboratories predicted a 25% to 15% reduction in CypA-/- frequency.
2.3 G93A-SODl/CypA knockout double transgenic 
mice
To observe the involvement of CypA on ALS disease onset and progression, G93A-SODl/CypA 
wild-type (CypA+/+), heterozygous (CypA+/-) or knockout (CypA-/-) were analysed and compared 
to non-transgenic littermates. G93A-SODl/CypA knockout mice were identified with PCR on DNA 
tail biopsies. The experimental groups were derived from breeding S0D1G93A 129S2/SvHsd mice 
with 129S6/SvEvTac PpiatmlLubn/PpiatmlLbn mice. First, G93A-SOD1 male mice wild-type for the CypA 
gene were backcrossed with female mice CypA+/- or CypA-/-. From this backcrossing male and 
female mice NTg or G93A-SOD1 carrying the wild-type gene for CypA or heterozygous for the 
deletion were obtained. The aim was to obtain the greatest number of male mice G93A- 
SODl/CypA+/- and female mice NTg/CypA+/-« These animals were considered as the FI progeny.
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Male mice G93A-SODl/CypA+/- FI and female mice NTg/CypA+/- F I were backcrossed obtaining 
all the genotypes used in the study. The progeny is defined as F2, and both male and female mice 
were used for further analyses.
2.4 Neuronal spinal primary cultures
Preparation of mouse astrocyte-neurons co-cultures was performed by Dr. Massimo Tortarolo 
and his co-workers in the laboratory of Dr. Caterina Bendotti, Molecular Neurobiology Laboratory, 
Mario Negri Institute, Milan.
Primary spinal neurons were prepared from 14 to 15 day old mouse embryos. SpC were isolated 
by dissection and the meninges were removed. SpC were then mechanically dissociated using a 
fire-polished glass Pasteur pipette in phosphate-buffered saline (Ca2+ and Mg2+-free PBS IX, 
Invitrogen) supplemented with 33mM glucose. The cell suspension was layered onto a 4% BSA 
cushion, centrifuged at lOOOrpm for lOmin, and cells from the pellet were resuspended in culture 
medium composed of Neurobasal medium (Invitrogen) supplemented with 10% inactivated horse 
serum, 16.5mM glucose,0.5mM L-glutamine, lOng/ml BDNF, 5pM p-mercaptoethanol, lOOpg/mL 
streptomycin and 60pg/mL penicillin, 5pg/ml gentamicine, 25pM L-glutamic acid and .2% B27 (all 
from Sigma). Cells were plated (one SpC/8 wells) in each well o f 48-well Nunc multiwell plates 
that had been previously coated with a confluent monolayer o f astrocytes, to support neuronal 
health and survival. Cells were cultured at 37°C in a humidified atmosphere of 95% air and 5% C02 
and used after 5-6 days in vitro. A mixture o f hormones and salts composed o f 25pg/mL insulin, 
lOOpg/mL transferrin, 60pM putrescine, 20nM progesterone and 30nM sodium selenate (all from 
Sigma) was added to the culture medium. Cells were fixed for immunocytochemistry experiments. 
Medium was removed, cells were washed with PBS IX and 4% paraformaldehyde (Merk) solution 
in PBS IX  was added for 30 min. After three washes in PBS IX slides were stored a 4°C.
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3. SAMPLE PREPARATION
3.1 Cell pellet preparation
Confluent cells were scraped from the flask (well) in an adequate volume of ice-cold collection 
buffer (lOmM Tris-HCI pH 7.4; 250mM sucrose) keeping the plate on ice, and the suspension was 
centrifuged at lOOOrpm for 5min at 4°C in a 5702/R centrifuge, rotor A-4-38 (Eppendorf). The 
pellet was resuspended in 1ml of ice-cold collection buffer and put in a 1,5ml tube. This solution 
was then centrifuged at 3200rpm for 3,5min at 4°C in a 5424/R microcentrifuge, rotor FA-45-24- 
11 (Eppendorf). The cell pellet obtained was further processed or quickly stored at -20°C until use.
3.2 Total protein extraction
By gentle pipetting the cell pellet was resuspended in ice-cold lysis buffer (lOmM Tris-HCI pH 7.5; 
0.5% Zwittergent; 0.5% sodium deoxycholate; protease inhibitors cocktail [Roche; 1 tablet/lOml]). 
To disrupt the DNA complexes the sample was passed for approximately 10 passages through a 
26-gauge needle of a 1,5ml syringe. The sample was further incubated with Benzonase 
Nuclease™ (375U for 500ul buffer) (Novagen) for 15 min at RT while shaking, then kept on ice.
3.3 Animal tissue protein extraction
Mouse SpC or brain tissues were stored at -80°C. When necessary the lumbar tract of the spinal 
cord was cut on a cryostat into ventral and dorsal horn sections. Samples were homogenized in 
50mM Tris-HCI, pH 7.5; 2% (w/v) CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-l-propane 
sulfonate, Sigma); 37.5U benzonase (Merck, Darmstadt, Germany), supplemented with Protease 
Inhibitors (Sigma) using a potter in ice. Homogenates were centrifuged at 13000rpm and 4°C for 
15min and supernatant proteins were stored at -20°C until quantification.
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3.4 Subcellular fractionation
HEK293 cells expressing wild-type and mSODl were harvested and washed in ice-cold PBS1X. Cell 
pellets were resuspended in RIPA-A buffer (0.3% Triton-X-100; 50mM Tris-HCI pH 7.4; Im M  EDTA; 
protease inhibitors cocktail [Roche; 1 tablet/lOml]) and incubated at 4°C for 30-60 min with slow 
t ilt rotation. Cell extracts were centrifuged to pellet nuclei at 12000g and 4°C for lOmin. The 
supernatant, that is the cytoplasmic fraction, was saved, while the nuclei pellet was washed with 
RIPA-A buffer and centrifuged at 12000g and 4°C for lOmin. Supernatant was discarded and the 
nuclei pellet was resuspended in RIPA-B buffer (1% Triton X-100; 1% SDS; 50mM Tris-HCI pH 7.4; 
500mM NaCI; Im M  EDTA; protease inhibitors cocktail [Roche; 1 tablet/lOml]). DNA complexes 
contained in this fraction were disrupted using an insulin syringe and further incubating with 
Benzonase Nuclease for 15 min at RT.
In order to validate each subcellular fractionation experiment, the immunoreactivity for actin was 
used as a specific cytosolic marker to exclude cytoplasmatic contamination of the nuclei 
preparation, whereas lamin A/C (an intermediate filament protein, component o f the nuclear 
envelope) and s ta tl (a transcription factor) were used as nuclear markers.
3.5 Aggregated proteins extraction
Extraction o f detergent-insoluble proteins was performed on the lumbar tract of the SpC splitted 
into dorsal and ventral horn sections. Only the MNs enriched fraction was considered for this 
analysis. Detergent concentration was optimized in this experimental setting.
Tissues were manually homogenized using a potter in ice in 10 volumes (w/v) o f ice-cold 
homogenization buffer 1 (15mM Tris-HCI pH 7.6; Im M  DTT; 0.25M sucrose; Im M  MgCI2; 0.25M 
Na3V04; 25mM NaF; 2mM NaPP; Im M  EGTA; 2.5mM EDTA; 5pM MG132; protease inhibitors 
cocktail [Roche; 1 tablet/lOml]). Samples were centrifuged at lOOOOrpm and 4°C for 15min. 
Supernatant (SI) was collected in a new tube. The pellet was resuspended in lOOpI ice-cold buffer 
2 (15mM Tris-HCI pH 7.6; Im M  DTT; 0.25M sucrose; Im M  MgCI2; 0.25M Na3V04; 25mM NaF; 
2mM NaPP; Im M  EGTA; 2.5mM EDTA; 5pM MG132; 2% Triton X-100; 150mM KCI; protease
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inhibitors cocktail [Roche; 1 tablet/lOml]). Samples were sonicated for three times for lOsec and 
shaken for lhour at 4°C. Samples were centrifuged at lOOOOrpm and 4°C for 15mm, obtaining the 
triton-resistant pellet. Supernatant (S2) was collected in a new tube. The pellet was washed for 
three times in 150pl ice-cold buffer 1 and centrifuged at lOOOOrpm and 4°C for lOmin. The pellet 
was resuspended in 50pl UTC buffer (7M urea; 2M thiourea; 4% CHAPS) and sonicated for lOsec 
in ice. Samples were centrifuged at RT and lOOOrpm for lOmin and the supernatant was saved as 
the TIF (Triton X-100-insoluble fraction). Proteins from the TIF were quantified using the Bradford 
assay. One third o f the volume of SI and S2 were pooled to obtain the soluble fraction. Proteins 
from the soluble fraction were quantified using the BCA assay. Samples were frozen at -80°C until 
further analyses.
3.6 Protein quantification
3.6.1 BCA assay
Proteins extracted from animal tissues or cultured cells were quantified using the bicinchoninic 
acid assay (Protein assay Reagent Kit BCA, Pierce Biotechnology, Rockford, Illinois). This is a 
colourimetric method based on the biuretic reaction, i.e. the reduction of Cu2+ to Cu1+ by proteins. 
25pl of cellular lysate diluted 1:10,1:20, 1:40 in H20  were pipetted into a 96-wells microplate in 
duplicate. A fresh set of protein standards was prepared by serially diluting bovine serum albumin 
(BSA) stock solution (2mg/ml). 200pl of reaction mix, prepared by mixing 50 parts o f BCA reagent 
A with 1 part of BCA reagent B, was subsequently added to each well and incubated for 30min at 
37°C in the dark. The absorbance of the solution was read at 575nm wavelength using Infinite® 
200 multimode reader (Tecan).
3.6.2 Bradford assay
Quantification o f protein samples extracted from the Triton X-100-insoluble fraction (TIF) or from 
the IP fraction was performed with a modified Bradford method (Bio-Rad Protein Assay). The
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assay is based on the observation that the absorbance maximum for an acidic solution of 
Coomassie brilliant blue G-250 shifts from 465nm to 595nm when binding to protein occurs. Both 
hydrophobic and ionic interactions stabilize the anionic form of the dye, causing a visible colour 
change. The dye reagent reacts primarily with arginine residues and less with histidine, lysine, 
tyrosine, tryptophan and phenylalanine residues.
lOpI o f cellular lysate diluted 1:5, 1:10, 1:20 in H20  were pipetted into a 96-wells microplate in 
duplicate. A fresh set of protein standards was prepared by serially diluting BSA stock solution 
(2mg/ml). 200pl of reaction mix, prepared by mixing 1 part of Bradford solution with 4 parts of 
H20, was added to each well and incubated for lOmin at RT in the dark. The absorbance of the 
solution was read at 595nm wavelength using Infinite® 200 multimode reader (Tecan).
4. PROTEIN IMMUNOPRECIPITATION (IP)
Magnetic beads with coupled sheep polyclonal antibodies anti-Mouse IgG (Dynabeads® M280 
sheep a-rabbit) or anti-Rabbit IgG (Dynabeads® M280 sheep a-mouse; Invitrogen) and a magnet 
(Dynal®; Invitrogen) were used to perform co-immunoprecipitation experiments. All the 
procedure, including starting sample preparation and dilution, washing buffers composition, 
primary antibody and dynabeads (DB) concentration, antibody cross-linking and IP complexes 
elution, were optimized for WB or 2-DE and MS analyses.
4.1 IP for 1-DE analysis
Cells were collected and lysed as previously described using ice-cold IP buffer (50mM Tris-HCI pH 
7.4; 2% CHAPS; protease inhibitors cocktail [Roche; 1 tablet/lOml]). Alternatively, when IP was 
performed in the cytosolic and nuclear fractions, the nuclei pellet was directly resuspended in ice- 
cold IP buffer. When confirmatory experiments were performed on animal tissues, samples were 
homogenized as previously described using ice-cold IP buffer. Protein concentration was
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determined by the BCA protein assay (Pierce). Protein extracts equivalent to 500pg of proteins 
were diluted to 0.5pg/pl using IP buffer and this corresponds to the INPUT fraction.
DB were washed with 0.1% BSA (Ig-free, Sigma) in PBS1X to remove preservatives. Approximately 
0.1-1 pg lg/107 beads were incubated at 4°C for at least 2hours with the primary antibody (Abl). 
DB were washed with 0.1% BSA in PBS1X to remove the excess of Abl unbound to the secondary 
antibody (Abll) coupled to the DB. The immunoglobulin chains were chemically cross-linked by 
30min incubation with 20mM dimethyl pimelimidate dihydrochloride (Sigma) in 0,2m  
triethanolamine pH 8.2. The reaction was stopped by 15min incubation with 50mM Tris-HCI pH 
7.5. DB cross-linked to the Abl were washed with 0.1% BSA in PBS1X and resuspended in 0.5% BSA 
in PBS1X. In the meantime protein lysates were pre-cleared by incubation at 4°C for at least 
2hours w ith the same amount of magnetic beads alone, in order to reduce aspecific binding.
Figure 25 Schematic representation of the immunoprecipitation procedure used in this study.
The sheep anti-rabbit or anti-mouse Ig covalently bound to the surface of the beads recognized 
defined antigens through a rabbit or mouse specific primary antibody. The target molecule and its 
interactors were eluted off the beads simply boiling the sample and denaturing it using Laemmli 
sample buffer.
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After beads removal, the cleared lysate was collected and incubated overnight at 4°C with Abl 
coupled to DB. The complexes of immunoprecipitated proteins (IP fraction) were separated from 
the supernatant (collected as the OUTPUT fraction) and washed with 50mM Tris-HCI pH 7.2 + 
0.3% CHAPS + 0.1% BSA and with 50mM Tris-HCI pH 7.2 + 0.3% CHAPS. The immunoprecipitated 
proteins were separated from the beads and eluted using Laemmli sample buffer (without DTT). 
Proteins from the OUTPUT fraction were quantified using the BCA assay. Protein samples from 
the IP fraction were boiled for lOmin and briefly spun. Samples were frozen at -20°C until further 
analyses. Samples from the IP, as well as the INPUT and OUTPUT fractions were subjected to SDS- 
PAGE separation and WB analyses to examine for specific immunoreactivity.
4.2 IP for 2-DE analysis
Samples were lysed as previously described and IP was performed starting from 4.5mg of proteins 
and a quantitatively proportional amount of Abl and DB. After IP, proteins from the IP fraction 
were eluted in 50mM Tris-HCI pH 6.8 + 2% SDS + lOOmM DTT and quantified using the Bradford 
assay. Proteins were precipitated in methanol/chloroform and resuspended in Destreak™ 
Rehydration Solution (GE Healthcare) added with 0,5% (v/v) IPG buffer (non linear ampholine pi 3- 
10; GE Healthcare). The solution was shacked for 2hours at RT and spun. Samples were loaded by 
in-gel rehydration on immobilized pH gradient (IPG) 3-10 non-linear 7cm strips and run in a IPG- 
phor apparatus (GE Healthcare). Strips were then re-equilibrated in NuPAGE LDS sample buffer 
(Invitrogen) and incubated with DTT and IAA for 15 min. Single gel strips were mounted on 10% 
or 12% polyacrylamide pre-cast gels (Invitrogen) and second dimension was run. Gels were fixed 
and stained with Sypro® Ruby protein gel stain (Invitrogen) for MS analyses or transferred to PVDF 
membranes for WB studies.
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5. SDS-POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE)
Equal amounts of proteins, prepared as previously described, were diluted in Laemmli sample 
buffer (2% SDS; 10% glycerol; 0.002% bromophenol blue; lOOmM Tris-HCI pH 6.8; lOOmM DTT) 
and denatured by heating for lOmin at 95°C and briefly spun in a microcentrifuge. Samples were 
loaded in wells at the top of 12% SDS-PAGE (sodium dodecyl sulphate-polyacrylamide) gels, made 
up of a stacking gel (4% polyacrylamide; SDS; Tris-HCI pH 6,8; ammonium persulfate; TEMED) and 
a running gel (12% polyacrylamide; SDS; Tris-HCI pH 8,8; ammonium persulfate; TEMED). Proteins 
moved into the gel when the electric field was applied: 15mA in the stacking gel to allow a correct 
alignment o f the proteins; then proteins were run at 30mA for approximately lhou r in the 
running gel. The electrophoretic separation was performed in a Mini-PROTEAN* electrophoresis 
cell (Biorad) in running buffer (3g/L Tris; 0,1% SDS; 14,44g/L glycine).
6. SLOT/DOT BLOTTING
For dot/slot-blot analyses, aliquots of 2-5|ig of proteins for each sample were diluted in equal 
volumes of TBS1X (20mM Tris-HCI pH 7.4; 150mM NaCI) and loaded in duplicate on 0.45pm 
nitrocellulose Trans-Blot Transfer Medium membrane (BioRad), by vacuum deposition on the Bio- 
Dot SF blotting apparatus (BioRad). Membranes were immunoblotted and immunoreactivity was 
normalized to the actual amount o f proteins loaded on the membrane, as detected after ATX 
Ponceau S red (Fluka BioChemika) staining.
7. TWO DIMENSIONAL GEL ELECTROPHORESIS 
(2DE)
Proteins from cell lysates were prepared for 2DE analysis: 50-75pg of total proteins were
precipitated using an excess volume of cold methanol. After an incubation of at least 4h at -80°C,
protein samples were centrifuged at 13000rpm and 4°C for 30min. The protein pellet was
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resuspended in Destreak™ Rehydration Solution (GE Healthcare) added with 0,5% (v/v) IPG buffer 
(non linear ampholine pi 3-10; GE Healthcare). Each sample was incubated at 22°C for lh  mixing, 
centrifuged at 13000rpm for 2min and loaded on IPG strip. Proteins were first separated by 
electrophoresis according to charge. Isoelectrofocousing (IEF) was carried out using gel strips 
forming an immobilized non-linear pH gradient from 3 to 10 (Immobiline™ DryStrip, pH 3-10 NL, 7 
cm; GE Healthcare). IPG strips were positioned into a holder, covered with oil, and run into an 
IPG-phor apparatus (GE Healthcare). Strips were re hydrated for lOh at 30V, IEF was performed at 
20°C with current limited to 50mA per strip (0.5h at 200V, 0.5h at 500V, 0.5h at 2000V, l,5h  o f a 
linear gradient to 3500V, 2h at 3500V, 2,5h of a linear gradient to 8000V followed by 8000V for 
4h, and forever at 30V). Proteins were then separated according to size. Prior to the second 
dimension, the gel strips were equilibrated for 15min in NuPage LDS Buffer (Invitrogen) containing 
1% DTT (Sigma) and washed with mqH20; IPG strips were alkylated for 15min in the same buffer 
containing 2.5% iodoacetamide (Sigma) and washed again. For SDS-PAGE separation, equilibrated 
IPG strips were mounted on the top of a pre-cast 10% or 12% Bis-Tris-acrylamide gel (Invitrogen) 
and, sealed with a 0.5% agarose solution. After agarose solidification, electrophoresis was 
performed at 200V for lhour at RT using MOPS (Biorad) as running buffer. Up to six gels were run 
in parallel and for each condition analysed, 2D-gels were made in triplicate from independent 
protein extractions.
Gels for 2D-WB were transferred on PVDF membranes (Millipore), while gels for protein 
identification by MS were fixed overnight in 50% methanol and 7% acetic acid, visualised with 
Sypro Ruby Gel Staining (Invitrogen) and scanned with Molecular Imager FX Laser Scanner 
(excitation, 532 nm; BioRad).
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Figure 26 General 2DE workflow.
Proteins are first separated by their isoelectric point in the first dimension (IEF). The strip with the 
gel is then laid horizontally on a second gel in which the proteins are separated by SDS-PAGE. Thus, 
horizontal separation reflects differences in pi, while vertical separation reflects differences in 
molecular weight.
8.1 Sypro Ruby Staining
Sypro Ruby staining is a sensitive method to detect proteins in SDS-PAGE and 2-DE gels or 
membranes which does not interfere with MS protein identification (Nishihara 2002).
After electrophoresis, gels were fixed in 50% methanol and 7% acetic acid for lh  at room 
temperature, incubated with Sypro Ruby Gel Stain (Bio-Rad Laboratories) overnight and washed 
with 10% methanol and 7% acetic acid for 30min.
PVDF membranes for 2DE-WB were air-dried, fixed in 10% methanol and 7% acetic acid for 15min, 
washed in deionized water, stained with Sypro Ruby Blot Stain (Bio-Rad Laboratories) for 15min 
and washed in deionized water.
8. Gel/membrane staining
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Total proteins, in gels or transferred onto membranes, were visualised by scanning using the 
Molecular Imager FX Laser Scanner (excitation, 532nm; Bio-Rad Laboratories), with the same 
parameters for all the gels/membranes in the analysis.
8.2 Red Ponceau S staining
Ponceau staining is a reversible negative stain for the detection of the positively charged amino 
groups of proteins. It also binds non-covalently to non-polar regions in the protein. Membranes 
were incubated for lOmin with Ponceau S (Sigma), briefly washed with deionized water and 
images were acquired with Epson Expression 1680 Pro scanner (Epson, Suwa, Japan).
9. WESTERN BLOTTING
Proteins separated by electrophoresis on polyacrylamide gels were transferred to a 
polyvinylidene fluoride membrane (PVDF Immobilion FL; Millipore) previously activated in 
methanol for 30sec, applying a constant current o f 250mA to a Mini Trans-blot’  (Biorad) 
apparatus for 2h or alternatively overnight at 85mA in transfer buffer (5,52g/L CAPS pH 11; 10% 
MeOH). To check for protein loading and transfer, membranes were incubated with ATX Ponceau 
S red staining solution and scanned for later analysis.
Membranes with separated proteins were rinsed in TBST (20mM Tris-HCI pH7.5; 150mM NaCI; 
0,1% Tween 20) to remove Ponceau-S stain and were blocked for 60min at RT in a 3% BSA (Sigma) 
or 5% non-fat dry milk-based solution diluted in TBST before incubation with primary antibody. 
Membranes were probed for lh  at RT or overnight at 4°C with a primary antibody, according to 
the manufacturer's protocol, followed by incubation for 60min at RT with a peroxidase- 
conjugated secondary antibody diluted 1:5000. Each antibody was diluted in blocking solution and 
after incubation membranes were washed in TBST to remove unbound antibody. When anti­
mouse or anti-rabbit or anti-goat peroxidase-conjugated secondary antibodies (Santa Cruz
Biotechnology) were used, blots were developed with Immobilon Western Chemiluminescent HRP
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Substrate (Millipore) on the Chemi-Doc XRS System (BioRad). This system uses horse radish 
peroxidase (HRP)-conjugated secondary antibodies for luminol-based detection. The oxidation of 
luminol by the HRP is then detected by exposure to Chemi-Doc XRS System (Biorad) at a 
wavelength o f 428nm. When Qdot800 or Qdot655 goat anti-mouse or anti-rabbit IgG-conjugated 
secondary antibodies (Molecular Probes, Invitrogen) were used, blots were scanned with 
Molecular Imager FX Laser Scanner (BioRad). WB signals and the corresponding red ponceau 
stained blots were digitalized and densitometry was determined using the Progenesis PG240 
Software (Non Linear Dynamics Ltd). For a correct quantification, the measured immunoreactivity 
was normalized on the total amount of proteins loaded on the gel (detected with Ponceau 
staining).
Primary antibodies were obtained from the following companies: polyclonal rabbit anti-SODl 
(1:2000; Upstate), monoclonal mouse anti-Nitro tyrosine (1:1000; Hycult Biotechnology), 
polyclonal rabbit anti-Nitro actin (1:7500), polyclonal rabbit anti-Cyclophilin A (1:2500; Upstate), 
monoclonal mouse anti-Myc tag (1:1000; OriGene), polyclonal goat anti-Actin (1:2000; Santa Cruz 
Biotechnology), monoclonal mouse anti-STATl p84/p91 (1:200; Santa Cruz Biotechnology), 
monoclonal mouse anti Lamin A+C (1:500; Chemicon); monoclonal mouse anti-Cyclophilin A 
(1:2000; Abeam); polyclonal rabbit anti-TDP43 (1:4000; kindly provided by Baralle Francisco, 
ICGEB, Trieste); polyclonal rabbit anti-TDP43 (1:2500; Protein Tech); polyclonal rabbit anti-Myc 
tag (1:30000; Bethyl laboratories); monoclonal mouse anti-Flag tag (1:10000; Sigma); monoclonal 
rabbit anti-Flag tag (1:2000; Sigma); monoclonal mouse anti-hnRNP A2/B1 (1:2000; Abnova); 
monoclonal mouse anti-TDP43 (1:1000; Abnova); monoclonal mouse anti-phS409/410 TDP43 
(1:2000; Cosmo Bio Co.,Ltd.); monoclonal anti-Ubiquitin (1:800; DAKO); polyclonal rabbit anti- 
HDAC6 (1:500; Santa Cruz); monoclonal mouse anti-Tubulin (1:1000; Sigma); monoclonal 
mouse anti-Acetyl-tubulin  (1:35000; Sigma); polyclonal rabbit anti-HSP90 (1:1000); 
monoclonal mouse anti-HSC70 (1:1000; Santa Cruz); monoclonal mouse anti-DNP (1:15000; 
Sigma); polyclonal rabbit anti-PDI (1:1000; StressMarq Biosciences Inc.).
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10. IDENTIFICATION OF PROTEINS BY MASS 
SPECTROMETRY
The protein spots of interest were located and excised from 2D-gels with the EXQuest spot cutter 
(Bio-Rad). Spots were de-stained for 2h in a solution containing 25mM ammonium bicarbonate + 
40% ethanol, and then washed with a sequentially increasing percentage of acetonitrile (0-50- 
100%). Protein spots were processed manually or in a protein digestor, DigestPRO MS (Intavis). 
Proteins were in gel-digested overnight at 37°C with lOng/pl of modified trypsin from bovine 
pancreas (Roche) in 25mM ammonium bicarbonate + 10% acetonitrile.
Peptide mass fingerprinting and MS/MS analysis were done on a 4800 MALDI-TOF/TOF mass
i
spectrometer (Applied Biosystem, Carlsbad, CA, USA) using a-cyano-4-hydroxycinnamic acid 
(Bruker Daltons, Billerica, MA, USA) matrix. Stock solution of matrix was prepared as saturated 
solution in 50% acetonitrile and 0.1% trifluoracetic acid (Sigma) and diluted 1:1 with the same 
solution before mixing with the samples. Tryptic digested peptides were desalted and 
concentrated using ZipTip® pipette tips with C18 resin and 0.2pl bed volume (Millipore) and 
MALDI target deposition were carried out on an automated protein digestor DigestPro (Intavis 
AG, Koeln, Germany). Tryptic digests were mixed with matrix solution 2:1 to be deposited on the 
target. The mass spectra were internally calibrated with trypsin autolysis fragments.
The five most abundant precursor ions, of the exclusion mass list (ions from human keratin and 
trypsin), were selected for MS/MS analysis. The combined MS and MS/MS data were submitted 
by the GPS Explorer v.3.6 software (Applied Biosystems) to the MASCOT database search engine 
(Version 2.1, Matrix Science, http://www.matrixscience.com) and searched with the following 
parameters: Swissprot 56.5 database over all Homo sapiens protein sequences deposited, no fixed 
modifications, as possible modifications carboamidomethylation o f cysteine and oxidation of 
methionine, one missed trypsin cleavage, a mass tolerance of ±0.1Da for the peptide mass values 
and of ±0.3Da for the MS/MS fragment ion mass values. Swiss-Prot is a high quality protein 
database with non-redundant and non-identical sequences allowing specific matches for an
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MS/MS search. A protein was regarded as identified if the MASCOT protein score, based on 
combined MS and MS/MS data, was above the 5% significance threshold for the database (Pappin 
1993), probability-based MOWSE scores greater than 51 were considered significant (p<0.05).
11. IMMUNOFLUORESCENCE
11.1 Primary cell cultures
Primary cells plated in 48-wells plate, as described in section 2.4, were fixed in 4% 
paraformaldehyde for 30 min and washed with PBS IX, incubated lh  in blocking solution (10% 
NGS (Vector) + 0.2% Triton X-100 (Fluka) in PBS IX) at RT, followed by overnight incubation at 4°C 
with primary antibodies (monoclonal anti-CypA, Abeam, 1:500; polyclonal anti-TDP-43, Protein 
Tech, 1:300; monoclonal anti-Smi-32, Covance, Princeton, NJ, USA, 1:3000) diluted in blocking 
solution. After washing with PBS IX, cells were incubated for lh  at RT with the appropriate 
secondary antibody conjugated to a fluorophore, generally Alexa Fluor®594 or 488 anti-mouse or 
rabbit (Invitrogen), prepared in blocking solution. The secondary antibody used for Smi-32 was an 
anti-mouse biotinylated antibody (Vector) diluted 1:500 in blocking solution for lh  at RT, followed 
by Tyramide signal amplification using the TSA™ system (Perkin-Elmer) as described in section
11.1.1. Alternatively Alexa Fluor®647 anti-mouse (Invitrogen) diluted 1:500 in blocking solution 
was used for lh  at RT. Three washes in PBS IX ended the protocol.
To visualise nuclei after the immunocytochemical procedure, wells were incubated for lOmin at 
RT with DAPI (Sigma; 20 mg/mL) diluted 1:500 in PBS IX or Hoechst (pentahydrate (bis- 
benzimide); Invitrogen; 10 mg/mL) diluted 1:1000 in PBS IX, then washed in PBS IX. Slides were 
finally blocked with Fluorsave (Millipore).
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11.1.1 Tyramide signal amplification
After biotinylated secondary antibody, samples were incubated for 150min in Blocking Reagent 
(Perkin Elmer proprietary formulation) and 30min in Streptavidin conjugated to horseradish 
peroxidase diluted 1:300 in blocking reagent. They were then washed in TNT (0.04% Tween in 
0.1M Tris/HCI pH 7.6) and finally, the reaction was developed by incubation for 8min in Tyramide 
(Perkin Elmer proprietary formulation) diluted 1:500 in Amplification Diluent (0.003% H20 2 in 
0.1M Borate pH 8.5). Samples were then washed in PBS IX.
11.2 Immortalized cell cultures
HEK293 cells were plated on round glass coverslips in 24 or 48-well plates and grown to 50% 
confluence. Cells were washed with PBS1X and fixed with 4% paraformaldehyde for lh o u r at RT. 
After washing with PBS1X, cells were permeabilized, to ensure free access of the antibody to its 
antigen, and blocked for non-specific binding using a blocking-permebilization solution (10% 
normal goat serum + 0.2% Triton-X-100 in PBS1X). Cells were incubated overnight at 4°C with 
primary antibody: polyclonal rabbit anti-CypA (1:500; Upstate); monoclonal mouse anti-CypA 
(1:500; Abeam); polyclonal rabbit anti-TDP43 (1:500; kindly provided by Baralle Francisco, ICGEB, 
Trieste); polyclonal mouse anti-TDP43 (1:250; Abnova); rabbit anti-Myc (1:2000; Bethyl 
laboratories); monoclonal mouse anti-Myc (1:200; Origene); monoclonal rabbit anti-FLAG (1:250; 
Sigma); monoclonal mouse anti-FLAG (1:2000; Sigma); monoclonal mouse anti-hnRNP A2/B1 
(1:200; Abnova); monoclonal mouse anti Smi-32 (1:3000; Covance). Cells were washed in PBS1X 
and incubated with fluorochrome-conjugated secondary antibodies (Alexa Fluor®; Invitrogen) 
diluted 1:500 in blocking solution for lhou r at RT. Finally, cells were washed 3 times with PBS1X 
and counterstained with DAPI (Sigma; 20 mg/mL) or Hoechst (Invitrogen; 10 mg/mL) diluted 
1:1000 in PBS IX  for lOmin.
Coverslips were mounted on the slides using Gel/Mount (Biomedia) and allowed to dry.
Appropriate negative controls w ithout the primary antibodies were performed. None o f the
immunofluorescence reactions revealed unspecific fluorescent signal in the negative controls.
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Confocal microscopy was performed on a Olympus FluoView™ FV1000 microscope, equipped with 
3 laser lines: Ar-Kr (488 nm), He-Ne red (646 nm), and He-Ne green (532 nm) (Olympus, Tokyo, 
Japan) and a UV diode. The lens used for the analysis were the 20X and the 40X. Three- 
dimensional images were acquired over a 6- 10pm z-axis with a 0.3pm step size and processed 
using Volocity® software (PerkinElmer Inc., USA).
12. SITE-DIRECTED MUTAGENESIS
To produce single aa substitutions in the wild-type sequence a site-directed mutagenesis 
approach was used. In particular, a overlap PCR approach was used that employs oligonucleotides 
containing the desired altered portion of the gene's nucleotide sequence as primers in a first 
round of PCR. The products of the first round are then used as primers for a second round of PCR, 
whose product corresponds to the cDNA coding for the mutant protein. The sequence obtained is 
then inserted into an expression vector so that the redesigned protein can be produced in cells.
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Figure 27 Schematic representation of the overlap PCR technique.
This site-directed mutagenesis approach has been used to obtain the cDNAs coding for CypA and 
TDP-43 mutants, (a) and (d) are the external primers while (b) and (c) are the internal "mutagenic" 
primers carrying inside their sequence the mutation we want to generate.
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As shown in Figure 27, the first PCR products (AB and CD) were obtained combining the external 
sense primer with the respective internal antisense primer, and vice versa. Once obtained these 
PCR fragments, they were used as new primers in the second PCR, and a single fragment (AD) was 
generated. This was then inserted in the vector of interest.
The cDNA encoding human wild-type CypA was cloned into the sites Sgf I and Mlu I of the pCMV6- 
AC-Myc vector (Origene), so that the construct carries wild-type human CypA with a Myc-Tag 
epitope at its C-terminus. This pCMV6-AC-CypA-Myc vector was purchased from Origene (Figure 
28) and was used in site-directed mutagenesis experiments and to transiently transfect cells.
Figure 28 Schematic representation of pCMV6-AC-Myc (Origene) plasmid.
The construct was cloned with the cDNA for Homo Sapiens Peptidyl-prolyl Isomerase A (PPIA), 
corresponding to the protein Cyclophilin A, into restriction sites Sgf I and Mlu I. This vector encodes 
for wild-type CypA fused with the Myc-tag at the C-terminus.
The PPIase-deficient mutant of CypA was generated mutagenizing the arginine in position 55 into 
an alanine(Arg-55-Ala or R55A) (Zydowsky 1992), corresponding to the substitution: AGA -> GCA. 
CypA is known to be post-translationally modified: in particular Lysine 125 was reported to be 
acetylated in mammals (Kim 2006). To study the influence of this PTM on CypA functions, lysine in 
position 125 was mutated into a glutamine (Lys-125-Gln or K125Q) or an arginine (Lys-125-Arg or 
K125R), corresponding respectively to the substitutions AAG -> CAG and AAG AGG. These
12.1 Cyclophilin A mutagenesis
c4fp-
pCMV6-AC-Myc |  'jgj
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mutant forms of CypA were characterised by non-modifiable amino acids in this crucial position, 
with glutamine and arginine mimicking a stably acetylated or not-acetylated form of the protein.
To insert specific mutations in wild-type cDNA, different overlap PCRs were performed. For each 
overlap PCR two ad hoc mutagenic oligonucleotidic sequences were synthesized while the 
oligonucleotides used as external primers were the same.
The following criteria were followed to design the primers:
- the length o f the annealing region to the cDNA was chosen to have a melting temperature (Tm) 
of approximately 55°C;
- the primers were designed to have one or more G/C at their 3' end, since it favours the correct 
annealing o f the primers with the target;
- the internal primers were characterised by a melting temperature (Tm) similar to the external 
primers, since in the first step of the overlap PCR they should anneal with the target at 
approximately the same temperature.
The external primers used for CypA overlap PCR were:
5'-TCAACGGGACTTTCCAAAATGTCG-3' (sense primer) (a)
5'-TATTAGGACAAGGCTGGTGGGCAC-3' (antisense primer) (d)
The internal primers used to generate the R55A-CypA sequence were: 
5'-TTTCAC^ATTATTCCAGGGTTTATG-3' (sense primer) (c) 
5/-TGGAATAATTGCGTGAAAGCAGGAAC-3/ (antisense primer) (b)
The internal primers used to generate the K125Q-CypA sequence were: 
5,-GATGGCCAGCATGTGGTGTTTGGC-3/ (sense primer) (c)
5'- C AC AT G CTG G CC AT CCA ACC ACT C-37 (antisense primer) (b)
The internal primers used to generate the K125R-CypA sequence were: 
5/-GATGGCAGGCATGTGGTGTTTGGC-3/ (sense primer) (c)
5'- CACATGCCTGCCATCCAACCACTC-3' (antisense primer) (b)
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Figure 29 Schematic representation of human CypA cDNA sequence.
The 0RF is in blue and it is inserted into the sites Sgfl and Mlul (cloning sites are in light blue) of the 
commercial plasmid pCMV6-Ac-Myc (Origene). Amino acids corresponding to each codon are in red, 
the sequence corresponding to the Myc-tag is in light green. Codons that have been mutagenized in 
this study are shown in green (AGA; arginine 55) and orange (AAG; lysine 125). The external primers 
used for the overlap PCR match with the red sequences bordering the cDNA of interest (FW: 833- 
856; RV:1677-1700). Restriction sites recognized by BamHl and Xhol, which correspond to the 
restriction enzymes used to digest the generated fragments, are highlighted in pink.
The first PCR (PCR #1) was performed using a thermal cycler (PTC-100; Mj Research) for 25 cycles
at 95°C for 15sec, 50°C for 30sec, and 68°C for 60sec. lOOng of template (pCMV6-AC-CypA-Myc
plasmid) were added to 50pl of reaction mixture containing 10% Accuprime™ Pfx reaction mix
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(Promega), 0,3pM of each primer and 1U of Pfx DNA polymerase (Promega) possessing a 
proofreading 3' to 5' exonuclease activity. The calculated length of the amplified fragments was 
379bp (AB) and 525bp (CD) for R55A-CypA; 307bp (AB) and 577bp(CD) for K125Q-CypA and for 
K125R-CypA.
A second PCR (PCR #2) was then performed for 5 cycles at 95°C for 15sec, 50°C for 60sec, and 
68°C for 60sec. The PCR #1 products (AB and CD) ( lp l of each fragment) were added to 50|il of 
reaction mixture containing 10% Accuprime™ Pfx reaction mix (Promega) and 1U of Pfx DNA 
polymerase (Promega). At the end of the first 5 cycles a mixture of external primers (0,6pM) was 
added and other 25 cycles o f PCR were executed (95°C for 15sec, 50°C for 60sec, and 68°C for 
60sec). The calculated length of the amplified fragments was 869bp (AD) for all the mutants. At 
the end of each PCR, as check over the experimental procedure, the obtained products were 
loaded on 1% low-melting agarose gels and the purity of the band was verified. In some cases, in 
order to further purify the correct PCR product, the Wizard® SV Gel and PCR Clean-up System 
(Promega) was used according to the procedures suggested by the manufacturer.
The purified PCR products were digested with an excess of BamHl (0,5pl; 20000U/ml) (New 
England Biolabs) and with an excess of Xhol (0,5|il; 20000U/ml) (New England Biolabs) for 6h at 
37°C. Digested samples were separated onto a 1% low-melting agarose gel and purified using the 
Wizard mini-columns (Promega). 5pg of pCMV6-AC-CypA-Myc plasmid were digested with an 
excess o f the same restriction enzymes used for the fragments: BamHl (l,5 |il; 20000U/ml) and 
Xhol (l,5p l; 20000U/ml) for 6h at 37°C. The linearized plasmid was then dephosphorylated by 
further 15min incubation with 1U of TSAP (Thermosensitive Alkaline Phosphatase, Promega). The 
enzyme was then heat inactivated at 74°C for 15min. At the end linearized-dephosphorylated 
plasmid was isolated from 1% low-melting agarose gel with the Wizard mini-columns (Promega). 
For the ligation reaction lOOng of linearized-dephosphorylated pCMV6-AC-CypA-Myc vector DNA 
(~6Kb) and 16,6ng of each insert DNA (550bp; R55A, K125Q, K125R) were incubated with 6U of 
bacteriophage T4 DNA ligase (Promega) in 2X rapid ligation buffer and nuclease free water 
(Ligafast™ Rapid DNA Ligation System). The reaction was performed for 5min at RT.
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lOng and 25ng of the ligation mixture were used to transform 50pl of MAX efficiency DH5a 
competent cells (Invitrogen) according to the protocol suggested by the kit. As negative control 
lOng of linearized-dephosphorylated pCMV6-AC-CypA-Myc vector DNA (not ligated with the 
insert) were added to the bacteria. Each transformation mixture was then spread on Luria Broth 
agar (Sigma) plates with lOOpg/ml ampicillin (Roche) and grown at 37°C overnight. 4 colonies 
selected for ampicillin resistance were isolated from each plate using a sterile pipette tip and 
were used to inoculate 4ml of Luria Broth (Sigma) containing lOOpg/ml ampicillin. After 10 hours 
bacteria from 2ml o f culture were harvested by centrifugation at lOOOOg for 5min in a 
microcentrifuge. After pouring o ff the supernatant, plasmid DNA was isolated from cell pellet 
using the Wizard Plus SV Minipreps DNA Purification System (Promega). 1/10 o f the total DNA 
sample (100 pi) was digested with 0,3pl of the same restriction enzymes used before (BamHl and 
Xhol) in a final volume of lOpI for 6h at 37°C, to release insert DNA from the plasmid. To screen 
for the presence of the insert, 5pl of digestion product were loaded in 1% agarose gel. The 
colonies were chosen based on the presence of the insert and the absence of abnormal products 
of digestion after restriction analysis. To confirm the presence of the mutation, cDNAs were 
sequenced by Primm srl (Milan, Italy) using 500ng of plasmid and lp M  of primers mix. The 
primers used for the sequencing were the following: 5'-GGACTTTCCAAAATGTCG-3' (sense) and 5'- 
ATTAGGACAAGGCTGGTGGG-3' (antisense) spanning respectively nucleotides 838-856 and 1680- 
1699 of the pCMV6-AC-CypA-Myc plasmid.
One third o f the starting liquid culture corresponding to the correct construct, was transferred to - 
80°C for long-term storage in a solution containing 15% sterile glycerol, while two thirds of the 
same bacterial culture were used to inoculate 250ml of fresh selective LB medium and grown 
overnight at 37°C with vigorous shaking. Plasmid DNA was then purified from the bacterial culture 
using a NucleoBond® Xtra Maxi Plus kit (Machery-Nagel) according to the protocol suggested by 
the manufacturer. Plasmid DNA was resuspended in ultrapure water and Nanodrop® ND1000 
spectrophotometer (Thermo Scientific) was used to quantify the amount o f DNA and evaluate the
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presence of contaminants. The vectors obtained were then used to transfect HEK293 cells, in 
order to check for the exogenous proteins expression.
12.2 TDP-43 mutagenesis
The cDNA coding for human wild-type TDP-43 cloned between the Hindlll and BamHl sites of 
pFLAG-CMV2 (Sigma) was kindly provided from Prof. Baralle F (ICGEB, Trieste) (Ayala 2008). This 
construct, carrying Flag-tagged N-terminal TDP-43, was used for transfection and site-directed 
mutagenesis experiments. To investigate the mechanism by which TDP-43 mutations lead to 
neurodegeneration in ALS, the constructs containing the A315T or R361S or Y374X mutations 
were generated. The procedure applied was the same previously described for CypA mutagenesis.
Figure 30 Schematic representation of the pFLAG-CMV2 (Sigma) plasmid.
This vector, carrying the cDNA coding for wild-type TDP-43 fused with the Flag-tag at the N-terminus, 
was used for transfection and site-directed mutagenesis experiments.
The external primers used for overlap PCR were:
5'- GTAATAACCCCGCCCCGTTGACG-3' (sense primer) (a)
5'- GGAGATTGCAGTGAGCCAAGATTGTGCC-3' (antisense primer) (d)
PFLAG-CMV2 (4 .7  kb)
N'Terminal
156
The internal primers used to generate the A315T-TDP-43 sequence were: 
5'- ACTTTGGTACGTTCAGCATTAATCCAGC-3' (sense primer) (c) 
5/-ATGCT6AACGTACCAAAGTTCATCCCACC-3, (antisense primer) (b)
The internal primers used to generate the Y374X-TDP-43 sequence were: 
5'- ATAACTCTTAAAGTGGCTCTAATTCTGG-3/ (sense primer) (c) 
S'-GAGCCACTTTAAGAGTTATTTCCAGAACC-S' (antisense primer) (b)
The internal primers used to generate the R361S-TDP-43 sequence were: 
5'-AC ATGCAGAGCGAGCCAAACCAGGCCTTCG-3' (sense primer) (c) 
5,-TTTGGCTCGCTCTGCATGTTGCCTTGG-3, (antisense primer) (b)
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IV. RESULTS
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1. HEK293 WT and G93A cell lines
ALS is a neurodegenerative disease that can be inherited directly in approximately 10% of affected 
families (Siddique 1996). SODl, the gene coding for the enzyme copper-zinc superoxide 
dismutase, was first linked to ALS and known mutations in its sequence account for about 20% of 
fALS cases (Rosen 1993). To investigate the molecular mechanisms activated in ALS pathogenesis 
we decided to generate an in vitro model of the disease by the expression of mutant SOD1. For 
this purpose, the Human Embryonic Kidney 293 (HEK293) cell line was chosen for its ease of 
handling as well as the wealth of available tools and information (Graham 1977).
1.1 In vitro ALS model generation
HEK293 cells were stably transfected with the empty vector (VEC) or the vector containing wild- 
type (WT-hSODl) or mutant (G93A-hSODl) human SOD1. For each cell line individual clones were 
isolated, grown and tested for the expression of hSODl protein by Western blotting (WB) or 
dot/slot blotting (Figure 1.1A-B). Single clones over-expressing comparable levels of WT or G93A- 
SOD1 were selected for this study. In particular, their immunoreactivity was two times higher 
than the endogenous protein in VEC cells, as measured by densitometry analysis through the 
Progenesis PG240® (Nonlinear Dynamics, Ltd.) software (Figure 1.1C).
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Figure 1.1 Western blot, slot blot and dot blot analyses fo r SODl.
(A) The expression of hSODl after stable transfection of HEK293 cells with empty vector (VEC), wild- 
type (WT) or mutant (G93A)-hSODl was first tested by WB for SODl to select individual clones with
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similar protein levels. (B) These were then tested by slot blotting for SODl and further selected. (C) 
Representative dot blot for SODl on selected cellular clones and corresponding histogram obtained 
by spot densities quantification normalized on the actual amount of protein loaded, as measured by 
Red Ponceau staining. Data (mean ± S.E., n>3) are expressed as percentages of immunoreactivity (IR) 
of control cells (VEC). Symbols indicate that samples are significantly different (H=p<0.001 VEC vs WT 
or G93A), as assessed by Student's t-test.
In order to characterise this in vitro model of fALS, the effect of the mutant protein on cell 
viability was evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay (see Materials and Methods section 1.4). The simple overexpression of WT-SOD1 
did not affect the survival o f HEK293 cells compared to the VEC cell line. Indeed a significant toxic 
effect of the mutant protein (G93A) on cell survival was observed already under basal conditions 
(UNT) (Figure 1.2). Cell-vulnerability was then investigated after serum withdrawal (STARV), in 
order to exacerbate the death-inducing effect of the mutant protein. In fact, serum withdrawal 
induces oxidative stress, with the generation of free radical species in the cell. All cell lines were 
susceptible to serum deprivation stress with an increased effect on G93A-hSODl expressing cells 
compared to both WT and VEC cells.
1.2 In vitro ALS model characterization
1.2.1 Cell viability evaluation
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Figure 1.2 Effect o f SODl overexpression on cell viability.
Histograms represent the effect of the empty vector (grey), WT-SOD1 (white) or G93A-SOD1 (black) 
overexpression on HEK293 cell survival, evaluated in basal condition (UNT) or after serum
withdrawal (STARV). The conversion of MTT to formazan was used as an index of cell viability. Data 
(mean ± S.E., n>4 for each sample) are expressed as percentages of control cells (UNT VEC). Symbols 
indicate that samples are significantly different (*=p<0.05 UNT vs. STARV; n=p<0.05 VEC vs. WT or 
G93A; §= p<0.05 WT vs. G93A), as assessed by two-way ANOVA test followed by Bonferroni multiple 
comparisons post-test.
1.2.2 Markers of nitrative stress 
To further characterise the in vitro model, we next considered molecular markers that have been 
previously associated with ALS in in vitro and in vivo animal models and in patients. First, markers 
of nitrative and oxidative stress were evaluated, since they are characteristic signs of a 
pathological process. Increased levels of free and protein-bound 3-nitrotyrosine (3-NT) in the 
central nervous system (CNS) are considered a marker o f oxidative stress for different 
neurodegenerative diseases (Pacher 2007), and increased levels o f free 3-NT have been found in 
the cerebrospinal fluid (CSF) and serum of patients with ALS and in the CNS of fALS mice (Abe 
1997; Beal 1997; Bruijn 1997; Ferrante 1997). Recently, in our lab, some 3-NT-modified proteins 
have been identified in the spinal cord o f fALS mice (Casoni 2005; Basso 2009) and in peripheral 
blood mononuclear cells (PBMC) from sALS patients and a rat model o f ALS (Nardo 2009 and 
2011). Immunostaining for 3-NT was performed in our in vitro model (Figure 1.3A), revealing a 
substantially increased level o f protein nitration in mutant cells if compared to WT cells, already 
under basal conditions (UNT). No significant difference in 3-NT levels was detected after serum 
withdrawal.
Moreover, an antibody developed in-house was used to evaluate the level o f a NT-linked protein: 
actinNT. The anti-actinNT antibody recognizes a band at 42kDa, which is the expected molecular 
weight for actinNT, but also other bands at higher molecular weight (MW), that are probably 
polymerized actin forms. The high MW species were essentially detected only in PBMC lysates 
from sALS patients, making the antibody especially useful to distinguish ALS patients from 
controls (Nardo 2011). The immunoreactivity pattern o f this antibody against lysates from WT and 
G93A-SOD1 over-expressing cells was analysed (Figure 1.3B). Under basal conditions, in WT and
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mutant cells a staining pattern similar to control and ALS patients respectively was observed. 
Quantitative analysis of the WB revealed a statistically significant difference between WT and 
mutant cells. In both cell lines there was a significant further increase after serum withdrawal, and 
it was still possible to appreciate a statistically significant difference between WT and G93A-SOD1 
over-expressing cells. Collectively, these data are indicative of the presence of nitrative and 
oxidative stress in this in vitro fALS model. This is in line with the observation that mutant SODl 
has an increased ability to catalyse aberrant oxidative reactions, including protein nitration 
(Beckman 1993; Estevez 1999).
WT G93A
UNT STARV UNT STARV
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Figure 1.3 Markers of nitrative and ER-stress in WT- and G93A-SOD1 HEK293 cells.
Representative WB for (A) total 3-nitrotyrosine (3-NT), (B) nitrated actin (actinNT) and (C) Protein- 
Disulfide Isomerase (PDI) from WT-SOD1 and G93A-SOD1 cells, under basal conditions (UNT) or after 
serum withdrawal (STARV). 15pg of total protein lysates were loaded, run on SDS-PAGE gels, 
transferred on PVDF membrane, stained with Red Ponceau as loading control, incubated with 
primary and secondary antibodies and detected by chemiluminescence. Histograms represent the 
quantification of total immunoreactivity normalized to the actual amount of protein loaded. Data 
(mean ± S.E., n>3) are expressed as percentages of control cells (UNT WT). Symbols indicate that 
samples are significantly different (*=p<0.05 UNT vs. STARV; §= p<0.05 WT vs. G93A), as assessed by 
Student's t-test.
1.2.3 Markers of ER-stress
Subsequently, the expression level of the Protein-Disulfide Isomerase (PDI) was considered. PDI is
an endoplasmic reticulum (ER) chaperone that catalyzes the formation and rearrangement of
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intra- and inter-molecule disulfide bonds. An increase in its levels is a typical cellular response to 
ER-stress that triggers the unfolded protein response, leading eventually to cell death (Kim 2008). 
Studies in SpC tissues (Atkin 2008) and PBMC of sALS patients (Nardo 2011) showed that PDI was 
up-regulated with the disease. Its alteration is considered a hallmark o f disease also in animal 
models and motor-neuron-like cellular models of fALS (Atkin 2006; Massignan 2007). 
Interestingly, quantitative analysis of PDI WB showed a significant up-regulation in mutant cells if 
compared with WT cells, already under basal conditions (Figure 1.3C). Increased amounts o f PDI 
were also observed in both cell lines after serum deprivation.
In summary, the protein profile changes detected demonstrated that G93A-SOD1 stably 
expressed in HEK293 cells is toxic and confers these cells important characteristic features o f fALS, 
such as nitrative, oxidative and ER-stress, that makes these cells a valid in vitro model to analyse 
the molecular events induced by SODl mutation.
1.3 Cyclophilin A analysis
CypA has been validated as a translational early biomarker of ALS in PBMC (Nardo 2011). In 
particular, CypA expression was increased in sALS patients compared to healthy controls, and was 
altered in a G93A-hSODl rat model of ALS before disease onset. CypA also contributed to 
discriminate between patients with high- and low-severity disease, and to distinguish ALS from 
other neurological disorders. Furthermore, CypA was demonstrated to be accumulated in the 
detergent-insoluble fraction isolated from spinal cord tissue of sALS patients (Basso 2009). 
Therefore, the biochemical properties o f CypA were investigated in selected HEK293 SOD1- 
overexpressing clones.
1.3.1 CypA expression level
First, CypA total level was evaluated in cell lysates from WT and mSODl expressing cells by WB
and slot blotting, and the ratio between CypA immunoreactivity and Red Ponceau signals was
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quantified. The result from this analysis did not reveal any statistically significant difference 
(Figure 1.4). This result is in agreement with the one obtained in the spinal cord of the G93A- 
SOD1 mouse model at an early presymptomatic stage of the disease, where the expression level, 
as detected by standard WB, did not change in respect to WT animals (Massignan 2007). 
However, when cells were serum-deprived, CypA protein level was increased in both cell lines, 
with a statistically significant difference between mutant and WT cells.
WT G93A
UNT STARV UNT STARV
140 -| 
120 -
pp: 0£ 100 
<  80 -
a  60 - 
U  40 - 
20 -
■|
Proeenesk Oiscoverv111 iioHware 0 -
UNT STARV
□  WT 
■  G93A
Figure 1.4 CypA expression level in WT- and G93A-SOD1 HEK293 cells.
Representative WB and 3D rendering for CypA from WT-SOD1 and G93A-SOD1 cells, under basal 
conditions or after serum withdrawal. 15pg of total protein lysates were loaded, run on SDS-PAGE 
gels, transferred on PVDF membrane, stained with Red Ponceau as loading control, blotted for CypA 
and detected by chemiluminescence. The histogram represents quantification of total 
immunoreactivity normalized to the actual amount of protein loaded. Data (mean ± S.E., n>3) are 
expressed as percentages of control cells (UNT WT). Symbols indicate that samples are significantly 
different (*=p<0.05 UNT vs. STARV; §= p<0.05 WT vs. G93A), as assessed by Student's t-test.
1.3.2 CypA isoform pattern 
Next, our attention was focused on the analysis of CypA behaviour by two-dimensional gel 
electrophoresis (2DE)-WB. From previous studies in our laboratory CypA was already 
demonstrated to be post-translationally modified, indeed four CypA positive isoforms could be 
detected by WB and MS in mouse spinal cord tissue (Massignan 2007). Protein extracts from WT 
and mutant HEK293 cells were separated on 2DE-gels and blotted. The membranes were probed 
with anti-CypA antibody and CypA appeared as a train of at least four spots at the same MW in 
the isoelectric point (pi) range 6.5-7.5 (Figure 1.5). Immunoreactivity for all CypA isoforms was
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measured and a variation in its isoform pattern was detected under basal conditions. In particular, 
isoform four almost disappeared in mutant cells with a shift towards the acidic forms of the 
protein, mainly isoform three, which is the N-terminally acetylated one. A similar isoform pattern 
change, a shift toward acidic pi, has been observed also in sporadic ALS patients (unpublished 
data from the laboratory) and in fALS mice (Massignan 2007).
WT
G93A
2 3 4
- 18kDa 
- 18kDa
6.5 pi 7.5
Figure 1.5 CypA isoform pattern in WT- and G93A-SOD1 HEK293 cells.
2DE blot for CypA from WT-SOD1 and G93A-SOD1 cells under basal conditions. 75pg of total protein 
lysates were separated by IEF, run on SDS-PAGE gels, transferred to PVDF membranes, stained with 
Sypro® Ruby Protein Blot stain as loading control, blotted for CypA and detected by 
chemiluminescence. The 2DE-WB was repeated several times with consistent results and 
representative images are shown here.
Mutant SODl expression produced an altered pattern of CypA isoforms, pointing out a variation 
in the post-translational modifications (PTM) profile, under basal conditions. PTM are likely to be 
key-features for protein versatility. Since CypA can have different activities in different cellular 
compartments, it is fundamental to associate CypA functions, localisation and interactors with 
specific PTM.
1.3.3 CypA subcellular distribution 
To have insights into CypA subcellular distribution, a protocol for the biochemical fractionation of 
HEK293 cells was set up. In particular, the cytoplasmic and the nuclear fractions were isolated 
from HEK293 cells stably expressing WT- or G93A-SOD1, as described in the Materials and 
Methods section. WB analyses for lamin A+C (nuclear envelope markers) and actin (a cytoplasmic
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marker) were performed in order to assess if the fractionation between the nuclear and the 
cytosolic compartments was effective (Figure 1.6).
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Figure 1.6 CypA subcellular distribution in WT- and G93A-SOD1 HEK293 cells.
Representative WB for CypA, lamin A+C and actin from WT- and G93A-SOD1 cells, in basal condition 
or after serum withdrawal. 15pg of cytosolic and corresponding nuclear protein fractions were 
loaded, run on SDS-PAGE gels, transferred to PVDF membranes, stained with Red Ponceau as a 
loading control, blotted and detected by chemiluminescence. Histograms represent the 
quantification of total immunoreactivity normalized to the actual amount of protein loaded. Data 
(mean ± S.E., n>3) are expressed as percentages of control cells (UNT WT) in the respective fraction. 
Symbols indicate that samples are significantly different (*=p<0.05 UNT vs. STARV; §= p<0.05 WT vs. 
G93A), as assessed by Student's t-test.
CypA subcellular localisation was evaluated in WT and mutant cells under basal conditions and
after serum withdrawal, replicating the conditions used to assess cell viability and CypA total
expression level. In the cytosolic fraction the level of CypA was higher in mutant cells than in WT
cells. This difference was exacerbated after starvation. In the nuclear fraction no differences were
detectable between WT and mutant cells when untreated. However, after starvation CypA had a
completely different behaviour: in WT cells the CypA expression level was increased greatly, while
no significant alteration was observed in mutant cells. These results indicate that WT cells react to
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a toxic stimulus by up-regulating CypA in the cytosol and especially in the nucleus. This feature is 
lost in mutant cells, where there is an increase only in CypA cytosolic levels.
To investigate further the alterations in CypA distribution, immunofluorescence (IF) staining for 
CypA was performed by confocal microscopy. In particular, images from HEK293 cells stably 
expressing WT or mutant SODl were acquired; DAPI staining was used to visualise the nuclei 
(Figure 1.7). In WT-SOD1 expressing cells CypA was widely distributed in the cell and its 
localisation in the nuclei was clear. Mutant cells showed a diffuse signal for CypA that seemed 
shifted from the nuclei towards the cytosol with a spot-like staining (as shown in the inset). After 
starvation it was possible to observe an overall increased staining for CypA in WT cells (mainly in 
the nuclei), which became higher in G93A cells (data not shown). The protein distribution 
observed by IF was in agreement with the results previously obtained by WB and biochemical 
fractionation.
WT-SOD1 G93A-SOD1
Figure 1.7 CypA immunofluorescence confocal analysis in WT- and G93A-SOD1 HEK293 
cells.
WT- and G93A-SOD1 cells were stained for CypA using Alexa®488 (green) (bar: 15pm). Nuclei were 
counter-stained with DAPI (blue). Insets show images at higher magnification. Immunofluorescence 
images shown represent consistent results obtained in multiple replicates.
Collectively, these data demonstrated that in this in v/tro model G93A-hSODl overexpression, 
even though not evidently altering CypA total level, was sufficient to alter the CypA isoform 
pattern, mirroring the trend observed in sALS patients and fALS murine models (Nardo,
unpublished data from the lab; Massignan 2007), and this should be directly correlated to the 
shift observed in its subcellular localisation and possibly PTM profile.
1.4 Cyclophilin A lysine-acetylation
CypA displays a complex pattern of maturation and PTM. Starting from the results obtained by 
2DE-WB analysis of CypA in WT and mutant cells, a deeper investigation of CypA PTM was 
performed, and in particular lysine-acetylation was explored in the in vitro model. In fact, this 
PTM has been described in human CypA and eight potential N6-acetyllysine sites were proposed 
on amino acids 28, 31,44,49,76, 82,125,131 (Kim 2006; Choudhary 2009; Chevalier 2012).
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Figure 1.8 CypA is lysine-acetyiated in the nucleus and its regulation is associated with 
stress response.
Equal amounts of proteins (500pg) were independently co-precipitated with the anti-Acetyl-lysine 
antibody from the cytosolic and the corresponding nuclear fractions of HEK293 cells stably 
expressing WT- or G93A-SOD1 under basal conditions or after serum withdrawal. Aliquots of the 
cytosolic and nuclear lysates (INPUT), of the immunoprecipitates (IP), of the proteins from the 
remaining fraction (OUTPUT) were loaded together, subjected to SDS-PAGE, transferred to PVDF 
membranes, stained with Red Ponceau as loading control, blotted for CypA and revealed through 
chemiluminescence. Representative WB are shown.
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WT and mutant cells were collected under basal conditions or after serum withdrawal and the 
cytosol/nuclei extraction was performed as previously described. An antibody raised against a 
mixture o f chemically acetylated antigens was used to specifically immunoprecipitate (IP) 
acetylated lysine (AcK)-containing proteins. CypA was detected by subsequent immunoblot 
analysis (Figure 1.8). The trend observed in the input fraction was the same reported previously in 
biochemical fractionation experiments. This experiment was replicated with a clear result: CypA 
was co-IP with the anti-AcK antibody only in the nuclear and not in the cytosolic fraction. 
Furthermore, from this experiment it was possible to infer that not all the nuclear protein was 
acetylated at lysine. In fact, an up-regulation of CypA expression in the nuclei after starvation, as 
observed in the input fraction, did not correspond to an increase of the protein in the IP fraction, 
that is lysine-acetylated CypA. Indeed a reduction in CypA lysine-acetylation was shown after 
starvation, both in WT and mutant cells.
These data demonstrate that CypA is acetylated at lysine exclusively in the nucleus with an 
altered pattern in mutant cells and in stress conditions, suggesting that the fine regulation of 
CypA lysine-acetylation and de-acetylation could play a role in the stress response.
1.5 Cyclophilin A knockdown
In order to directly observe the effects of the loss o f CypA function in WT and mutant cells RNA 
interference technology has been used. CypA silencing experiments were performed in HEK293 
cells delivering specific siRNACypA or, as a negative control for knockdown, a scrambled siRNA that 
did not lead to the degradation of any aspecific cellular message. Several siRNA molecules 
targeting different regions on CypA locus, both coding and untranslated regions, were transiently 
transfected using a cationic lipid-mediated transfection system. RNA silencing experimental 
conditions were optimized to obtain a reduction in CypA protein expression of up to 95% (Figure 
1.9A). In all experiments performed, CypA knockdown was always verified analysing the protein 
expression level by Western or dot blotting (Figure 1.9B).
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Figure 1.9 CypA knockdown in HEK293 cells.
HEK293 cells were untreated, or transfected with siRNAscramb,e or siRNACypA. (A) The graph represents 
the quantification of CypA expression level by slot blotting, normalized to the amount of protein 
loaded as detected by Red Ponceau staining, using different siRNACypAat different time points. (B) 
Representative WB for CypA in cells treated with the selected siRNACypA. (C) Representative 
immunofluorescence images of HEK293 cells stained for CypA (red) after silencing (bar: 15pm). 
Nuclei were stained with DAPI (blue).
To further confirm CypA silencing, immunofluorescence (IF) staining for CypA was performed and 
cells were counter-stained with DAPI to visualise the nuclei. In scrambled siRNA transfected cells 
the protein was homogenously expressed, both in the nuclei and in the cytosol, with a marked 
staining also in cellular protrusions (Figure 1.9C). In cells treated with siRNACypA the extent of CypA 
silencing was clear also by IF, confirming the results obtained by WB.
1.6 Myc-tagged CypA overexpression
To further investigate CypA function, a plasmid carrying the human CypA coding sequence was
purchased from OriGene and sequenced to confirm the sequence. In order to specifically detect
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the exogenous protein and to distinguish the transfected protein from endogenous CypA, the 
sequence was fused with a Myc-tag epitope at the C-terminal end. Transfection was optimized to 
obtain the highest expression level in cells.
1.6.1 Myc-CypA expression level
To verify the correct expression of the exogenous Myc-tagged CypA protein, HEK293 cells were 
transiently transfected with either an empty vector or with the vector expressing Myc-CypA. Cells 
were lysed and the expression of both endogenous and exogenous CypA was tested by WB 
analyses, using an antibody against CypA or alternatively an antibody against the Myc-tag (Figure 
1.10A1-2). The tagged protein was clearly detectable only in Myc-CypA transfected cells, and not 
in cells transfected with the empty vector and could be easily distinguished also using the anti- 
CypA antibody. A good expression level of the transfected protein was measured (comparable to 
endogenous CypA) thus indicating that HEK293 were efficiently transfected and effectively 
expressed the exogenous protein. The Myc-tag adds 18 aas to the original protein, which explains 
the increased molecular weight. In fact, the observed MW coincided with the predicted MW, 
computed through the proteomic server Expasy (www.expasv.org) at the Swiss Institute of 
Bioinformatics.
1.6.2 Myc-CypA isoform pattern
Once verified Myc-CypA expression, it was checked if the exogenous protein could undergo the 
same post-translational modifications as the endogenous CypA protein when transiently 
transfected in HEK293 cells. To do that, cell lysates were subjected to 2DE separation, followed by 
WB for CypA or the Myc-tag. Using the anti-Myc-tag antibody, four protein spots were clearly 
detected. When a polyclonal antibody against CypA was used, eight major spots were 
distinguished and corresponded to four isoforms of the endogenous protein and, four isoforms at
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higher MW, of the exogenous tagged protein, positive for both CypA and Myc-tag antibodies 
(Figure 1.10B1-2).
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Figure 1.10 Myc-CypA expression in HEK293 cells.
HEK293 cells were transiently transfected with the empty vector or the vector cloned with Myc- 
CypA. (A) 15 pg of total protein lysates were loaded, run on 12% SDS-PAGE gels, transferred to a 
PVDF membrane, stained with Red Ponceau as loading control, analysed by WB using the anti-Myc- 
tag (1) or the anti-CypA (2) antibodies and detected by chemiluminescence. (B) 75pg of total protein 
lysates from Myc-CypA transfected cells were separated by IEF, run on 12% SDS-PAGE gel, 
transferred on a PVDF membrane, stained with Sypro Ruby Blot® stain as loading control, analyzed 
by WB using the anti-Myc-tag (1) or the anti-CypA (2) antibodies and detected by 
chemiluminescence. Representative 2DE blots are shown. (C) Representative immunofluorescence 
images of HEK293 cells stained for Myc-tag (1) or CypA (2) after Myc-CypA transfection (bar: 10pm). 
Nuclei were stained with DAPI (blue). Experiments were repeated several times with consistent 
results and representative images were chosen for display.
The isoform patterns observed were similar for endogenous CypA and Myc-CypA, suggesting that 
they were prone to be post-translationally modified in a similar way. Apart from the molecular 
weight, the only difference between the two proteins was the isoelectric point (pi): the 
endogenous unmodified CypA has a predicted pi of 7.68, whereas the computed pi of Myc-CypA 
was 6.90, as evidenced by a shift in the gel towards a more acidic pi. So, the values calculated 
through the Expasy proteomic server perfectly fitted with the experimental observations. By
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comparison with data previously obtained in the laboratory (Massignan 2007), it was possible to 
deduce that isoforms one and three were the N-terminally acetylated ones, while isoforms two 
and four were the non N-terminally acetylated ones. The shift towards more acidic pi of isoforms 
one and two can be due to the presence of a combination of post-translational modifications 
(PTMs), such as phosphorylation, Lys-acetylation and methylation (Chevalier 2012).
1.6.3 Myc-CypA localisation
The expression of the exogenous tagged protein was also verified by immunofluorescence using
confocal microscopy. HEK293 cells transfected with the empty vector were used as controls. CypA 
immunostaining in these cells revealed a homogeneous localisation of the endogenous protein, as 
previously shown, while, as expected, no signal was detectable using the Myc-tag antibody. 
HEK293 cells transfected with the Myc-CypA vector were clearly recognizable with both stains. In 
particular using the CypA antibody, overexpressing cells were distinguishable from non­
transfected cells because of a more intense immunostaining, whereas using the Myc-tag antibody, 
only cells overexpressing CypA were selectively stained (Figure 1.10C1-2). Moreover, the Myc-tag 
staining revealed that the exogenous protein retained the same cellular localisation of the 
endogenous one and showed a good expression of the plasmid, denoting a transfection efficiency 
greater than 50%.
1.6.4 Cell viability evaluation after CypA 
overexpression
In order to determine whether overexpression o f CypA in this in vitro model o f ALS could have a 
protective or a toxic effect, cell viability was assessed by MTT assay in three independent 
experiments. An increase in CypA protein level had no statistically significant effects on cell 
survival rate (Figure 1.11).
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Figure 1.11 Effect of CypA overexpression on cell viability.
Histograms represent the effect of Myc-CypA overexpression in HEK293 cells stably expressing VEC 
(grey), WT-SOD1 (white) or G93A-SOD1 (black) on viability, compared to cells transfected with the 
empty vector (CTR). The conversion of MTT to formazan was used as an index of cell survival. Data 
(mean ± S.E., n>4 for each sample) are expressed as percentages of control cells (WT CTR). Symbols 
indicate that samples are significantly different (§= p<0.05 WT vs G93A), as assessed by two-way 
ANOVA test followed by Bonferroni multiple comparisons post-test.
174
2. Identification of Cyclophilin A interacting 
proteins
A possible involvement of CypA in ALS pathogenesis has been hypothesised. Nevertheless its role 
and possible effects in the disease have remained elusive. Recently, different aspects of CypA 
biological functions have emerged, suggesting that it is involved in multiple signalling events of 
eukaryotic cells. CypA either possesses enzymatic peptidyl-prolyl isomerase activity, which is 
essential to protein folding in vivo (Schiene 2000), or it might form stoichiometric complexes with 
target proteins without necessarily isomerizing a peptidyl-prolyl bond, thereby preventing 
misfolding and/or modulating activity of the target protein (Braaten 1997; Streblow 1998; Brazin 
2002). We decided to investigate the CypA interactome because the identification o f novel 
interactions can be the key to provide further insights into the (patho)physiologically relevant 
molecular functions of this protein in ALS.
2.1 CypA interactome in HEK293 cells
A proteomic-based strategy was employed to investigate the CypA interactome network. Novel 
potential interactors were first identified through mass spectrometry and then the most 
interesting results were validated through WB. The experimental approach is outlined in Figure
2.1 and it foresaw the separation of CypA interactors from wild-type and mutant SOD1 stably 
expressing cells. Proteins from whole cell lysates were first solubilised by a weak detergent-based 
buffer, in order to maintain non-covalent interactions within intact protein complexes. The 
complexes of CypA-interacting proteins were enriched by co-immunoprecipitation (IP) using anti- 
CypA antibodies, separated by isoelectrofocusing (IEF) and then by SDS-PAGE. Protein spots were 
located on 2DE-gels stained with Sypro® Ruby Protein Gel Stain (Invitrogen), excised by a spot 
cutter, incubated with trypsin in a protein digestor and analysed by MALDI-TOF/TOF mass 
spectrometry (further details are discussed in Materials and Methods section). Benzonase® 
Nuclease, an endonuclease that attacks and degrades all forms of DNA and RNA (single stranded,
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double stranded, linear and circular), was included in all reaction mixtures to exclude the 
possibility of protein interactions mediated by protein-RNA/DNA-protein interaction through 
possibly contaminating RNA/DNA.
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Figure 2.1 Analytical w orkflow  used to identify CypA interactors.
The experimental procedure included: collecting samples from cultures of HEK293 cells expressing 
WT- or G93A-SOD1, preparing 4.5mg of protein extracts for each experimental condition per 
replicate, performing sample pre-clearing using uncoated magnetic beads, cross-linking anti-CypA 
antibody (Abl) to the secondary antibody-conjugated magnetic beads, immunoprecipitating the 
complexes of CypA-interacting proteins, eluting the immunoprecipitate fraction from the magnetic 
beads, preparing the sample for 2DE analysis by methanol/chloroform precipitation and 
solubilization, separating the proteins by IEF and SDS-PAGE, staining the gels with Sypro Ruby, 
scanning the gels and identifying protein spots, picking the spots of interest, digesting proteins with 
trypsin, preparing samples for mass spectrometry, performing peptide mass fingerprinting and 
MS/MS analysis to identify potential interactors.
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Figure 2.2 2DE maps of CypA interactome in HEK293 cells.
Representative preparative 2DE gels of CypA co-immunoprecipitated proteins from WT- or G93A- 
SOD1 expressing HEK293 cells transfected with a scrambled siRNA or a specific siRNA against CypA 
sequence. (A-C) After CypA knockdown, 4.5mg of proteins were used to immunoprecipitate CypA 
and the IP fraction (B) was separated by 2DE in parallel with the corresponding INPUT (A) and 
OUTPUT (C) fractions. (D) At the same time 15pg of proteins from cells silenced with lOnM of a 
scrambled sequence or a CypA-specific siRNA underwent SDS-PAGE and WB for CypA (small box) to 
verify protein down-regulation and Red Ponceau staining as a loading control (lower panel). (E-F) 
4.5mg of proteins from HEK293 cells stably expressing WT (E) or mutant hSODl (F) were 
immunoprecipitated for CypA and underwent two-dimensional gel electrophoresis. Proteins in 2DE- 
gels were stained with Sypro® Ruby Protein Gel Stain (Invitrogen). Proteins are distributed vertically 
according to their molecular weight and horizontally according to their pi.
As a negative control for this experimental procedure, co-IP experiments followed by 2DE
separation, were also performed in cells depleted of CypA by RNA interference (Figure 2.2A-D).
CypA knockdown has been performed delivering a specific small interfering RNA (siRNA)
molecule, as previously described. The comparison between the co-IP fractions isolated from cells
expressing CypA or silenced for CypA provided a powerful tool to discern specific CypA-binding
partners. Furthermore, only proteins co-purified in independent IP experiments using two
different antibodies for CypA, one polyclonal and one monoclonal, were considered as specific
CypA interactors, and corresponding spots were selected for MS analysis.
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Figure 2.3 CypA interactome in HEK293 cells.
2DE map of CypA interacting proteins showing spots identified by MALDI-TOF/TOF. Proteins in the 
gel were stained with Sypro Ruby Protein Gel Stain (Invitrogen). Proteins are distributed vertically 
according to their molecular weight and horizontally according to their pi.
In Figure 2.2 a representative experiment is shown with 2DE-gels of CypA co-IP fractions isolated 
from total protein homogenates of HEK293 cells expressing wild-type (Figure 2.2E) or mutant 
SOD1 (Figure 2.2F) or cells previously silenced for CypA (Figure 2.2B) as negative control. This 
procedure seems really specific since in the negative control sample only IgG were present. This 
means that when CypA was silenced, the antibody against CypA was not co-immunoprecipitating 
any aspecific protein complex, and that the spots observed in the other two gels are specific 
CypA-binding partners. 28 proteins, found in association with CypA, were identified by mass 
spectrometry in both WT and mutant cells (Table 2.1).
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Spot Entry AC Mr(aic plcaic Mr0bs pi obi Score(Coverage Peptide Matched/ Best ion (%)b count unmatched1 score
Peptide sequence
DNA/RNA binding proteins
1 ROA1 P09651 38.7 9.21 34.2 9.27 66 21 7 7/38
2 ROA2 P22626 37.4 8.97 37 8.9 555 47 13 13/8
3 HNRPC P07910 33.6 4.95 34 4.9 222 14 4 4/10
4 HNRPG P38159 42.3 10.06 43 5.3 105 28 11 11/15
5 HNRPK P61978 50.9 5.39 51 5.4 287 33 14 14/18
6 HNRPM P52272 77.5 8.84 77 8.84 77 41 28 28/110
7 TADBP Q13148 44.7 5.85 44.7 6.5 78 4 1 1/16
8 IF4A3 P38919 46.8 6.30 46.8 6.3 97 13 5 5/13
9 IF4A2 Q14240 46.4 5.33 46 5.3 92 6 3 3/10
10 IF4A1 P60842 46.1 5.32 46 5.3 92 6 3 3/10
11 DDX3X 000571 73.2 6.73 73.2 6.8 117 18 13 13/17
12 PRP19 Q9UMS4 55.1 6.14 55.1 6.1 90 24 7 7/17
13 SFPQ P23246 76.1 9.4 76 9.4 73 31 24 24/72
14 HKR1 P10072 75.1 9.44 75.1 9.44 69 44 25 25/157
15 NR1I2 075469 49.7 8.70 45 5.5 59 31 13 13/84
16 NPM P06748 32.5 4.64 32.5 4.6 95 14 4 4/18
Protein biosynthesis
17 EF2 P13639 95.3 6.41 95.3 6.8 127 11 8 8/9
Protein folding and degradation
18 TCP A P17987 60.3 5.80 60.3 5.8 108 13 6 6/13
19 HSP71 P08107 70.0 5.48 70 5.5 660 41 22 22/14
Trafficking
20 RAN P62826 24.42*7.01 24 7.0 65 10 3 3/17
Cytoskeletan-associated proteins
21 ACTB P60709 41.71 5.29 41.8 5.3 458 37 11 11/15
22 TBA1B P68363 50.1 4.94 50 4.9 384 46 13 13/24
23 VIME P08670 53.6 5.06 53.6 5.06 60 27 10 10/42
24 TMOD2 Q9NZR1 39.5 5.21 40 8.9 61 37 13 13/96
Energy metabolism
25 ENOA P06733 47.14 7.01 47.1 7.0 375 29 9 9/5
26 G3P P04406 36.03 8.57 37 8.6 76 4 1 1/14
27 KCRU P12532 47.01 8.6 44.5 8.5 87 12 4 4/11
Others
28 PHB P35232 29.8 5.57 29.8 5.4 628 39 8 8/11
15 R.SSGPYGGGGQYFAKPR.N
114 R.GGGGNFGPGPGSNFR.G
83 R.MIAGQVLDINLAAEPK.V
16 R.RGPPPPPR.S
83 R.TDYNASVSVPDSSGPER.I
71 R.FGGNPGGFGNQGGFGNSR.G 
64 R.GIYAYGFEKPSAIQQR A
72 R.GIYAYGFEKPSAIQQR.A
72 R.GIYAYGFEKPSAIQQR.A
31 R.VGNLGLATSFFMER.N
30 K.TVPEELVKPEELSK.Y
70 R.MTDQEAIQDLWQWR.K
65 K.AYLPVNESFGFTADLR.S
66 R.AFHNEAQVNPER.K
88 K.DAGVIAGLNVLR.I
44 K.NLQYYDISAK S
116 K.SYELPDGQVITIGNER.F
96 R.AVFVDLEPTVIDEVR.T
147 R.AAVPSGASTG1YEALELR.D
69 K.USWYDNEFGYSNR.V
56 R LYPPSAEYPDLR.K
190 K.AAEUANSLATAGDGUELR.K
Table 2.1 CypA interacting proteins identified by MALDI-TOF/TOF mass spectrometry.
List of CypA interactors classified by the proteins' main function. Identified proteins correspond to 
spots shown in Figure 2.3. AC, accession numbers from swissprot database; calc, calculated; obs, 
observed, hatched/unmatched, the number of peaks that match/unmatch to the theoretical 
peptide mass fingerprinting. Sequence coverage as the number of amino acids spanned by the 
assigned peptides divided by the sequence length. cProtein score based on combined MS and MS/MS 
spectra from MALDI-TOF/TOF analysis using MASCOT search engine (Matrix Science). The proteins 
that had a statistically significant (P < 0.05) protein score (>51), were considered successfully 
identified.
Notably, although CypA is predominantly a cytosolic protein, the CypA interactome revealed 
interaction with both nuclear and cytoplasmic proteins (Table 2.2). In order to understand 
whether CypA co-purified proteins, belonging to these two cellular components, differed also
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with respect to their functions, the Gene Ontology (GO) database was searched for functional 
classification. Analysis of the biological processes-GO terms, revealed that CypA interacting 
proteins largely cluster into functionally distinct protein networks (Figure 2.3). Remarkably, CypA 
has extensive interactions with proteins that associate with DNA/RNA and a set o f proteins 
involved in multiple steps of RNA metabolism (Figure 2.4). These results are consistent with the 
observation that CypA is a cellular component of both the nucleus and the cytoplasm, and provide 
an important perspective about how CypA could be involved in different biological pathways, 
likely suggesting a possible functional role in these processes too.
Gene name Protein name Biological function Cellular component
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 mRNA processing, splicing, transport Cytoplasm, Nucleus
HNRNPA2B1 Heterogeneous nuclear ribonudeoproteinsA2/Bl mRNA processing, splicing Cytoplasm, Nucleus
HNRNPC Heterogeneous nuclear ribonudeoproteins C1/C2 mRNA processing, splicing Nucleus
HNRPG Heterogeneous nudear ribonucleoprotein G mRNA processing, splicing, transcription Nucleus
hnRNPK Heterogeneous nuclear ribonucleoprotein K mRNA processing, splicing Cytoplasm, Nucleus
HNRNPM Heterogeneous nudear ribonucleoprotein M mRNA processing, splicing Nucleus
TARDBP TAR DMA-binding protein 43 mRNA processing, splicing, transcription Nucleus
EIF4A3 Eukaryotic initiation factor 4A-III mRNA processing, splidng, transport Cytoplasm, Nucleus
EIF4A2 Eukaryotic initiation factor 4A-II Protein biosynthesis Cytoplasm
EIF4A1 Eukaryotic initiation factor 4A-I Protein biosynthesis Cytoplasm
DDX3X ATP-dependent RNA helicase DDX3X mRNA processing, splidng Cytoplasm, Nucleus
PRPF19 Pre-mRN A processing factor 19 mRNA processing, splicing, DNA repair Cytoplasm, Nucleus
SFPQ Splicing factor, proline- and glutamine-rich mRNA processing, splicing, DNA repair Cytoplasm, Nucleus
HKR1 Krueppel-related zinc finger protein 1 Transcription/Transcription regulation Nucleus
PXR Nuclear receptor subfamily 1 group 1 member 2 Transcription, Transcription regulation Nucleus
MPM1 Nudeophosmin Ribosome assembly, DNA repair, protein transport Cytoplasm, Nucleus
EEF2 Elongation factor 2 Protein biosynthesis Cytoplasm
TCP1 T-complex protein 1 subunit alpha Protein folding Cytoplasm
HSPA1A Heat shock 70 kDa protein 1A/1B Protein folding Cytoplasm
RAN GTP-binding nuclear protein Ran Protein transport Cytoplasm
ACTB Actin, cytoplasmic 1 Cytoskeleton Cytoplasm
TUBA1B Tubulin alpha-lB chain Cytoskeleton Cytoplasm
VIM Vimentin Cytoskeleton Cytoplasm
TM0D2 Tropomodulin-2 Cytoskeleton Cytoplasm
EN01 Alpha-enolase Glycolysis Cytoplasm
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Glycolysis Cytoplasm
CKMT1A Creatine kinase U-type, mitochondrial Creatine metabolic process Mitochondrion
PHB Prohibitin DNA synthesis, transcription Mitochondrion, Nucleus
Table 2.2 CypA interactome functional classification.
List of CypA interactors with corresponding name retrieved from UniProt Knowledgebase 
(UniProtKB) database (http://www.uniprot.org/). and functional classification using Gene Ontology 
terms.
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Among the identified CypA interacting proteins, there are several members of the heterogeneous 
nuclear ribonucleoprotein (hnRNP) family. HnRNPs are abundant nuclear proteins that shuttle 
between the nucleus and the cytosol and, organized in large complexes, have key roles in RNA 
processing, transport, localisation, translation and stability (Dreyfuss 2002).
Biological process
Ribosome assembly DNA synthesis 
2% 2%
Cytoskeleton _ 22% mRNA processing
Energy metabolism 6%
Protein transport 4% 
Protein folding 4%
DNA repair 6%
Protein biosynthesis 22% mRNA splicing
Transcription regulation 4%
1 0 % 4% mRNA transport
Transcription
Figure 2.4 Functional blocks of CypA-interacting proteins.
The pie-chart representation is indicative of the impact of a single functional class on the total 
functions classified. Percentages on slices are calculated as number of proteins associated to a 
particular block, normalized to all the proteins associated with functional blocks, set as 100.
2.2 Verification of CypA interacting proteins
In order to validate the observations made by mass spectrometry analyses, a subset of CypA 
interacting proteins was verified by co-immunoprecipitation followed by WB.
Among all CypA novel interactors, the 43kDa transactivation response element (TAR)-DNA-binding 
protein (TDP-43) (Figure 2.5A) was of exceptional interest, as it has recently emerged as a key 
player in ALS pathology and has been associated with other neurodegenerative diseases (Geser 
2009a). TDP-43 is a RNA/DNA binding protein and it structurally resembles a typical hnRNP. TDP- 
43 has been identified as the major component of neuronal ubiquitinated inclusions (Neumann
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2006) in sALS and SODl-negative fALS patients, and is considered the most striking pathological 
hallmark o f ALS. Furthermore, mutations in the TARDBP gene were found both in sporadic and 
familial ALS patients (Kabashi 2008; Sreedharan 2008), mainly in the C-terminal region that is the 
site of interaction with other proteins, and among them also members of the hnRNP A/B family 
(Buratti 2005). TDP-43 is involved in multiple steps of the RNA lifecycle including transcription, 
splicing, transport, translation, stability, degradation and miRNA processing (reviewed in Fiesel 
2011). Nevertheless, its precise role in ALS pathogenesis has not been deciphered yet. Thus, this 
interaction was further validated by different approaches and studied in different systems for its 
possible significance in ALS pathogenesis.
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Figure 2.5 Mascot Search Result for TDP-43 and hnRNP A2/B1 identifications.
(A) TDP-43 (TADBP_HUMAN) and (B) hnRNP A2/B1 (ROA2_HUMAN) have been positively identified 
by a significant Mascot Score in the Mascot database search software. The Mascot Score is a 
statistical score for how well the experimental data match the database sequence 
(www.matrixscience.com).
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2.2.1 In vitro interaction validation using
endogenous proteins
First, candidate CypA-interacting proteins were investigated in vitro to confirm the interactions. 
Thus, endogenously expressed proteins were immunoprecipitated from HEK293 cells 
overexpressing WT- or G93A-SOD1.
2.2.1.1 CypA interacts with TDP-43
An antibody anti-CypA was used to co-IP and an antibody anti-TDP-43 was used to evaluate its 
presence in CypA IP fraction (Figure 2.6A). The interaction between CypA and TDP-43 was 
confirmed, both in wild-type and in mutant SOD1 expressing cells. The association of CypA with 
TDP-43 was specific, as determined by several positive and negative controls. In particular, 
different starting IP solutions were used as experimental controls in the co-IP assay. The starting 
IP mix contained respectively: [Buffer] the magnetic beads conjugated to a secondary antibody 
(Abll), with neither the cellular lysate nor a primary antibody (Abl); [Abl] the magnetic beads 
conjugated to the Abll and pre-incubated with anti-CypA Abl, w ithout cellular lysate; [Lysate] the 
magnetic beads conjugated to the Abll were incubated with the cellular lysate w ithout Abl. In the 
first control [Buffer], only the heavy and light chains of the Immunoglobulins (Ig) o f the Abll were 
detected in the IP fraction. In the second control [Abl], a stronger signal was observed in the IP 
fraction, corresponding to the Ig o f the Abl and Abll. In both cases there was only a faint signal in 
the post-IP fractions corresponding to residual BSA contained in the washing buffers used in 
several steps of the co-IP procedure. In the third control [Lysate], the band pattern in the IP 
fraction overlapped to the first one, where only the IgG of the Abll were present, while in the 
post-IP fraction TDP-43 was detected as in the input and output fractions, because in the absence 
of the Abl no cellular proteins were co-IP and TDP-43 was completely recovered in the remaining 
fraction.
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Figure 2.6 CypA and TDP-43 interact in vitro.
Equal amounts of proteins (500|ig) were co-precipitated with the anti-CypA antibody (A) or with the 
anti-TDP-43 antibody (B) from HEK293 cells stably expressing WT- or G93A-SOD1. Aliquot of the cell 
lysates (INPUT), of the immunoprecipitates (IP) and of the proteins from the remaining fraction 
(OUTPUT) were loaded together with three different IP controls and their relative output fractions 
(POST), and subjected to SDS-PAGE. Proteins were transferred to a PVDF membrane, stained with 
Red Ponceau as loading control and probed with specific antibodies. TDP-43 was revealed through 
chemiluminescence measurements (A), while Qdot®800 fluorescence was used to detect CypA (B). 
Shown are representative of several independent experiments with similar results, indicating specific 
binding of CypA and TDP-43.
To further verify the interaction between CypA and TDP-43 the same co-IP experiment was 
repeated in HEK293 cells expressing WT-SOD1 or G93A-SOD1 reversing the primary antibodies 
previously used (Figure 2.6B). In particular, the immunoprecipitation by the anti-TDP-43 antibody, 
was followed by CypA WB, providing additional evidence that CypA interacts with TDP-43. The
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same IP controls were included in the reverse analysis, obtaining analogous results. Moreover, to 
confirm the specificity of this binding, CypA and TDP-43 co-IP assays were performed using 
different commercially available polyclonal and monoclonal antibodies for both proteins. These 
preliminary studies revealed that a specific interaction between the two proteins occurred in 
mammalian cells.
2.2.1.2 CypA interacts with hnRNP A2/B1
HnRNP A2/B1 is one of a large number o f hnRNPs found to interact with CypA in this proteomic 
analysis (Figure 2.5B). HnRNPA2/Bl was previously demonstrated to form a complex with CypA 
that undergoes nuclear export in response to chemokine stimulus (Pan 2008). HnRNP A2/B1 is 
one of the major components of the hnRNP core complex in mammalian cells (Kozu 1995) and 
participates to post-transcriptional regulation in both the nucleus and cytoplasm and also is 
involved in telomere biogenesis. Together with CypA and TDP-43, this protein was up-regulated in 
PBMC of sALS patients (Nardo 2011), suggesting an involvement for hnRNP A2/B1, and possibly 
also its interactions with TDP-43 and eventually with CypA, in the pathogenesis o f ALS. Thus, the 
interaction between CypA and hnRNP A2/B1 was investigated in this in vitro model.
HnRNP A2/B1 immunoprecipitation followed by CypA WB confirmed the interaction between 
these two proteins both in WT-SOD1 and in G93A-SOD1 expressing cells (Figure 2.7A). A reverse 
co-IP approach was applied to further evaluate the association between CypA and hnRNP A2/B1 
in HEK293 cells overexpressing WT or mutant SOD1 (Figure 2.7B). This experiment provided 
additional evidence that endogenous CypA forms complexes with hnRNP A2/B1 in mammal cells. 
The same IP controls previously described, were also analysed in these experiments and a similar 
band pattern was observed in all IP and Post fractions, supporting the specificity o f these 
observations.
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Figure 2.7 CypA and hnRNP A2/B1 interact in vitro.
Equal amounts of proteins (500pg) were co-precipitated with the anti-hnRNP A2/B1 antibody (A) or 
with the anti-CypA antibody (B) from HEK293 cells stably expressing WT- or G93A-SOD1. Aliquots of 
the cell lysates (INPUT), of the immunoprecipitates (IP) and of the proteins from the remaining 
fraction (OUTPUT) were loaded together with three different IP controls and their relative output 
fractions (POST), and subjected to SDS-PAGE. Proteins were transferred to PVDF membranes, stained 
with Red Ponceau as loading control, probed with specific antibodies and the signal was detected by 
chemiluminescence. IP were analysed by WB using an anti-CypA (A) or an anti-hnRNP A2/B1 (B) 
antibody. Representative of several independent experiments with similar results are shown, 
indicating specific association of CypA and hnRNP A2/B1.
2.2.1.3 TDP-43 interacts with hnRNP A2/B1
HnRNP A2/B1 is also a binding partner of TDP-43 and it seems to be crucial for at least one of its 
putative functions (Buratti 2005). Given the importance of TDP-43 and hnRNP A2/B1 in ALS, it was 
fundamental to replicate their interaction, previously described by Buratti and co-workers (Buratti 
2005), also in this experimental setting. The antibodies against TDP-43 or hnRNP A2/B1 were 
alternatively used in co-IP and reverse co-IP experiments followed by the WB analyses of the two 
proteins. The association between TDP-43 and hnRNP A2/B1 was thus replicated both in wild-type 
and mutant HEK293 cells (Figure 2.8). The same IP controls were tested also in these experiments, 
confirming the specificity of the interactions observed.
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Figure 2.8 TDP-43 and hnRNP A2/B1 interact in vitro.
Equal amounts of proteins (500|ig) were co-precipitated with the primary antibody. Aliquots of the 
cell lysates (INPUT), of the immunoprecipitates (IP) and of the proteins from the remaining fraction 
(OUTPUT) were loaded together with three different IP controls and their relative output fractions 
(POST), and subjected to SDS-PAGE. Proteins were transferred to PVDF membranes, and stained with 
Red Ponceau as loading control. (A) Lysates from HEK293 cells stably expressing WT-SOD1 or G93A- 
SOD1 were blotted for TDP-43 after hnRNP A2/B1 IP and protein signal was revealed through 
Qdot®655 fluorescence. (B) Wild-type and mutant cells were blotted for hnRNP A2/B1 after TDP-43 
IP and the signal was detected by chemiluminescence. Representative of several independent 
experiments with similar results are shown, indicating a specific interaction of TDP-43 and hnRNP 
A2/B1.
2.2.2 In vitro interaction validation using 
exogenous tagged proteins 
To confirm the interaction between CypA and TDP-43, and to further characterise it, tagged 
exogenous proteins were used in co-immunoprecipitation assays. In particular, a plasmid carrying
CypA cDNA with a Myc-tag epitope at its C-terminal end and a plasmid encoding TDP-43 with a 
short sequence codifying a Flag-tag epitope at its N-terminus (Ayala 2008) were used for these 
experiments. Transient co-transfection of HEK293 cells with both expression vectors allowed to 
specifically detect only the exogenous proteins. Moreover, a transfection protocol was optimized 
to obtain the highest expression levels when vectors were used individually or in combination.
2.2.2.1 Myc-CypA and Flag-TDP-43 co- 
transfection and co-expression
First, HEK293 cells were tested to verify if both plasmids could be co-transfected in an efficient 
way producing the tagged proteins together and with good expression levels. To do that, cells 
were simultaneously transfected with equal ratio of the two plasmids and the expression of the 
tagged proteins was evaluated both by WB and confocal microscopy. The WB results clearly 
indicated that Myc-CypA and Flag-TDP-43 proteins were expressed at good levels also when they 
were co-transfected together (Figure 2.9A-B).
Furthermore, the analysis of the immunofluorescence images showed that single cells that had 
been efficiently transfected with one plasmid and overexpressed one tagged protein, were 
preferentially transfected also with the other vector and expressed at similar levels the other 
tagged protein of interest too (Figure 2.9C-D). These experiments clearly demonstrated that 
transfected HEK293 cells were able to express both Myc-CypA and Flag-TDP-43 at the same time, 
and thus could be suitable to perform co-IP experiments with overexpressed tagged proteins.
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Figure 2.9 Co-transfected HEK293 cells express both tagged CypA and TDP-43.
Cells were transfected with an empty vector (negative control) or co-transfected with Flag-TDP-43 
and Myc-CypA plasmids. (A-B) Expression of the endogenous and exogenous tagged proteins was 
verified after 48h by WB. The same membrane was probed with polyclonal antibodies to allow the 
detection of both endogenous and exogenous tagged proteins. (A) First WB for TDP-43 was 
performed to check for the presence of Flag-TDP43, and then (B) the membrane was incubated with 
anti-CypA antibody to evaluate the expression of Myc-CypA. In both cases, exogenous proteins could 
be distinguished from the endogenous ones, thanks to a higher molecular weight given by the tag 
fused to the protein sequence. (C-D) Exogenous protein expression was also verified in cells 
transiently co-transfected with both plasmids by immunofluorescence (bar: 10pm). Co-transfected 
cells were stained with anti-Flag-tag and anti-Myc-tag antibodies followed respectively by Alexa®488 
(green)-conjugated and Alexa®647 (red)-conjugated secondary antibodies (C). Co-transfected cells 
were also reverse-stained using different anti-Flag-tag and anti-Myc-tag antibodies followed 
respectively by Alexa®647 (red)-conjugated and Alexa®488 (green)-conjugated secondary antibodies 
(C). Nuclei were counter-stained with DAPI (blue). Images representative of several independent 
experiments are shown, indicating that almost all cells transfected with one plasmid were 
transfected also with the other, and consequently cells expressing one tagged protein expressed also 
the other one.
Flag-tag
189
2.2.2.2 In vitro interaction between Myc-
CypA and Flag-TDP-43
Additional experiments to verify the interaction between CypA and TDP-43 were also performed 
using exogenous tagged proteins. The previously described approach was adapted to whole cell 
lysates from HEK293 cells co-transfected with Myc-CypA and Flag-TDP-43, where antibodies 
raised against the epitope tag were used to co-immunoprecipitate the corresponding tagged 
protein.
IP: Flag-tag
Myc-CypA 
Flag-TDP-43 
Empty vector
B IP: Myc-tag
Myc-CypA 
Flag-TDP-43 
Empty vector
M I M I
INPUT
INPUT
Flag-TDP-43
Myc-CypA
<- Myc-CypA 
<-CypA
<- Flag-TDP-43 
« -TDP-43
Myc-CypA
TDP-43
«- Flag-TDP-43 
TDP-43INPUT
INPUT
Figure 2.10 Myc-CypA and Flag-TDP-43 interact in transiently co-transfected HEK293 cells.
Equal amounts of protein (500pg) were co-precipitated with the primary antibody. Aliquots of the 
cell lysates (INPUT) and o f the immunoprecipitates (IP) were loaded, subjected to SDS-PAGE, 
transferred to PVDF membranes, stained with Red Ponceau as loading control, probed with different 
primary antibodies and the signal was detected by chemiluminescence. (A) Myc-CypA co- 
immunoprecipitated with Flag-TDP-43. HEK293 cells were transfected with an empty vector 
(negative control), with Flag-TDP-43, or co-transfected with Flag-TDP-43 and Myc-CypA plasmids. 
Cells were lysed and Flag-TDP-43 was selectively immunoprecipitated using an anti-Flag-tag 
antibody, as detected using an antibody against TDP-43 (upper panel IP fraction). Potentially 
associated CypA was detected by WB using an anti-Myc-tag antibody. (B) Flag-TDP-43 co- 
immunoprecipitated with Myc-CypA. HEK293 cells were transfected with an empty vector (negative 
control), with Myc-CypA, or co-transfected with Myc-CypA and Flag-TDP-43 plasmids. Cells were 
lysed and Myc-CypA was specifically immunoprecipitated using an anti-Myc-tag antibody. TDP-43- 
associated proteins were detected by WB using an anti-TDP-43 antibody, while the 
immunoprecipitated Myc-CypA was detected using an antibody against CypA (upper panel IP 
fraction). Prior to IP experiments, 15|ig of the same input samples were analysed by WB to verify the 
expression of the endogenous and exogenous tagged proteins. Representative of several
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independent experiments with consistent results are shown, indicating that overexpressed tagged 
Myc-CypA and Flag-TDP43 interacts in vitro.
First, the antibody specifically recognizing the Flag-tagged N-terminal portion of the exogenously 
transfected TDP-43 was used (Figure 2.10A). Flag-TDP-43, and not endogenous TDP-43, was 
selectively immunoprecipitated, as shown in the IP fraction (upper panel). WB analysis revealed 
the presence of Myc-CypA in the IP fraction only when cells were co-transfected with both 
constructs, while no signal was detected in cells transfected only with Flag-TDP-43 or with the 
empty vector. This experiment showed an association between the two exogenous proteins. The 
correct expression of these proteins was also verified analysing by WB the inputs o f the same 
samples, as shown in the lower panels.
In the reverse approach, the antibody against the Myc-tag at the C-terminus of exogenously 
expressed CypA was used to selectively immunoprecipitate the Myc-CypA protein, as shown in 
the upper panel o f Figure 2.10B. Co-precipitated TDP-43 was then detected by WB and the 
presence of Flag-TDP-43 was observed in the IP fraction of double transfected cells. In this 
experiment the interaction between the two proteins was further confirmed. The WB analysis of 
the input fractions of these samples (shown in the lower panels) revealed a correct expression of 
the proteins. Collectively, these data clearly demonstrate an association between Myc-CypA and 
Flag-TDP-43 and further support data previously obtained with the endogenous proteins.
The interaction was further confirmed with a different co-IP approach, where antibodies against 
endogenous proteins (anti-CypA and anti-TDP-43) were used to immunoprecipitate and the IP 
fractions were subsequently probed with the antibodies recognizing the tag portions of the 
transfected proteins. Together, these findings provide the first evidences that CypA and TDP-43 
interact in mammalian cells.
191
2.2.3 In vivo interaction validation
Since a novel interaction was observed in vitro, it was really important to validate it also in vivo. 
To confirm the interaction between CypA and TDP-43, co-immunoprecipitation experiments were 
performed on animal tissues.
2.2.3.1 CypA interacts with TDP-43 in mouse 
tissues
Co-immunoprecipitation was performed from mouse lumbar spinal cord and brain homogenates 
to confirm that the interaction between CypA and TDP-43 occurs with the endogenous proteins in 
two tissues that are frequently affected in TDP-43 related diseases. Tissues from age and sex- 
matched mice that express (CypA+/+, n=3), have a deficient expression (CypA+/-, n=3) or do not 
express (CypA-/-, n=3) CypA were used to perform co-immunoprecipitation assays (Figure 2.11). 
In particular, CypA knockout mice were used as negative experimental controls, together with 
coated magnetic beads (Ctr). An anti-CypA antibody was used to immunoprecipitate and the 
following WB for TDP-43 clearly detected the protein in the IP fraction, only in mice expressing 
(CypA+/+) or with a reduced CypA expression (CypA+/-), and not in knockout mice (CypA-/-), thus 
confirming previous results. Furthermore, CypA deficiency (CypA+/-) was associated in both cases 
with a marked reduction of TDP-43 in the IP fraction. Collectively, these data confirm the 
specificity o f the novel interaction described between CypA and TDP-43, demonstrating also the 
relevance of this association in ALS disease-related animal tissues.
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Figure 2.11 CypA and TDP-43 interact in mouse lumbar spinal cord and brain.
Representative experiments, performed on mouse lumbar spinal cord (A, C) and brain (B), are 
shown. Equal amounts of proteins (lmg) from tissue homogenates of CypA+/+ (n=3), CypA+/- (n=3) 
and CypA-/- (n=3) mice were co-precipitated with anti-CypA primary antibody. Aliquots of the tissue 
homogenates (INPUT), of the immunoprecipitates (IP) and of the remaining fraction (OUTPUT) were 
loaded together with coated beads as IP control, subjected to SDS-PAGE, transferred to PVDF 
membranes, stained with Red Ponceau as loading control, probed with anti-TDP-43 antibody and 
detected by chemiluminescence. Results representative of several independent experiments are 
shown, indicating that interaction between CypA and TDP-43 was confirmed in vivo.
2.3 CypA interacts with TDP-43 mainly in the nucleus
To determine the subcellular compartment in which the interaction between CypA and TDP-43 
occurs, two different approaches were pursued: CypA and TDP-43 co-immunoprecipitation after 
biochemical fractionation and immunocytochemistry experiments were conducted in HEK293 
cells.
2.3.1 CypA and TDP-43 interact in the nuclear 
fraction
In order to investigate where the interaction occurred, co-IP experiments were performed 
starting from nuclear and cytosolic-enriched fractions isolated from HEK293 cells stably
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expressing WT-S0D1 or G93A-SOD1 (Figure 2.12A). The nuclear fraction was separated from the 
cytosolic fraction as described in Materials and Methods. The correct nuclei-cytosol separation 
was first checked by WB analyses of lamin A+C, as nuclear marker, and actin, as cytoplasmic 
marker. Then, each subcellular fraction was separately immunoprecipitated with an antibody 
against CypA, followed by TDP-43 detection by WB. In these cells TDP-43 was expressed both in 
the nucleus and in the cytoplasm, as shown in the input. However CypA was able to co- 
immunoprecipitate TDP-43 only in the nuclear fraction, both in wild-type and mutant cells.
2.3.2 Myc-CypA and Flag-TDP-43 interact in the 
nuclear fraction
In order to confirm this observation, subcellular fractionation and co-IP experiments were 
repeated in HEK293 cells transiently transfected with an empty vector (negative control) or co­
transfected with Myc-CypA and Flag-TDP-43 (Figure 2.12B). In this case, a reverse co-IP approach 
is shown: each subcellular fraction was independently immunoprecipitated using the anti-Flag-tag 
antibody, which allowed the specific immunoprecipitation of Flag-tagged TDP-43 (upper panel). 
Subsequently the presence of the co-immunoprecipitated CypA in the IP fraction was verified by 
WB using an anti-Myc-tag antibody (lower panel). Also using this approach a preferential 
interaction between CypA and TDP-43 was demonstrated in the nuclear compartment; indeed the 
band corresponding to Myc-CypA was detected mainly in the IP lane of the nuclear fraction and 
not in the cytosolic one.
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Figure 2.12 CypA and TDP-43 interact mainly in the nuclear fraction.
(A) Representative CypA co-immunoprecipitation in the cytosolic and corresponding nuclear 
fractions of HEK293 cells over-expressing WT-SOD1 or G93A-SOD1. Aliquots of the cytosolic and 
nuclear lysates (INPUT), of the immunoprecipitates (IP) and of the remaining fractions (OUTPUT) 
were loaded separately, subjected to SDS-PAGE, transferred to a PVDF membrane, stained with Red 
Ponceau as loading control, probed with the anti-TDP-43 antibody and detected by 
chemiluminescence. TDP-43 was present only in the IP fraction corresponding to the nuclear 
compartment (lower panel) and not in the cytosolic portion (upper panel), even if the protein was 
correctly expressed both in the cytosol and in the nucleus (input fraction). (B) The cytosolic and the 
nuclear fractions from HEK293 cells co-expressing Myc-CypA and Flag-TDP-43 were used to 
selectively immunoprecipitate Flag-TDP-43, as detected using an antibody against TDP-43 (upper 
panel). Cells transfected with an empty vector were used as control for the IP procedure. Potentially 
associated CypA was detected by anti-Myc-tag blotting (lower panel). 15pg of the corresponding 
input samples were loaded on the same gel and blotted with the same antibodies. The signal relative 
to the co-immunoprecipitated Myc-CypA was present mainly in the nuclear fraction, demonstrating 
that also the association between exogenous tagged CypA and TDP-43 occurs preferentially in this 
cellular compartment. Subcellular fractionation efficiency was verified before each co-IP experiment. 
Immunoprecipitation was repeated at least three times on independent sample sets with consistent 
results. Representative images were chosen for display.
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Taken together, these data indicate that both endogenous and exogenous CypA and TDP-43 
interact mainly in the nuclear fraction.
2.3.3 CypA and TDP-43 colocalize in the nuclear 
region
To further demonstrate CypA and TDP-43 association and to investigate the subcellular 
compartment in which the interaction occurred, HEK293 cells were analyzed by standard 
immunofluorescence microscopy and by double-label laser-scanning confocal microscopy to 
simultaneously visualise the two proteins.
Spatial colocalisation between fluorescently labelled CypA and TDP-43 was first performed on 
untransfected HEK293 cells to visualise the endogenously expressed proteins. Cells were co- 
immunostained with anti-CypA and anti-TDP-43 antibodies and the two-conjugated 
fluorochromes were simultaneously detected in the same area. As shown by single protein 
staining, CypA and TDP-43 both displayed the expected subcellular distribution and in the overlay 
were found to predominantly co-localize in the nucleus (merge) (Figure 2.13A).
The subcellular colocalisation of the two proteins was also visualised in HEK293 cells transiently 
co-transfected with both Myc-CypA and Flag-TDP-43 plasmids. This time exogenous tagged 
proteins were selectively immunostained, using the anti-Myc-tag and the anti-Flag-tag antibodies. 
As shown in Figure 2.13B, cells were efficiently transfected with the two constructs, and also the 
tagged proteins co-localized mainly in the nuclei (merge).
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Figure 2.13 CypA and TDP-43 colocalisation analysis in HEK293 cells.
(A) Immunofluorescence was used to visualise the localisation of CypA and TDP-43 in HEK293 cells 
on endogenous proteins. Cells were co-immunostained with anti-CypA and anti-TDP-43 antibodies 
followed respectively by Alexa®488 (green)-conjugated and Alexa®594 (red)-conjugated secondary 
antibodies. (B) Alternatively cells were co-transfected with Flag-TDP-43 and Myc-CypA plasmids and 
after 48h exogenous tagged proteins were visualised by immunofluorescence. Co-transfected cells 
were stained with anti-Myc-tag and anti-Flag-tag antibodies followed respectively by Alexa®488 
(green)-conjugated and Alexa®647 (red)-conjugated secondary antibodies. The dual channel,look-up 
table for green and red gave rise to yellow hotspots where the two proteins of interest were present 
in the same pixels (merge) (bar: 10pm). CypA and TDP-43 colocalized mainly in the nuclear and peri­
nuclear area. The immunofluorescence data shown represents consistent results obtained in 
multiple replicates using different primary and secondary antibodies.
2.4 CypA-TDP-43 colocalisation analysis in dual-colour 
confocal images
When visualizing protein-protein colocalisation, overlay methods help to generate visual 
estimates of colocalisation events in two-dimensional images. To more accurately evaluate 
colocalisation events three dimensional images were acquired along the z-axis. Furthermore, a 
statistical approach was adopted for quantification purposes to correctly interpret the 
colocalisation events observed (Bolte 2006).
Flag-tag MergeMyc-tag
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2.4.1 CypA and TDP-43 visual colocalisation in 3D 
confocal microscopy in HeLa cells
Colocalisation analysis was also performed in HeLa cells, providing a second cell type in which this 
novel interaction was observed in vitro. Spatial colocalisation was generated by the z-stack 
projection o f serial confocal section acquired by dual-confocal microscopy. Overlays o f CypA 
(green) and TDP-43 (red) images demonstrated areas o f yellow (merge) in the nuclear and mainly 
in the peri-nuclear area, indicating molecular association o f the proteins in this region and thus 
demonstrating the ir relationship (Figure 2.14Figure 2.14).
A
B
Figure 2.14 CypA and TDP-43 co-labelling in HeLa cells.
Representative immunostaining micrographs show spatial colocalisation of endogenous CypA 
(green) and TDP-43 (red) proteins in HeLa cells. (A) CypA was detected by immunofluorescence using 
a monoclonal mouse antibody and an Alexa®488-conjugated secondary antibody, while TDP-43 was 
detected by immunostaining with a polyclonal rabbit antibody followed by incubation with an 
Alexa®594-conjugated secondary antibody. Partial nuclear co-localisation between CypA and TDP-43 
was observed in overlay of red and green images (right panel), with areas of yellow indicating 
colocalisation of the proteins (bar: 7.0pm). (B) 4'-6-Diamidino-2-phenylindole (DAPI) was used to 
stain the nuclei (blue). Strong perinuclear colocalisation was evidenced in overlay of red and green 
and blue images (right panel), w ith areas of yellow indicating colocalisation of the proteins (bar: 
7.0pm). (C) Orthogonal views through one cell showed co-labelling of the proteins on XY (central
DAPI
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panel), XZ (upper panel) and YZ (left panel) projections, further highlighting CypA and TDP-43 
colocalisation (bar: 3.5pm). The figure panels are z-stack projections of 20 to 34 confocal sections.
These data further supported the hypothesis o f an interaction between TDP-43 and CypA within 
the nucleus o f mammalian cells.
2.4.2 CypA and TDP-43 quantitative colocalisation 
analysis
To provide a quantitative estimate of proteins colocalisation, HEK293 cells were further analysed 
to obtain 3D confocal immunofluorescence microscopy images by sequential scanning for each 
channel (Figure 2.15A-D). Based on the evaluation of colour components o f the selected pair of 
channels (Chl=TRITC, TDP-43 and Ch2=Cy5, CypA), the degree of colocalisation was estimated 
using a dedicated analysis software. Colocalisation in two-colour images (CypA in red and TDP-43 
in green) was visualised in a two-dimensional histogram, where the number o f pixels with red and 
green intensities was plotted as a scatter gram with each axis representing the intensity of each 
colour (Figure 2.15E). Pearson's Correlation Coefficient (PCC) was among the variables used to 
analyze the entire scatter plot, which is one of the standard techniques applied in pattern 
recognition for matching one image to another in order to describe the degree of overlap 
between the two patterns. Thresholded PCC analysis (Manders 1992) was performed by Volocity® 
(PerkinElmer, Inc., USA) image analysis software using the Costes algorithm to automatically 
estimate threshold values (Costes 2004). Both Costes thresholded PCC (0.701) and global PCC 
(0.803) generated values close to 1, clearly demonstrating a positive correlation between the two- 
channel images (Barlow 2010).
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Channel 1: G reen (TRITC, TDP-43)
■ H
Pearson's Correlation 0.701
Colocalization Coefficient (M l) 0.855
Colocalization Coefficient (M2) 0.889
Overlap Coefficient (R) 0.819
Overlap Coefficient (k l) 0.738
Overlap Coefficient (k2) 0.91
Pearson's Correlation 0.803
Total Voxels 12480000
Figure 2.15 CypA and TDP-43 quantitative coiocalisation analysis in HEK293 cells.
Volocity® (PerkinElmer, Inc., USA) image analysis software was used for quantitative colocalisation 
analysis. (A-C) Confocal representative slice of cultured HEK293 cells simultaneously labelled with 
CypA (Cy5, red) and TDP-43 (TRITC, green). Single channel and overlay of double channel 
fluorescence micrograph of the same field of cells for CypA and TDP-43. (C) The image represents the 
z-stack projection of 25 confocal sections: XY (central panel), YZ (left panel) and XZ (upper panel) 
projections are shown. The figure shows one representative experiment out of eight analysed. (D) 
Three-dimensional images were processed using Imaris® (Bitplane, Zurich, Switzerland) software and 
3D rendering shows proteins colabeling further highlighting their colocalisation. (E) Representative 
2D scatter plot o f pixel intensities in the two channels: the red channel (CypA) is on the y axis and the 
green (TDP-43) is on the x axis. The partial colocalisation event observed resulted in a pixel 
distribution o ff the axes whose slope depended on the fluorescence ratio between the two channels
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and whose spread was quantified by the Pearson' Correlation Coefficient (PCC) (F), which was close 
to 1, since red and green channel intensities were linked. In the tables other statistical parameters 
generated by quantitative colocalisation analysis are reported, including global PCC, the total overlap 
coefficient (R), as well as the individual k(x), and M(x) co-localisation coefficients.
Manders' Colocalisation Coefficient M(x) was calculated as a further descriptor o f colocalisation 
(Manders 1993): M l (0.855) was utilized to describe the contribution o f the channel 1 
fluorophore to the co-localized area, while M2 (0.889) was used to describe the contribution of 
the channel 2 fluorophore. The most important output data from Volocity® software analysis was 
the Overlap Coefficient (R=0.819), which indicates the actual overlap between signals and 
represents the true degree of overlap. This value ranges between 0 and 1 and is not sensitive to 
intensity variations in the image analysis. Overlap coefficients k(x) were also calculated to 
describe differences in intensities between the channels, with k l (0.738) being sensitive to the 
differences in the intensity of channel 2 (red signal), while k2 (0.91) depends linearly on the 
intensity of the pixels from channel 1 (green signal). All coefficients used to estimate 
colocalisation under Volocity® analysis demonstrated with clarity and accuracy a relationship 
between CypA and TDP-43.
1 2.4.3 CypA and TDP-43 colocalize in primary
neuronal cultures
To extend these findings from the proteomics and immunocytochemistry to a model relevant to 
neuronal proteinopathy, immunocytochemistry was performed on primary spinal cord cultures 
from non-transgenic (Ntg) mouse embryos. In particular, CypA and TDP-43 colocalisation was 
investigated in this biological setting by multiple-colour confocal microscopy.
Since spinal neuronal cultures contain different central nervous system populations, Smi-32 
staining (blue), recognizing non-phosphorylated neurofilament H, was used to specifically label 
the neuronal population. Neuronal cell bodies, dendrites and some thick axons were clearly 
visualised, allowing to specifically identify colocalisation events in this cellular population (Figure
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2.16). Dual staining of primary spinal neuronal cultures for TDP-43 (green) and Smi-32 (blue) 
revealed that TDP-43 displayed predominantly nuclear localisation, both in Smi-32 negative cells 
and in Smi-32 positive neurons, with some faint staining present also in soma and neurites. The 
combined immunostaining of CypA (red) and Smi-32 (blue) evidenced CypA expression in motor 
neurons as well as in other cellular populations; immunoreactivity was present both in the nuclei 
and in the cytoplasm of these cells. In particular, in Smi-32 positive cells, CypA labelling was 
clearly visualised in neuronal cell bodies, as well as in dendrites and axons. CypA (red) and TDP-43 
(green) co-labelling evidenced areas of extensive overlap (yellow), particularly in association with 
Smi-32 staining. Interestingly, colocalisation events were clearly visualised in neuronal cell bodies, 
where a more intense labelling corresponded to the nuclear area. This staining profile indicated 
that also neuronal populations, and importantly MNs, showed CypA and TDP-43 colocalisation.
■ ■H H
Figure 2.16 CypA and TDP-43 colocalisation in neuronal cultures.
Representative confocal micrograph of primary spinal cord cultures derived from non-transgenic 
embryos were co-stained for CypA (red, FITC), for TDP-43 (green, TRITC) and Smi-32 (blue, Cy5) and 
acquired by confocal microscopy (bar: 20pm). Insets with images at high magnifications show spatial 
colocalisation of endogenous CypA and TDP-43 proteins in motor neuron cells.
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2.5 CypA/TDP-43 interaction is RNA-dependent
Since CypA (Montague 1994 and 1997; Krummrei 1995; Castello 2012), as well as TDP-43 (Ou 
1995; Buratti 2001), and many of its interacting proteins identified in this proteomic analysis/are 
nucleic acid-binding proteins, we sought to determine if and how DNA or RNA binding influenced 
this interaction. CypA immunoprecipitation was performed in the presence of DNase I to degrade 
DNA or in the presence of RNase A to degrade RNA, followed by WB for TDP-43 (Figure 2.17A). 
This approach revealed that the association between CypA and TDP-43 was not abolished by DNA 
digestion, but was dependent upon RNA, since the interaction was almost lost after treatment 
with RNase A. Not treated (UNT) and coated magnetic beads (Ctr) samples were used respectively 
as positive and negative experimental controls.
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Figure 2.17 Nucleic acids impact on CypA and TDP-43 interactions.
HEK293 cells were used in co-IP experiments after pre-treatment with 5pl DNase I (Life Technologies 
Corporation) or 0.2mg/ml RNase A (Roche Applied Science) or 375U/ml Benzonase® Nuclease 
(Novagen, Inc.) for 15' at RT. Aliquot of whole cell lysates (INPUT), of the immunoprecipitates (IP) 
and of the remaining fractions (OUTPUT) were loaded together with coated beads as IP control, 
subjected to SDS-PAGE, transferred to PVDF membranes, stained with Red Ponceau as loading
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control, probed with primary antibodies and detected by chemiluminescence. (A) TDP-43 was co­
precipitated using an anti-CypA antibody. A band corresponding to TDP-43 was enriched in the IP 
fractions of untreated or DNase l-treated cells and was strongly reduced after RNase A treatment.
(B) CypA co-immunoprecipitated with hnRNPA2/Bl in untreated or DNase l-treated cells. An altered 
staining pattern for CypA was observed in the IP fraction of RNase A-treated cells. (C-D) Some TDP- 
43 interactions are RNA-dependent. HnRNP A2/B1 co-immunoprecipitation with TDP-43 (C) and TDP- 
43 co-immunoprecipitation with FUS/TLS (D) were used as controls to validate this experimental 
approach. Immunoprecipitation was repeated at least four times with consistent results and 
representative images were chosen for display.
To further examine the influence of RNA on CypA interactions, hnRNP A2/B1 was 
immunoprecipitated in the presence of DNase I or RNase A and CypA presence was detected by 
WB. Also the association between CypA and hnRNP A2/B1 was dependent upon RNA, since 
binding was lowered by RNase A treatment and not by DNase I (Figure 2.17B).
To demonstrate the validity of this approach, we evaluated known interactions of TDP-43. First, 
RNase A treatment was demonstrated to partially mitigate the ability of TDP-43 to bind hnRNP 
A2/B1 (Figure 2.17 C). This observation was in accordance with previous data, indeed TDP-43 was 
reported to associate in vitro with hnRNP A2/B1 also in the absence of (UG)6 RNA (Buratti 2005). 
Then TDP-43 was immunoprecipitated in the presence of RNase A or Benzonase® Nuclease, to 
evaluate its binding with FUS/TLS. TDP-43 and FUS/TLS interaction was strongly lowered, but not 
completely abolished, by RNase A and not by Benzonase® Nuclease (Figure 2.17D). Consistent 
with this finding, TDP-43 and FUS/TLS were demonstrated to associate with HDAC6 mRNA in 
intact cells and in vitro, but they were also shown to interact as purified proteins in vitro in an 
RNA-independent manner (Kim 2010).
RNase A treatment is likely to completely disassemble ribonucleoprotein complexes, thus 
abolishing both direct and indirect interactions between CypA and RNA binding proteins, as in the 
case of TDP-43 and hnRNP A2/B1 or FUS/TLS. Thus there are two possible hypothesis: the 
association of CypA with TDP-43 can be indirect and mediated by interaction with the same
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transcript, as in the case of TDP-43 and FUS/TLS binding, or CypA can be present in a multimeric 
protein complex together with TDP-43 and other hnRNPs, like hnRNP A2/B1.
In conclusion, CypA and TDP-43 were demonstrated to associate in the nuclear and peri-nuclear 
region in the presence of RNA. These findings provide the first direct evidence that CypA and TDP- 
43 interact in mammalian cells.
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3. Functional consequences of CypA-TDP-43 
interaction
Evidence that CypA and TDP-43 are present in a biochemical complex was provided. The 
significance of this interaction, and the specific contribution and role of CypA in this complex 
needed to be further investigated. Several approaches were considered: first the construction of 
CypA mutants and then the protein knockdown helped to better characterise this interaction and 
to establish a possible functional role for this complex in vitro; subsequently, experiments on 
CypA knockout mice further evidenced putative functional effects in vivo.
3.1 In vitro evidence: Cyclophilin A mutants
The Myc-CypA construct was used to perform studies on the protein structure-function 
relationship: starting from site-directed mutagenesis on the protein sequence, the PPIase activity 
and one of its post-translational modifications (PTM) were examined to determine their 
requirement for CypA import and export to the nucleus or for its activity in a specific 
compartment of the cell, or for the interaction with other proteins.
3.1.1 PPIase-deficient mutant of CypA 
To investigate the relevance and the involvement of CypA catalytic activity within this 
experimental setting, a mutant form of CypA that is deficient in the PPIase activity was generated. 
Several amino acid residues, such as His-54, Trp-121, Phe-113, His-126, Phe-60, and Arg-55, play a 
crucial role in the cis-trans isomerisation of the substrates mediated by CypA (Ansari 2002). While 
mutation of these individual amino acid residues differentially reduces the PPIase activity of CypA, 
alanine (Ala) replacement for the catalytic arginine (Arg) at position 55 has been shown to result 
in maximal reduction of its PPIase activity (PPIase catalysis was demonstrated to decrease by 
1000 fold by Zydowsky 1992). Therefore, this substitution (Arg-55-Ala) generated a CypA lacking
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its catalytic activity and thus unable to mediate the isomerisation of the peptidyl-prolyl bonds 
within the proteins (Figure 3.1).
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Figure 3.1 3D representations of the predicted surfaces of Arg-55-CypA and mutated Ala- 
55-CypA proteins.
Predicted 3D surface and cartoon representations of CypA molecular structure produced by PyMOL® 
Molecular Graphics System (Schrodinger). The PPIase cavity of CypA is shown in both wild type (left 
panel) and mutant (right panel) proteins; Arg-55, a critical residue for CypA catalytic activity, is 
highlighted in green, while the mutated Ala-55 is shown in red. R55A substitution within the active 
site of CypA causes a structural rearrangement of the PPIase pocket, thus leading to a nearly 
complete loss of the enzymatic activity.
3.1.2 Lysine 125 mutants of CypA 
In order to deeply investigate the role of Lysine-acetylation, that is one of CypA PTMs, Lysine (Lys) 
in position 125 was mutagenized. In fact, CypA was demonstrated to be post-translationally 
modified in mammals, and in particular acetylated, on this specific residue by several studies (Kim 
2006; Choudhary 2009; Chevalier 2012). Lys-125 is particularly interesting because it is located in 
a loop surrounding the active site of CypA and, although acetylation in this position does not 
seem to distort CypA conformation or rearrange its active site, it can notably alter the active site 
charge of the protein thus affecting/modulating the interaction with its binding partners. For 
example, acetylation at Lys-125 has been described to negatively affect the binding between CypA 
and its main ligand, cyclosporine A (CsA) (Lammers 2010). Moreover, mutations o f this residue
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with an anionic or neutral residue rendered the mutant protein unable to associate with 
calcineurin, even if both PPIase activity and high affinity for CsA were retained (Etzkorn 1994).
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Figure 3.2 3D molecular structures of wild-type CypA and predicted representations of 
Gln/Arg-125-CypA mutants.
Predicted 3D surface and cartoon representations of CypA molecular structure produced by PyMOL® 
Molecular Graphics System (Schrodinger). Lysine (Lys) 125 (highlighted in green) is located in 
proximity of the PPIase cavity (active site) of CypA. In this picture the catalytic cavity is located just 
above this residue. The two substitutions, Lys-125-Gln (K125Q) and Lys-125-Arg (K125R) lead to the 
generation of mutant CypA proteins that cannot be acetylated at this position, and mimic a steadily 
acetylated (Ac) or non-acetylated CypA respectively (Gin and Arg in mutagenized CypA proteins are 
shown in red).
In this mutagenesis approach, Lys-125 was substituted with either a glutamine (Gin) or with an 
arginine (Arg) residue. Both mutations did not enable this position to be acetylated any more. In
particular, the substitution with Gin mimicked a 
constitutively acetylated Lys, since Gin conserves the 
same structure as Lys, but abolishes its positive charge; 
whereas the substitution of the Lys with an Arg 
mimicked a constitutively non-acetylated Lys, since Arg
Lvsine Acetvl-Lvsine
Y Y preserves the same positive charge of the non-
acetylated CypA isoform (Figure 3.2).
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3.1.3 CypA mutant generation
Point mutations were introduced in the CypA coding sequence by overlap-PCR (detailed 
procedure is explained in Materials and Methods section). Mutagenic primers were designed to 
alter the nucleotide sequence of CypA in a first round of PCR. The products o f the first PCR were 
used as substrates in a second round of PCR, whose products were run on an agarose gel to verify 
the correct length of each fragment. Each cDNA fragment, carrying the point mutation, was 
digested and purified to be inserted into the original expression vector. This was used to 
transform competent bacteria that were plated on ampicillin-containing LB-agar plates. When 
ligation and transformation reactions had been achieved correctly, colonies grew only on plates 
where ligation products, and not digested-dephosphorylated plasmids, had been plated. To 
identify bacterial colonies containing the recombinant plasmid, colony screening was carried out 
by restriction analysis. At least four colonies for each condition were picked up and grown in 
liquid cultures in the presence of ampicillin. Extracted plasmid DNAs were digested and analysed 
on agarose gels. Correct constructs were selected when only two bands, corresponding to the 
linearized vector and the excised cDNA insert, were detected. Furthermore, to ensure the 
existence of the correct point mutations inside the generated cDNA and to exclude the presence 
of other unpredicted missense/non sense mutations, constructs were sequenced. Both forward 
and reverse sequence analyses were used to verify that the constructs carried the expected 
nucleotide substitutions and did not present any other mismatches (Figure 3.3).
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Figure 3.3 Sequencing of the cDNAs coding fo r Myc-CypA mutants.
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Sequencing was performed on both DNA strands. The images shown highlight the codons carrying 
the point mutations generated and correspond to sequencing analyses performed on the reverse 
anti-sense DNA strand. Sequencing of the forward sense DNA strand (not shown) confirmed the 
same results.
Finally, selected vectors were tested for correct protein expression in HEK293 cells after transient 
transfection and were then amplified in bacteria to generate large amounts of plasmid DNA.
3.1.4 CypA mutant expression in HEK293 cells 
First, plasmids encoding CypA mutants were tested for being efficiently transfected in HEK293 
cells. To verify that, cells were transiently transfected with wild type, or R55A- or K125Q- or 
K125R-Myc-CypA and after 48 hours total lysates were analysed by WB. As shown in Figure 3.4B, 
the staining with the anti-CypA antibody revealed good expression levels. Myc-CypA 
immunoreactivity was quite similar for each mutated protein, indicating that each construct was 
easily received by the cells and that the corresponding protein was expressed correctly. As a 
negative control, cells were transfected with an empty vector.
Myc-CypA -zokDa
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Figure 3.4 Myc-CypA mutants are expressed at similar levels in HEK293 cells.
HEK293 cells were transiently transfected with the empty vector (CTR) or the vector cloned with WT- 
or R55A- or K125R- or K125Q-Myc-CypA. 15 pg of total protein lysates were loaded, run on 12% SDS- 
PAGE gel, transferred on a PVDF membrane, stained with Red Ponceau as loading control, analysed 
by WB using the anti-CypA antibody and detected by chemiluminescence. Representative image was 
chosen for display.
3.1.5 Cell viability in cells expressing CypA mutants
In order to determine whether overexpression of mutagenized CypA proteins (R55A, K125Q. or
K125R) could affect cell viability, MTT assay was performed. Cells were transiently transfected
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with plasmids encoding wild-type, R55A-, K125Q-, K125R- CypA or with an empty vector (CTR) as a 
control, and then cell viability was analysed after 48h. This experiment was repeated three times 
without any statistically significant alteration in cell survival among cells expressing different CypA 
isoforms. This result indicated that in this cell line the expression of the newly generated CypA 
mutated proteins (R55A, K125Q, K125R) did not have any significant effect on cell viability 
compared to control cells (Figure 3.5).
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Figure 3.5 Effect o f CypA mutants overexpression on cell survival.
Histograms represent the effect of wild-type and R55A-, K125Q- and K125R-Myc-CypA mutants 
overexpression in HEK293 on viability, compared to cells transfected with the empty vector (CTR). 
The conversion of MTT to formazan was used as an index of cell survival. Data (mean ± S.E., n>5 for 
each sample) are expressed as percentages of control cells (CTR). Statistical analysis by Student's T- 
test did not evidenced any statistical significant difference in any experiment.
The same experiment was also performed in cells previously silenced for CypA and then 
transfected with the different constructs carrying different CypA mutations. Also in this case no 
differences in viability were detected among the samples analysed (data not shown). These 
observations were consistent with data previously obtained (Results section 1.6.4).
3.1.6 CypA mutants isoform pattern
Once we had verified correct expression of Myc-CypA mutants in HEK293 cells, their isoform 
pattern was analysed by 2DE separation and WB for Myc-tag and CypA. Using the anti-Myc-tag
antibody, four protein spots were clearly detected (Figure 3.6A); while at least eight spots were 
distinguished when a polyclonal antibody against CypA was used (Figure 3.6B). These 
corresponded to four isoforms of the endogenous protein whereas four spots at higher MW were 
positive to both CypA and Myc-tag and corresponded to the exogenous tagged protein.
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Figure 3.6 Myc-CypA mutants isoform pattern.
2DE-WB analysis of HEK293 cells transiently transfected with wild-type or R55A- or K125R- or K125Q- 
Myc-CypA. 50|ig of total protein lysates were separated by IEF using 7cm pH 3-10NL pi range strips, 
run on 12% SDS-PAGE gels, transferred on PVDF membranes, stained with Sypro® Ruby Protein Blot 
stain as loading control, analyzed by WB using the anti-Myc-tag (A) or the anti-CypA (B) antibodies 
and detected by chemiluminescence. Aligned 2DE blots are shown.
The isoform pattern was different for each Myc-CypA mutant when compared both to wild-type 
Myc-CypA or to the endogenous protein. Furthermore, endogenous CypA behaviour by 2DE was 
variable, suggesting that the protein was prone to differential post-translational modification 
depending on the exogenous Myc-CypA mutant expressed. In addition to the difference in the 
molecular weight between the endogenous and the transfected proteins, due to the Myc-tag 
fused at the C-terminal end of the protein sequence, the isoelectric point (pi) also varied.
The expected pi values for CypA mutant proteins were computed through the proteomic server 
Expasy by the Swiss Institute of Bioinformatics (www.expasv.org). The PPIase-deficient mutant
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and the glutamine mutant at Lys-125 of CypA had both a predicted pi o f 6.43, whereas the 
computed pi of the Arg-125 mutant was 6.90 and thus similar to wild-type Myc-CypA. The pi 
values observed perfectly fitted with the predicted ones. In fact, all Myc-CypA proteins were 
shifted towards a more acidic pi, compared to the endogenous unmodified CypA, whose 
predicted pi is 7.68. In particular, the R55A and K125Q mutants were further shifted towards a 
more acidic pi if compared to the other Myc-tagged proteins. Indeed, in both cases a positively 
charged residue was substituted with a residue containing a neutral side chain.
Interestingly, Lys-125 mutants could not be acetylated at this position, and this was evidenced in 
the 2DE blots of both K125R and K125Q mutants by an almost complete loss of the spots 
corresponding to isoform one and a striking reduction of isoform two, with an overall shift 
towards more basic forms. This observation is in agreement with a recent work demonstrating 
that Lysine-acetylation is one of the PTM responsible for the shift o f CypA isoforms one and two 
towards more acidic pi (Chevalier 2012).
3.1.7 Subcellular distribution of CypAmutants 
Endogenous CypA can be found within the nucleus or the cytoplasm (Results section 1.3.3). To 
establish whether mutant Myc-CypA proteins retained the same distribution as the wild-type 
protein, two independent methods were used: biochemical fractionation of the cytoplasmic and 
nuclear compartments and confocal microscopy of transfected cells.
The biochemical approach consisted of the separation of the cytosolic and nuclear fractions in 
cells transiently transfected with wild-type or mutagenized Myc-CypA proteins or the empty 
vector as a negative control. To rule out nuclear and/or cytoplasmic contaminations during 
cellular fractionation, cytoplasmic and nuclear-specific markers, respectively actin and lamin A+C, 
were evaluated. Then, each subcellular fraction was independently analysed by WB using 
antibodies for CypA or the Myc-tag portion of the protein.
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Figure 3.7 Myc-CypA mutants subcellular distribution.
HEK293 cells were transfected with the empty vector (CTR), or WT- or R55A- or K125Q- or K125R- 
Myc-CypA, then equal amounts of cytosolic and the corresponding nuclear fractions were 
independently analyzed by WB and detected by chemiluminescence. Lamin A+C and actin were 
evaluated as controls for nuclear and/or cytoplasmic contamination of the two fractions. Histograms 
represent the quantitative analysis of Myc-CypA band densities in the two subcellular 
compartments, normalized on the actual amount of proteins loaded, as detected by Red Ponceau 
staining. Data (mean ± S.E., n=3) are expressed as percentages of control cells (WT) in each 
subcellular fraction. Symbols indicate that samples are significantly different (*=p<0.05 R55A vs. WT;
H= p<0.01 K125R vs. K125Q), as assessed by One-way Anova followed by Newman-Keuls multiple 
comparison test. R55A and K125R mutants displayed a lower nuclear expression.
The quantification of Myc-CypA blots clearly indicated that in the cytoplasmic fraction signals 
corresponding to mutagenized CypA proteins were comparable to the wild-type protein, while in 
the nuclear compartment Myc-CypA mutant expression changed (Figure 3.7). In particular, 
K125Q-Myc-CypA was present in the nucleus with similar levels to WT-Myc-CypA, whereas R55A- 
and K125R-Myc-CypA expression was significantly reduced in this cellular compartment. Indeed a 
substantial decrease in the intensity of the bands corresponding to R55A and K125R mutants was 
observed by WB in the nuclear fraction o f transfected HEK293 cells. These pieces of evidence 
suggested that R55A and K125R substitutions within CypA sequence, resulted in a partial impaired
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nuclear localisation of the protein. This could be caused by a reduction in nuclear import or, 
alternatively, by an increase in the rate o f nuclear export of these mutated CypA proteins.
Data obtained with the PPIase-deficient mutant of CypA could be linked to a lack of enzymatic 
activity, that could be required for a correct localisation of this protein. Alternatively this 
modification, leading to a conformational structural change of the protein, could result in an 
anomalous folding of the polypeptide chain which likely impairs the nuclear translocation of this 
mutated form of CypA.
The results obtained with Lys-125 mutants, could be explained hypothesizing that CypA 
undergoes a covalent modification on this residue promoting its association with the nuclear 
transport machinery, thus resulting in an efficient nuclear translocation. Indeed the K125Q-CypA 
mutant, which mimics the acetylated form of CypA, was demonstrated to be more abundant in 
the nuclear fraction compared to the K125R mutant, which on the contrary mimics the non- 
acetylated CypA isoform. This evidence indicated that acetylation at Lys-125 could represent one 
of the factors that triggers the nuclear translocation of CypA in mammalian cells. This is in 
accordance with the data described in Results section 1.4, where the presence of lysine- 
acetylated CypA was clearly demonstrated only in the nuclear compartment and not in the 
cytosolic fraction.
The presence of all Myc-CypA mutants was also tested in the extracellular media o f transiently 
transfected HEK293 cells in order to evaluate their ability to be secreted. Both Lysine-125 mutants 
and PPIase-deficient CypA were released from these cells, suggesting that nor acetylation at Lys- 
125 neither the enzymatic activity of CypA have any influence on its secretion (data not shown).
3.1.8 Localisation of CypA mutants
Additional evidence in support of the biochemical fractionation experiments was provided by
confocal microscopy analysis. In particular, colocalisation of endogenous and overexpressed Myc-
tagged CypA proteins was investigated to visualise whether CypA distribution could be affected by
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specific point mutations in its sequence. HEK293 cells transiently transfected w ith WT- or R55A- or 
K125Q- or K125R-Myc-CypA were sequentially stained w ith a polyclonal anti-CypA antibody and a 
monoclonal anti-Myc-tag antibody (Figure 3.8). This double labelling allowed a fa ir comparison of 
the whole CypA (endogenous and exogenous, revealed by the CypA antibody) w ith the signal 
relative only to  the exogenous one (detected w ith the anti-Myc-tag antibody) in the same image. 
The IF experiments did not show any striking variation in Myc-CypA distribution among the 
different mutants. However, dual staining revealed a clearer nuclear colocalisation signal in cells 
transfected w ith WT- or K125Q-Myc-CypA proteins compared to cells expressing the R55A or 
K125R mutants. Indeed, R55A- and K125R-Myc-CypA showed a more diffuse Myc-tag staining, 
thus resulting in a slight depletion from the nucleus.
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Figure 3.8 Myc-CypA mutants immunofluorescence analysis.
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Representative immunostaining micrographs show spatial colocalisation of CypA (green) and Myc- 
tagged CypA (red) proteins in HEK293 cells 48h after transient transfection with WT- or R55A- or 
K125Q- or K125R-Myc-CypA (bar: 15|im). CypA was detected by a polyclonal rabbit antibody and an 
Alexa®488-conjugated secondary antibody, while Myc-CypA was detected by a monoclonal mouse 
antibody followed by incubation with an Alexa®594-conjugated secondary antibody. 4'-6-Diamidino- 
2-phenylindole (DAPI) was used to stain the nuclei (blue). Both the endogenous CypA and the 
exogenous tagged CypA were immunostained by CypA antibody (green) whereas using the anti-Myc- 
tag antibody only transfected Myc-CypA were recognized (red). Co-localisation between endogenous 
CypA and exogenous Myc-CypA was observed in overlay of red and green images (right panels), with 
areas of orange and yellow indicating colocalisation of the proteins. As negative experimental 
control, cells were transfected with an empty vector, co-immunostained with the same antibody 
mixture and absence of the Myc-tag signal was verified (images not shown). Experiments were 
repeated several times with consistent results and representative images were chosen for display. 
R55A- and K125R-Myc-CypA mutants showed an impaired nuclear localisation.
Immunofluorescence results supported the hypothesis, based on previous biochemical 
observations, that R55A and K125R substitutions in CypA sequence resulted in an impaired or less 
efficient translocation of these mutated proteins in the nucleus. The K125Q. mutant instead was 
shown to maintain a correct distribution, similar to the WT protein, thus suggesting that the 
presence of an acetyl group on Lysl25 which in this case was mimicked by an amino acid like Gin, 
could favour a nuclear localisation for CypA. In fact, lysine acetylation is widely reported to 
regulate the cellular localisation of proteins, especially for nuclear import and export. For some 
proteins, acetylation enhances localisation in the cytoplasm, whereas for others acetylation will 
preferentially favours a nuclear localisation. The mechanism by which acetylation influences 
cellular localisation can be either the modification of an interaction with a binding partner leading 
to retention in a particular compartment, or an altered interaction with nuclear import/export 
factors (reviewed in Sadoul 2011).
3.1.9 Interaction of CypA mutants with TDP-43
To gain a better understanding of the relationship between CypA and TDP-43, their binding was
characterised using mutated CypA proteins. In particular, to understand whether the substituted
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amino acids in CypA sequence could have an influence in modulating this protein-protein 
interaction, a co-immunoprecipitation approach was adopted. HEK293 cells were transiently co­
transfected with Flag-TDP-43 along with WT-Myc-CypA or alternatively with different Myc-CypA 
proteins carrying the R55A, K125Q, K125R mutations. As negative control for the co- 
immunoprecipitation experiment, cells were transfected with an empty vector (CTR). Whole cell 
lysates were then subjected to immunoprecipitation with the anti-Myc-tag antibody, resolved by 
SDS-PAGE, and immunoblotted with a polyclonal anti-TDP-43 antibody. Subsequently, the same 
blots were re-probed with an anti-CypA antibody to evaluate the immunoprecipitation efficiency. 
This approach allowed to selectively immunoprecipitate only transfected Myc-CypA proteins 
(both WT and mutated ones) and to detect by WB the associated TDP-43 molecules (Figure 3.9 
and Figure 3.10). Indeed, only tagged Myc-CypA proteins were immunoprecipitated in a specific 
way, w ithout significant contaminations, as shown in the IP fraction. This was further confirmed 
by the experimental negative control, whose IP fraction contained negligible amounts of proteins. 
Moreover, the input fractions of the same samples are shown (lower panels), indicating the 
presence of equal amounts o f transfected and endogenous proteins.
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Figure 3.9 PPIase-deficient CypA interacts w ith TDP-43.
HEK293 cells were transfected with the empty vector (CTR), or co-transfected with Flag-TDP-43 and 
WT- or R55A-Myc-CypA. Myc-CypA was selectively immunoprecipitated from the cell lysate using an 
anti-Myc-tag antibody. Co-precipitated proteins were separated by 12% SDS-PAGE, transferred to a 
PVDF membrane, and reversibly stained with Red Ponceau, as a loading control. Potentially
218
associated TDP-43 proteins were then detected by WB using an anti-TDP-43 antibody, whereas 
immunoprecipitated Myc-CypA proteins were detected using an anti-CypA antibody (upper panels). 
15pg of the corresponding input samples were loaded on the same gel and blotted with the same 
antibodies (lower panels). Representative results of three independent experiments are shown, 
indicating that despite the mutation in the active site, R55A-Myc-CypA maintains its capability to 
bind TDP-43.
PPIase-deficient CypA, like the WT protein, was able to co-immunoprecipitate TDP-43 (upper 
panel), thereby suggesting that the R55A mutation, which is located within CypA active site, did 
not affect the physical interaction with TDP-43 (Figure 3.9). Only a slight difference was observed 
between the WT condition and the R55A mutant in the IP fraction, where a lower signal for TDP- 
43 detected. However, it should be considered that R55A-Myc-CypA could not be efficiently 
immunoprecipitated, nor by the anti-Myc-tag antibody neither by the anti-CypA antibody, both 
monoclonal and polyclonal (not shown). For this reason, no quantification for this interaction has 
been reported, because it was considered not reliable, and only a qualitative evaluation was 
appropriate. This anomalous behaviour in IP could be explained by a decreased affinity o f the 
primary antibody for the R55A-Myc-CypA in non-denaturing conditions. These data demonstrated 
that PPIase enzymatic catalysis mediated by CypA was not required for an efficient binding with 
TDP-43.
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Figure 3.10 K125Q-CypA binds TDP-43, while K125R-CypA binding is impaired.
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(A) HEK293 cells were transfected with the empty vector (CTR), or co-transfected with Flag-TDP-43 
and WT- or K125Q- or K125R-Myc-CypA. Myc-CypA was selectively immunoprecipitated from whole 
cell lysates using an anti-Myc-tag antibody. Aliquot of the lysates (INPUT) and of the 
immunoprecipitates (IP) fractions were separated by 12% SDS-PAGE, transferred to a PVDF 
membrane, and reversibly stained with Red Ponceau, as a loading control. Potentially associated 
TDP-43 proteins were detected by WB using an anti-TDP-43 antibody, whereas immunoprecipitated 
Myc-CypA proteins were detected using an anti-CypA antibody. Representative results of three 
independent experiments are shown, indicating that K125Q but not K125R preserves the capability 
of binding TDP-43 as the WT protein. (B) Histograms represent the quantitative analysis of TDP-43 
band densities in the IP fraction, normalized on the actual amount of Myc-CypA proteins 
immunoprecipitated. Data (mean ± S.E., n=3) are expressed as percentages of control cells (WT). 
Asterisk indicates that K125R was significantly different compared to both WT- and K125Q-Myc-CypA 
(*=p<0.01), as assessed by Student's t-test.
Myc-CypA mutants at Lys-125 were both able to form complexes with TDP-43, but a sharp 
distinction could be made among the two proteins. In particular, K125Q-Myc-CypA co- 
immunoprecipitated TDP-43 like the WT protein, while there was a marked reduction in the co- 
immunoprecipitation rate of TDP-43 with K125R-Myc-CypA (Figure 3.10A-B). These experiments 
demonstrated that the substitution of Lys-125 with Arg was sufficient to impair the binding 
between TDP-43 and CypA in a statistically significant way. Interestingly, an Arg was introduced to 
mimic the absence of the acetyl group on a Lys residue, and Gin to mimic acetylation. These 
results suggested that CypA Lys-acetylation in position 125 might be one factor that promoted a 
correct interaction with TDP-43.
Additional experiments performed using a slightly different approach were able to replicate the 
observations previously described. In particular, HEK293 cells were transfected only with Myc- 
CypA constructs, Myc-CypA was selectively immunoprecipitated and endogenous TDP-43 was 
detected by WB in the co-IP fraction (images not shown).
Taken together, these data from co-immunoprecipitation experiments suggested that intrinsic 
PPIase activity was not essential for the binding of CypA with TDP-43, and that acetylation of a
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specific lysine residue of CypA could play an essential role in regulating its affinity for its binding 
partner TDP-43.
3.1.10 CypA mutants expression did not alter TDP-43 
or hnRNP A2/B1 subcellular distribution
CypA mutants showing an impaired interaction with TDP-43, also displayed an altered subcellular 
distribution with a decreased localisation in the nuclear compartment, that is where the two 
proteins were found associated. In order to understand if CypA mutant proteins expression was 
sufficient to influence also the subcellular localisation of other proteins, CypA binding partners 
distribution was analysed by biochemical fractionation (Figure 3.11). In particular, the cytosolic 
and the nuclear fractions were separated in HEK293 cells transiently transfected with wild-type or 
PPIase-deficient CypA or lysine-125 mutants or the empty vector as negative control. Each 
subcellular fraction .was independently analysed by WB for TDP-43 and hnRNP A2/B1. No 
significant differences were detected in either the cytosolic or the nuclear compartment o f CypA 
mutants transfected cells compared to both WT or CTR cells. These results clearly indicate that 
neither CypA Lysine-acetylation nor its catalytic activity could modify TDP-43 or hnRNP A2/B1 
relative distribution in HEK293 cells.
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Figure 3.11 TDP-43 and hnRNP A2/B1 subcellular distribution w ere not altered by Myc- 
CypA mutants expression.
HEK293 cells were transfected with the empty vector (CTR), or WT- or R55A- or K125Q- or K125R- 
Myc-CypA, then equal amounts of cytosolic and the corresponding nuclear fractions were 
independently analysed by WB and detected by chemiluminescence. Lamin A+C and Actin were 
evaluated as controls for nuclear and/or cytoplasmic contamination of the two fractions (not 
shown). Histograms represent the quantitative analysis of (A) TDP-43 or (B) hnRNP A2/B1 band 
densities in the two subcellular compartments, normalized on the actual amount of proteins loaded 
as detected by Red Ponceau staining. Data (mean ± S.E., n=3) are expressed as percentages of 
control cells (WT) in each subcellular fraction. Samples were not significantly different, as assessed 
by One-way Anova.
3.2 In vitro evidence: CypA knockdown
CypA has long been known to function as a peptidyl-prolyl cis-trans isomerase, and it was also 
demonstrated to function as a chaperone (Freskgard 1992; Moparthi 2010). Nevertheless, the 
PPIase catalytic centre of CypA was not involved in the CypA/TDP-43 recognition event, as 
demonstrated by overexpression of the CypA-R55A mutant (Results section 3.1.9). These findings 
raise the interesting possibility that CypA may play alternative roles in the assembly of this 
complex. For example, CypA could act as a chaperone molecule. Molecular chaperones, like
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cyclophilins, have diverse roles to regulate protein conformation (Morimoto, 2008), and have only 
incremental effects on protein folding, arguing against an essential role for them in protein 
maturation (Dolinski 1997). Cyclophilins can bind at hydrophobic patches on their target protein 
w ithout necessarily isomerising a peptidyl-prolyl bond, thereby preventing misfolding (Baker 
1994; Ferreira 1996; Arie 2001) and accelerating folding (Wang 2010), assisting in assembly and 
disassembly of macromolecular complexes (Teigelkamp 1998), regulating translocation (Rycyzyn 
2000; Ansari 2002; Pan 2008) and modulating the activity of the target protein (Braaten 1997; 
Streblow 1998; Shen 1998; Crenshaw 1998; Wu 2000). A particularly interesting question is 
whether CypA can have any influence on proper localisation of TDP-43 or can play a significant 
role in folding and disaggregation. A first answer came from in vitro experiments where CypA was 
specifically silenced, in order to directly observe the effects o f the loss of CypA function. In 
particular, CypA knockdown was performed in HEK293 cells delivering a specific siRNA or a control 
siRNA (scramble).
3.2.1 TDP-43 expression and localisation after 
CypA knockdown
To start addressing this issue, 48 hours after silencing, HEK293 nuclei were separated from the 
cytoplasm by biochemical fractionation, and TDP-43 was detected by WB in both subcellular 
compartments. The quantification of TDP-43 blots clearly indicated that, in the cytoplasmic 
fraction, signals corresponding to CypA silenced samples were comparable to scrambled siRNA 
treated cells (Figure 3.12A). Instead, in the nuclear compartment, TDP-43 expression was 
significantly reduced after CypA knockdown (Figure 3.12B). The specific reduction in TDP-43 
nuclear expression following CypA silencing could not be appreciated in whole cellular lysates, as 
shown in Figure 3.12D.
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Figure 3.12 CypA silencing influenced TDP-43 nuclear distribution w ithout significantly 
affecting its total expression.
HEK293 cells were transiently transfected with lOnM siRNAscramble or siRNACypA for 48h. Equal 
amounts of whole cell lysate, and the corresponding cytosolic and nuclear fractions were 
independently analysed by WB and detected by chemiluminescence. Reversible Red Ponceau 
staining was used as loading control. (A-B) Representative WB for TDP-43 and relative histograms of 
the cytosolic (A) and nuclear (B) fractions, representing the quantitative analysis of TDP-43 band 
densities in the two subcellular compartments, normalized on the actual amount of proteins loaded, 
as detected by Red Ponceau staining. Data (mean ± S.E., n=6) are expressed as percentages of 
control cells (scramble) in each subcellular fraction. Symbols indicate that TDP-43 displayed a 
significantly lower nuclear expression after CypA knockdown (**=p<0.01 siRNACvpA vs. siRNAscramble), 
as assessed by Student's t-test. (C) Lamin A+C and Actin were evaluated as controls for nuclear 
and/or cytoplasmic contamination of the two fractions. CypA expression was strongly reduced in 
each compartment after siRNACvpA treatment compared to siRNAscramb,e. (D) Representative WB for 
CypA (lower panel) or TDP-43 (upper panel) and relative histogram with its quantification are shown 
in whole cell lysate, where TDP-43 protein levels did not vary.
These data suggested that CypA knockdown did not substantially influence the global expression 
of TDP-43, but it could alter the subcellular distribution of the protein.
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Figure 3.13 TDP-43 localisation in CypA silenced cells.
HEK293 cells were transiently transfected with lOnM siRNAscramble or siRNACypA for 48h. 
Representative immunofluorescence images of HEK293 cells after silencing stained for CypA (red) 
using Alexa®647-conjugated secondary antibody and TDP-43 (green) using Alexa®488-conjugated 
secondary antibody are shown (bar: 15pm). A less intense TDP-43 nuclear staining was detected 
following CypA knockdown.
The effect o f CypA knockdown on TDP-43 was then analysed by confocal immunofluorescence. 
TDP-43 (green) localisation was visualised simultaneously with CypA (red) staining in cells 
transfected with siRNACypA or siRNAscramble. This approach helped to distinguish cells efficiently 
silenced for CypA from cells still expressing the protein. In cells treated with the scrambled siRNA, 
TDP-43 was predominantly localized in the nucleus whereas CypA was present mainly in the 
cytosol but also in the nucleus (Figure 3.14), as previously observed (Figure 3.13). In cells 
incubated with CypA siRNA, TDP-43 seemed to preserve its localisation pattern as in control cells, 
although displaying a less intense nuclear staining.
Immunofluorescence results further corroborated biochemical observation, indicating that CypA 
could be required for TDP-43 correct localisation/redistribution inside the nucleus. However, 
further analyses are needed to define the real effects mediated by CypA depletion on intracellular 
TDP-43 trafficking and function.
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3.2.2 CypA is involved in hnRNP complex formation 
TDP-43 functionally associates with several hnRNP proteins and, in particular, hnRNP A2, that is 
the major hnRNP protein recognized by TDP-43 according to pull-down assays (Ayala 2005). This 
interaction leading to formation of a hnRNP-rich complex seems to be essential for the splicing 
inhibitory activity of TDP-43 (Buratti 2005). The results previously described clearly demonstrated 
that CypA, TDP-43 and hnRNP A2/B1 may form a complex with each other and these interactions 
are RNA-dependent. In this respect, it is possible to hypothesise that they are together part of a 
larger protein complex. It is therefore likely that CypA might be a component of hnRNP-rich 
complexes, together with TDP-43 and other hnRNP proteins, like hnRNP A2/B1, abundantly 
represented in CypA interactome. Indeed TDP-43 and CypA have been previously demonstrated 
to co-immunoprecipitate with anti-hnRNP A2/B1 antibody (Results section 2.2.1). In order to test 
whether CypA is required for hnRNP complex assembly or stabilization, the same co-IP assay was 
replicated in cells expressing or silenced for CypA. In particular, HEK293 whole cellular lysates 
were co-IP 48 hours after treatment with siRNAscramble or siRNACvpA. CypA knockdown was verified 
at the protein level, as shown in the input fraction. When the CypA expression level was 
decreased by a specific siRNA molecule, the presence of TDP-43 in hnRNP A2/B1 co-IP fraction 
was dramatically reduced in respect to scrambled siRNA treated cells, despite comparable 
expression levels in the starting samples (Figure 3.14). This experiment was repeated several 
times, replicating the same observation: when CypA is silenced TDP-43 and hnRNP A2/B1 
interaction is severely impaired. These results suggested that CypA is fundamental for the 
interaction of TDP-43 with at least hnRNP A2/B1. Indeed CypA absence could disrupt the binding 
between these two proteins within this hnRNP complex.
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Figure 3.14 CypA interaction with TDP-43 is implicated in hnRNP complex formation.
HEK293 cells were transiently transfected with with siRNAscramble or siRNACypA. TDP-43 was co­
precipitated using an anti-hnRNPA2/Bl antibody. Aliquot of whole cell lysates (INPUT) and of the 
immunoprecipitates (IP) were loaded together, subjected to SDS-PAGE, transferred to a PVDF 
membrane, stained with Red Ponceau as loading control, probed with primary antibodies and 
detected by chemiluminescence. A band corresponding to TDP-43 was enriched in the IP fractions of 
cells treated with siRNAscramble and was strongly reduced after siRNACypA treatment. The input fraction 
was first probed for TDP-43 to verify that the protein was expressed with comparable levels after 
silencing, and then for CypA to check knockdown efficiency. Immunoprecipitation was repeated at 
least three times with consistent results and representative images were chosen for display.
In this model, CypA could simply function in mediating a protein-protein interaction with TDP-43 
and hnRNP A2/B1, or it could induce a conformational change in one of its target proteins. 
Another possibility is that the aberrant hnRNP complex formation is directly linked to the 
observed depletion of TDP-43 from the nucleus following CypA knockdown. In this case CypA 
could function in balancing TDP-43 intracellular distribution, thus contributing to the correct 
hnRNP complex assembly. Whatever its identity, target proteins appeared to be directly involved 
in this hnRNP complex formation, since CypA knockdown negatively affected the efficient binding 
of TDP-43 with hnRNP A2/B1.
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3.2.3 CypA/TDP-43 are involved in regulation of 
HDAC6 expression
To further establish the functional significance of CypA/TDP-43 association, we sought to 
understand how the described hnRNP complex could operate in putative TDP-43 physiological 
functions. Several RNA targets of TDP-43 are now known. Among them, recent microarray screens 
identified Histone Deacetylase 6 (HDAC6) as an altered transcript in TDP-43 silenced cells (Fiesel 
FC 2010) and in conditional knockout mice (Chiang 2010). Moreover, HDAC6 was consistently 
identified by systematic sequencing of RNA isolated by CLIP using TDP-43 antibodies in vivo 
(Tollervey 2011; Polymenidou 2011). TDP-43 was demonstrated to bind to HDAC6 mRNA and to 
regulate its expression (Fiesel 2010) in complex with FUS/TLS (Kim 2010). Interestingly, HDAC6 
down-regulation after TDP-43 silencing was associated to impaired cellular turnover of 
aggregating proteins and reduced neurite outgrowth (Fiesel 2010 and 2011), a molecular 
mechanisms that could contribute to pathogenesis.
To gain insights on possible common biochemical pathways operated by TDP-43 and CypA, we 
investigated whether CypA could modulate this RNA-related TDP-43 activity. First, TDP-43 
knockdown conditions were replicated treating HEK293 cells with a siRNA molecule targeting the 
3'-UTR within TDP-43 locus (Results section 4.2). TDP-43 knockdown of up to 90% was evaluated 
at the protein level by WB on whole cell lysates (upper panel). HEK293 cells treated with a 
scrambled siRNA were used as a negative experimental control. TDP-43 silencing was confirmed 
to reduce HDAC6 protein level relative to cells transfected with control siRNA (scramble) (Figure
3.15), supporting previous findings (Fiesel 2010; Kim 2010). Next, we tested whether CypA 
silencing could affect TDP-43-dependent regulation of HDAC6 expression. First, CypA silencing 
efficiency was verified by WB. Surprisingly, a downregulation of HDAC6 protein expression was 
detected also after CypA knockdown, relative to scrambled siRNA control cells. Furthermore, the 
effect observed on HDAC6 protein level was almost comparable to the one found in TDP-43 
silenced cells. Equal protein expression among different samples was revealed by WB for Tubulin.
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Figure 3.15 CypA has a role in TDP-43-mediated HDAC6 expression regulation.
HEK293 cells were transiently transfected with siRNAscramble or siRNATDP‘43 or siRNACypA. (A) 15 pg of 
total protein lysates were loaded, run on SDS-PAGE gels, transferred on PVDF membranes, stained 
with Red Ponceau as loading control, analysed by WB and detected by chemiluminescence, TDP-43 
and CypA were evaluated to check the corresponding protein knockdown (upper panels). WB for 
Tubulin and HDAC6 showed respectively equal protein expression and specific downregulation after 
silencing (lower panels). Representative images were chosen for display. (B) Histograms represent 
the quantitative analysis of HDAC6 band densities, normalized on the actual amount of proteins 
loaded, as detected by Red Ponceau staining. Data (mean ± S.E., n=4) are expressed as relative 
immunostaining values. Asterisks indicate that siRNATDP’43 (**=p<0.01) or siRNACypA (*=p<0.05) were 
significantly different compared to siRNAscramble, as assessed by One-way Anova followed by 
Bonferroni multiple comparison test.
The finding that RNA silencing of either TDP-43 or CypA reduced the expression of HDAC6 protein, 
indicated a co-requirement of TDP-43 and CypA for optimal HDAC6 expression, and thus 
established a possible biological role for the protein-protein interaction among CypA and TDP-43. 
Furthermore, based on previous work (Kim 2010), it is possible to speculate that the hnRNP 
complex described may be involved in HDAC6 mRNA processing and/or nuclear export.
3.3 In vivo evidence: CypA knockout mice
In vitro data consistently demonstrated the essential features of CypA/TDP-43/hnRNP A2/B1 
functional association in hnRNP complex assembly/disassembly. To validate in vivo some of the
1 siRNA
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CypA 
HDAC6 
TUBULIN
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effects observed in vitro after CypA knockdown, tissues from mice expressing (CypA +/+) with a 
reduced (CypA +/-) or absent (CypA -/-) expression of CypA were analysed.
3.3.1 CypA is involved in TDP43/hnRNP A2/B1RNP 
complex formation
With the goal of investigating protein-protein interactions in the hnRNP complex in more detail, 
co-immunoprecipitation experiments were performed in a mouse tissue that is affected in TDP- 
43-related pathology in ALS. In particular, mouse spinal cord homogenates were analysed to 
further demonstrate that the interaction between TDP-43 and hnRNP A2/B1 was negatively 
regulated by a reduced or absent CypA expression.
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WB: TDP-43
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Figure 3.16 CypA interaction w ith  TDP-43 is implicated in hnRNP complex form ation in 
mouse lumbar SpC.
Equal amounts of proteins (lmg) from lumbar SpC homogenates of CypA+/+ (n=3), CypA+/- (n=3) 
and CypA-/- (n=3) mice were co-precipitated with anti-hnRNP A2/B1 primary antibody. Aliquot of the 
tissue homogenates (INPUT), of the immunoprecipitates (IP) and of th e , remaining fractions 
(OUTPUT) were loaded together with coated beads as IP control, subjected to SDS-PAGE, transferred 
to a PVDF membrane, stained with Red Ponceau as loading control, probed with anti-TDP-43 
antibody and detected by chemiluminescence. Results representative of several independent 
experiments are shown, indicating that CypA/TDP-43 interaction is implicated in hnRNP complex 
formation in vivo.
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Lumbar SpC from age and sex-matched mice that express (CypA+/+, n=3), have a reduced 
expression (CypA+/-/ n=3) or do not express (CypA-/-, n=3) CypA were used in co-IP assays (Figure
3.16). Coated magnetic beads (Ctr) were used as negative experimental control. An anti-hnRNP 
A2/B1 antibody was used for immunoprecipitation and the WB for TDP-43 clearly detected the 
protein in the co-IP fraction of mice expressing CypA (CypA+/+), with a decrease and a striking 
reduction respectively in CypA+/- and knockout (CypA-/-) mouse samples, thus confirming 
previous results. This finding was further supported by the observation that TDP-43 marked 
reduction in the IP fraction was associated with an increased recovery o f the protein in the output 
fraction of CypA knockout mice.
Collectively, these data suggested possible key roles o f CypA in the architecture of this RNA- 
binding protein complex and demonstrated the relevance of this function of CypA also in vivo, in a 
disease-related tissue. However, it should be noted that TDP-43 and hnRNP A2/B1 interaction, 
and thus this hnRNP complex formation, was not completely inhibited in CypA knockout mice. 
Given the presence of multiple immunophilins in the nucleus, also identified as part of the 
spliceosome (reviewed in Mesa 2008), arguing for a possible functional redundancy in the splicing 
system, a compensatory mechanism may be hypothesised for CypA knockout mice.
3.3.2 CypA absence alters TDP-43 solubility
One of the potential consequences of TDP-43/hnRNP A2/B1 complex disruption upon CypA knock­
down/out could be an impaired turnover o f this hnRNP complex. Since TDP-43 is an intrinsically 
aggregation-prone protein (Johnson 2009), its propensity for toxic misfolding could be thus 
accentuated in vivo by CypA reduction or absence. In fact, TDP-43 depletion from the nucleus, 
together with its accumulation in ubiquitinated cytoplasmic inclusions are important pathological 
features of ALS and FTLD-U (Neumann 2006), and this could represent a possible mechanism by 
which CypA could contribute to TDP-43-related diseases.
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To investigate whether CypA deficiency may cause protein complex instability in vivo we isolated 
and characterised the protein composition of the Triton X-100-insoluble fraction (TIF) from mouse 
spinal cord tissues of CypA+/+, CypA+/- and CypA-/- mice. TIF was used as our experimental 
model o f protein aggregates because previous analyses conducted in our laboratory on Triton- 
insoluble fractions extracted from the spinal cord of mutant SOD1 mice demonstrated that are 
enriched in ubiquitinated protein aggregates and more generally in improperly folded or damaged 
proteins (Basso 2006 and 2009).
Figure 3.17 Total TIF in ventral horn mouse lumbar SpC.
Analysis of detergent-insoluble proteins from the ventral horn portion of the lumbar spinal cord of 
sex and age-matched CypA+/+ (n=6), CypA+/- (n=6) and CypA-/- (n=6) mice. Total TIF is the ratio of 
the amount of Triton-XlOO-insoluble proteins to the total proteins extracted in the soluble fraction. 
Proteins were quantified respectively by the Bradford and the BCA assays. Data (mean ± S.E., n=6) 
are expressed as percentages of control (CypA+/+)- Asterisks indicate values significantly different 
from controls (**=p<0.01 CypA-/- vs. CypA+/+; *=p^0.05 CypA+/- vs. CypA+/+)/ as assessed by One­
way Anova followed by Bonferroni multiple comparison test.
For this analysis, potentially aggregating proteins were enriched and separated from other 
contaminants, which were removed from the isolated aggregates by detergent-rich buffer 
extraction. The detergent-insoluble aggregates were then solubilised in an urea-based buffer and 
quantified. Total TIF obtained from CypA-/- mice were significantly more abundant than in 
CypA+/+ mice, with a higher, but not significant, amount of TIF in CypA+/- mice compared to CypA 
knockout mice (Figure 3.17).
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Figure 3.18 Protein composition of the insoluble and soluble fractions.
Immunoblot analysis of TIF from ventral horn lumbar spinal cord tissues of Cyp +/+ (n=6), CypA+/- 
(n=6) and CypA-/- (n=6) mice. The level of Ubiquitin (A), TDP-43 (B), hnRNP A2/B1 (C), phospho- 
Serine-409/410 TDP-43 (D) were measured in TIF. TDP-43 (E) and hnRNP A2/B1 (F) were also 
analysed in the Soluble fraction. Aliquot of TIF or Soluble proteins were analysed independently by 
WB (15pg) or dot blotting (3|ig), probed with the specific antibodies and detected by 
chemiluminescence. Histograms represent the im mu noreactivity normalised to the actual amount of 
protein loaded, detected after Red Ponceau or Sypro® Ruby Protein Blot staining. Values are 
percentages of control (CypA+/+) and are the mean ± S.E., n=6. Symbols indicate values significantly 
different from controls (*=p<0.05 vs. CypA+/+; §=p^0.05 vs. CypA+/-)/ as assessed by One-way Anova 
followed by Neuman-Keuls multiple comparison test.
A quantitative approach was employed to analyse single proteins of interest by WB, following 
qualitative detergent-insoluble protein enrichment. In particular, the same amounts o f TIF or 
soluble samples were resolved on SDS-PAGE gels, blotted on PVDF membranes and probed with 
different primary antibodies. Alternatively, aliquots o f TIF or soluble protein extracts were diluted, 
loaded in duplicate on nitrocellulose membranes by dot blotting, stained with Red Ponceau as 
loading control and blotted. We found that TIF from SpC of CypA+/- and CypA-/- mice were 
enriched in polyubiquitinated proteins (Figure 3.18A). Furthermore, TDP-43 was recovered as 
insoluble material, with an increasing trend, when CypA was reduced or absent (Figure 3.18B). 
Also hnRNP A2/B1 was significantly accumulated in TIF o f CypA-/- and CypA+/- mice in 
comparison with CypA+/+ animals (Figure 3.18C). We then used an antibody raised against TDP-
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43 phosphorylated at Serine-409/410, that allows the sensitive and specific labelling of disease- 
associated species (Inukai 2008). Interestingly, hyper-phosphorylated TDP-43 was also 
significantly enriched in tissues from CypA knock-down/out mice compared to control animals 
(Figure 3.18D). The increased amount of Triton-insoluble TDP-43 and hnRNP A2/B1 recovered 
when CypA protein expression was completely abrogated, was not mirrored by a significant 
reduction in the level of the same protein in the soluble fraction (Figure 3.18E-F).
These results demonstrated that in the detergent-insoluble/urea-soluble fraction from CypA 
knockout mice ubiquitin was co-enriched with TDP-43. Thus, TIF contained ubiquitinated and 
aberrantly phosphorylated TDP-43, making it possible to conclude with confidence that extracted 
proteins were qualitatively similar to TDP-43 aggregates and therefore had the fundamental 
biochemical features of protein inclusions in TDP-43-linked human pathology. Furthermore, 
reduction or absence of CypA augmented the amount of TDP-43 aggregates in a dose-dependent 
manner and, in these fractions hnRNP A2/B1 was found to co-aggregate with TDP-43. These data 
suggest that CypA expression at physiological levels could be protective against aggregate 
formation of mislocalised TDP-43.
In conclusion, in vivo experiments provided a framework for understanding how dysregulation of 
TDP-43/CypA hnRNP complex assembly could contribute to pathogenesis, in addition to HDAC6 
altered expression regulation, observed in vitro. So, it is possible to speculate that the absence or 
an impaired CypA/TDP-43 binding could contribute to accelerate improper folding of this 
complex, leading to TDP-43 aggregation and abnormal inclusion formation, that is a highly 
consistent feature of TDP-43 proteinopathies (Geser 2009).
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4. TDP-43-associated disease
A fraction o f CypA was found to complex with TDP-43 and hnRNP A2/B1 in vitro and in vivo. These 
interactions are RNA-dependent and substantially enhanced by CypA lysine-acetylation. Two of 
the key questions for understanding the role of this protein complex are (i) what are the normal 
functions and (ii) what are the acquired toxicities and/or perturbed normal functions in disease 
conditions. To address the first question we showed that CypA is involved in the assembly and 
maintenance of the hnRNP complex formed by TDP43 and hnRNP A2/B1, both in vitro and in vivo. 
Additionally, a possible involvement of this hnRNP complex in HDAC6 expression regulation was 
defined in vitro. Furthermore, in the absence of CypA, TDP-43 was significantly enriched and 
aberrantly phosphorylated in proteinaceous inclusions in mouse spinal cord. Here, we tried to 
understand whether this hnRNP complex was involved or altered in TDP-43-related pathological 
conditions, when it is mutated (Kabashi 2008; Sreedharan 2008) or aberrantly phosphorylated, 
fragmented and ubiquitinated (Arai 2006; Neumann 2006), as in ALS or FTLD-U patients.
4.1 WT-TDP-43 over-expression in HEK293 cells
To investigate the normal functions of TDP-43, the wild-type protein was transiently expressed in 
the HEK293 cell line. In order to specifically detect the exogenous protein and to distinguish the 
transfected protein from endogenous TDP-43, an N-terminal Flag-tag was added to the TDP-43 
expression construct. This time, contrary to the position of the Myc-tag fused at the C-terminal 
end of CypA sequence, the N-terminal end of TDP-43 was preferred, because of the peculiar 
structural/functional features of its C-terminal region. In fact, many works suggest that the C- 
terminus of TDP-43 is essential for its solubility, cellular localisation and protein-protein 
interactions (Buratti 2005; Ayala 2008). Thus, the introduction of an epitope at this end side o f the 
protein could have a detrimental effect on its physiological activities.
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4.1.1 Flag-tagged WT-TDP43 expression level 
A transfection protocol was optimized to obtain the highest Flag-tagged TDP-43 expression level 
in HEK293 cells with the lowest cytotoxicity.
Empty Flag- D  Empty Flag-
vector TDP-43 vector TDP-43
Flag-TDP-43
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43kDa43kDa-
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Figure 4.1 Flag-TDP-43 expression in HEK293 cells.
HEK293 cells were transiently transfected with the empty vector or the vector cloned with Flag- 
TDP43. 15pg of total protein lysates were loaded, run on SDS-PAGE gels, transferred onto a PVDF 
membrane, stained with Red Ponceau as loading control, analysed by WB using the anti-Flag-tag (A) 
or the anti-TDP-43 (B) antibodies and detected by chemiluminescence. The anti-Flag-tag antibody 
revealed only the signal corresponding to exogenous TDP-43 (computed MW ~ 45kDa), while the 
anti-TDP-43 antibody detected the signals relative to both the endogenous TDP-43 (43kDa) and the 
exogenous Flag-tagged protein. Flag-TDP-43 was expressed at high levels in HEK293 cells.
In order to verify the expression of the N-terminal Flag-tagged TDP-43 in this experimental 
system, HEK293 cells were transiently transfected with either an empty vector or with the vector 
encoding WT-Flag-TDP-43. The expression of the exogenous and the endogenous proteins was 
thus verified by WB analyses on whole cell lysates, using respectively an antibody for the Flag-tag 
or alternatively an antibody for TDP-43. The anti-Flag-tag antibody revealed only the presence of 
the tagged protein in the lane corresponding to cells transfected with the Flag-TDP-43 construct 
(Figure 4.1A). Using a polyclonal antibody for TDP-43, only one band at 43kDa was detected in 
cells transfected with the empty vector, while two bands, corresponding to the endogenous TDP- 
43 and the exogenous Flag-TDP-43 at a higher MW, were detected in cells transfected with Flag- 
TDP-43 plasmid (Figure 4.1B). Interestingly, another band below 37kDa was recognized by the
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anti-TDP-43 antibody only in cells overexpressing TDP-43. This signal was probably due to the 
presence o f C-terminal TDP-43 fragments, since they were not recognized by the anti-Flag-tag 
antibody that targets the N-terminus. C-terminal fragments were generated by the increased 
cleavage o f TDP-43 in HEK293 cells after overexpression, as already reported in cell cultures and 
human disease (Zhang 2007; Neumann 2007).
4.1.2 Flag-tagged WT-TDP43 localisation
B
TDP-43 MERGE
Flag-tag MERGE
Figure 4.2 Flag-TDP-43 is expressed mainly in the nucleus of HEK293 cells.
HEK293 cells transiently transfected with the empty vector or the vector cloned with Flag-TDP-43 
(bar: 15pm). Representative immunofluorescence images of HEK293 cells expressing Flag-TDP-43, 
immunostained with (A) polyclonal anti-TDP-43 antibody followed by Alexa®488 (green)-conjugated 
antibody or (B) with monoclonal anti-Flag-tag antibody followed by Alexa®647 (red)-conjugated 
antibody. Nuclei were detected using DAPI staining (blue). The anti-TDP-43 antibody revealed the 
signals of both endogenous and exogenous TDP-43, whereas with the anti-Flag-tag antibody only the 
signal concerning the exogenous protein was detected.
The expression o f the exogenous tagged protein was also verified by immunofluorescence using
confocal microscopy. Exogenous TDP-43 had to be visualised via fused Flag-tag, as HEK293 cells
show robust endogenous expression o f TDP-43. Cells were transfected w ith  good efficiency and
expressed Flag-TDP-43 at high levels. In particular, cells overexpressing TDP-43 were
characterised by a more intense TDP-43 immunostaining (Figure 4.2A), while the staining fo r the
Flag-tag was present only in transiently transfected cells correctly expressing the exogenous
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tagged protein (Figure 4.2B). As already observed in Figure 2.9, the immunostaining by the anti- 
Flag-tag antibody further confirmed the observation that ectopic WT-Flag-TDP-43 mainly localized 
to the nucleus of these cells, as highlighted by magenta areas of overlay of red and blue (merge). 
Thus, TDP-43 immunostaining in these cells confirmed that both endogenous TDP-43 and Flag- 
TDP-43 had primarily nuclear localisation, nevertheless TDP-43 staining was also detected in the 
cytoplasm. This evidence was in accordance with data from the literature demonstrating that 
TDP-43 was able to shuttle continuously between the nucleus and the cytoplasm (Ayala 2008). 
HEK293 cells transfected with the empty vector were used as controls: Flag-tag staining was not 
present in these cells, whereas only basal TDP-43 signal for the endogenous protein was detected 
(images not shown).
4.1.3 Cell viability evaluation after Flag-tagged 
WT-TDP43 overexpression
□  Empty vector
□  Flag-TDP-43
24h 48h
Figure 4.3 Flag-TDP-43 overexpression reduced cell survival.
HEK293 cells were transfected with the empty vector or with Flag-TDP-43. Cell viability was assessed 
by MTT assay 24h and 48h after transfection. Values are the mean ± S.E.M. (n>4) and are expressed 
as a percentage of control cells (empty vector). Asterisk indicates values significantly different from 
control (*=p<0.05), as assessed by Student's t-test.
In order to determine whether an overexpression of TDP-43 in this experimental setting could 
have any effect on cell viability, the survival rate of transiently transfected cells was assessed by
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MTT assay. A statistically significant reduction in viability was detected in cells overexpressing 
Flag-TDP-43 after 48h (Figure 4.3). These data suggested that an overexpression of wild-type TDP- 
43 could be toxic per se also in vitro, as previously reported by other work on yeast, mice, 
zebrafish, or Drosophila (Johnson 2008; Xu 2010; Wils 2010; Hanson 2010; Li 2010; Ritson 2010; 
Estes 2011; Miguel 2011). Furthermore, TDP-43-induced toxicity is dependent on the level of 
transgene expression, with intermediate expression o f TDP-43 producing an attenuated 
phenotype, compared with models expressing higher TDP-43 levels (Johnson 2008; Stallings 2010; 
Wils 2010; Xu 2010; Igaz 2011). Thus, in subsequent experiments cells were analysed 24h after 
Flag-TDP-43 transfection, when the exogenous protein was expressed at good levels but there 
was no overt cytotoxicity.
4.2 TDP-43 knockdown in HEK293 cells
In order to directly observe the effects of the loss o f TDP-43 function in vitro, RNA interference
technology was used. TDP-43 silencing experiments were performed in HEK293 cells delivering a
specific siRNATDIM3 or, as a negative control for knockdown, a scrambled siRNA that did not lead to
the degradation o f any specific mRNA. The siRNATDP'43 molecule, targeting the 3'-UTR of TDP-43
locus was transiently transfected through a cationic lipid-mediated transfection system. Once the
siRNA concentration and transfection system yielding the highest efficiency of knockdown was
established, the optimal time interval for in vitro knockdown was determined: HEK293 cells were
treated with either TDP-43 or control siRNA for 24, 48, 72 and 96 hours. As shown in Figure 4.4A,
treatment with TDP-43 siRNA markedly reduced the protein expression in a time-dependent
manner, with very little detectable protein observed by WB for TDP-43 48, 72 and 96 hours after
treatment compared with scramble siRNA. Thus, RNA silencing experimental conditions were
optimized to obtain a constant reduction in TDP-43 protein expression up to 90% (Figure 4.4A). In
all subsequent experiments performed, 48 hours was used as the time point to evaluate effects of
TDP-43 knockdown, that was always verified analysing the protein expression level by Western or
dot blotting. Targeting by siRNA the untranslated region o f TDP-43 allowed to selectively silence
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only the endogenous protein, and not the exogenously transfected Flag-tagged TDP-43 (Figure 
4.4B).
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TDP-43 siRNA -
Flag-TDP-43 -*■ TDP-43 ">
Red
Ponceau
Red
Ponceau
*
19
4r~ MERGE
Hir *
Figure 4.4 TDP-43 knockdown.
HEK293 cells were transfected with siRNAscramb,e or siRNATDP"43. (A-B) 15pg of total protein lysates 
were loaded, run on SDS-PAGE gels, transferred on PVDF membranes, stained with Red Ponceau as 
loading control, analysed by WB for TDP-43 and detected by chemiluminescence. (A) Representative 
WB for TDP-43 in cells silenced at different time points. (B) Representative WB for TDP-43 in cells 
transfected with siRNAscramble or siRNATDfM3 or co-transfected with Flag-TDP-43 and siRNAscramble or 
Flag-TDP-43 and siRNATDP'43. (C) Representative immunofluorescence images of HEK293 cells stained 
for TDP-43 (green) after silencing (bar: 15pm). Nuclei were stained with Hoechst (blue).
To further demonstrate the specific knockdown of TDP-43 in vitro, immunofluorescence (IF) 
staining fo r TDP-43 was also performed in cells that were counter-stained with Hoechst to
visualise the nuclei (Figure 4.4C). In cells treated with siRNATDP'43 the extent of TDP-43 silencing
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was clear also by IF (white arrows), compared to flanking cells that were not efficiently silenced. 
Notably, in silenced cells TDP-43 expression was almost absent in the nucleus, while a faint 
staining for the protein was still noticeable in the cytosol, although it was clearly down-regulated. 
TDP-43 silencing did not significantly alter cell survival rate (data not shown).
4.3 ALS-mutant TDP-43
The effect o f pathogenic mutations of the TDP-43 gene was then tested in this experimental 
system to evaluate their impact on the interaction with CypA and, on the functions of the hnRNP 
complex these proteins are involved in.
asfijuss
A315T Familial Kabashi 2008 Gitcho2008
Motor phenotype when overexpressed in 
mice, nematode (C.elegans),zebrafish.
R361S Sporadic Kabashi 2008
Can't restore HDAC6 mRNA expression. 
Alters SG formation.
Increases n. of TDP-43 aggregates.
Y374X Sporadic Daoud 2009 First frameshift mutation identified. Truncated protein.
Table 4.1 TDP-43 ALS-mutations analysed in this work.
The analyses in this study compared the effects of three different ALS-mutations. In particular, 
two missense mutations, A315T and R361S, and the frameshift mutation Y374X were considered 
in this work. The A315T (Gitcho 2008; Kabashi 2008) mutation causes dominantly inherited ALS, 
while the R361S (Kabashi 2008) and Y374X (Daoud 2009) mutations were found in sporadic ALS 
cases (Table 4.1). These three mutations are located inside the C-terminal glycine-rich domain of 
TDP-43, with the R361S and Y374X being respectively inside or close to the minimal hnRNP 
binding region (D'Ambrogio 2009; Budini 2012) (Figure 4.5).
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Figure 4.5 TDP-43 structural regions.
Schematic representation of human TDP-43 protein drawn to scale. TDP-43 has five functional 
regions, including two RNA recognition motifs (RRM1 and RRM2) important for DNA/RNA binding, a 
nuclear localisation signal (NLS) and a nuclear export signal (NES) that mediate nucleo-cytoplasmic 
shuttling, and a glycine rich domain (GRD) that mediates protein-protein interactions. The prion-like 
Q/N rich region (Cushman 2010) has been highlighted, in addition to the location of the ALS- 
associated mutations introduced in Flag-TDP-43 sequence in this study. A structural region mediating 
the binding with hnRNP A2, as identified by the group of Prof. Baralle F. (D'Ambrogio 2009; Budini 
2012), also spans part of the C-terminal tail of TDP-43.
Our chosen experimental approach was transient transfection of HEK293 cells with Flag-TDP- 
43 cDNA with or w ithout mutations, following the specific knockdown of the endogenous 
protein with siRNA targeting the endogenous transcript 3'-UTR.
4.3.1 Generation of TDP-43 ALS-mutants 
Point mutations were introduced in TDP-43 coding sequence by overlap-PCR (detailed procedure 
is explained in Materials and Methods section 12.2), as previously described for CypA (Results 
section 3.1.3). Briefly, mutagenic primers were designed to alter the nucleotide sequence of TDP- 
43 in a first round of PCR and the products obtained were used as substrates in a second round of 
PCR. The products o f the second PCR were run on agarose gels to verify the correct length of each 
fragment. Each cDNA fragment, carrying the point mutation, was digested and purified to be 
inserted into the starting expression vector. This was used to transform competent bacteria that 
were plated on ampicillin-containing agar plates. When ligation and transformation reactions had
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been achieved correctly, colonies grew only in plates where ligation products, and not digested- 
dephosphorylated plasmids, had been plated. To identify bacterial colonies containing the 
recombinant plasmid, colony screening was carried out by restriction analysis. At least four 
colonies for each condition were picked and grown in liquid cultures in the presence of ampicillin. 
Extracted plasmid DNAs were digested and analysed on agarose gel. Correct constructs were 
selected when only two bands, corresponding to the linearized vector and the excised cDNA 
insert, were detected. Furthermore, to ensure the existence of the correct point mutations inside 
the generated cDNA, and to exclude the presence of other unpredicted missense/nonsense 
mutations, constructs were sequenced. Both forward and reverse sequence analyses were used 
to verify that the constructs carried the expected nucleotide substitutions and did not present any 
other mismatches (Figure 4.6). Finally, selected vectors were tested for correct protein expression 
in HEK293 cells after transient transfection and were then amplified in bacteria to generate large 
amounts o f plasmid DNA.
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Figure 4.6 Flag-TDP-43 ALS-mutants sequencing.
Sequencing was performed on both DNA strands. The images shown highlight the codons carrying 
the point mutations generated and correspond to sequencing analyses performed on the reverse 
anti-sense DNA strand. Sequencing of the forward sense DNA strand (not shown) confirmed the 
same results.
4.3.2 TDP-43 ALS-mutants expression level 
First, plasmids encoding TDP-43 ALS-mutants were tested for being efficiently transfected into 
HEK293 cells. To this extent, cells were transiently transfected with the WT- or A315T- or R361S- 
or Y374X-Flag-TDP-43 constructs or with the empty vector, as a negative control. Cells were
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collected 24 hours after transfection, to minimize cytotoxicity after TDP-43 over-expression. WB 
for the Flag-tag portion of the exogenous proteins on whole cell lysates confirmed that wild-type 
and mutant forms of TDP-43 were expressed correctly and with comparable levels (Figure 4.7A). 
As shown in Figure 4.7B, also the staining with a polyclonal anti-TDP-43 antibody revealed high 
and similar expression levels compared to the endogenous protein and the WT-Flag-TDP-43, 
respectively. The Y374X-Flag-TDP-43 mutant produced a truncated form of the protein, missing 
the last 41 amino acids (Daoud 2009). This feature was evidenced in WB analyses for both Flag-tag 
and TDP-43 by a band running at a lower molecular weight. Furthermore, all three ALS-patient 
derived mutations produced aberrant cleavage products of TDP-43, as evidenced by the presence 
of 35-kDa and 25-kDa C-terminal fragments (Figure 4.7B). This is in accordance with the 
observation that mutant forms of TDP-43 form fragments more readily than wild-type TDP-43 in 
cell cultures (Sreedharan 2008).
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Figure 4.7 Flag-TDP-43 ALS-mutants overexpression in HEK293 cells.
HEK293 cells were transiently transfected with the empty vector (VEC) or the vector cloned with WT- 
or A315T- or R361S- or Y374X-Flag-TDP43. 15|ig of total protein lysates were loaded, run on SDS- 
PAGE gel, transferred on a PVDF membrane, stained with Red Ponceau as loading control, analysed 
by WB using the anti-Flag-tag (A) or the anti-TDP-43 (B) antibodies and detected by 
chemiluminescence. All Flag-TDP-43 proteins were expressed at comparable levels in HEK293 cells.
4.3.3 Localisation of TDP-43 ALS-mutants 
In physiological conditions TDP-43 is mainly localised within the nucleus. To establish whether 
ALS-mutant Flag-TDP-43 proteins retained the same distribution of the wild-type protein, two
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independent methods were used: biochemical fractionation of the cytoplasmic and nuclear 
compartments and confocal microscopy of transiently transfected cells.
The biochemical approach consisted in the separation o f the cytosolic from the nuclear fraction in 
cells expressing the wild-type or mutagenized Flag-TDP-43 proteins. Each subcellular fraction was 
independently analysed by WB using antibodies for TDP-43 or the Flag-tag portion o f the protein.
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Figure 4.8 Flag-TDP-43 ALS-mutants subcellular distribution in HEK293 cells.
HEK293 cells were transiently transfected with WT- or A315T- or R361S- or Y374X-Flag-TDP-43. Equal 
amounts of cytosolic (B) and the corresponding nuclear (C) fractions were independently loaded, run 
on SDS-PAGE gels, transferred on PVDF membranes, stained with Red Ponceau as loading control, 
analysed by WB using the anti-Flag-tag antibody and detected by chemiluminescence. (A) 
Histograms represent the quantitative analysis of Flag-TDP-43 band densities in each compartment, 
normalized on the actual amount of proteins loaded, as detected by Red Ponceau staining. Data 
(mean ± S.E.M., n=4) in each subcellular fraction are proportioned to control cells (WT), whose value 
was set as one, and represented as the ratio of the values between the cytosolic and the 
corresponding nuclear fraction (CNR). Asterisks indicate that samples are significantly different 
(*=p<0.01) compared to control (WT), as assessed by One-way analysis of variance followed by 
Bonferroni's Multiple Comparison Test.
If the ALS-mutants of TDP-43 increased the proportion of cytosolic Flag-TDP-43, the ratio of 
cytoplasmic to nuclear protein (CNR) should be higher in cells expressing the mutant protein. To 
investigate this possibility, the quantification of the Flag-tag signal in the cytoplasm and in the
nucleus of independent samples, after normalization to the wild-type protein in the respective 
subcellular compartment, was used to calculate the CNR for each sample. Indeed, the mean CNR 
was significantly higher in cells expressing the A315T and R361S mutations, compared to WT-Flag- 
TDP-43 (Figure 4.8). This observation indicated that the A315T and R361S mutations enhanced 
protein mislocalisation and, in particular, significantly increased the protein cytoplasmic 
localisation, in agreement with reports by different groups (Barmada 2010; Liu-Yesucevitz 2010). 
In fact, in the nuclear fraction, signals corresponding to mutagenized TDP-43 proteins were 
comparable to the wild-type protein, while in the cytosolic compartment their levels were 
increased. Thus, the A315T and R361S ALS-derived mutations promoted the redistribution of the 
protein, increasing the proportion of cytoplasmic TDP-43 and possibly stimulating inclusions 
formation. In fact, increasing TDP-43 in the cytoplasm may disproportionately expose the protein 
to endogenous proteases, in a process generating high cytoplasmic concentrations of C-terminal 
TDP-43 fragments, as observed in Figure 4.7, which are enriched in cytoplasmic inclusions found 
in affected neurons (Igaz 2008). The results in this study add to previous work analysis of the 
frameshift mutation Y374X. In contrast to the other ALS-mutants, the cytosol/nuclei ratio for the 
Y374X mutant was comparable to the wild-type protein. These results suggested that enhanced 
cytoplasmic translocation might not be a general mechanism by which mutations in TDP-43 
stimulate toxicity. These findings further corroborated the observation that mutations in TDP-43 
are mechanistically divergent (McDonald 2011).
Additional evidence for biochemical fractionation experiments was provided by confocal 
microscopy analyses. In particular, colocalisation of endogenous and overexpressed Flag-tagged 
TDP-43 proteins was investigated to visualise whether TDP-43 distribution was altered by 
pathogenic mutations in its sequence. HEK293 cells were transiently transfected with the empty 
vector or WT- or A315T- or R361S- or Y374X-Flag-TDP-43 after silencing the endogenous protein. 
Cells were sequentially detected with a polyclonal anti-TDP-43 (left panels) and a monoclonal 
anti-Flag-tag (central panels) specific antibody (Figure 4.9), with overlays showing nuclei stained 
using Hoechst (right panels, merge). Under these conditions, double labelling allowed to evaluate
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the knockdown of endogenous TDP-43 and to compare the localisation of the total protein 
(endogenous and exogenous, as revealed by the TDP-43 antibody) with the signal relative only to 
the exogenous one (detected with the anti-Flag-tag antibody) in the same image. All Flag-TDP-43 
proteins remained largely in the nucleus of transfected cells, consistent with previous reports 
(Voigt 2010). However, the dual staining revealed that ALS-mutant TDP-43, and in particular the 
C-terminally truncated Y374X mutant protein, localised to distinct nuclear puncta. This is in 
accordance with a decreased TDP-43 mobility reported upon removal o f the C-terminal region 
(Ayala 2008).
Thus, the IF experiments did not show any striking variation in Flag-TDP-43 distribution among the 
different mutants. Biochemical fractionation resulted a more sensitive method to detect 
differences in protein subcellular distribution, especially in the cytoplasm, where TDP-43 
expression is particularly low, compared to the nucleus.
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Figure 4.9 Flag-TDP-43 ALS-mutants localisation in HEK293 cells.
HEK293 cells were transiently co-transfected with siRNAscramble and the empty vector (VEC) or 
siRNATDP"43 and the empty vector or WT- or A315T- or R361S- or Y374X-Flag-TDP-43 (bar: 15pm). 
Cells were immunostained with polyclonal anti-TDP-43 antibody followed by Alexa®647 (red)- 
conjugated antibody (left panels) and with monoclonal anti-Flag-tag antibody followed by Alexa®488 
(green)-conjugated antibody (central panels). Nuclei were detected using Hoechst staining (blue). 
Colocalisation of the proteins was evidenced with areas of yellow in overlays of red and green and 
blue images (right panel). Representative immunofluorescence images were chosen for display.
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4.3.4 Cell viability evaluation after overexpression 
ofTDP-43ALS-mutants
It was then of interest to examine whether transfection with the Flag-TDP-43 ALS-mutants was 
associated with increased cellular toxicity, as determined by MTT assay. HEK293 cells were 
transiently transfected with plasmids encoding wild-type, A315T-, R361S-, Y374X-TDP-43 or with 
an empty vector (VEC) as a control, and then analysed after 48 hours. This experiment was 
repeated several times confirming that the overexpression of the wild-type protein was sufficient 
to induce cell death in this cellular model. This observation was consistent with data previously 
obtained (Results section 4.1.3). Furthermore, under these conditions, a significant increase in cell 
death was induced also by the overexpression of TDP-43 ALS-mutants (Figure 4.10). Nevertheless, 
the results of this assay failed to detect any significant alteration in MTT conversion in the 
presence of ALS-TDP-43 constructs with respect to the wild-type protein, consistent with previous 
reports in primary rat cortical neurons (Barmada 2010).
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Figure 4.10 Flag-TDP-43 ALS-mutants overexpression reduced cell v iability in HEK293 
cells.
HEK293 cells were transiently transfected with the empty vector (VEC) or the vector cloned with WT- 
or A315T- or R361S- or Y374X-Flag-TDP43. Cell viability was assessed by MTT assay 48h after 
transfection. Values are the mean ± S.E.M. (n>4) and are expressed as percentages of control cells 
(empty vector). Asterisks indicate values significantly different from control (*=p<0.001), as assessed 
by Student's t-test.
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The same experiment was also performed in cells previously silenced for endogenous TDP-43 and 
then transfected with the different Flag-TDP-43 constructs. Also in this case the expression of the 
newly generated TDP-43 mutated proteins (A315T, R361S, Y374X) significantly altered cell survival 
in respect to control cells transfected with the empty vector or silenced using a scrambled siRNA. 
The effect observed was comparable to the toxicity induced by the overexpression of the wild- 
type protein.
Thus, three different mutations in TDP-43, all of which are associated with the development of 
ALS, caused substantial toxicity in vitro. These results suggest that Flag-TDP-43 overexpression, 
both wild-type or ALS-mutants, exhibited toxicity that led to cell death regardless of the amount 
of protein in the cytoplasm. Despite the simplicity of the system, the expression of Flag-TDP-43 
proteins in HEK293 cells recapitulated key features of TDP-43 patho/physiology, including nuclear 
localisation of the wild-type protein, mislocalisation of point mutants to the cytoplasm and 
cytotoxicity.
4.3.5 TDP-43 ALS-mutants impaired binding with 
CypA andhnRNPA2/B1 
Attention was then concentrated on molecular changes, such as protein-protein interactions, 
which may account for the toxicity of TDP-43 ALS-mutants. In fact, pathogenic mutations are 
located in the putative protein-protein interaction domain of TDP-43, so they could contribute to 
the increased proportion of cytoplasmic TDP-43 by enhancing its association with cytoplasmic 
binding partners, which would impair its nuclear import, and facilitate its nuclear export, or by 
disrupting its affinity for nuclear binding partners.
In particular, in HEK293 cells the effect of three ALS-patient derived mutations on the interaction 
with CypA and hnRNP A2/B1 was investigated. Co-IP experiments were performed in cells silenced 
for endogenous TDP-43 and transiently transfected with Flag-tagged TDP-43 constructs. TDP-43 
knockdown efficiency and a comparable expression of the transfected wild-type and mutant
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proteins were assessed by WB for TDP-43 on the input fraction (Figure 4.11A, lower panel). All 
Flag-TDP-43 ALS-mutants analysed showed differences in the ability o f binding CypA compared to 
the wild-type protein (Figure 4.11A, upper panel). In particular, both monoclonal and polyclonal 
anti-CypA antibodies were not able to immunoprecipitate mutant TDP-43 as much as the wild- 
type protein, indicating that CypA is not able to efficiently interact with TDP-43 when it is 
mutated. In particular, the Y374X mutation, that leads to the expression o f a C-terminally 
truncated form of the protein lacking the last 41 amino acids, is the one that most severely 
affected the interaction, while the A315T mutation seemed to have a very mild, or nearly no 
effect on the interaction (Figure 4.11B). This last result is consistent with recent reports 
(Freibaum 2010), where the A315T and M337V disease-causing mutations were demonstrated 
not to grossly alter the function of TDP-43 or its binding partners. Interestingly, the R361S 
mutation, that is located within the minimal hnRNP A2 interaction domain o f TDP-43 (D'Ambrogio 
2009; Budini 2012), decreased CypA/TDP-43 interaction, as well as CypA/hnRNP A2/B1 binding 
(data not shown), that it is a loss-of-function mutation with respect to this hnRNP complex 
formation. In these samples CypA was selectively immunoprecipitated with comparable levels
t
(Figure 4.11C).
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Figure 4.11 CypA binding w ith  Flag-TDP-43 ALS-mutants is impaired.
HEK293 cells were transiently co-transfected with siRNAscramble and an empty vector (VEC) or with 
siRNATDP'43 and an empty vector (VEC) or WT- or A315T- or R361S- or Y374X-Flag-TDP-43. CypA was
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immunoprecipitated from whole cell lysates using a monoclonal anti-CypA antibody. Aliquot of the 
lysates (INPUT) and of the immunoprecipitate (IP) fractions were separated by SDS-PAGE, 
transferred to PVDF membranes, and reversibly stained with Red Ponceau, as a loading control. (A) 
TDP-43 proteins potentially associated with CypA were detected by WB using a polyclonal anti-TDP- 
43 antibody (upper panel, IP fraction), while expression of the endogenous and exogenous tagged 
proteins was verified in the Input fraction (lower panel). Shown is a representative of several 
independent experiments with similar results, indicating that TDP-43 ALS-mutants display an altered 
capability of binding CypA compared to the WT protein. (B) Histograms represent the quantitative 
analysis of TDP-43 band densities in the IP fraction, normalized on the actual amount of Flag-TDP-43 
overexpressed, detected in the Input fraction. Data (mean ± S.E.M., n=10) are expressed as 
percentages of control cells (WT). Symbols indicate values significantly different from controls 
(*=p<0.01 vs. WT; #= <0.05 vs. A315T; §=p<0.01 vs. R361S), as assessed by One-way ANOVA followed 
by Newman-Keuls Multiple Comparison Test. (C) CypA was specifically immunoprecipitated with the 
same yield in each experimental condition, as detected using a polyclonal antibody against CypA.
To evaluate whether TDP-43 mutations may effectively affect its binding with hnRNP A2/B1, Flag- 
TDP-43 ALS-mutants were tested by co-IP. In particular, HEK293 cells were transiently transfected 
with the empty vector or WT- or A315T- or R361S- or Y374X-Flag-TDP-43 after knockdown of the 
endogenous protein. TDP-43 efficient silencing and equal expression levels of the transfected 
Flag-tagged proteins were assessed by WB for TDP-43 on the input fraction (Figure 4.12A, lower 
panel). Whole protein lysates were co-IP with the anti-hnRNP A2/B1 antibody and hnRNP A2/B1 
was specifically immunoprecipitated with comparable levels in all samples (Figure 4.12C). While 
only small differences or high variability in the interaction with TDP-43 were detected in cells 
expressing respectively the A315T and Y374X mutations, the association between TDP-43 and 
hnRNP A2/B1 was significantly decreased in R361S-TDP-43 cells (Figure 4.12A-B) compared to the 
wild-type sample. This result was similar to that observed in the same experiment with siRNATDP'43 
and thus confirmed that the R361S is a loss-of-function mutation with regards to hnRNP A2/B1 
binding. Also in these samples the R361S-TDP-43 mutant showed a decreased interaction 
between CypA and hnRNP A2/B1 (data not shown). These observations were in accordance with 
the results previously described. Therefore, the R361S mutation could contribute to toxicity
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enhancing TDP-43 mislocalisation, by disrupting its affinity for nuclear binding partners, as 
suggested by co-IP experiments with CypA or hnRNP A2/B1.
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Figure 4.12 hnRNP A2/B1 binding w ith  R361S-TDP-43 ALS-mutant is impaired.
HEK293 cells were transiently co-transfected with siRNAscramble and an empty vector (VEC) or with 
siRNATDP'43 and an empty vector (VEC) or WT- or A315T- or R361S- or Y374X-Flag-TDP-43. hnRNP 
A2/B1 was immunoprecipitated from whole cell lysates using a monoclonal anti-hnRNP A2/B1 
antibody. Aliquot of the lysates (INPUT) and of the immunoprecipitate (IP) fractions were separated 
by SDS-PAGE, transferred to PVDF membranes, and reversibly stained with Red Ponceau, as a 
loading control. (A) TDP-43 proteins potentially associated with hnRNP A2/B1 were detected by WB 
using a polyclonal anti-TDP-43 antibody (upper panel, IP fraction), while expression of the 
endogenous and exogenous tagged proteins was verified in the Input fraction (lower panel). Shown 
is a representative of two independent experiments with similar results, indicating that the R361S- 
TDP-43 ALS-mutant shows an altered capability of binding hnRNP A2/B1 compared to the WT 
protein. (B) Histograms represent the quantitative analysis of TDP-43 band densities in the IP 
fraction, normalized on the actual amount of Flag-TDP-43 overexpressed, detected in the Input 
fraction. Data (mean ± S.E.M.) are expressed as percentages of control cells (WT). Asterisk indicates 
values significantly different from controls (*=p<0.05 vs. WT), as assessed by One-way ANOVA 
followed by Newman-Keuls Multiple Comparison Test. (C) hnRNP A2/B1 was IP with a comparable 
yield.
The effect of disease-associated TDP-43 mutations on the association with CypA was then 
analysed by confocal immunofluorescence. Endogenous CypA (red) localisation was visualised 
simultaneously with Flag-tagged TDP-43 (green) staining in cells transiently transfected with WT-
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or A315T- or R361S- or Y374X-Flag-TDP-43 (Figure 4.13). Wild-type and mutant TDP-43 proteins 
were mainly located in the nucleus, as previously observed (Figure 4.9). Colocalisation o f CypA 
and TDP-43 was clearly nuclear in w ild-type cells efficiently expressing Flag-tagged TDP-43, as 
already described in Results section 2.3. In accordance w ith co-IP experiments, CypA and Flag- 
TDP-43 co-labelling evidenced areas o f overlap (yellow) in the nuclei o f A315T-TDP-43 ALS- 
mutants expressing cells, while only rare co-localisation events were visualised in R361S- or 
Y374X-TDP-43 cells (Figure 4.13). Thus, also dual staining by IF revealed that some pathogenic 
mutations in TDP-43 sequence could impair its binding w ith CypA. In particular, this feature was 
observed when the R361S or the C-terminally truncated Y374X m utant proteins, whose staining 
profile did not fu lly correspond to  endogenous TDP-43 localisation pattern, were expressed.
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Figure 4.13 CypA co-iocalisation w ith Flag-TDP-43 ALS-mutants in HEK293 cells.
HEK293 cells were transiently transfected with WT- or A315T- or R361S- or Y374X-Flag-TDP-43 
(bar:15pm). Cells were immunostained with polyclonal anti-CypA antibody followed by Alexa®647 
(red)-conjugated antibody (left panels) or with monoclonal anti-Flag-tag antibody followed by 
Alexa®488 (green)-conjugated antibody (central panels). Nuclei were detected using Hoechst 
staining (blue). Colocalisation of the proteins was evidenced with areas of yellow in overlays of red
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and green (central panels) and blue images (right panels, merge). Representative 
immunofluorescence images were chosen for display.
Summarising, TDP-43 disease-associated mutants did not efficiently bind CypA as the wild-type 
protein. This feature was particularly relevant in the presence of the mutation thought to impair 
the binding with hnRNPs (R361S), and further enhanced by the mutant missing the last forty 
amino acids of the C-terminal domain (Y374X). These experiments indicated that in pathological 
conditions an aberrant interaction may occur between TDP-43 and CypA, thus altering hnRNP 
complex formation, involving also hnRNP A2/B1. The results obtained with TDP-43 ALS-mutants 
also suggested that the C-terminal region of TDP-43 is relevant for a correct binding with CypA.
4.3.6 TDP-43 ALS-mutants influence CypA and 
hnRNP A2/B1 subcellular distribution
On account of a reduced binding between CypA and TDP-43 disease-associated mutants> together 
with altered complex formation with hnRNP A2/B1, the effect of the three ALS-patient derived 
mutations was further investigated on the subcellular distribution and expression o f CypA and 
hnRNP A2/B1. To address this issue, HEK293 nuclei were separated from the cytoplasm of cells 
transiently transfected with the empty vector or WT- or A315T- or R361S- or Y374X-Flag-TDP-43 
and silenced for the endogenous protein, by biochemical fractionation. Each subcellular fraction 
was independently analysed by WB for CypA (Figure 4.14A) and hnRNP A2/B1 (Figure 4.14B).
No significant differences were detected for cytosolic or nuclear CypA in TDP-43 silenced samples 
transfected with VEC or WT-TDP-43 compared to scrambled siRNA treated cells. Interestingly, the 
quantification of CypA blots clearly indicated that, in the cytosolic fraction, signals corresponding 
to TDP-43 disease-associated mutants were comparable to wild-type cells, except fo r the R361S 
mutation, that caused a statistically significant up-regulation in CypA levels (Figure 4.14A, blue 
graph). Instead, in the nuclear compartment, CypA was significantly increased after the 
expression o f all TDP-43 ALS-mutants (Figure 4.14A, red graph). These variation in CypA nuclear
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and cytosolic expression, follow ing TDP-43 pathologic mutants transfection, were not observed in 
whole cellular lysates (data not shown). Nevertheless the trend described fo r CypA after 
biochemical observations could be also appreciated by confocal immunofluorescence in cells 
efficiently expressing TDP-43 Flag-tagged proteins (Figure 4.13). These data suggested that TDP- 
43 ALS-mutants did not substantially influence the global expression o f CypA, but they could 
differentially alter the subcellular distribution o f the protein.
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Figure 4.14 CypA and hnRNP A2/B1 subcellular distribution in cells expressing TDP-43 
ALS-mutants.
HEK293 cells were transiently co-transfected with siRNAscramble and an empty vector (VEC) or 
siRNATDP"43 and an empty vector (VEC) or WT- or A315T- or R361S- or Y374X-Flag-TDP-43. Equal
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amounts of cytosolic and the corresponding nuclear fractions were independently loaded, run on 
SDS-PAGE gels, transferred on PVDF membranes, stained with Red Ponceau as loading control, 
analysed by WB using the anti-CypA (A) or the anti-hnRNP A2/B1 (B) antibodies and detected by 
chemiluminescence. Histograms represent the quantitative analysis of CypA (A) or hnRNP A2/B1 (B) 
band densities in each compartment, normalized on the actual amount of proteins loaded, as 
detected by Red Ponceau staining. Data (mean ± S.E.M., n=4) in each subcellular fraction are 
proportioned to control cells (siRNAscramble + VEC), whose immunoreactivity (IR) value was set as one.
The cytosolic and the corresponding nuclear fractions are represented in blue and red, respectively. 
Asterisks indicate that samples are significantly different (*=p<0.05) compared to WT, as assessed by 
One-way analysis of variance followed by Bonferroni's Multiple Comparison Test.
In cells incubated with siRNATD[M3 together with VEC or WT-TDP-43 constructs, hnRNP A2/B1 
preserved its localisation pattern as in control cells, treated with a scrambled siRNA. However, in 
the cytosolic fraction, the level of hnRNP A2/B1 was significantly higher in ALS-mutant cells than 
in WT-TDP-43 cells (Figure 4.14B, blue graph). This increase could also be appreciated in whole 
cellular lysates o f R361S- and Y374X-TDP-43 expressing cells (data not shown). In the nuclear 
fraction no differences were detectable between wild-type and TDP-43 mutant cells (Figure 
4.14B, red graph). Together these results indicated that TDP-43 associated mutations could 
modify hnRNP A2/B1 relative expression and distribution in the cytoplasm of HEK293 cells.
Under basal condition CypA is predominantly localised in the cytoplasm, whereas hnRNP A2/B1 is
almost exclusively localised in the nucleus. TDP-43 down-regulation did not significantly influence
the stoichiometry of the other hnRNP complex protein components analysed, CypA and hnRNP
A2/B1. Instead, a shift in the subcellular localisation o f both CypA and hnRNP A2/B1, whose levels
were increased respectively in the nuclear and in the cytosolic fractions, was detected in all TDP-
43 ALS-mutants analysed. Furthermore, TDP-43 disease-causing mutations could alter the binding
with CypA and hnRNP A2/B1. In particular, at least one TDP-43 ALS-causing mutation severely
impacted on this hnRNP complex formation and on both CypA and hnRNP A2/B1 levels. In fact, in
cells expressing the R361S-TDP-43 mutant CypA was increased not only in the nucleus, but,
together with hnRNP A2/B1, an up-regulation of the cytosolic protein was also observed. Notably,
these cells not only showed a decreased ability o f interaction between CypA and TDP-43, but also
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among TDP-43 and hnRNP A2/B1, and CypA and hnRNP A2/B1. Thus, in this case a correct hnRNP 
complex assembly and trafficking was impaired not only by CypA/TDP-43 altered binding, but also 
by TDP-43/hnRNP A2/B1 loss o f interaction due to the presence of the R361S mutation within the 
minimal hnRNP A2 binding domain o f TDP-43 (D'Ambrogio 2009; Budini 2012).
Taking these experiments together, it is possible to hypothesise that the effects of the three ALS- 
patient derived mutations on the interaction with CypA and hnRNP A2/B1 and their subcellular 
localisation in HEK293 cells are linked. In fact, alterations of the CypA/TDP-43 interaction, 
detected when TDP-43 is mutated, could have important implications for hnRNP complex 
formation and maintenance, and in TDP-43 cytoplasmic mislocalisation, which is considered a 
hallmark of TDP-43 proteinopathies. Thus, the changes observed in CypA and hnRNP A2/B1 
subcellular distribution could represent a compensatory mechanism to restore the hnRNP 
complex.
Interestingly, CypA was reported to play an important regulatory role in the trafficking of hnRNP 
A2, since they formed a complex, which underwent nuclear export in response to chemokine 
stimuli (Pan 2008). In association with a reduced binding between CypA and TDP-43 mutants, we 
detected a shift in the subcellular localisation of both TDP-43 mutants and hnRNP A2/B1, that 
increased in the cytosolic fractions. These results indicated that CypA could be required for the 
correct localisation or redistribution of the members of this hnRNP complex. However, further 
analyses are needed to define the effects mediated by CypA on intracellular wild-type and ALS- 
mutant TDP-43 trafficking and function.
4.3.7 TDP-43 ALS-mutants cannot rescue HDAC6 
protein expression level in HEK293 cells 
Given these observations, the functional effect of TDP-43 clinical mutations were assessed on one 
well characterised mRNA target of TDP-43: HDAC6. In fact, in this study, the CypA/TDP-43 hnRNP 
complex involvement was already established in HDAC6 expression regulation (Results section
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3.2.3). To further address this issue, HEK293 cells were silenced for endogenous TDP-43 targeting 
its 3'-UTR, thus allowing the efficient retransfection with Flag-TDP-43 cDNA. HDAC6 protein level 
was detected by WB analysis. As previously observed, HDAC6 protein expression was significantly 
downregulated on TDP-43 knockdown (Figure 4.15). Decreased HDAC6 protein levels could be 
restored to normal levels after retransfection of silenced cells with WT-TDP-43 cDNA, replicating 
the work by Fiesel and coworkers. The A315T- and R361S-TDP-43 pathogenic point mutants were 
able to restore HDAC6 protein levels with a slightly reduced capacity compared to the wild-type 
protein, similar to as described for HDAC6 mRNA levels (Fiesel 2009). In contrast, the Y374X-TDP- 
43 mutant failed to restore HDAC6 levels, consistent with a previous report on a truncated form 
of TDP-43 lacking the C-terminal glycin-rich domain (Fiesel 2009).
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Figure 4.15 ALS-TDP-43 mutants-mediated HDAC6 expression regulation.
HEK293 cells were transiently co-transfected with siRNAscramble (scr) and an empty vector (VEC) or 
siRNATDFM3 and an empty vector (VEC) or WT- or A315T- or R361S- or Y374X-Flag-TDP-43. 15 pg of 
total protein lysates were loaded, run on SDS-PAGE gels/transferred on PVDF membranes, stained 
with Red Ponceau as loading control, analysed by WB for HDAC6 and detected by 
chemiluminescence. Histograms represent the quantitative analysis of HDAC6 band densities, 
normalized to the actual amount of proteins loaded, as detected by Red Ponceau staining. Data 
(mean ± S.E., n=4) are expressed as percentage of the immunoreactivity (IR) values. Symbols indicate 
values significantly different from controls (*=p<0.05 vs. siRNAscramble; H= <0.05 vs. siRNATDP'43 + VEC; 
§=p<0.05 vs. WT), as assessed by One-way ANOVA followed by Bonferroni's Multiple Comparison 
Test, or (#=p<0.05 vs. WT) as assessed by Student's t-test.
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Nuclear localisation o f TDP-43 as well as its nucleic acid and protein-binding capacities are 
important determinants of HDAC6 regulation (Fiesel 2009). These features were severely 
impaired by the ALS-mutations described in this work, and significantly impacted on a well 
established function of TDP-43. Correct protein-protein interaction between hnRNPs, such as TDP- 
43 and hnRNP A2/B1, as well as their efficient association with molecular chaperones, like CypA, 
may thus contribute to RNA-protein complex formation along with direct RNA-protein interaction 
between hnRNPs and mRNAs (Kim 2000).
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5. SODl-associated disease
A novel protein interaction between CypA and TDP-43 was described, demonstrating the 
importance of CypA for TDP-43/hnRNP A2/B1 complex formation, maintenance and function in 
normal or TDP-43-related disease conditions. These findings opened up interesting new avenues 
for investigating CypA functions in other biological processes and contexts. Indeed, previous 
studies in our laboratory have demonstrated that CypA was altered both in sporadic ALS patients 
and in in vivo animal models carrying SOD1 mutation (Basso 2009; Nardo 2011), already at a pre- 
symptomatic stage of the disease (Massignan 2007). This left open the possibility that CypA could 
have a relevant role in ALS pathogenesis and that this hnRNP complex could be also directly or 
indirectly involved in TDP-43-independent cases of ALS pathology. To investigate this option, CypA 
functions were explored in pathological conditions associated with SOD1.
5.1 CypA interacts with ALS-mutant SOD1
Recently, the proteomic study of the Triton-insoluble proteins extracted from the spinal cord of 
fALS mice demonstrated that CypA is recovered, together with G93A-SOD1, as insoluble material 
in protein aggregates. This feature was not observed in wild-type mice, thus CypA co-aggregated 
specifically with ALS-mutant SOD1. Interestingly, CypA was present also in the aggregates from 
post-mortem spinal cord tissues of sporadic ALS patients (Basso 2009). Therefore, the hypothesis 
that CypA and SOD1 could specifically interact was tested. Indeed, mutant SOD1 is known to 
cause motor neuron degeneration by toxic gain-of-function(s). Thus, the toxic properties of 
mutant SOD1 may be exerted, at least in part, through aberrant interactions with other proteins.
5.1.1 In vitro interaction using endogenous 
proteins
To determine whether CypA could interact with SOD1 and if this association could have any 
functional role, a co-immunoprecipitation approach was adopted. First this interaction was
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studied in vitro, analysing HEK293 cell lines stably expressing WT-S0D1 or G93A-SOD1. CypA was 
immunoprecipitated in whole cellular lysates and the antibody anti-SODl was used to evaluate its 
presence in CypA co-IP fraction. Interestingly, SOD1 was recovered mainly in the IP fraction from 
mutant SOD1 cells (Figure 5.1A), suggesting that CypA has a preferential affinity for G93A-SOD1. 
The association of CypA with ALS-mutant SOD1 was specific, as determined by several positive 
and negative controls. In particular, different starting IP solutions were used as experimental 
controls, as previously described in Results section 2.2.1.1, obtaining analogous results.
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Figure 5.1 CypA preferentially interacts w ith mutant SOD1 in vitro.
Equal amounts of proteins (500pg) were co-precipitated with the primary antibody. Aliquots of the 
cell lysates (INPUT), of the immunoprecipitates (IP) and of the proteins from the remaining fraction 
(OUTPUT) were loaded together with three different IP controls and their relative output fractions 
(POST), and subjected to SDS-PAGE. Proteins were transferred to PVDF membranes, reversibly
262
stained with Red Ponceau as loading control, probed with specific antibodies and the signal was 
detected by chemiluminescence. (A) Lysates from HEK293 cells stably expressing WT-SOD1 or G93A- 
SOD1 were blotted for SOD1 after CypA immunoprecipitation. (B) Wild-type and mutant cells were 
blotted for CypA after SOD1 immunoprecipitation. (C) HEK293 cells were transiently transfected with 
WT- or G37R- or I113T-SOD1 plasmids. Cellular lysates, together with coated beads as IP control, 
were immunoprecipitated using an anti-CypA antibody and potentially associated SOD1 was 
detected by WB. Representative of several independent experiments with similar results are shown, 
indicating CypA preferential interaction for ALS-mutant SOD1.
Moreover, to confirm the specificity of this binding, CypA co-IP assay was performed using 
different commercially available polyclonal and monoclonal antibodies. These preliminary 
experiments revealed that CypA interacted preferentially with G93A-SOD1 in mammalian cells.
To further verify the interaction between CypA and G93A-SOD1 the same co-IP experiment was 
repeated in HEK293 cells expressing WT-SOD1 or G93A-SOD1 reversing the primary antibodies 
previously used (Figure 5.1B). In particular, the immunoprecipitation by the anti-SODl antibody, 
was followed by the WB for CypA, providing additional evidence that the two proteins interacted 
preferentially in mutant cells.
5.1.2 In vitro interaction using transiently- 
transfected SOD 1 ALS-mutants
In order to evaluate if mutSODl/CypA gain-of-interaction was specific for the G93A mutation or it
was a common feature of ALS-associated mutant SOD1, the co-IP analysis of two more hSODl
ALS-mutants was performed. In particular, plasmids carrying hSODl cDNA wild-type or w ith the
G37R or I113T mutations (kindly provided by Dr. Grierson, University o f Sheffield, UK), both of
which give rise to an ALS phenotype in vivo, were used for these experiments. HEK293 cells were
transiently transfected with the three constructs. First, an efficient transfection method was
optimized to produce the exogenous proteins with good and similar levels, as shown by the WB
for SOD1 in the input fraction (Figure 5.1C). Then, the antibody anti-CypA was used to co-IP and
co-precipitated SOD1 was detected by WB. Coated magnetic beads (CTR) were used as negative
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experimental control. This experiment was repeated several times with the common effect of 
both mutant proteins to preferentially interact with CypA. Thus, the interaction of mutant SOD1 
with CypA was not limited to the G93A ALS-mutant. Indeed, both G37R- and, to a greater extent, 
I113T-SOD1 mutants were co-IP by anti-CypA antibodies when overexpressed in HEK293 cells. 
These mutations, like the G93A, can accelerate SOD1 unfolding kinetics compared to the wild- 
type protein (Ip 2011), suggesting a prominent role for protein misfolding in this protein-protein 
interaction.
5.1.3 In vivo interaction validation
To confirm the novel interaction observed in vitro between ALS-mutant SOD1 and CypA, 
validation experiments were performed in vivo. Indeed, the tissue mostly affected in ALS was 
analysed in mouse models o f the disease. Protein extracts of lumbar spinal cord (containing the 
motor neurons innervating the lower limbs) from symptomatic double transgenic mice over­
expressing ALS-mutant hSODl and expressing (G93A-SODl/CypA+/+) or knock-out (G93A- 
SODl/CypA-/-) for CypA, and age and sex-matched control mice over-expressing wild-type hSODl 
(WT-SODl/CypA+/+) were used in co-IP assays. In particular, CypA knockout mice were used as 
negative experimental controls. An anti-CypA antibody was used to immunoprecipitate and the 
following WB for SOD1 clearly detected the protein in the co-IP fraction, only in mutant SOD1 
mice expressing CypA (G93A-SODl/CypA+/+), and neither in wild-type SOD1 mice nor in CypA 
knockout mice (Figure 5.2A). As in in vitro experiments, failure to detect complexes of CypA and 
wild-type SOD1, was not due to lack of protein expression (Input fraction). Thus, CypA was 
confirmed as a novel mutant-SODl interacting protein, validating previous results in vivo and 
demonstrating the specificity of these findings.
To further evaluate if this gain o f interaction was specifically linked to ALS, the previous 
experiment was repeated splitting the lumbar spinal cord tract into the dorsal (DH) and the 
ventral (VH) horn, that is the motor neuron-enriched portion. CypA preferential interaction for
G93A-SOD1, in respect to WT-SOD1, was confirmed and it was clearly detected mainly in the 
ventral horn, where motor neurons are located (Figure 5.2B).
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Figure 5.2 CypA preferentially interacts w ith mSODl in vivo.
. (A) Lumbar SpC of WT-SODl/CypA+/+ (n=3), G93A-SODl/CypA+/+ (n=3) and G93A-SODl/CypA-/- 
(n=3) mice were analysed. (B) Lumbar SpC of WT-SOD1 (n=3) and G93A-SOD1 (n=3) mice split into 
dorsal (DH) and ventral (VH) horn sections were analysed. Equal amounts of proteins (lmg) from 
tissue homogenates were co-precipitated with anti-CypA primary antibody. Aliquots of the tissue 
homogenates (INPUT) and of the immunoprecipitates (IP) were loaded together, subjected to SDS- 
PAGE, transferred to PVDF membranes, reversibly stained with Red Ponceau as loading control, 
probed with anti-SODl antibody and detected by chemiluminescence. Representative experiments 
with consistent results are shown, indicating that interaction between CypA and ALS-mutant G93A- 
SOD1 was confirmed in vivo.
Collectively, these data demonstrated that ALS-mutant SOD1 co-immunoprecipitated with CypA, 
confirmed the specificity of the novel interaction described, and also its relevance in ALS disease- 
related animal tissues.
5.2 CypA absence alters G93A-SOD1 solubility
In order to understand if this gain of interaction could have a role in ALS pathogenesis, detergent- 
insoluble proteins were analyzed as a model o f protein aggregates. In fact, proteinaceous 
inclusions rich in mutant SOD1 have been found in tissues from fALS patients, mutant SOD1
A
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animals and cellular models (Wood 2003; Basso 2006 and 2009). The propensity of mutant SOD1 
to aggregate is one of the most sustained hypotheses to explain the toxicity of this enzyme.
In particular, Triton X-100-insoluble proteins (TIF) were extracted from ventral horn lumbar spinal 
cords o f G93A-SOD1 mice, expressing (G93A-SODl/CypA+/+)/ with a deficient expression (G93A- 
SODl/CypA+/-) or not expressing (G93A-SODl/CypA-/-) CypA, just prior to the expected onset of 
clinical symptoms. Potentially aggregating proteins were indeed enriched in detergent-insoluble 
fractions and separated from soluble proteins. The same amount o f TIF and the corresponding 
soluble samples were independently analysed by WB for SOD1. The relative quantification of 
SOD1 blots revealed that an increasing amount of insoluble mutant SOD1 was recovered when 
CypA was reduced or totally deficient (Figure 5.3A), while no differences were observed in the 
soluble fraction (Figure 5.3B).
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Figure 5.3 CypA absence increases mutant SOD1 in the insoluble but not in the soluble 
fractions.
Immunoblot analysis of TIF from ventral horn lumbar spinal cord tissues of G93A-SODl/CypA+/+ 
(n=3), G93A-SODl/CypA+/- (n=3) and G93A-SODl/CypA-/- (n=3) mice. Aliquots of TIF (A) or Soluble 
(B) proteins were analysed independently by dot (3pg) blotting for SOD1 and detected by 
chemiluminescence. Histograms represent the immunoreactivity normalised to the actual amount of 
protein loaded, detected after Red Ponceau staining. Data (mean ± S.E.M., n=3) are expressed as 
relative immunoreactivity values. Asterisks indicate values significantly different from controls 
(*=p<0.05 vs. G93A-SODl/CypA+/+), as assessed by One-way Anova followed by Neuman-Keuls 
multiple comparison test.
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These results demonstrated that depletion of CypA resulted in more mutant SOD1 aggregates 
formation. Thus, it is possible to speculate that in ALS-mutant SOD1 motor neurons, where the 
interaction between CypA and mutant SOD1, as well as their presence in the detergent-insoluble 
fraction have been described, CypA could act as a chaperone.
In order to describe which are the most relevant features of the TX-insoluble fraction when CypA 
is depleted in fALS mice, in addition to SOD1, some insoluble/aggregate components previously 
characterised (Basso 2009) in TIF spinal cord o f G93A-SOD1 mice were analysed. WB analysis for 
Ubiquitin confirmed that insoluble ubiquitinated proteins were isolated from the spinal cords of 
fALS mice (Figure 5.4A). Also CypA was significantly enriched in TIF of G93A-SOD1 mice, 
replicating a previous study performed in our laboratory (Basso 2009) on the G93A-SOD1 mouse 
model and on ALS patients (Figure 5.4B). Therefore TIF was confirmed to have the biochemical 
features of ALS protein inclusions. Furthermore, TIFs recovered from CypA+/- mice were 
significantly enriched in ubiquitinated proteins and the same trend was observed in knockout 
mice (Figure 5.4A). Moreover, protein carbonyl content, a marker of protein oxidation (Castegna 
2002), was significantly enriched in TIFs from CypA depleted mice (Figure 5.4C). In addition to 
oxidative damage to proteins, nitration o f actin, but not total protein 3-nitro-tyrosine levels, was 
increased in spinal cords of CypA depleted G93A-SOD1 mice (Figure 5.4D-E). The expression of 
individual chaperone proteins in the soluble fraction of mutant SOD1 mice, both HSC70 (Figure 
5.4G) and HSP90 (Figure 5.41), was not modified by CypA depletion. Nevertheless, HSC70 (Figure 
5.4F), but not HSP90 (Figure 5.4H), was specifically increased in the detergent-insoluble fraction in 
association with CypA absence.
Summarizing, knockout animals being deficient in CypA chaperoning activity, formed more 
aggregates of mutant SOD1 and irreversibly damaged proteins (ubiquitinated and aberrantly 
oxidized), possibly sequestering other protein components essential for motor neuronal function, 
such as HSC70. In fALS mice CypA, together with other chaperones, could form complexes with 
mutant misfolded SOD1 and thus could contribute to protect cells from mutant SOD1 toxicity by
direct interaction, preventing aggregation and facilitating degradation of damaged protein.
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Figure 5.4 Protein composition of TIF in G93A-SODl/CypA double transgenic mice 
samples.
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Immunoblot analyses of TIF from ventral horn lumbar spinal cord tissues of age-matched non- 
transgenic/CypA+/+ (N+/+), G93A-SODl/CypA+/+ (G+/+), G93A-SODl/CypA+/- (G+/-) and G93A- 
SODl/CypA-/- (G-/-) mice at disease onset. The level of Ubiquitin (A), CypA (B), HSC70 (F) and HSP90 
(H) were measured in TIF. Carbonylated proteins (C), 3-Nitro-tyrosine (D), nitrated Actin (E), HSC70 
(G) and FISP90 (I) were analysed in the Soluble (SOL) fraction. Aliquot of TIF or Soluble proteins were 
analysed independently by Western (15|ig) or dot blotting (3pg), probed with the specific antibodies 
and detected by chemiluminescence. Flistograms represent the immunoreactivity normalised to the 
actual amount of protein loaded, detected after Red Ponceau staining. Data (mean ± S.E.M., n=3) are 
expressed as percentages of control samples. Symbols indicate values significantly different from 
controls (*=p<0.05 vs. G93A-SODl/CypA+/+) as assessed by One-way ANOVA followed by Neuman- 
Keuls multiple comparison test, or (H=p<0.05 vs. Ntg/CypA+/+) as assessed by t test.
5.3 Mutant SOD 1 alters CypA/ TDP-43 interaction
At the same time, mutant SOD1 interaction with CypA could exert a negative effect. In fact, the 
binding of CypA to mutant forms of a protein abundant in motor neurons, such as SOD1, could 
make it unavailable for other intracellular functions. For example, mutant SOD1 association with 
CypA could have the effect of decreasing its availability for interactions with other proteins, like 
TDP-43.
5.3.1 In vitro evidence: G93A-SOD1 HEK293 cells
To investigate this possibility, CypA/TDP-43 interaction was evaluated in HEK293 cells stably 
expressing WT-SOD1 or G93A-SOD1. WB for TDP-43, and its relative quantification, showed that 
the anti-CypA antibody was not able to co-immunoprecipitate TDP-43 in G93A-SOD1 cells as much 
as in wild-type cells (Figure 5.5A-B). In association with a reduced binding, we detected an 
abnormal subcellular localisation of both CypA (Figure 1.6) and TDP-43 (Figure 5.5C), that 
increased in the cytosolic fractions.
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Figure 5.5 CypA/TDP-43 binding is altered in HEK293 stably expressing m utant SOD1.
(A) Equal amounts of proteins (500|ig) from HEK293 cells stably expressing WT-SOD1 or G93A-SOD1, 
together with coated beads as IP control (CTR), were immunoprecipitated using an anti-CypA 
antibody. Aliquots of the cell lysates (INPUT), of the immunoprecipitates (IP) and of the proteins 
from the remaining fraction (OUTPUT) were loaded, subjected to SDS-PAGE, transferred to PVDF 
membranes, reversibly stained with Red Ponceau as loading control, probed for TDP-43 and 
detected by chemiluminescence. (B) Histograms represent the quantitative analysis of TDP-43 band 
densities in the IP fraction, normalized on the actual amount of proteins immunoprecipitated, as 
detected by Red Ponceau staining. (C) Equal amounts of cytosolic and the corresponding nuclear 
fractions from HEK293 cells stably expressing WT-SOD1 or G93A-SOD1 were independently analysed 
for TDP-43 by WB. Histograms represent the quantitative analysis of TDP-43 band densities in each 
compartment, normalized on the actual amount of proteins loaded, as detected by Red Ponceau 
staining. Data (mean ± S.E.M., n=3) are expressed as percentages of control cells (WT). Asterisk 
indicates values significantly different from controls (*=p<0.05 vs. WT), as assessed by Student's t- 
test.
These results suggested that alterations of the CypA/TDP-43 interaction, as well as their 
cytoplasmic mislocalisation, could be detected in presence of mutant SOD1. These events could 
have important implications in hnRNP complex formation and stability, as well as in TDP-43- 
related functions. In particular, these effects could be particularly detrimental in the context of a 
diseased tissue, like lumbar spinal cord in ALS.
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5.3.2 In vivo evidence: G93A-S0Dl/CypA knockout 
double transgenic mice 
The impaired binding between CypA and TDP-43 significantly increased TDP-43 insolubility in NTg 
mice knockout for CypA (Results section 3.3). To explore if their altered association could be 
detrimental in SODl-related pathological conditions, TDP-43 was analysed in TIFs from ventral 
horn spinal cord of G93A-SODl/CypA double transgenic mice at disease onset. Interestingly, TDP- 
43 was recovered in the detergent-insoluble fraction of mutant SOD1 mice, and higher amount of 
insoluble TDP-43 was accumulated when CypA was completely absent (Figure 5.6A), thus 
confirming previous results. While, no statistically significant differences were detected in the 
soluble fractions (Figure 5.6D). No differences were observed for hnRNP A2/B1 both in TIFs 
(Figure 5.6B) and in the soluble fractions (Figure 5.6E) of G93A-SOD1 animals. In the absence of 
CypA also in mutant SOD1 mice spinal cord there was a huge increase of aberrantly 
phosphorylated TDP-43 in the aggregates, compared to G93A-S0Dl/CypA+/+ animals (Figure 
5.6C).
TDP-43 deficiency, as it may occur in SODl-related fALS in association with CypA depletion, by 
cytosolic sequestration of this nuclear protein in insoluble complexes, may contribute to motor 
neuron disease through impaired TDP-43 functions. To rule out this possibility, HDAC6 protein 
levels were analysed by WB in the soluble fractions of double transgenic mice. Interestingly, 
ventral horn spinal cords from G93A-SODl/CypA knockout mice showed a significant reduction of 
HDAC6 protein expression (Figure 5.6F). Even though only indirectly disturbed in SODl-associated 
disease, early alterations in this pathway, that is decisive for neurite outgrowth (Fiesel 2011), may 
thus contribute to neurodegenerative events in ALS.
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Figure 5.6 Protein composition of TIF in G93A-SODl/CypA double transgenic mice 
samples.
Immunoblot analyses of TIF from ventral horn lumbar spinal cord tissues of age and sex-matched 
G93A-SOD 1/CypA+/+ (n=3), G93A-SODl/CypA+/- (n=3) and G93A-SODl/CypA-/- (n=3) mice at 
disease onset. The level of TDP-43 (A), hnRNP A2/B1 (B) and pS409/pS410-TDP-43 (C) were 
measured in TIF. TDP-43 (D), hnRNP A2/B1 (E), and HDAC6 (F) were also analysed in the Soluble 
fraction. Aliquot of TIF or soluble proteins were analysed independently by Western (15pg) or dot 
blotting (3pg), probed with the specific antibodies and detected by chemiluminescence. Histograms 
represent the immunoreactivity normalised to the actual amount of protein loaded, detected after 
Red Ponceau or Sypro® Ruby Protein Blot staining. Data (mean ± S.E.M., n=3) are expressed as 
percentages of control samples (G93A-SODl/CypA+/+)- Symbols indicate values significantly 
different from controls (*=p<0.05 vs. G93A-SODl/CypA+/+), as assessed by One-way Anova followed 
by Neuman-Keuls multiple comparison test.
Finally, in order to determine whether the results described at disease onset could represent a 
relevant mechanism for ALS pathogenesis and disease progression, TDP-43 was quantified in TIFs 
of G93A-SODl/CypA double transgenic mice at different stages of the disease. In particular, 
samples from ventral horn spinal cords were analysed just prior to the expected onset of clinical 
symptoms (14 weeks of age) and at a late symptomatic stage of the disease (20 weeks of age), 
and compared to sex and age-matched NTg mice expressing, with a reduced expression or 
knockout for CypA.
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Figure 5.7 CypA absence or reduction increase TDP-43 in TIF of ALS-mutant SOD1 mice 
samples and enhance its aberrant phosphorylation.
Immunoblot analyses of TIF from ventral horn lumbar spinal cord tissues of age and sex-matched 
G93A-SOD1 and NTg mice for three different CypA genotypes at disease onset and end stage. 
Histograms represent the immunoreactivity of TDP-43 (A) and pS409/pS410-TDP-43 (B) normalised 
to the actual amount of protein loaded, detected after Red Ponceau or Sypro® Ruby Protein Blot 
staining. Data (mean ± S.E.M., n=3) are expressed as percentages of control samples (NTg/CypA+/+) 
at the respective age. Symbols indicate values significantly different from controls (*=p<0.05 NTg vs. 
G93A-SOD1; #=p<0.05 vs. NTg/CypA+/+; H=p<0.05 vs. G93A-SODl/CypA+/+ onset; A=p<0.05 vs. 
G93A-SODl/CypA+/+ end stage; §=p<0.05 onset vs. end stage), as assessed by One-way Anova 
followed by Neuman-Keuls multiple comparison test.
The expression of mutant SOD1 was sufficient to enhance TDP-43 aggregation into pathological 
inclusions at disease onset compared to NTg mice, with a statistically significant increase at the 
end stage (Figure 5.7A). Nevertheless, both in NTg and in mutant SOD1 mice, TDP-43 was 
increasingly recovered in the insoluble fraction when CypA expression was reduced or completely 
absent. These results suggested that CypA protein level was inversely proportional to the amount 
of insoluble TDP-43 recovered. Furthermore, the accumulation of TDP-43 in TIFs of NTg/CypA 
knockout mice was comparable with mutant SODl/CypA+/+ mice at both disease stages, 
indicating that respectively CypA direct or indirect depletion could contribute to TDP-43 
detergent-insolubility.
A pattern similar to TDP-43 was observed with the antibody raised against aberrantly
phosphorylated TDP-43 species, with CypA knockout mice expressing mSODl displaying greater
differences. Furthermore, aberrantly phosphorylated TDP-43 could clearly differentiate the two
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stages of the disease. In these animals, both mutant S0D1 expression and CypA depletion 
contributed to enhance sequestration of hyper-phosphorylated TDP-43 into pathological 
inclusions, that accumulated with disease progression (Figure 5.7B). In particular, this analysis 
suggested that CypA absence could have an influence on disease progression. In fact, the early 
presence of TDP-43 alterations in the detergent-insoluble fraction of G93A-SODl/CypA-/- mice 
was comparable with G93A-SODl/CypA+/+ animals at the end stage of the disease, indicating that 
CypA should influence both initiation and progression of the pathology.
Summarizing, CypA was confirmed to interact specifically with mutant SOD1, possibly acting as a 
chaperone. As a consequence of chaperones preferential binding for misfolded proteins, mutant 
SODl/CypA complex may recruit also other proteins to form aggregates. Indeed, mutant SOD1 
could sequester CypA in the cytosol impeding CypA functions in the nucleus, including its 
association with TDP-43. Dysregulation of TDP-43/CypA hnRNP complex could contribute to alter 
TDP-43 subcellular distribution, thus further favouring aggregation and impairing TDP-43 nuclear 
functions, such as HDAC6 mRNA processing.
In conclusion, alterations of the CypA/TDP-43 interaction, detected both when TDP-43 or SOD1 
were mutated, could have important implications in hnRNP complex formation and stability, and 
in TDP-43 mislocalisation and functions. Given these observations, CypA should be considered an 
aggregation modifier in ALS.
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V. DISCUSSION
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The purpose of this thesis work was to investigate the overall contribution of CypA to ALS and 
possibly its involvement in the patho-mechanisms of the disease. In particular, this study was 
carried out to test whether an early systemic translational biomarker for ALS could shed light on 
disease-causing mechanisms. Indeed, CypA revealed to be an interesting molecule that is 
worthwhile to deeply study and characterise for its relevance as a possible molecular link 
between two pathogenic mechanisms in sporadic and familial ALS.
CypA was previously identified in our lab as a hallmark of the disease in the G93A-SOD1 mouse 
model of fALS (Massignan 2007; Basso 2009) and in sALS patients (Nardo 2011). In particular, an 
altered expression pattern of CypA isoforms was observed already at a milder stage of the 
pathology in PBMC from sALS patients, and at a pre-symptomatic stage of the disease in the SpC 
of mSODl mice (Massignan 2007; unpublished data from the lab). Moreover, elevated levels of 
CypA were detected in PBMC from sALS and G93A-SOD1 rats, already at the pre-symptomatic 
stage (Nardo 2011). Furthermore, CypA was recovered as insoluble material together with mSODl 
in SpC extracts of fALS mice, and was significantly enriched also in the insoluble fraction of SpC of 
ALS patients (Basso 2009).
CypA best characterised properties are the peptidyl-prolyl cis-trans isomerase and chaperone 
activities, which are linked to its intracellular beneficial functions in protein folding and in 
protecting from oxidative stress. In addition, CypA has been recently suggested to play important 
roles in diverse cellular processes including intracellular trafficking (Uittenbogaard 1998), signal 
transduction (Brazin 2002), cell cycle regulation (Zander 2003), transcription regulation 
(Krummerei 1995), neuronal differentiation (Hovland 1999; Nahreini 2001; Chiu 2003; Song 2004; 
Urano 2006), ribonucleoprotein trafficking (Pan 2008), viral replication (Foster 2011). Here we 
show that CypA has a protective role in ALS, not only as an antioxidant (Lee 1999), but also as a 
chaperone and in maintenance of multi-protein complex stability.
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1. Establishment of a cell model of ALS disease
To provide further insights into CypA functions and to unravel if this protein is involved in ALS 
pathogenesis, HEK293 cells overexpressing mutant SOD1 or TDP-43 were used as in vitro model of 
ALS. Since CypA is an ubiquitous protein, we used the HEK293 cell line as a versatile cellular model 
to investigate molecular mechanisms that can take place in different cell types. Interestingly, 
although the HEK293 cell line was derived by transformation of primary cultures of human 
embryonic kidney (HEK) cells (Graham 1977), they resemble developing neurons and neuronal 
stem cells. In fact, they express the neurofilament (NF) subunits NF-L, NF-M, NF-H, and a- 
internexin, as well as many other proteins typically found in neurons. Moreover, HEK293 cells 
reveal little spontaneous electrical activity and electrophysiological studies have shown 
expression of several endogenous voltage-activated ion currents, thus further arguing that 
transformed HEK lines belong to neuronal lineage (Shaw 2002).
HEK293 cell lines stably expressing human WT-SOD1 and the fALS mutant G93A-SOD1, were 
generated. Although this is a simple system that cannot accurately model more complex 
pathological features associated with mammalian nervous system dynamics, it allowed us to 
model some cellular and molecular changes already reported in fALS models of the disease and in 
patients. Indeed, the overexpression of mSODl was sufficient to increase the cell death rate in 
respect to WT cells, demonstrating that mSODl stably expressed in HEK293 cells is toxic. Further 
analyses revealed also increased levels of free and protein-bound 3-nitrotyrosine, nitrated actin 
and protein-disulfide isomerase, that are important characteristic features of nitrative, oxidative 
and ER-stress, respectively. These protein profile changes are in line with similar findings in ALS 
patients, as well as in in vivo and in vitro models (Abe 1997; Beal 1997; Bruijn 1997; Ferrante 
1997; Casoni 2005; Atkin 2006 and 2008; Massignan 2007; Basso 2009; Nardo 2009 and 2011), 
and with the observation that mSODl has an increased ability to catalyse aberrant oxidative 
reactions, including protein nitration (Beckman 1993; Estevez 1999). So, we can consider these 
cells a valid in vitro model to dissect mSODl-related disease mechanisms at a molecular level. 
Nevertheless, the selective neuronal vulnerability or the focal onset, progression, and spreading
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of ALS require a model with the complexity of the mammalian CNS architecture. Thus, the most 
interesting results were also investigated in relevant animal models.
1.1 Cyclophilin A in HEK293 cells stably 
expressing mutant SOD1
Starting from the observation that CypA is up-regulated early in the disease in fALS animal models 
and in patients (Nardo 2011), we investigated the biochemical properties of CypA in our in vitro 
system. CypA alterations previously found in sALS patients and fALS animal models were mirrored 
in our experimental model, suggesting that it is a relevant system to dissect the determinants of 
CypA impairment. In particular, mSODl overexpression was sufficient to alter CypA pattern of 
isoforms, with a pattern change, a shift toward acidic pi, similar to sALS patients and fALS mice 
(Massignan 2007; unpublished data from the laboratory). Moreover, CypA was significantly up- 
regulated in mSODl cells compared to WT cells following serum withdrawal, but not under basal 
conditions. The change detected in CypA pattern of isoforms in mSODl-overexpressing cells 
points out a variation in its post-translational modification (PTM) profile in a pathological 
condition, that could interfere, directly or indirectly, with its functions or subcellular distribution. 
Indeed, CypA has been implicated in multiple extracellular and intracellular functions, both within 
the nucleus or the cytoplasm, and possibly its multifaceted nature is linked to its high propensity 
to undergo PTMs. In mSODl cells, the modified PTMs profile observed directly affected nuclear 
CypA, with a concomitant increase in the cytosolic protein levels. Impairment of CypA subcellular 
localisation may thus reflect disturbancies in its nuclear activities, that are still poorly 
characterised. A recent work demonstrates that acetylation is one of the PTM responsible for the 
shift of CypA isoforms towards a more acidic pi (Chevalier 2012). Possibly, this indicates that CypA 
impairment in ALS is likely linked to an altered acetylation pattern.
CypA is extensively lysine-acetylated (Kim 2006; Choudhary 2009; Chevalier 2012), nevertheless 
this still represents a poorly examined aspect of CypA biology. Lysine-acetylation is a very
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important PTM and it can exert its impact via alteration of protein-protein interactions, 
subcellular localisation, enzymatic activity. Here, we demonstrated for the first time that lysine- 
acetylated CypA was present exclusively in the nucleus and not in the cytoplasm, suggesting that 
lysine acetylation influences CypA nuclear translocation. Since CypA nuclear levels as well as 
lysine-acetylation displayed an altered pattern in mSODl cells and as well in stress conditions, our 
findings suggest that the fine regulation of CypA lysine-acetylation and de-acetylation could play a 
role in disease and stress response.
Lysine-acetylation occurs on several nuclear substrates (Glozak 2005), such as histones, DNA- 
binding transcription factors, acetylases, but also non-nuclear proteins, such as a-tubulin, and 
proteins that shuttle from the nucleus to the cytoplasm, such as the nuclear import factor 
importin-a. In many cases lysine-acetylation occurs in known or putative nuclear localisation 
signal (NLS) sequences, therefore a change of subcellular localisation may be one of the effects of 
this modification (Kim 2006). The results obtained, prompt us to suppose that also CypA 
acetylation is likely to have a marked effect on its subcellular distribution, in a similar way that 
acetylation regulates the nuclear-cytoplasm trafficking of importin-a (Bannister 2000). Indeed, 
importin-a acetylation on a specific residue (Lys-22) promotes the binding with a second nuclear 
import factor (importin-P), thus allowing the correct translocation of the protein into the nucleus. 
CypA does not possess a classical NLS (Rycyzyn 2000) and the mechanism of CypA nuclear 
translocation has long been elusive. Nevertheless, roles for CypA in nuclear trafficking of cellular 
factors have been proposed in several studies (Ansari 2002; Zhu 2007; Pan 2008). Recently, the 
comparison of CypA and hnRNP A1 protein sequences revealed a M9-like motif embedded in the 
glycine-rich domain (aa 41-125) of CypA, that directs its nuclear translocation through transportin 
1 (Pan 2008). Interestingly, CypA-Lysl25, that has been recently shown to be acetylated in 
mammal cells, is located within this motif (Kim 2006; Choudhary 2009). These observations 
possibly suggest that lysine acetylation within CypA M9-like motif may be a PTM promoting CypA 
nuclear localisation. Lysl25 is located in a loop in proximity of the PPIase cavity of CypA and 
provides the greatest positive charge within the active site region, and this charge is largely
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neutralized when an acetyl-group is introduced (Lammers 2010). Although Lysl25 acetylation 
does not seem to substantially rearrange CypA active site, it markedly affects CypA surface 
electrostatics (Lammers 2010). To deeply explore this PTM, Lysl25 was substituted either with a 
Gin (K125Q), in order to mimic a constitutively acetylated-Lys, or with an Arg (K125R) which 
mimics a constitutively non-acetylated-Lys. When transfected in HEK293 cells, the K125Q-CypA 
mutant displayed a normal subcellular distribution, while K125R-CypA showed a reduced nuclear 
localisation, thus confirming acetylation as the PTM promoting CypA efficient nuclear localisation. 
Nevertheless, CypA nuclear import was not completely abolished in the absence of the acetyl- 
group on Lysl25, but only decreased. This possibly suggests that additional PTM are required to 
enable the bidirectional trafficking of CypA across the nuclear envelope, or alternatively that, in 
addition to Lysl25, acetylation is also needed on the other lysines within the M9-like motif of 
CypA, to efficiently regulate its nuclear trafficking in mammalian cells. Thus, the possible additive 
effect of acetylation on multiple lysines should be further investigated on the nucleo-cytoplasm 
shuttling of CypA.
Collectively, our data demonstrated that in this in vitro model the overexpression of G93A-hSODl, 
even though not evidently altering CypA total level, was sufficient to alter CypA isoform pattern, 
mirroring the trend observed in sALS patients and fALS murine models, and this directly 
correlated to the shift observed in its subcellular localisation and possibly PTMs profile. Thus, this 
experimental model of fALS is relevant to investigate the role of CypA and the molecular events 
induced by SOD1 mutation in ALS.
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2. Identification of Cyclophilin A interacting 
proteins
CypA is present as a relatively abundant protein in the cytoplasm and in the nucleus of all 
mammalian cells. In particular, brain tissue constitutively expresses CypA in high amount (Goldner 
1996) and several works reported CypA involvement in neuronal differentiation (Hovland 1999; 
Nahreini 2001; Chiu 2003; Song 2004; Urano 2006). Nevertheless the specific functions CypA plays 
in neurons and MNs, beyond its PPIase and chaperone activities, have not been defined yet. On 
the basis of these observations, of our in vitro findings and previous data from the lab describing 
CypA as a hallmark of ALS in patients and in vivo models, also additional evidences support a 
possible involvement of CypA in ALS pathogenesis. In particular, three independent studies 
conducted on the G93A-SOD1 fALS animal model have shown that treatment with the 
immunosuppressive drug CsA extends mice survival (Keep 2001; Kirkinezos 2004; Karlsson 2004). 
CsA binds and inhibits CypA with more efficiency in respect to other Cyps (Mikol 1994), thus 
suggesting that CypA could represent an attracting pharmacological target for ALS and that CsA 
could exert an effect on CypA functions in the CNS. In addition, CypA is required for the efficient 
nuclear translocation of AIF in degenerating MNs of G93A-SOD1 mice (Tanaka 2010), suggesting 
that CypA and AIF may cooperate to mediate the late stage of MN death in diseased fALS mice. 
On the contrary, a protective role for CypA PPIase activity has been hypothesised in mSODl in 
vitro model of fALS, independently from its CsA-dependent function (Lee 1999). These evidences 
provided sufficient basis to hypothesise that CypA is mechanistically linked to ALS, although the 
fundamental question of whether CypA participates to neurodegeneration through gain of toxic 
function or a loss of protective function remains controversial.
Several reports have noted that CypA associates with specific proteins, nevertheless these 
findings have not led to a general model for CypA function in mammalian cells or possible 
aberrant function in disease conditions. Thus, we employed a global proteomic approach to 
investigate CypA interactome network, in order to provide insights into the (patho)physiologically 
relevant molecular functions of this protein.
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We identified twenty-eight proteins in association with CypA by mass spectrometry in HEK293 
cells stably expressing WT- or G93A-SOD1. Most of these were unknown CypA-binding partners 
and all need to be deeply investigated to establish a functional link among them. Some proteins 
showed common biological denominator, and were divided into seven main functional categories: 
DNA/RNA binding proteins (TDP-43, hnRNP A l, A2/B1, C1/C2, G, K ,M, IF4A1/2/3, DDX3X, PRP19, 
SFPQ, HKR1, NR1I2, NPM), cytoskeleton-associated proteins (actin, tubulin, vimentin, 
tropomodulin-2), energy metabolism (ENOA, KCRU, G3P), protein biosynthesis (EF2), protein 
folding and degradation (TCPA, HSP71), trafficking (RAN), and other functions (PHB). Therefore, 
we found that CypA is able to interact with different groups of proteins, thus providing an 
important perspective about how CypA could be involved in different biological pathways, likely 
suggesting a possible functional role in these processes too. Moreover, CypA was largely 
associated with nuclear proteins, cytoplasmic proteins, and proteins known to undergo nucleo- 
cytoplasmic shuttling. Our results are consistent with the observation that CypA is a cellular 
component of both the nucleus and the cytoplasm, and possibly indicate that CypA could have 
important unknown functions in the nucleus. Possibly, we can hypothesise that mSODl-mediated 
decrese of nuclear CypA, as described in our in vitro model, could contribute or be caused by the 
impaired interaction with one of these proteins, and further perturb the processes listed, through 
a loss of nuclear function of CypA.
2.1 DNA/RNA binding proteins
The main result presented in this thesis is the novel observation that CypA is strongly associated 
with RNA processing, whose misregulation is emerging as a common patho-mechanism in ALS. In 
particular, we revealed extensive interaction of CypA with proteins that regulate multiple steps of 
RNA metabolism, and these include proteins involved in mRNA splicing, transport and stability, 
RNA helicases, as well as several hnRNPs, and interestingly also TDP-43, that is a major disease 
protein in ALS, thus adding evidence to a mechanistic involvement of CypA in ALS pathogenesis.
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Notably, CypA has been already associated with RNA in a wide proteomic study of HeLa mRNA 
interactome (Castello 2012). In particular, CypA was among the PPIases identified as RNA-binding 
proteins. Indeed, PPIases have been previously demonstrated to play diverse regulatory roles in 
spliceosome and ribonucleoprotein dynamics, and possibly their role in RNA biology is broader 
than previously suggested (Mesa 2008). Thus, our findings provide added evidence to support a 
role for CypA in RNA processing and this is likely to be the the most relevant feature of CypA to 
investigate in association with neurodegeneration in ALS.
Among the identified CypA interacting proteins, there are several members of the hnRNP family, 
specifically hnRNPs A l, A2/B1, C1/C2, G, K, M and TDP-43. HnRNPs are abundant nuclear proteins 
that rapidly shuttle between the nucleus and the cytosol and, organized in large complexes, have 
key roles in RNA processing, transport, localisation, translation and stability (Dreyfuss 2002). 
CypA involvement in ALS results a particularly interesting possibility since here it has been shown 
to interact with TDP-43. Indeed, TDP-43 has been identified as the major component of neuronal 
ubiquitinated inclusions (Neumann 2006), the most striking pathological hallmark of ALS, in sALS 
and SODl-negative fALS patients. Furthermore, both sALS and fALS patients present mutations in 
the TARDBP gene (Kabashi 2008; Sreedharan 2008), mainly in the C-terminal region that is the site 
of interaction with other proteins, and among them also members of the hnRNP family (Buratti 
2005). It is a RNA/DNA binding protein that structurally resembles a typical hnRNP and is involved 
in multiple steps of RNA lifecycle including transcription, splicing, transport, translation, stability, 
degradation and miRNA processing (see Introduction section 1.5.6). Nevertheless, its precise role 
in ALS pathogenesis has not been deciphered yet. Notably, CypA was previously identified in a 
global proteomic analysis of TDP-43 interacting proteins, although it was not considered a specific 
interactor since it was enriched in the control sample relative to the TDP-43 co- 
immunoprecipitate (Freibaum 2011). Instead, here we demonstrated the specificity of this 
interaction and established a functional connection.
Interestingly, hnRNP A2 had already been demonstrated to form a complex with CypA which
undergoes nuclear export in response to chemokine stimulus, thus suggesting a regulatory role of
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CypA in the trafficking of hnRNP A2 (Pan 2008). In this analysis both hnRNP A2 and Bl, that are 
alternative splicing isoforms differing from each other by only a 12-aa insertion in the N-terminal 
region of A2 (Kozu 1995), have been identified. The interaction between CypA and hnRNP A2/B1 
is particularly interesting for its possible significance in ALS pathogenesis. Indeed, (i) hnRNP A2/B1 
is one of the best characterised interactor of TDP-43 (Buratti 2005), (ii) it was identified as a 
potential biomarker in sALS patients together with CypA and TDP-43 (Nardo 2011), (iii) it is known 
to interact with the C/G-rich repeats that form RNA foci in another neurodegenerative condition 
(FXTAS) (Sofola 2007) and possibly it is dysregulated in a similar way in C90RF72 (G4C2)n repeats 
carrier (Dejesus-Hernandez 2011). Thus, the involvement of CypA and hnRNP A2/B1 in ALS was 
further investigated in this study.
CypA interaction with hnRNP K could be of interest to investigate whether CypA plays a role in 
chemotaxis. Indeed, CypA was demonstrated to bind N-WASP and stabilise its complex formation 
with Arp2/3 for nucleation/initiation of actin polymerisation (Calhoun 2009). Interestingly, also 
hnRNP K is involved in cytoskeletal organisation, cell spreading and migration through direct 
association with N-WASP (Yoo 2006). Thus, CypA could be involved in chemotaxis and cytoskeletal 
organisation, regulating hnRNP K nuclear-cytoplasm transport, as demonstrated for hnRNP A2 
(Pan 2008).
CypA was found to interact with a large number of RNA helicases, specifically with the ATP-
dependent RNA helicase DDX2A (elF4Al), DDX2B (elF4A2), DDX48 (elF4A3) and DDX3X. These
proteins are members of the DEAD/DEXH-box protein family, characterised by the conserved
motif Asp-Glu-Ala-Asp (DEAD). RNA helicases are implicated in a number of cellular processes
involving alteration of RNA secondary structure, such as translation initiation, splicing, nonsense-
mediated decay, and ribosome and spliceosome assembly. Possibly CypA/RNA helicases complex
within RNP particles, which undergo many conformational rearrangements at the RNA and
protein level, and it is likely that proteins of the DEAD/DEXH-box RNA helicase family and CypA
mediate some of these conformational changes through a direct interaction with RNA or proteins,
respectively. Moreover, the interaction between CypA and DDX3X could be of interest in
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association with their roles in HIV-1 and HCV viral replication (Braaten 2001; Foster 2011; 
Yedavalli 2004; Owsianka 1999).
PRP19 (Pre-mRNA-processing factor 19) is essential for spliceosome assembly, and may also be 
important for its stability and activity. It also plays a role in DNA repair and pre-mRNA splicing. 
Interestingly, PRP19 was demonstrated to function as a neuron-astroglial switch during retinoic 
acid (RA)-induced neuronal differentiation in vitro, and CypA was identified as a specific binding 
partner of the PRP19|3-variant (Urano 2006). In particular, CypA participates in the early stages of 
neuronal differentiation (Song 2004) acting as a transcriptional activator, and its activity is 
suppressed by PRP19p binding (Urano 2006). It would be interesting to deeply investigate this 
mechanism in association with ALS, where astrogliosis is emerging as a prominent feature of 
disease (Vargas 2010).
PSF/SFPQ (Splicing factor, proline- and glutamine-rich) is a nuclear splicing factor and 
transcriptional regulator, and it also functions in DNA repair (Ha 2011). SFPQ is a core protein of 
paraspeckles, that are dynamic ribonucleoprotein bodies found in the interchromatin space of 
mammalian nuclei formed around long noncoding RNA (Bond 2009). Moreover, it is a host factor 
essential for HCV and influenza virus infection (Landeras-Bueno 2011; Harris 2006). Interestingly, 
it was recently found depleted in the nucleus and accumulated in the cytoplasm in tau-mediated 
pathological conditions in Alzheimer's and Pick's disease (Ke 2012), similar to what has been 
reported for TDP-43 and FUS in ALS and FTLD. This possibly suggests that an altered nucleo- 
cytoplasm redistribution of proteins implicated in mRNA processing might be a prominent patho- 
mechanism under neurodegenerative conditions. Moreover, in this context the interaction 
between SFPQ and CypA should be further investigated, since CypA has a role in the nuclear 
transport of cellular factors, such as hnRNP A2 (Pan 2008), AIF (Cande 2004) and Zprlp (Ansari
2002).
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2.2 Trafficking and cytoskeleton-associated 
proteins
CypA was found to interact with a small number of trafficking and cytoskeleton-associated 
proteins, particularly actin, tubulin, vimentin, tropomodulin-2 and the GTP-binding nuclear 
protein RAN (Ras-related nuclear protein or GTPase Ran). This finding is consistent with previously 
described roles for CypA (see Introduction section 2.4), in maintaining the native folding of actin 
and associated proteins during transit in axons, and assembly and disassembly in growth cones 
(Yuan 1997), and in linking client proteins, bound to hsp90, to the dynamitin component of the 
movement machinery for retrograde movement, including dynein and tubulin, along microtubules 
(Galignana 2004). Moreover, in hippocampal neurons from developing brain CypA was found 
among the adaptor proteins in RNA-transporting granules which translocate to dendritic spines 
(Elvira 2006). The presence of CypA, together with ribosomal proteins, RNA-binding proteins 
already implicated in transport (hnRNP A1 and hnRNP A2), the transport motor complex 
dynein/dynactin and TDP-43, is in line with our findings, possibly suggesting that it is involved in 
RNA trafficking within neuronal processes. In addition, the identification of RAN is particularly 
interesting given its involvement in the nucleo-cytoplasmic transport pathway mediated by M9- 
NLS (Moroianu 1996; Chook 1999): it is required for the bidirectional transport of several mRNA 
processing proteins, including hnRNPs A1 and A2/B1 through transportin, also known as 
karyopherin[32 (KapP2) (Lee 2006), and thus possibly for RNA export. The binding with this protein 
should be further investigated, especially in a pathologic context, consistent with the observation 
that CypA is in the cytoplasm and in the nucleus, and likely reflecting a functional role for CypA in 
nucleo-cytoplasmic trafficking of other proteins (see Introduction section 2.4.5).
2.3 Protein folding
The association of CypA with other molecular chaperones, in this case TCPA and HSP71, is in
accordance with previous reports describing CypA cooperating with (i) Hsc70 in maintaining the
native folding of actin and associated proteins during transit in axons (Yuan 1997), or with (ii)
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HSP56 and Cyp40 as part of a cytosolic caveolin-chaperone complex involved in cholesterol 
intracellular trafficking (Uittenbogaard 1998). TCPA (TCP1 orT-complex protein 1 subunit alpha) is 
a molecular chaperone known to play a role in the folding of actin and tubulin in vitro (Seo 2010). 
HSP71 (HSPA1 or Heat shock 70 kDa protein 1A/1B) is a chaperone belonging to the heat shock 
protein 70 family. It is localized in cytoplasmic mRNP granules containing several hnRNPs and 
untranslated mRNAs (Jpnson 2007). These observations further strengthen CypA functional 
involvement in other aspects correlated with protein folding, such as the formation of 
heterocomplexes mediating trafficking dynamics.
2.4 Energy metabolism
Several enzymes important in energy metabolism were also identified in our proteomic analysis of 
CypA interactors. In particular, KCRU (ubiquitous mitochondrial creatine kinase or CKMT), GBP 
(glyceraldehyde-3-phosphate dehydrogenase or GAPDH), and ENOA (alpha-enolase or MBP-1, 
NNE or non-neural enolase).
Creatine kinase (CK) reversibly catalyzes the transfer of phosphate between ATP and various 
phosphogens (e.g. phosphocreatine). CK is a key enzyme of cellular energy metabolism and plays 
a central role in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, 
brain and spermatozoa. The identification of this protein is in line with previous reports 
demonstrating the ability of CypA to accelerate CK refolding and improve the reactivation yields in 
vitro, independently of its PPIase activity (Yang 1997; OU 2001). Our finding results particularly 
interesting, since it likely suggests a chaperone-like activity of CypA on CK also in living cells. 
Indeed CypA chaperone activity in living cells was demonstrated only on procollagen I triple-helix 
(Steinmann 1991). Furthermore, in vitro CypA is able to accelerate folding of other metabolic 
enzymes, namely carbonic anhydrase (Freskgard 1992) and citrate synthase (Moparthi 2010), 
possibly indicating a chaperoning activity of CypA also on analogous protein substrates.
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Also G3P represents an interesting protein interactor of CypA, since in addition to playing a role in 
glycolysis through its glyceraldehyde-3-phosphate dehydrogenase activity, it also functions within 
signal transduction cascades as a nuclear S-nitrosylase (Kornberg 2010). Indeed, regulated 
protein-protein transnitrosylation represents a mechanism of signal transduction with 
implications for nitric oxide biology and redox signalling. CypA has been found to be S-nitrosylated 
(Wu 2011; Camerini 2007) and this possibly indicates a common transnitrosylation-mediated 
mechanism of signaling regulation.
2.5 Other interactors
EF2 (EEF2 or elongation factor2) belongs to the GTP-binding elongation factor family and catalyzes 
the GTP-dependent ribosomal translocation step during translation elongation. CsA/CypA 
complex was found to alter EF2 by affecting transcriptional regulation or enzymatic activity, thus 
causing widespread disturbances that may underlie the wide spectrum of toxicities observed 
during CsA therapy (Buss 1994) and possibly when CypA intracellular functions are impaired.
PHB (prohibitin) has been connected to diverse cellular functions including inhibition of cell 
proliferation, stabilization of imported proteins in mitochondria, cell cycle control, senescence, 
and apoptosis. PHB interacts with all members of the Retinoblastoma (RB) tumor suppressor 
family, thereby preventing the transcriptional activity of E2F members (Rajalingam 2005). Also 
CypA binds RB, and their interaction interferes with CsA/CypA complex, negatively affecting CsA- 
inhibited NFAT signaling (Cui 2002). In addition, in a model of neuronal differentiation, the nuclear 
translocation of CypA, the appearance of hypophosphorylated RB and the enhancement of 
RB/CypA complex formation correlates with retinoic acid induced neuronal differentiation (Chiu
2003). Possibly, PHB and CypA converge on RB pathway, with relevant functions in tumors.
Overall, our proteomic analysis of CypA interactors is in accordance with previous reports, and
further contributes to underscore the pleiotropic nature of this protein, that likely carries out its
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diverse functions by varying its binding partners, as well as PTMs and subcellular localisation, and 
possibly sharpens underrated roles of this protein in ribonucleoprotein dynamics. Indeed, CypA 
emerged as a relatively new player in a growing list of proteins, especially RNA binding proteins. 
Moreover, linking CypA interactome with a pathologic condition, in which CypA is altered in its 
levels, PTMs and subcellular localisation, as it is in sALS patients and mSODl fALS models, 
contributes to explain the broad spectrum of impaired pathways observed to converge in a 
common phenotype. This latter aspect is particularly relevant in the pathogenesis of sALS and 
mSODl-linked fALS, since we show that CypA and TDP-43 interact, thus providing the first 
connection between two patho-mechanism almost established as independent.
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3. CypA/TDP-43 interaction
Among all CypA interactors, we have shown here that TDP-43, the major constituent of the 
proteinaceous inclusions that are characteristic of most forms of ALS and FTLD (Neumann 2006) 
and are associated with other neurodegenerative diseases (Geser 2009), is in complex with CypA. 
Despite the progresses toward revealing the full spectrum of TDP-43 pathology in human 
neurodegenerative diseases (Geser 2009), it remains to be determined which particular aspect of 
TDP-43 biology is perturbed in common amongst these diseases. There is a growing consensus 
that misfolding and abnormal protein aggregation are a common underlying mechanism of 
neurotoxicity in neurodegeneration. It has been shown previously that the toxicity of protein 
aggregation is due to soluble intermediate forms rather than the insoluble end product inclusions 
that accumulate in tissues. Species formed early in the aggregation process of disease-associated 
proteins are inherently highly cytotoxic rather than simply non-functional, thus providing 
evidence that avoidance of protein aggregation is crucial for the preservation of biological 
functions (Bucciantini 2002). Hence, either a loss or a gain of neurotoxic interactions may precede 
the formation of inclusions, and the control of protein misfolding and aggregation is of 
fundamental importance to preserve cell viability. Notably, molecular chaperones, ubiquitination 
enzymes and proteasome are evolutionary conserved means to increase the efficiency of folding 
and rescuing misfolded proteins after biosynthesis.
Cyclophilins form a structurally well characterised family of closely related proteins that exhibit 
PPIase activity and thereby accelerate the folding of proteins requiring the isomerisation of a 
peptidyl-prolyl bond. However, there is a growing evidence that their main function may be to act 
as chaperones (Baker 1994; Zhao 1997). In particular, CypA can interact with proteins to guide 
their proper folding and assembly. Therefore, we have hypothesised a function for CypA as a 
chaperone in directing proper folding and stabilization of TDP-43.
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3.1 Verification and characterization of 
CypA/TDP-43 interaction
We tested the reliability of CypA/TDP-43 interaction by different approaches and in different 
systems. We showed that CypA and TDP-43 interact in vitro at endogenous expression levels and 
when transiently overexpressed. Their interaction occurred in the nuclear region, in an RNA- 
dependent manner. Moreover, CypA and TDP-43 specifically associated in mouse spinal cord and 
brain extracts. The combined colocalisation analyses in HEK293 cells, HeLa cells and primary 
neuronal cultures, and the binding studies provided definitive evidence that CypA and TDP-43 
exist in complex in mammalian cells in vitro and in vivo. These results further strengthened our 
hypothesis that the two proteins are part of a common intracellular pathway, which might result 
impaired in ALS. Moreover, the finding that these proteins interact in the nucleus and that their 
interaction depends on RNA, further suggest a novel important role for CypA in the nuclear 
compartment in RNA-related biological processes.
Our data indicate that CypA lysine-acetylation occurs only in the nucleus. Besides affecting CypA 
nuclear import (see Discussion section 1.1) and stability (see Introduction section 2.6.6), 
acetylation could also impact on protein-protein or protein-nucleic acid interactions. Indeed, 
lysine acetylation not only neutralizes a positive charge, but also increases the hydrophobicity and 
the size of lysine's side chain, thus it is likely to induce significant conformational changes of 
substrate proteins. For example, acetylation induced the formation of a docking site within a- 
tubulin, that resulted into a major affinity with other motor proteins (Reed 2006; Dompierre
2007). In a similar way, CypA lysine-acetylation, modifying the external surface of the protein, can 
possibly lead to changes in its function and affect its binding with protein partners, such as TDP- 
43. We used CypA mutants at Lys-125 to evaluate this possibility, and observed that acetylation 
on this residue is required for a more efficient binding with TDP-43. Moreover, it should also be 
considered that acetylation frequently occurs in a position directly adjacent to the DNA/RNA 
binding domain of a protein, and results in the consequent stimulation of nucleic acid binding (Gu 
1997; Boyes 1998; Zhang 1998; Martinez-Balbas 2000). Possibly, also in this case, CypA acetylation
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could influence recognition of RNA and thus enhance the binding with TDP-43. Our findings 
indicate that lysine-acetylation, besides regulating the nuclear import of CypA, could also favour, 
either directly or indirectly, the interaction with TDP-43. However one note of caution should be 
considered: we cannot exclude that the lack of acetylation on Lys-125, affecting the import of 
CypA into the nucleus, also reduced the binding with TDP-43, or alternatively, that both nuclear 
import and effective TDP-43 binding were impaired, possibly with a synergistic effect. Notably, we 
observed an altered pattern of CypA acetylation in stress conditions and in mSODl fALS cells, and 
this could possibly modify its interaction with TDP-43 or other RNA-binding proteins, such as 
members of the hnRNP family.
Complexes of RNA-binding proteins often contain interactions dependent on both protein-protein 
and protein-RNA interactions. The interaction between CypA and TDP-43 likely reflects a mixed 
mechanism involving protein-protein as well as protein-RNA interactions. Notably, a previous 
work demonstrated that CypA enahances HCV RNA replication stimulating the RNA binding ability 
of the NS5A protein, modulating the conformation of the RNA binding motif by cis-trans 
isomerisation (Foster 2011). Possibly, CypA could impact on the RNA binding activities of TDP-43 
with a similar mechanism. We investigated this possibility using the PPIase-deficient CypA carrying 
the Arg55Ala substitution which is predicted to completely inhibit CypA isomerase activity 
(Zydowsky 1992). Indeed, Arg55 is located within the active site and it plays a crucial role during 
the transition state of the isomerisation reaction. Despite the mutation in its active site, and in 
contrast with other known CypA-protein interactions, PPIase-deficient CypA was still able to bind 
TDP-43, although a slight decrease was observed in respect to the WT protein. However, it should 
be considered that PPIase-deficient CypA could not be efficiently immunoprecipitated, possibly 
because Arg55Ala replacement significantly disturbed the overall folding of the protein, with a 
reduced affinity for the primary antibody in non-denaturing conditions. Similar results were 
obtained using CsA, which is as well reported to bind CypA catalytic site (unpublished data from 
the lab). Therefore, our data only demonstrate that CypA PPIase activity is not essential for 
CypA/TDP43 interaction, but do not completely exclude the possibility that CypA rotamase
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activity may be required for the cis-trans isomerisation of a prolyl-bond within TDP-43 sequence. 
Further experiments for addressing this question are under way in our laboratory. In addition, 
PPIase-deficient CypA displayed an altered nuclear import/export ratio, suggesting that the 
protein was not efficiently translocated in the nuclear compartment, possibly because the 
enzymatic activity is required for a correct localisation of this protein, or more likely because the 
Arg55Ala point mutation induces conformational changes impairing the binding with proteins 
important for its nuclear translocation, such as transportin.
Overall, although CypA consists only of the CLD, with no other distinguishable domains, still the 
catalytic pocket, and as a result the isomerase activity, are not essential for TDP-43 binding, while 
acetylation of a specific lysine residue of CypA could play an essential role in regulating its affinity 
for its binding partner TDP-43. It will be of considerable interest to investigate in more detail 
which domains of the two proteins participate in complex formation and, in particular, whether 
other PTMs are involved in this recognition event.
3.2 CypA/TDP-43 interaction: implications in 
hnRNP complex formation and stability
TDP-43 is a 414 aa protein with two RNA-recognition motifs (RRM1 and RRM2) that enable the 
interaction with nucleic acids, and a C-terminal glycine-rich domain that mediates protein-protein 
interactions. TDP-43 functionally associates with the majority of the hnRNP proteins and is an 
integral component of hnRNP-rich complexes (D'Ambrogio 2009; Freibaum 2010; Ling 2010). 
Previous studies have shown that TDP-43 binds hnRNPs, and in particular hnRNP A2/B1, through 
its C-terminal tail (Buratti 2005). Indeed, hnRNP A2/B1 is the major hnRNP protein recognized by 
TDP-43 (Ayala 2005), and it is one of the major components of the hnRNP core complex in 
mammalian cells (Kozu 1995). hnRNP A2/B1 and TDP-43 are, in association with other RNA 
binding proteins, components of larger protein complexes required for the stabilization, 
transport, and metabolism of mRNA. Moreover, hnRNP A2/B1 is also one of a large number of
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hnRNPs found to interact with CypA in our proteomic analysis, and it was previously 
demonstrated to form a complex with CypA (Pan 2008). We confirmed the association of hnRNP 
A2/B1 with either CypA and TDP-43 in vitro. Thus, CypA, TDP-43 and hnRNP A2/B1 may form a 
complex with each other and these interactions are RNA-dependent. In this respect, it is possible 
to hypothesise that they are together part of a larger protein complex. It is therefore likely that 
CypA might be a component of hnRNP-rich particles, in complex with TDP-43 and other hnRNP 
proteins, such as hnRNP A2/B1, abundantly present in the interactome (Table 2.1). This is in line 
with a previous work where CypA was identified in RNA-transporting granules from developing 
brain, together with hnRNPs, TDP-43, RNA helicases and the transport motor complex 
dynein/dynactin (Elvira 2006).
In order to deeply elucidate CypA functions within such complexes, we adopted a siRNA 
interference technology approach to selectively knock-down CypA. When CypA was silenced, TDP- 
43 and hnRNP A2/B1 interaction was severely impaired, suggesting that CypA absence could 
disrupt the binding between these two proteins within this hnRNP complex. Similar results were 
obtained in SpC extracts from mice with a reduced (CypA+/-) or absent (CypA-/-) expression of 
CypA, in respect to non-transgenic animals (CypA+/+)- Thus in vivo experiments provided added 
evidence to in vitro data evidencing a fundamental role of CypA in the interaction of TDP-43 with 
at least hnRNP A2/B1. In this paradigm, CypA could simply function in mediating a protein-protein 
interaction with TDP-43 and hnRNP A2/B1, or more likely it could induce a conformational change 
in one of its target proteins, overall suggesting an important role in the assembly of TDP-43 and 
hnRNP A2/B1 into a complex. For example, CypA could act as a chaperone-like molecule and, due 
to its interaction with TDP-43, impart it a protein conformation necessary for complex formation 
with the hnRNP proteins or with RNA target molecules. In this way, CypA could resemble 
somewhat the function of Drosophila NinaA cyclophilin, which stably binds and thus prevents 
misfolding of rhodopsin (Baker 1994). Another possibility is that the aberrant hnRNP complex 
formation is directly linked to the observed depletion of TDP-43 from the nucleus following CypA 
knockdown. In this case CypA could function in TDP-43 trafficking, as in the case of hnRNP A2 (Pan
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2008), and thus contribute to the correct hnRNP complex assembly. Unexpectedly, it was not 
possible to reconstitute a stable CypA/TDP-43/hnRNPA2Bl protein heteromer with recombinant 
proteins on a chip in Surface Plasmonic Resonance experiments (data not shown), suggesting that 
this assembly process has more complex requirements that were not met by our in vitro 
conditions. A simple explanation for the lack of complex formation could be that one or more 
PTMs, such as lysine-acetylation, that were missing from the in v/tro-synthesized proteins, are 
required for a stable interaction. Alternatively, it may be possible that one or more factors 
facilitating the stable association of TDP-43 with hnRNP A2/B1 and CypA in vivo, such as RNA, 
were lacking from our reconstitution system.
Our findings raise the interesting possibility that CypA may play a key role in the architecture of 
the RNA binding protein complements. One of the potential consequences of TDP-43/hnRNP 
A2/B1 complex disruption upon CypA knock-down/out could be protein complex instability in vivo 
caused by an impaired turnover of this hnRNP complex. We isolated Triton-insoluble fractions 
(TIF), that are enriched in ubiquitinated protein aggregates and more generally in improperly 
folded or damaged proteins (Basso 2006 and 2009), from SpC of CypA+/+; CypA+/- and CypA-/- 
mice. The total amount of insoluble proteins in CypA knockout mice was higher than in non- 
transgenic animals, providing direct and added evidence to CypA chaperone activity in vivo. 
Moreover, triton-insoluble fractions extracted from the SpC of CypA knockout mice were enriched 
in poly-ubiquitinated proteins. TDP-43 and hnRNP A2/B1 were significantly accumulated in TIF of 
CypA knock-down/out mice, in comparison with CypA+/+ mice, without any significant variation in 
the soluble fraction. Since TDP-43 is an intrinsically aggregation-prone protein (Johnson 2009), its 
propensity for toxic misfolding was accentuated in vivo by CypA reduction or absence. Moreover, 
insoluble TDP-43 was also hyper-phosphorylated in tissues from CypA knock-down/out mice 
compared to control animals, with a dose-dependent effect. Our data suggest that CypA 
expression at physiological levels is protective against aggregates formation of ubiquitinated and 
aberrantly phosphorylated TDP-43, that are a highly consistent feature of TDP-43 proteinopathies 
(Geser 2009). Indeed, in CypA knockout mice insoluble TDP-43 displayed the fundamental
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biochemical features of protein inclusions in TDP-43-linked human pathology, suggesting that this 
could represent a possible mechanism by which CypA contributes to TDP-43-related diseases and 
this could eventually be considered a model to study TDP-43 aggregation process.
Overall, CypA has a key role in the interaction of TDP-43 with hnRNP A2/B1, possibly promoting a 
correct architecture and stability of the complex. The absence or an impaired CypA/TDP- 
43/hnRNPs binding could accelerate improper folding of this complex and dysregulate complex 
assembly, leading to TDP-43 aggregation and associated pathology. These findings further 
strengthens the hypothesis that normal interactions of TDP-43 with other hnRNPs might keep 
TDP-43 soluble, that protein-protein contact rather than RNA binding may modulate the 
aggregation process, and that the trigger may be a defect in the TDP-43 normal interactions 
(Budini 2012).
We speculate that these events represent a more relevant (patho)mechanism in MNs, where such 
proteins may be transported as a multiprotein complex in axons. This hypothesis is supported by 
previous findings demonstrating a prominent role for CypA in maintaining the native folding of 
actin and associated proteins during transit in axons and assembly in growth cones (Yuan 1997). 
Thus, these evidences, together with the high concentrations of CypA in brain, as well as its role in 
neuronal growth, underlie the importance of its chaperone activity in neuronal processes.
3.3 CypA has a role in TDP-43-mediated HDAC6 
expression regulation
To further establish the functional significance of CypA/TDP-43 association, we sought to 
understand how the described hnRNP complex could operate in putative TDP-43 physiological 
functions. TDP-43 is a RNA binding protein and several RNA targets of TDP-43 are now known. 
Among them, HDAC6 has been consistently identified in a number of works, including in mouse 
brain (Polymenidou 2011; Tollervey 2011). TDP-43, by binding to HDAC6 mRNA, regulates its 
expression (Fiesel 2010; Kim 2010). HDAC6 down-regulation after TDP-43 knock-down/out is
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associated to impaired cellular turnover of aggregating proteins and reduced neurite outgrowth 
(Chiang 2010; Fiesel 2010 and 2011), molecular mechanisms that could be relevant in TDP-43 
diseases. We therefore investigated whether CypA could modulate this TDP-43 activity. TDP-43 
silencing was confirmed to reduce HDAC6 protein level, which supports previous findings (Fiesel 
2010; Kim 2010). We found a comparable downregulation of HDAC6 also after CypA knockdown 
and the effect observed was almost comparable to the one detected in TDP-43 silenced cells. Our 
data suggest that a reduction of CypA levels can affect TDP-43-dependent HDAC6 expression 
regulation, thus revealing a co-requirement of TDP-43 and CypA for optimal HDAC6 expression. 
Our findings established a biological role for CypA/TDP-43 complex, and we speculate that the 
hnRNP complex described may be involved in HDAC6 mRNA processing and/or nuclear export. 
Indeed, these complexes are likely involved in one or multiple steps of RNA lifecycle, processes 
that involve extremes rearrangements of the RNA components, that imply also significant 
rearrangements and conformational changes of a number of proteins. CypA was found associated 
with proteins of the DEAD/DEXH-box RNA helicase family, that play an important role in 
mediating some of these conformational changes through a direct interaction with RNA. In this 
context, due to its PPIase and chaperone activities, it is conceivable that CypA may also function 
as a molecular switch by directly triggering conformational changes in one or more proteins, and 
these changes could in turn influence the RNA binding ability of its target interactors, as in the 
case of CypA/NS5A complex (Foster 2011). Therefore CypA, being a small and versatile protein 
could be a good candidate to catalyze such conformational changes in large multiprotein 
complexes.
Moreover, HDAC6 is a common RNA target of the RNA-binding proteins TDP-43 and FUS, both 
identified as causative factors of fALS and sALS (see Introduction section 1.4.1). Since the 
mutation or the cytoplasmic aggregation of either TDP-43 or FUS cause similar phenotypes in 
humans, and both proteins are involved in the same RNA-processing steps, a plausible hypothesis 
is that the RNA-targets affected by both proteins may be the most relevant for disease 
(Polymenidou 2012). Therefore, disregulation of HDAC6 RNA metabolism following TDP-43
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deficiency, as it may occur in human disease by cytosolic sequestration of this nuclear protein, 
and possibly upon CypA loss-of-interaction, as it may occur when CypA is depleted or aberrantly 
post-translationally modified, may contribute to MN disease in ALS, and if occurring in the frontal 
and temporal cortex also to FTLD-TDP, through deregulation of aggregating toxic protein turnover 
(Fiesel 2010), and impaired neurite outgrowth (Fiesel 2011).
3.4 Alterations of CypA/TDP-43 interaction in 
association with ALS-linked mutations
We evaluated whether the effect of pathogenic mutations in (i) TDP-43 or (ii) SOD1 sequence 
impacted on CypA/TDP-43 interaction, (i) We considered three different mutations previously 
found in fALS and sALS patients (Gitcho 2008; Kabashi 2008; Daoud 2009): the missense 
mutations A315T and R361S, and the frameshift mutation Y374X. All ALS-mutants, as well as WT- 
TDP-43, displayed substantial cytotoxicity when overexpressed in HEK293 cells. Moreover, the 
A315T and R361S ALS-derived mutations enhanced TDP-43 mislocalisation to the cytoplasm, while 
the frameshift mutation Y374X did not. Our findings suggest that enhanced cytoplasmic 
translocation might not be a general mechanism by which mutations in TDP-43 stimulate toxicity, 
further corroborating the observation that mislocalisation alone is not responsible for TDP-43 
driven neurodegeneration (Liachko 2010) and that mutations in TDP-43 are mechanistically 
divergent (McDonald 2011). Therefore, other molecular changes, such as protein-protein 
interactions, may account for the toxicity of TDP-43 ALS-mutants. In fact, TDP-43 mutations are 
located inside the C-terminal glycine-rich domain, which is the putative protein-protein 
interaction domain of TDP-43, with the R361S and Y374X being respectively inside or close to the 
minimal hnRNP binding region (D'Ambrogio 2009; Budini 2012). TDP-43 disease-associated 
mutants did not efficiently bind CypA as the wild-type protein. In particular, the A315T mutation 
had very mild or nearly no effect on the interaction with either CypA and hnRNP A2/B1, consistent 
with previous reports (Freibaum 2010) where the A315T and M337V disease-causing mutations 
were demonstrated not to grossly alter the function of TDP-43 or its binding partners. The
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association between TDP-43, CypA and hnRNP A2/B1 was significantly decreased in R361S-TDP-43 
cells, suggesting that the R361S is a loss-of-function mutation with respect to this hnRNP complex 
formation. This was consistent with the observation that the R361S mutation is located within the 
minimal hnRNP A2 interaction domain o f TDP-43 (D'Ambrogio 2009; Budini 2012). The Y374X 
mutation, that led to the expression of a C-terminally truncated form of the protein lacking the 
last 41 aa, is the one that mostly affected the interaction between CypA and TDP-43. Combining 
these data, it seems likely that the C-terminal region o f TDP-43 is relevant for a correct binding 
with CypA, and in particular, the minimal hnRNP A2 binding region o f TDP-43 could serve as an 
anchor site for CypA, which may act as a chaperone or PPIase, possibly facilitating rearrangements 
of protein interactions during RNA processing/complex formation. In addition, our data indicate 
that in pathological conditions associated with ALS-TDP-43, it may occur an aberrant interaction 
between TDP-43 and CypA, that could have negative implications for hnRNP complex formation 
and stability.
In association with a reduced binding between CypA and TDP-43, we detected a shift in the 
subcellular localisation o f both CypA and hnRNP A2/B1, whose levels were increased in the 
nucleus and in the cytoplasm, respectively. Under basal condition CypA is predominantly localised 
in the cytoplasm, whereas hnRNP A2/B1 is almost exclusively localised in the nucleus. Moreover, 
in association with an altered CypA/TDP-43/hnRNP A2/B1 complex formation in cells expressing 
the R361S-TDP-43 mutant, CypA was also up-regulated in the cytosol. Thus, the changes observed 
in CypA and hnRNP A2/B1 subcellular distribution could represent a compensatory mechanism to 
restore a correct hnRNP complex. It has been recently shown that CypA plays an important 
regulatory role in the trafficking o f hnRNP A2, since they form a complex that undergo nuclear 
export in response to chemokine stimuli (Pan 2008). Either TDP-43 mutants and hnRNP A2/B1 
displayed a shift in their subcellular localisation concomitantly with a reduced binding between 
CypA and TDP-43. Our results possibly subtend an important role for CypA for the correct 
localisation or subcellular redistribution of the members o f this hnRNP complex, that could
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represent an early impairement in desease conditions. However, this remains to be 
demonstrated.
TDP-43 ALS-mutations were also analysed for their impact on a well established function of TDP- 
43: HDAC6 expression regulation. In TDP-43-silenced cells, decreased HDAC6 protein levels were 
restored to normal levels after retransfection with the WT protein, whereas the A315T and R361S 
mutants were able to restore HDAC6 protein levels, but with a reduced capacity compared to the 
wild-type protein, replicating a previous work on HDAC6 mRNA levels (Fiesel 2009). In contrast, 
the Y374X mutant failed to restore HDAC6 levels, consistent with previous findings on a truncated 
form of TDP-43 lacking the C-terminal glycin-rich domain (Fiesel 2009). In particular, the latter 
result was similar to what observed after TDP-43 knockdown, suggesting that the Y374X is a loss- 
of-function mutation with regards to HDAC6 regulation, as well as CypA/TDP-43 hnRNP complex 
formation. Therefore, our findings indicate that a correct protein-binding capacity could represent 
a more important determinant of HDAC6 regulation than TDP-43 nuclear localisation, since TDP- 
43/CypA interaction was necessary to maintain physiological levels of HDAC6. We speculate that 
the efficient association with CypA could contribute to RNA-protein complex formation along with 
direct interaction between TDP-43 and other hnRNPs. Thus, in the pathology, it is plausible that 
TDP-43/CypA/hnRNPs impaired binding may lead to defective RNA metabolism, contributing to 
pathogenesis and disease progression. In particular, HDAC6 is a key player in autophagy-mediated 
degradation of misfolded proteins (Boyault 2006) and HDAC6 downregulation upon a severely 
damaged hnRNP complex may lead to subsequent impairment in toxic protein turnover, further 
enhancing proteotoxicity. These results are in line with previous works suggesting that the 
mutations in TDP-43 found in patients do not contribute to a drastic protein loss-of-function, 
whereas they may more likely contribute to a predisposition to deveop the disease (i.e. more 
readily form aggregates) (D'Ambrogio 2009), possibly through an impaired interaction with CypA.
(ii) In addition, we detected a reduced CypA/TDP-43 binding, as well as their cytoplasmic
mislocalisation in presence of mSODl. Our findings likely suggest that the consequences of an
impaired hnRNP complex formation and stability could be particularly detrimental in a disease
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context already associated with mSODl, as they could have negative implications for TDP-43- 
related functions, further contributing to the pathology. An interesting possibility is that the 
altered pattern o f CypA lysine-acetylation observed in mSODl cells could represent a primary 
causative event that affects CypA import into the nucleus and impairs its binding with TDP-43, and 
possibly also its trafficking. Therefore, the fine regulation of CypA lysine-acetylation and de- 
acetylation could be an important element in pathological conditions. A future challenge for basic 
research, but also for the putative implications in disease treatment, is the identification of the 
acetyltransferases (HATs) and deacetylases (HDACs) able to modulate CypA acetylation. 
Moreover, it would be of particular interest to test whether these enzymes could also modulate 
CypA subcellular distribution or the binding with other proteins, and overall confer CypA 
specificity for its substrates. Indeed, acetylation may inhibit binding to some substrates but allow 
CypA to bind (and to isomerise) new ones, and an imbalance between the activities o f HATs and 
HDACs could lead to a disease state. HDAC inhibitors, that have recently emerged as potential 
neuroprotective drugs for the treatment of neurodegenerative diseases such ALS, could be tested 
and used in order to modulate CypA acetylation.
Overall, alterations of the CypA/TDP-43 interaction, detected when TDP-43 is mutated or in 
presence of mSODl, could have important implications for hnRNP complex formation and 
stability; the slight disruption of its activity perpetuated over a long time might be the cause for 
TDP-43 mislocalisation and possibly the trigger for pathological inclusions formation, hallmarks of 
TDP-43 proteinopathies. This mechanism of neurodegeneration is in accordance with the recently 
proposed "two-hit" model of pathology (Dormann 2010).
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4. CypA/mSODl interaction
Protein aggregation is strongly implicated in the pathogenesis of MN degeneration due to mSODl. 
The propensity of mSODl to aggregate is one of the most sustained hypotheses to explain the 
toxicity of this enzyme. SOD1 has been recognized as a primary component of protein aggregates 
in patients carrying SOD1 mutations and in mSODl rodent disease models (Wood 2003). 
Antibodies specific for misfolded forms of SOD1 have shown that granular SOD1 inclusions can be 
found in autopsy tissues from sALS patients, providing a possible mechanistic link between the 
sporadic and familial forms of disease (Bosco 2010; Forsberg 2010 and 2011). However, not very 
much is known about the role o f SOD1 aggregation in the pathogenesis of ALS. Insoluble SOD1 
complexes can start to be detected prior to disease onset (Basso 2006; Johnston 2000). Several, 
contributing factors have been proposed for the formation of SODl-rich protein inclusions: 
structure instability and aggregation propensity of mSODl (Lindberg 2002; Stathopulos 2003; 
Tiwari 2003), inhibition of chaperone activity (Tummala 2005), and alteration of the UPS (Kabashi 
2004; Cheroni 2005). Ubiquitinated protein aggregates are TX-insoluble (Ouyang 2001) and 
mSODl has an altered solubility in TX with the progression of the disease (Cheroni 2005).
4.1 CypA interacts specifically with mutant, but 
not with wild-type SOD 1
The aggregate protein constituents of TX-insoluble fractions enriched in ubiquitinated protein
aggregates and mSODl, have been studied in our laboratory. CypA was recovered in protein
aggregates isolated from the SpC of the G93A-SOD1 mouse model together with mSODl, and in
the aggregates from post-mortem SpC tissues of sALS patients (Basso 2009). Inclusions present in
disease commonly contain many different types of proteins, and some of the associated proteins
are Hsps and chaperones that might reflect the cellular response to lim it protein aggregation
(Morimoto 2008). Nevertheless, a possible mechanism of toxicity of SODl-rich aggregates is that
they may sequester other protein components essential for MN function, such as chaperones and
anti-apoptotic molecules (Pasinelli 2004), inhibit the ubiquitin-proteasome system (Bence 2001)
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and, by associating with motor proteins, impair axonal transport (Ligon 2005). mSODl is known to 
cause MN degeneration by toxic gain-of-function(s) that could be exerted, at least in part, through 
aberrant interactions with other proteins, unless prevented from doing so by association with 
chaperone proteins. Studies in our laboratory have shown that CypA is up-regulated in ALS, 
suggesting that it could play a role in protecting cells from the toxicity o f mSODl. This hypothesis 
was supported by the finding that CypA has a preferential affinity for G93A-SOD1 in our in vitro 
model. Similar results were obtained with other SOD1 ALS-mutants transiently expressed in 
HEK293 cells, providing added evidence that the two proteins associate preferentially in mutant 
cells, and suggesting that mSODl/CypA gain-of-interaction was a common feature of the ALS- 
associated SODl-mutants analysed. Furthermore, we confirmed CypA as a novel mutant-SODl 
interacting protein also in mouse lumbar SpC ventral horn, that is where the two proteins have 
been found to co-aggregate. Therefore, this gain-of-interaction between mSODl and CypA was 
observed in vitro and in vivo, and may be particularly critical for fALS-associated mSODl. Since 
SOD1 mutations destabilize SOD1 or the dimer (Borchelt 1994; Deng 1993), leading to misfolding 
and aggregation of the protein (Durham 1997), our data support the hypothesis that CypA, by 
direct association with the mutant protein, could help stabilize and refold misfolded SOD1. 
Moreover, the binding of CypA, as a molecular chaperone, could be protective by preventing 
abnormal protein-protein interactions and/or facilitating degradation.
4.2 CypA is an aggregation modifier
The involvement of CypA in the development o f the disease was further investigated through the
generation of double transgenic animals G93A-SOD1 expressing (G93A-SODl/CypA+/+)/ w ith a
reduced expression (G93A-SODl/CypA+/-) or knockout (G93A-SODl/CypA-/-) fo r CypA (Pozzi,
manuscript in preparation). CypA reduced or absent expression worsened motor performances
and disease progression in G93A-SOD1 mice. Moreover, CypA deficiency anticipated the disease
and reduced the survival time of G93A-SOD1 mice. From these analyses CypA emerged as a
disease modifier gene. In addition, we evaluated the detergent-insoluble proteins extracted from
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ventral horn SpC of G93A-SODl/CypA double transgenic mice, as a model of protein aggregates, 
just prior to the expected onset of clinical symptoms. We recovered an increasing amount of 
insoluble mSODl in mice with a reduced or a totally deficient expression of CypA, while no 
differences were observed in the soluble fractions. These results indicate that depletion of CypA 
resulted in more mSODl aggregates formation. Therefore, we speculate that in mSODl MNs, 
where the interaction between CypA and mSODl, as well as their presence in the detergent- 
insoluble fraction have been described, CypA could act as a chaperone, promoting protein folding 
and refolding. Our findings are consistent with a previous report suggesting a protective role for 
CypA in mSODl-induced cell death, in association with its rotamase activity (Lee 1999). This is also 
in line with other works demonstrating that mSODl toxicity could be ameliorated upregulating 
heat-shock protein chaperones in order to refold the soluble misfolded protein (Brotherton 2012). 
Moreover, previous co-IP studies already reported mSODl interaction with chaperones, such as 
Hsp25, Hsp70, Hsp40 and aB-crystallin, with mSODl/HSP70 forming complexes predominantly in 
the detergent-insoluble fraction (Shinder 2001; Okado-Matsumoto 2002). Therefore, as suggested 
for heat shock proteins, CypA could protect cells from mSODl toxicity by direct interaction, thus 
preventing aggregation and facilitating degradation, or indirectly by protecting cells from 
downstream consequences of some other toxic properties. In diseased tissues CypA may also be 
needed to refold other proteins that are partly denatured by oxidative damage. CypA has been 
proposed to be a protective agent against oxidative stress by reducing ROS production (Choi 
2007; Hong 2004), inducing anti-oxidant protein (Lee 2001; Jaschke 1998; Reddy 1999) or pro­
survival factors (Boulos 2007). MNs may be especially sensitive to the free radical damage 
induced by mSODl, because of their high oxidative activity, at least partly resulting from their 
large surface area and dependence on intracellular transport of proteins (Collard 1995) and 
muscle-derived trophic factor signaling. G93A-SODl/CypA knockout animals, being deficient in 
CypA chaperoning activity, not only formed more aggregates of mSODl, but also irreversibly 
damaged proteins (ubiquitinated and aberrantly oxidized) were significantly enriched, possibly 
further enhancing the co-sequestration of other protein components essential for MN function,
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including HSC70. Interestingly, specifically nitrated actin, but not general protein nitration, was 
increased in association with CypA absence in mSODl mice. Possibly this finding is consistent with 
previous reports demonstrating a role for CypA in the maintenance of a normal actin structure 
(Calhoun 2009; Haskova 1994; Kotcz 1999), also in association with slow axonal transport in MNs 
(Yuan 1997). Overall our data suggest that in mSODl fALS mice CypA, together with other 
chaperones, could form complexes with misfolded mSODl, and thus could contribute to protect 
cells from mSODl toxicity by direct interaction, preventing aggregation, or indirectly by protecting 
cells from down-stream consequences of some other toxic event, such as facilitating degradation 
of damaged proteins and maintaining the native folding of actin.
On the other side, the binding of CypA to mutant forms of a protein abundant in MNs, such as 
SOD1, makes it unavailable for other physiological functions. Indeed, we showed that CypA is a 
highly interactive protein, with potential relevant activities in multiple neuronal pathways; thus, 
mSODl association with CypA could have the effect o f decreasing its availability for interactions 
with other protein partners. In particular, the involvement of CypA in mSODl aggregation in MN 
degeneration may be interesting in view of its interaction with other RNA-binding proteins, 
especially TDP-43, given its causative role in ALS. Indeed, we observed the presence of detergent- 
insoluble TDP-43 in mSODl mice, and the highest levels of insoluble TDP-43 were observed in 
CypA knockout mice, although no differences were detected in the soluble fraction. Moreover, we 
observed robust phosphorylation of TDP-43 at Ser-409/410, that are major sites o f pathological 
phosphorylation and indicate the presence of toxic misfolded species (Liatchko 2010). hnRNP 
A2/B1 was recovered in the detergent-insoluble fraction of mSODl animals, but no differences 
were observed in the absence of CypA, either in TIFs and in the soluble fractions. We speculate 
that TDP-43 pathology, commonly associated with sporadic and non-SODl fALS (Mackenzie 2007), 
could also contribute to mSODl-associated disease, through impaired TDP-43 functions in 
association with CypA depletion and sequestration of this nuclear protein in insoluble complexes. 
In fact, HDAC6 protein levels, whose control is mediated by TDP-43, were reduced in ventral horn 
SpC from G93A-SODl/CypA knockout mice. Hence, early alterations in this pathway that is
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decisive for neurite outgrowth and clearance of misfolded proteins through the autophagy 
pathway (Boyault 2007; Fiesel 2010 and 2011), even though only indirectly disturbed in SOD1- 
associated disease, may contribute to neurodegenerative events in ALS. Therefore, there are 
likely multiple effects mediated by CypA that could be relevant to explain several pathogenic 
features o f ALS, some of which converge on TDP-43, and others that do not.
Finally, we demonstrated the relevance of the mechanisms described for disease progression, 
analysing ventral horn SpC of mSODl/CypA double transgenic mice at different stages of the 
pathology: just prior to the expected onset o f clinical symptoms and at a late symptomatic stage 
of the disease. In these animals we recovered detergent-insoluble and hyper-phosphorylated 
TDP-43 independent of ALS causing TDP-43 mutations. Therefore, the overexpression of mSODl 
can enhance wild-type TDP-43 aggregation. In particular, the increasing amount o f insoluble and 
aberrantly phosphorylated TDP-43 correlated with disease progression and with CypA depletion, 
either in non-transgenic and in mSODl mice. Our findings indicate that CypA direct or indirect 
depletion, following CypA knockout or mSODl/CypA interaction respectively, could contribute to 
TDP-43 detergent-insolubility. Moreover, in the absence of CypA, the progressive misfolding or 
aggregation o f wild-type TDP-43 could contribute to neurotoxicity, as a cellular consequence of 
TDP-43 dysfunction, thus accelerating mSODl pathology. These findings indicate that CypA could 
influence both initiation and progression of the pathology. However, the presence of pathological 
lesions containing detergent insoluble, phosphorylated, and aggregated TDP-43, that are a key 
feature of TDP-43 proteinopathies, should be deeply investigated by immunohistochemistry in 
these animals. Furthermore, since TDP-43 misfolding contributes to neurodegenerative diseases 
very broadly, its association with CypA should be analysed also in other systems.
In summary, as a consequence of chaperones preferential binding for misfolded proteins, CypA
interacts with mSODl. Possibly, mSODl sequesters CypA to insoluble aggregates in the cytosol,
thus depleting CypA in the nucleus and impeding its physiologic functions, including its association
with TDP-43. In fact, interactions o f multi-component complexes, such as CypA/TDP-43/hnRNPs
complex, could be influenced by specific neuronal microenvironment, as demonstrated in the
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case of aggregating mSODl. Dysregulation of TDP-43/CypA hnRNP complex could contribute to 
alter TDP-43 solubility and subcellular distribution, or possibly RNA-binding properties, thus 
favouring aggregation and impairing TDP-43 nuclear functions. Moreover, the multi-component 
complex containing CypA that interacts with TDP-43 and hnRNP A2/B1 could be important for 
maintaining homeostasis of several mRNA transcripts, including HDAC6, and alterations of this 
complex can contribute to give rise to a pathological state. Therefore, alterations of CypA/TDP-43 
interaction, detected both when TDP-43 or SOD1 were mutated, could have important 
implications for hnRNP complex formation, stability, and function.
Overall, our work reveals a novel role for CypA as a molecular chaperone of mSODl and TDP-43. 
Hence, accumulations of TDP-43 and mSODl insoluble species in degenerating M Ns resulted from 
an alteration in an interaction intended to maintain protein functional solubility. Given these 
observations, CypA should be considered an aggregation modifier in ALS. Therefore, regardless of 
the point at which mutations in either SOD1 or TDP-43 introduce an aberrant gain- or loss-of- 
function, the net effect may be an impairment of the same multi-component complex, thereby 
causing a vicious cycle of pathological aggregates formation and compromised RNA metabolism at 
multiple levels. These events represent a severe damage for cells, particularly for MNs, that 
progressively degenerate. Thus, since the upstream triggering event could arise from alteration of 
individual components within the complex or from their altered interactions in the complex or 
with components in other pathways in the cell, it is likely that different perturbations could arise 
in diverse neurodegenerative settings, possibly synergizing to contribute to a clinically and 
genetically heterogeneous disease phenotype, as ALS is.
We conclude that CypA, being an interacting partner of both SOD1 and TDP-43, represents the 
"missing link" of two pathogenic mechanisms of ALS, that converge on CypA functional network.
307
VI. CONCLUSION
As most neurodegenerative diseases, clinically indistinguishable ALS phenotypes can be caused by 
genetic mutations in different genes, including SOD1 and TDP-43, that destabilize the encoded 
proteins and predispose them to aggregation, or can occur in the absence of known mutation as 
sporadic disease. The mechanistic relationship between SOD1- and TDP-43-associated familial or 
sporadic forms of the disease is not well understood. In fact, concomitantly with protein 
misfolding, there is a series of poorly understood events that lead to degeneration of a selective 
subset o f cells, resulting in loss of function. Several aberrant regulatory processes have been 
reported, such as mitochondrial dysfunction, impaired RNA processing, glutamate cytotoxicity, 
impaired axonal transport and oxidative stress. Some of these pathways have been linked to one 
another in a sequential manner, while there are many that are not obviously connected. In spite 
of these complexities, there are common features of disease pathogenesis between sporadic and 
familial, SODl-dependent ALS suggesting that common (Ferrante 1997; Beal 1997; Atkin 2008; 
Pokrishevsky 2012), but unknown molecular mechanisms are at work. Identifying and deciphering 
these connections is thus crucial to understanding the disease and for effectively developing 
therapies. In the present work, this issue has been approached investigating an early systemic 
translational biomarker for sporadic and SODl-linked fALS.
The study o f CypA revealed an unexpected relationship between TDP-43 and SOD1, with relevant 
implications for disease pathogenesis and progression. In fact, we demonstrate that two ALS- 
causing proteins, SOD1 and TDP-43, share CypA as interacting partner, suggesting a direct 
molecular link between two pathogenic mechanisms in sporadic and familial ALS. In particular, 
this thesis work indicates that when SOD1 is mutated, it can bind and sequester CypA in 
proteinaceous aggregates, altering CypA physiological activities including the interaction with 
TDP-43, which is in fact recovered in the aggregates. When TDP-43 is mutated or altered, the 
interaction with CypA is impaired, leading to the disruption of hnRNP-associated complexes and 
downregulation of HDAC6. Thus, regardless the cause of the disease, mutations in SOD1 or 
alterations in TDP-43, the net effect is the formation of pathological aggregates and a 
compromised RNA metabolism. Therefore, impaired association with a common chaperone
309
protein, CypA, could cause misfolding, that is a critical molecular event in the unified 
pathogenesis of sALS and fALS, likely further triggering misfolding and propagating the disease.
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Figure 1. Schematic representation of the working hypothesis.
(A) This thesis work shows that CypA functionally associates with proteins regulating RNA 
metabolism, including several hnRNPs and TDP-43, forming a highly dynamic multi-component RNP 
complex. (B) In pathological conditions, (i) CypA altered PPIase activity or PTM (e.g. lysine- 
acetylation), (ii) aberrant TDP-43 or (iii) SOD1 mutation, the interaction between CypA and TDP-43 is 
impaired. The equilibrium of the complex is shifted toward a more static structure, the complex 
looses its dynamic modulation and possibly function, leading to the disruption of the complex. The 
net effect is the formation of TDP-43 rich aggregates that may lead to a compromised RNA 
metabolism.
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The identification of CypA interactome thus provides a tool for understanding pathogenic 
mechanisms common for this neurodegenerative disorder (see Figure 1). In fact, CypA associates 
with distinct protein interaction networks, one implicated in RNA processing and others involving 
protein folding, trafficking and cytoskeleton-associated proteins, suggesting that CypA could 
Couple protein folded state to the trafficking pathway. Furthermore, CypA specifically binds 
hnRNP A2/B1. Since TDP-43 and hnRNP A2/B1 are both structurally typical hnRNP proteins, CypA 
presumably binds both proteins in a similar mode, and they participate in a multi-component 
complex that modulates HDAC6 expression. In this model, CypA functions as a molecular 
chaperone, binding the functional state of a protein (e.g. TDP-43/RNA) and stabilizing it or 
inducing a conformational change, and it can prevent its denaturation and misassembly into 
cytotoxic aggregates. These are important features for proteins that form heterocomplexes 
involved in multiple steps of RNA processing. Knowledge about protein-protein interactions 
between hnRNPs is limited and further analyses of hnRNP complexes with different components 
may shed light on the functions of hnRNPs in the many different RNA-related biological processes. 
Whatever its identity, CypA is directly implicated in hnRNP-rich complexes formation and 
maintenance, since its downregulation significantly reduces the interaction between TDP-43 and 
hnRNP A2/B1, affecting also HDAC6 expression. Therefore, CypA can be considered a novel 
modifier o f TDP-43 activity. Notably, other two disease-relevant proteins have been associated 
with HDAC6: FUS modulates HDAC6 expression in complex with TDP-43 (Kim 2010), while a finely 
tuned balance between VCP and HDAC6 directs ubiquitinated aggregates either to the UPS or to 
the autophagic pathway (Boyault 2006). Thereby, a disturbance in the expression or in the 
equilibrium between the different functions of HDAC6 could play an important role in 
neurodegeneration (d'Ydewalle 2012). We also provide preliminary evidence that CypA/TDP-43 
binding may be involved in TDP-43 mislocalisation and that CypA acetylation at lysine-125 is 
specifically required for the interaction. The role of CypA PTMs in modulating its various functions 
has yet to be investigated, as well as the function of the extracellular and circulating CypA. Clearly 
we are still at a very early stage in understanding the biology o f CypA in ALS. Additional
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exploration in this area may provide further insight into the very early observation that CypA is 
required for the correct hnRNP complex assembly and maintenance, and HDAC6 expression 
regulation. Moreover, experiments in CypA knockout animals, where very specific questions are 
addressed, will be important in determining the significance of the various interactions of CypA 
that have been demonstrated in vitro. This study further highlights the importance of aberrant 
RNA metabolism as a cause of disease and supports the idea that accumulation of insoluble TDP- 
43 plays an important role in ALS pathogenesis. In fact, considering the sheer number of 
potentially misregulated targets/pathways after changes in cellular distribution and solubility of 
TDP-43, it is likely that even small alterations in a member of the multi-component complex 
described might cause neurodegeneration over a long period of time, especially if we consider 
that the ability of cells to compensate for even small changes from normality gradually diminishes 
with age.
Finally, the identification of a common molecular pathway in ALS has important implications for 
the effective treatment of this devastating disease. Our observations have implications regarding 
the potential use o f chaperone proteins or agents that modulate their activity or PTMs to correct 
the deficits. In particular, CypA could be a potential therapeutic target to delay ALS progression.
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